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Abstract 
 
Investigating the Molecular Mechanisms of Crosstalk Between NF-κB and Nrf2 
Signalling Pathways 
 
In order to maintain tissue homeostasis, cells must respond swiftly to inflammatory 
and oxidative challenges, ensuring appropriate processes are sequentially activated 
and repressed when stress conditions are normalised.  
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and Nuclear Factor-κB (NF-κB) 
are the key regulators of cellular antioxidant and inflammatory responses 
respectively. Imbalance between these processes is a contributing factor in many 
human diseases, including neurodegeneration, autoimmune disorders and cancers. 
Pharmacological and genetic studies suggest that there is functional crosstalk 
between these two pathways, however mechanistic details of conditional dominance 
between them remain unclear.  
To address this, we have generated multiple, low expression, fluorescent molecular 
tools that allow monitoring of the distribution and activity of Nrf2 and NF-κB 
proteins in primary living neurons and astrocytes. This allowed us to characterise the 
cell-specific antioxidant and inflammatory signalling, as well as to understand the 
patterns in basal activity. 
 
We also investigated patterns of crosstalk in a cancer-related context utilising a 
previously generated SK-N-AS neuroblastoma cell line, engineered to stably express 
Nrf2-Venus, from a bacterial artificial chromosome (BAC). This model cell-line was 
first extensively characterised in order to define conditional Nrf2 responses to 
antioxidant compounds in real-time. We then proceeded to investigate the effect of 
acute inflammation on the cellular antioxidant activity, in order to define the extent 
and nature of functional crosstalk between NF-κB and Nrf2. Data from these studies 
provide definitive proof of a self limiting reciprocal mechanism of interplay in 
neuroblastoma cells, in which NF-κB-mediated inflammatory signalling promotes an 
increase in Nrf2 transcription which then in turn supresses further NF-κB signalling. 
In addition, results from single cell imaging and population level studies show that 
Nrf2 responses are fine tuned, by either Keap1-mediated mechanism of repression. 
 
To define the intricate mechanisms of basal Nrf2 activity, we utilised a photo-
switchable fluorescent protein fusion, which provided the first direct measurements 
of Nrf2 nuclear import and export dynamics in live-cells.  
Finally, we used the sophisticated live cell imaging approaches to define the 
mechanism of action of the Nrf2 inhibiting drug brusatol. Significantly, these results 
contradict published data and reveal a more general explanation for the potential 
therapeutic utility of brusatol. 
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1. General Introduction 
 
1.1.1. The Introduction to the Nrf2 Pathway 
 
The emergence of oxygen in the early Earth’s atmosphere produced by 
photosynthetic ancestors of Cyanobacteria over 2.4 billion years ago triggered the 
biggest step in animal evolution. The engulfment of aerobic mitochondria yielding 
higher energy through effective respiratory processes facilitated inception of more 
complex life forms. However, the cost of this ‘upgrade’ to the host cell was the 
requirement for an efficient detoxification system to deal with the constant 
production of reactive oxygen species, which are associated with normal 
mitochondrial activity (Embley & Martin, 2006).  
 
There is increasing realisation that the effects of this symbiotic relationship, which is 
maintained in all eukaryotic cells, within all multicellular organisms, may 
significantly contribute to the process of aging and age-related diseases. The more 
effective production of energy through oxidative phosphorylation is paired with a 
constant battle against the resulting reactive oxygen species (ROS). The aerobic cell 
has evolved mechanisms to defend itself from these potentially harmful reactive 
oxygen and nitrogen species. In essence, eukaryotic cells encode sensor proteins that 
react to reactive oxygen or nitrogen species by turning on transcription of a 
collection of cytoprotective antioxidant genes (Pajares et al, 2015). The Nuclear 
factor (erythroid-derived 2)-like 2 (Nrf2) transcription factor performs a central role 
in this process, regulating around 1% of human gene expression, many of which 
perform powerful protective functions (Cuadrado et al, 2009). 
 
The coding sequence of the Nrf2 gene was first characterised by Yuet Wai Kan, who 
discovered that the encoded protein was able to bind to the activator ptotein-1 (AP-1) 
and NEF-E2 tandem repeat consensus DNA sequence. The first evidence of the 
involvement of Nrf2 in the regulation of glutathione-S transferase (GST) and 
NAD(P)H dehydrogenase (quinone 1) (NQO1) antioxidant genes expression was 
demonstrated by Massayuki Yamamoto, and this observation initiated a global 
explosion in Nrf2 pathway research (Hayes & Dinkova-Kostova, 2014). The Nrf2 
protein belongs to the Cap’n’Collar family of proteins (CNC) and to the subfamily of 
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basic leucine zipper (bZIP) proteins, which also include Jun, Fos and ATF4 
transcription factors (Hirotsu et al, 2012; Jyrkkanen et al, 2011). The transcriptional 
activity of the Nrf2 protein requires the formation of a heterodimer complex with 
another member of the bZIP subfamily- the small MAF (sMaf) proteins, such as 
MafK, MafG or MafF. This interaction facilitates bind to a cis regulatory DNA 
element called the Antioxidant Response Element (ARE), which is contained within 
the promoters of Nrf2 target genes (Hirotsu et al, 2012; Bryan et al, 2013). The 
consensus ARE sequence is defined as 5’-TGACNNNGC-3’ (N- unspecified 
nucleotide) and it is usually encoded downstream of the consensus sMaf binding site,  
 
 
 
 
 
also termed the Maf Recognition Element (MARE) (5’-TGCTGAGCAGCA-3’) 
(Hirotsu et al, 2012). Binding of the sMaf-Nrf2 dimer to target DNA sequences 
initiates recruitment of the RNA Polymerase II, promoting the subsequent assembly 
of the transcriptional apparatus (Belleza et al, 2010). The sMaf proteins are widely 
expressed in most tissues and are though to play redundant roles in transcription 
process, acting as DNA-binding enhancers for bZIP proteins such as Nrf2, Nrf1 and 
p45. sMaf are regulated predominantly though transcription and interestingly smafG 
variant contains an ARE sequence in its promoter, which can be modulated by Nrf2 
(Blank, 2008). The Nrf2 protein contains a single nuclear localisation signal (NLS) 
Figure 1.1 The domain topologies of Nrf2 and Keap1 proteins. Schematic 
representation of Nrf2 and Keap1 proteins showing the distribution of 
functional domains and binding sites/residues. (Adapted from Hayes & 
Dinkova-Kostova, 2014).   
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and two nuclear export signal (NES) motifs, which regulate its cellular localisation 
(Cuadrado et al, 2009). Nrf2 knockdown mice develop normally, but are highly 
susceptible to environmental stress and the toxic effects of compounds such as 
tobacco smoke and paracetamol; they are also prone to developing cancers and 
neurodegenerative or inflammatory diseases (Bryan et al, 2013; Neymotin et al, 
2011; Vargas & Johnson, 2009). This highlighted the protective role of Nrf2 and 
prompted extensive research, which validated its regulatory function in lipid 
oxidation, anabolic metabolism, protein degradation, responses to chemical stimuli, 
immune signalling, multidrug resistance, expression of molecular chaperones and 
wound healing (Papp et al, 2012; Wu et al, 2011; Mitsuishi et al, 2012a; Sporn & 
Liby, 2012; Wakabayashi et al, 2010).  
 
Nrf2 is ubiquitously expressed in all cell types, with the highest levels being detected 
in lungs, brain, testis, spleen, skeletal and heart muscle and in the kidney (Chan et al, 
1996). The key characteristic of this transcription factor is its very low basal activity 
and its stringent regulation, as the half-life of Nrf2 protein has been estimated to last 
only 10-30min (Belleza et al, 2010). The stability of Nrf2 dramatically increases as a 
result of diverse stimuli including plant-derived phytochemicals and intracellular and 
extracellular stress factors, such as ultraviolet (UV) and gamma (or ionising) 
radiation, electrophiles, pollution, inflammation and reactive oxidant species (ROS) 
(Lee et al, 2005; Bryan et al, 2013). 
 
The regulation of antioxidant pathway activity is very complex and is not yet fully 
understood, however, research into the antioxidant pathway is growing rapidly, as its 
protective properties show promise in the treatment of a wide array of diseases. The 
paradigm and complexity of Nrf2 protein regulation are described in the next 
paragraph.  
 
1.1.2. The Regulation of the Nrf2 Protein Stability and Activity by Keap1 
 
Expression levels of the Nrf2 protein are primarily controlled at a post-
transcriptional level, through an interaction with proteins that trigger proteasome 
mediated degradation (Suzuki & Yamamoto, 2015; Cuadrado et al, 2009). The best 
understood negative regulator of Nrf2 is the Kelch-like ECH-associated protein 
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(Keap1), which is an actin-bound zinc metalloprotein that acts as an E3-ligase, 
facilitating the attachment of ubiquitin chain to Nrf2 (Ghosh et al, 2011). Keap1 
binds as a dimer to the Neh2 domain within Nrf2 forming bonds with the high 
affinity ETGE and low affinity DLG amino acid sequences (Figure 1.1). This 
interaction brings the Nrf2 protein into proximity with Cullin3 and Ring Box 1 
(Rbx1), which then catalyze the process of ubiquitin attachment (Baird et al, 2013). 
The domain topology of Nrf2 and Keap1 proteins are shown in Figure 1.1. Keap1 is 
located mainly in the cytosol where it constantly sequesters and ubiquitinates Nrf2, 
thereby restricting basal Nrf2 activity to very low levels. The Keap1 has been also 
reported to enter the nuclear space, however its nuclear function requires 
clarification. An unusually high number of reactive cysteine (Cys) residues are 
encoded within Keap1 (27 Cys residues), makes it an extremely sensitive sensor of 
oxidative stress, with C151, C257, C273, C288 and C297 being especially sensitive 
to oxidation (Bryan et al, 2013; Figiel, 2008).  
 
Figure 1.2 The Keap1-dependent Nrf2 regulation. The basal (left) and the 
ROS/pharmacological inducer (right) inflicted modes of Nrf2 regulation are 
represented. The Nrf2 becomes sequestered to Keap1 and the complex closes 
allowing attachment of the ubiquitin chain. The Keap1 is then recycled and 
binds to another Nrf2 molecule. Some basal activity is allowed (left). In the 
event of modification of cysteine residues on Keap1 by oxidation or 
attachment of electrophilic compounds the Keap1 is unable to form the closed 
complex and therefore catalyse the ubiquitin attachment. The newly made 
Nrf2 is then accumulated in the nuclear space and leads to ARE genes 
transcription. (Adapted from Baird et al, 2013). 	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The reactivity of Cys residues is characterised by the pKa value of its thiol residues, 
and this value can be lowered (rendered more reactive) by the presence of basic and 
aromatic amino acids, or metal centres located around it (Bryan et al, 2013). The 
oxidation of thiols within Cys residues leads to the formation of disulphide bridges 
between cysteines, resulting in a conformational change in Keap1 protein structure, 
which in turn prevents the effective ubiquitination and degradation of Nrf2 (Baird et 
al, 2013; Chiu & Dawes, 2012).  
The Nrf2/Keap1 model of regulation has been described as the ‘conformational 
cycling mechanism’ (Baird et al, 2013), in which the Nrf2 is constantly sequestered 
by Keap1 dimers and targeted for degradation through the formation of closed 
complex between the N-terminal BTB domain and C-terminal DC domain of Keap1 
and the ETGE and DLG motifs in Nrf2 (see Figure 1.1) (Tanji et al, 2013). 
Following degradation of the Nrf2 protein, the Keap1 dimer is recycled and is able to 
bind newly made Nrf2 protein (Baird et al, 2014). In the event of oxidative stress, or 
pharmacological intervention, specific Cys residues on Keap1 become modified 
leading to the release of the DLG domain of Nrf2, thus forming an open complex 
that can no longer be ubiquitinated and degraded (Figure 1.2). Newly formed Nrf2 
proteins will still bind to free Keap1 dimers, however as Keap1 becomes saturated, 
free Nrf2 is then allowed to enter the nucleus, where it will subsequently 
heterodimerise with sMaf and bind to ARE containing promoter sequences (Baird et 
al, 2013). The additional consequence of the open complex formation is that it 
exposes the Nrf2 protein for competitive interactions with other partners such as p21, 
p62 and prothymyosin, as well as phosphorylation by various kinases, leading to the 
activation of ARE gene expression (Baird et al, 2014; Chen et al, 2012). Therefore, 
antioxidant pathway activation will rely on Nrf2 protein synthesis to overcome the 
levels of Keap1, which are usually present in cells at very low (near-saturated) levels 
(Suzuki et al, 2013). Covalent modification of Keap1 cysteines sensitises it to 
degradation by Sequestosome 1 (p62)-mediated autophagy. The Keap1-p62 
interaction is possible due to change in the Keap1 conformation resulted from 
oxidative stress. This exposes it for binding to the STGE motif within the p62, which 
mimics the low affinity ETGE site present within the Nrf2 protein. This process 
initiates an assembly of autophagy machinery and depletion of Keap1, allowing Nrf2 
to accumulate in the nuclear space (Bryan et al, 2013). Suzuki et al demonstrated 
that Nrf2 gene expression can be modulated by the relative abundance of Nrf2 and 
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Keap1, so the basal activity of Nrf2 will be dependent on both newly formed Nrf2 
protein and the levels of Keap1 protein in the cytoplasm (Suzuki et al, 2013; Baird et 
al, 2014). This hypothesis has been reinforced by studies investigating the negative 
regulation of Keap1, which show that enhanced expression of micro RNAs miR27 
and miR2000a, both of which target Keap1 mRNA, as well as an increase in Keap1 
promoter methylation, lead to a rise in basal levels of Nrf2 activity (Bryan et al, 
2013; Suzuki  & Yamamoto, 2015). On the other hand, the ubiquitin specific 
peptidase 15 (USP15) deubiquitinating enzyme was shown to negatively regulate 
Nrf2 function as it enhances Keap1 activity and complex formation with Cul3/Rbx1, 
by catalysing the removal of the ubiquitin chains on Keap1 (Ashabi et al, 2013). 
Efforts to generate Keap1-/- mice to investigate Keap1-mediated regulation of Nrf2 
responses failed because the animals die shortly after birth, due to hyperkeratinosis 
of the upper digestive track (Suzuki & Yamamoto, 2015; Stepkowski et al, 2011). 
However, a liver specific Keap1 knockout has been generated, allowing the effects of 
high Nrf2 expression on hepatocyte physiology to be investigated (Suzuki & 
Yamamoto, 2015). 
 
1.1.3. The Regulation of Nrf2 Protein Stability by GSK-3/β-TrCP/PI3K Axis 
 
The Keap1/Cull3/Rbx1 complex is extremely robust and efficient in restricting Nrf2 
protein expression, however, several other negative regulators of Nrf2 protein have 
been described. The recently described GSK-3/β-TrCP axis exhibits a notable 
difference to Keap1-mediated inhibition. Whereas, Keap1 acts as an extremely 
sensitive sensor of oxidative and chemical stress, the GSK-3 pathway acts by 
adjusting the antioxidant activity in tune with cellular signalling cascades and the 
metabolic status of the cell, as such its input varies greatly between tissues (Kim et 
al, 2013; Nisole et al, 2013). GSK-3 is a serine/threonine kinase characterised first 
through its role in the inhibition of glycogen synthase in low nutrient environments 
(Lee & Kim, 2007). However since its discovery, GSK-3 has been implicated in 
diabetes mellitus (DM) and in psychological and neurodegenerative disorders. GSK-
3 is encoded by two isoforms (GSK-3α and GSK-3β), which share 86% sequence 
homology and have redundant biological functions (Guan et al, 2014; Lee & Kim, 
2007). GSK-3 is active basally and requires priming phosphorylation of its targets, 
which then prompts further attachment of a phosphate group onto a serine or 
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threonine residue. In the presence of glucose the insulin/Akt/PI3K pathway leads to 
GSK-3 phosphorylation at Ser9 (β isoform) and Ser21 (α isoform), which terminates 
its activity. Therefore, high nutrient environments inhibit GSK-3 activity allowing 
glycogen re-synthesis (Lee & Kim, 2007). Nrf2 is also a target for GSK-3 
phosphorylation, on the Neh6 domain (Figure 1.1), facilitating docking of the β-
TrCP E3 ubiquitin ligase and formation of the β-TrCP/Skp1/Cull1/Rbx1 complex, 
which like Keap1/Cull3/Rbx1 catalyses ubiquitination of Nrf2 and subsequent 
degradation (Rojo et al, 2012; Chowdhry et al, 2013). While Keap1 dominates the 
control of cytoplasmic Nrf2 levels, the GSK-3/β-TrCP axis is thought to be 
predominantly active in the nucleus, directing Nrf2 protein for nuclear proteasomal 
degradation (Chowdhry et al, 2012). GSK-3 activity is regulated by insulin 
signalling and extracellular signals such as hormones and growth factors, 
consequently Nrf2 activity can be fine-tuned in line with glucose availability and 
growth signals (Clodfelder et al, 2005; Cuadrado, 2015). 
 
1.1.4. The RNF4-mediated Degradation 
 
There is at least one further alternative degradation pathway of Nrf2, which was 
described recently by Malloy et al.  This mechanism involves the accumulation of 
Nrf2 into promyolytic leukaemia nuclear bodies (PML-NBs) and takes place 
independently of the Keap1 and GSK-3 activity. The PML-NBs are dynamic nuclear 
structures that perform multiple cellular roles, such as transcriptional regulation and 
protein degradation, however the exact mechanism of their action still remains to be 
elucidated (Lallemand-Breitenbach & Hugues, 2010). This route of Nrf2 degradation 
requires the SUMOylation of Nrf2 proteins, which are then recognised by the RNF4 
E3 ubiquitin ligase, leading to the further modification of Nrf2 by the attachment of 
ubiquitin chains. The modified Nrf2 is then sequestered into mature PML-NBs, 
which contain the proteasome subunits that mediate Nrf2 degradation. The 
mechanisms that control this route of degradation and tissue specificity are not well 
defined and the environmental conditions that favour this mode of control remain to 
be further established (Malloy et al, 2013; Guo et al, 2014). 
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1.1.5. The Role of Post-translational Modifications in Regulating Nrf2 Activity 
 
1.1.5.1.  Phosphorylation 
 
The regulation of Nrf2 can be fine-tuned by several post-translational modifications, 
such as, phosphorylation, which regulate antioxidant gene expression and facilitate 
rapid responses to subtle changes in the cellular environment. The best defined 
phosphorylation event is mediated by the Protein kinase C (PKC), which targets 
Ser40 within the Neh2 domain of Nrf2 that is located within the proximity to the 
Keap1 binding sites, leading to enhanced nuclear accumulation (Cuadrado et al, 
2009; Bryan et al, 2013). Also, PKC is activated by PI3K signalling in response to 
growth factors and by catalysing the inhibitory phosphorylation of GSK-3 thereby 
indirectly augmenting Nrf2 activity (Belleza et al, 2010; Kim et al, 2013). Cellular 
antioxidant activity can also be modulated by nutrient availability, by the mammalian 
target of rapamycin (mTOR) pathway. In a nutrient rich environment, mTOR 
activation leads to the phosphorylation of serine on the STGE motif of 
p62/SQSTM1. This increases its competitive binding to Keap1 leading to Nrf2 
nuclear shuttling, leading to an increase in antioxidant target gene expression 
(Figure 1.3) (Ichimura et al, 2013).  Similarly, endoplasmic reticulum (ER) stress, 
resulting from the accumulation of misfolded proteins can activate the protein kinase 
RNA-like endoplasmic reticulum kinase (PERK), which subsequently mediates 
phosphorylation of Nrf2.  This is thought to promote dissociation (or open complex 
formation) from Keap1, allowing Nrf2 nuclear localisation and the transcription of 
protective genes (Stepkowski et al, 2011; Mitsuishi et al, 2012a, Cullinan et al;  
2003). Other kinases that have been reported to inhibit Keap1-mediated degradation 
include JNK, ERK1/2, p38 and MEK5. At this point it should be noted that Nrf2 is 
predicted to be involved in ~ 281 binary protein interactions, although a significant 
number of these interactions have yet to be verified.  Nevertheless, it is highly 
probable that in the near future additional mechanisms of conditional Nrf2 regulation 
will be identified (Papp et al, 2012). 
Phosphorylation of Nrf2 not only dictates its Keap1-regulated degradation, but also 
governs its cellular localisation. The Src family of proteins includes Fyn, Fgr, Yes 
and Src, promote the nuclear export of Nrf2 by modification the Tyr568 residue 
(Niture et al, 2011; Jain et al, 2006). Nuclear localisation of the Src proteins is also 
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regulated by GSK-3, which enhances their nuclear retention. Therefore, increased 
GSK-3 activity not only regulates the nuclear degradation of Nrf2 but also plays an 
important role in controlling its export into the cytoplasm for Keap1-mediated 
degradation, thus ensuring the efficient termination of antioxidant signalling 
(Cuadrado, 2015).  
 
1.1.5.2. Dephosphorylation  
 
Antioxidant gene expression is also modulated by de-phosphorylation. The 
phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has been 
identified as a negative regulator of Nrf2 function, as demonstrated by the fact that 
PTEN negative cancers display increased levels of Nrf2 transcriptional activity 
(Cuadrado, 2015; Mitsuishi et al, 2012b). Lack of PTEN was associated with 
Figure 1.3 Regulation of Nrf2 by phosphorylation. Diagram depicting major 
modes of regulation of Nrf2 protein through phosphorylation including PI3K, Akt, 
mTOR, GSK-3 and PTEN. GF=growth factor, RTK=receptor tyrosine kinase 
(Adapted from Papp et al, 2012; Belleza et al, 2010; Stepkowski et al, 2011 and 
Carracedo et al, 2008). 
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enhanced Nrf2 activation in response to antioxidant inducers such as tert-
Butylhydroquinone (tBHQ) in Jurkat human leukaemia cells, suggesting that PTEN 
has an inhibitory effect on Nrf2 function (Sakamono et al, 2009). Overexpression of 
PTEN leads to inhibition of PI3K, thus affecting its downstream targets such as 
Akt/mTOR signalling and preventing the subsequent boost in Nrf2 target gene 
expression (Figure 1.3) (Carracedo et al, 2008). Furthermore, this triggers activation 
of GSK-3, which in turns enhances the degradation of Nrf2 through the GSK-3/β-
TrCP axis (Rojo et al, 2014). Therefore, high activity of PTEN not only leads to 
functional repression of Nrf2 but also enhanced protein clearance. The summary of 
regulatory phosphorylation and de-phosphorylation events is depicted in diagram in 
Figure 1.3. 
 
1.1.5.3. Acetylation 
 
Together with many other transcription factors Nrf2 requires acetylation by the 
transcriptional co-factor the p300/CBP histone acetylase protein (HAT), which 
augments Nrf2 DNA binding and gene transcription (Sun et al, 2009). The Neh1 
DNA binding domain within Nrf2 contains 18 lysine (Lys) residues, which can be 
modified by acetyl group attachment. This creates a positive charge on the surface of 
Neh1 and augments its interaction with negatively charged phosphate groups within 
the DNA backbone.  Deletion of the individual Lys residues within Nrf2 did not have 
a significant effect on ARE-driven gene transcription, suggesting that they have 
redundant functions. However, deletion of all 18 residues was effective in reducing 
antioxidant activity (Sun et al, 2009). Besides, p300/CBP-mediated Nrf2 acetylation, 
the hMOF acetylase has also been identified as an enzyme that is capable of 
acetylating Lys588 of Nrf2, which also increases Nrf2 nuclear retention and gene 
transcription. The activity of hMOF is high in NSCLC tissue, and this increase in 
activity has been shown to be associated with the cancer resistance to drug treatment 
and poor patient prognosis (Chen et al, 2014). 
 
Protein acetylation can be reversed by the action of histone deacetylase enzymes 
(HDACs), which are grouped into 4 classes accordingly to their homology with the 
yeast counterparts, which have been shown to have different substrate specificity (Lu 
et al, 2015).  
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HDACs inhibitors have been shown to have pleiotropic effects on the transcription of 
ARE response genes.  For example, inhibition of the SirT1 deacetylase (HDAC class 
III) led to increased Nrf2 transcriptional activity and nuclear retention, coupled with 
increased acetylation of Lys558 and Lys591 residues (Kawai et al, 2011). 
Enhancement of acetylation by inhibition of HDAC enzymes, using the antibiotic 
trichostatin A (TSA), which targets classes I, II and IV HDACs, had a positive effect 
on Nrf2 transcriptional activity, by reducing Keap1 expression (Wang et al, 2012). 
Also, HDACs inhibitors were shown to improve neuronal viability during glucose 
starvation and ischemic damage in a mouse model of stroke. In addition, there are 
also reports of the positive effect of HDACs inhibitors on antioxidant expression in 
Parkinson’s disease (Wang et al, 2012; Lu et al, 2015). In contrast to these studies, 
deletion of HDAC II by siRNA and pharmacological agents led to a decrease in H2O2 
induced Nrf2 nuclear accumulation and an increase in oxidative stress (Mercado et 
al, 2011). Therefore, different classes of HDACs are involved in modulating the 
antioxidant gene expression and the outcome of their function may well be cell type 
specific and may also depend on the prevailing cell signalling signature. 
 
1.1.6. Transcriptional Regulation of Nrf2 
 
The fine balance between Keap1 and Nrf2 protein expression levels may dictate the 
basal expression of ARE-response genes. The importance of the transcriptional 
regulation of Nrf2 was highlighted by studies investigating single nucleotide 
polymorphisms (SNPs) within the NRF2 gene promoter. Variations in SNPs in the 
upstream promoter sequence are associated with significantly decreased Nrf2 mRNA 
and protein expression. Population analysis of SNPs variations revealed profound 
increases in the risk of developing lung cancer, even in patients that have not smoked 
in the past (Hayes & Dinkova-Kostova, 2014). The NRF2 gene has been predicted to 
be regulated by 34 transcription factors based on the consensus sequences encoded 
within its proximal promoter. So far the AhR, RXRα, SP-1, PPARγ, Myc, Pax, AP-
1, NF-κB transcription factors and also Nrf2 itself have been shown to modulate the 
activity of the NRF2 gene promoter region (Papp et al, 2012; Cuadrado et al, 2009; 
Wakabayashi et al, 2010; Hayes & Dinkova-Kostova, 2014; Rushoworth et al, 2012; 
Kwak et al, 2002; Pajares et al, 2015). 
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The transcriptional regulation of Nrf2 is achieved, in part, by the Aryl hydrocarbon 
receptor (AhR), which like Nrf2 is an inducible transcription factor that responds to 
xenobiotic stress, mediating the transcription of phase I and II metabolising enzymes 
(Wakabayashi et al, 2010, Tang et al, 2010). The AhR resides basally within the 
cytoplasm in complex with Hsp90 and 38-kDa immunophilin like protein and its 
nuclear translocation is initiated by the polycyclic hydrocarbons (e.g. dioxins). The 
AhR protein recognises the xenobiotic response element (XRE) in the promoter of 
gene targets including the NRF2 promoter (Wakabayashi et al, 2010). In addition, 
the Nrf2 promoter contains 2xARE sequences, which means that it has the potential 
to modulate its own transcription, however, as yet it is unclear whether this 
mechanism of transcriptional regulation operates during either inducible or basal 
activity (Hayes & Dinkova-Kostova, 2014; Kwak et al, 2002). Interestingly, the κB 
transcriptional response sequence, was detected within the 1.2kb proximal promoter 
region, and experiments in AML cells have shown that high Nrf2 activity, resulting 
from inflammatory signalling, contributed to the resistance of cancer cells to 
bortezomib treatment (Rushworth et al, 2012). 
 
1.1.7. Function of Nrf2 Gene Targets 
 
Nrf2 controls the transcription of over 200 genes and depending on the tissue 
context, these genes have prominent roles in the maintenance of redox status and the 
generation of reducing equivalents, protein folding and degradation, cell metabolism, 
calcium homeostasis and drug metabolism (Thimmulappa et al, 2002; Hayes & 
Dinkova-Kostova, 2014). The main pathways regulated by Nrf2 response genes are 
described below.  
 
1.1.7.1. Iron Metabolism  
 
Heme oxidase (HO-1) is an inducible microsomal enzyme abundant in most tissues 
responsible for catalysing the cleavage of the porphyrin ring of heme to yield ferrous 
iron (Fe2+), carbon monoxide (CO) and biliverdin, which is subsequently converted 
to bilirubin (Vargas & Johnson, 2009; Dorresteijn et al, 2015). The Fe2+ generated in 
this reaction triggers the activation of the iron ATPase pump, which then mediates 
the export of intracellular iron ions.  Fe2+ ions can also trigger the expression of 
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ferritin iron storage protein, an Nrf2 target gene, which sequesters free intracellular 
ferrous iron (Soares et al, 2004). The concentration of free Fe2+ and heme is higher 
under oxidative stress and this significantly increases the concentration of free 
radical species, which are generated as a result of the Fenton reaction and can lead to 
cytokine induced programmed cell death. In contrast, bilirubin has a potent 
antioxidant activity, which prevents apoptotic cell death (Gozzelino et al, 2010). The 
Nrf2 is though to be the main regulator of inducible HO-1 expression, however other 
transcription factors have also been reported to bind to the HMOX-1 promoter 
sequence, such as c-fos, c-jun and Ap-1 (Lu et al, 2014).  
 
1.1.7.2. The Antioxidant Properties of the Nrf2 Target Genes  
 
Many proteins equipped with reactive cysteine residues rely on transient ROS signals 
to modulate their activity. As a result, basal ROS concentration have the potential to 
effect multiple important cellular signalling events, thereby acting as a local, 
transient second messenger. The resulting increase in free radical species leads to the 
modification of thiol group in the cysteine residues and formation of sulfenic acid, 
disulfides, and mixed disulfides with glutathione or nitrosothiols. These are often 
necessary for appropriate protein function, however sometimes they may also hinder 
its activity (Bindoli et al, 2013). 
 
Elevation of ROS levels triggers the oxidative stress responses, which involves 
global changes in gene transcription and cell growth. Furthermore, extreme levels of 
ROS can initiate apoptosis (Pajarez et al, 2015). Nrf2 mediates the transcription of 
genes involved in reversing oxidative cysteine modifications, thereby preventing 
toxic accumulation of free radicals. The key function of Nrf2 is to ensure the 
replenishment of the cellular redox potential, by ensuring de novo synthesis of 
glutathione (GSH) by controlling the expression of the glutamate-cysteine ligase, 
catalytic subunit (GCLC) and the glutamate cysteine ligase, modifier subunit 
(GCLM) (Hayes & Dinkova-Kostova, 2014; Mitsuishi et al, 2012a). GSH is a potent 
antioxidant tripeptide present in the cell at mM concentration, where it acts as an 
electron donor, forming disulphide-bridges (S-S) on oxidised cysteines (Findlay et 
al, 2005).  This can be achieved either by reducing the S-S bridges back to the un-
oxidised state, or by enabling protein glutathionylaiton (post-translational 
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modification), which protects it from further oxidation (Findlay et al, 2005). The 
oxidised form of GSH, glutathione disulfide (GSSG), can be restored by expression 
of ARE-driven glutathione reductase (GSR) (Gozzelino et al, 2010; Vargas & 
Johnson, 2009). The NAD(P)H dehydrogenase quinine 1 (NQO1) is another example 
of canonical Nrf2 gene target, which reduces the highly reactive quinines preventing 
the formation of reactive oxygen compounds (Hayes & Dinkova-Kostova, 2014; 
Thimmalappa et al, 2002).  
The cysteines residues within the antioxidant proteins are effective electron acceptors 
and are therefore able to buffer cellular free radical concentration. The oxidation of 
reactive Cys residues takes place sequentially, from cysteine to sulfenic acid and 
then from sulfenic acid to sulfinic acid, each step leading to progressive alternations 
in protein structure and function (Findlay et al, 2005). Nrf2 regulates expression of 
the small redox protein sulfiredoxin (SFXN), which can reverse the oxidation of 
sulfinic acid Cys residues back to the more readily reversible sulfenic acid form, as 
well as thioredoxin (TRXDN), which then sequentially convert sulfenic acid back 
into the native thiol group (Winyard et al, 2005).  In simple terms, the process of 
reducing involves an exchange of disulphide bonds between the cysteines and the 
reducing proteins. These are just  a few examples of antioxidant proteins regulated 
by Nrf2 however there are several others such as catalase, prostaglandin reductase 
and peroxiredoxin-1 (Prx1) and all have significant roles in maintaining the 
intracellular redox balance protecting the sensitive structural building blocks of cells 
(Hayes & Dinkova-Kostova, 2014; Dowell & Johnson, 2013). 
 
1.1.7.3. Proteasomal Degradation and Autophagy 
 
The proteasome is a molecular “furnace” which clears away proteins within both the 
nuclear and cytoplasmic compartments. The proteasome displays selectivity for 
degradation of proteins depending on its subunit composition. The 20S proteasome 
primarily degrades unfolded proteins and does not require ubiquitin attachment to its 
targets, furthermore it can form the 26S proteasome by pairing with one or two 19S 
subunits, which changes its preference towards native-ubiquitinated proteins (Pajarez 
et al, 2015).  Thomas Kensler and colleagues first reported that the structural and 
catalytic subunits of the 20S proteasome are regulated by Nrf2 activity, adding to the 
wide portfolio of Nrf2 inducible genes (Hayes & Dinkova-Kostova, 2014).  
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Proteasomal degradation targets individual proteins. Importantly, Nrf2 also 
modulates the expression of p62/SQSTR1 that plays a key role in autophagosome 
formation, which in assistance from lysosomal digestion leads to the disposal of 
unwanted cellular components, such as, damaged organelles and protein aggregates 
(Taguchi et al, 2012; Pajarez et al, 2015). The damaged cargo is usually extensively 
labelled by ubiquitin chain attachment and recognised by the p62/SQSTR1 adaptor 
protein, which marks it for loading into the autophagosome (Fujita et al, 2011). The 
autophagosome then fuses with the lysosome and the cargo is digested by the action 
of the proteolytic enzymes within the lysosomal lumen. This form of 
autophagosomal degradation is active during starvation, as the presence of nutrients 
effectively inhibits mTOR activity (Pajarez et al, 2015, Krejci, 2012). Therefore, 
Nrf2 regulates the clearance of unfolded and native proteins by increasing 
proteasome availability and augmenting the clearance of whole organelles through 
by autophagy. 
 
1.1.7.4. PPP pathway  
 
The Nrf2 transcriptional activity has been shown to play a pivotal role in redirection 
of glucose metabolism into pentose phosphate pathway (PPP) under sustained PI3K 
activity (Mitsuishi et al, 2012a; Wu et al, 2011). PPP is an alternative route for 
anaerobic glucose utilisation and around 2-3% of the brain glucose is being shunt 
into the PPP (Takahashi et al, 2012).  The net product of PPP is the production of 
ribose-5 phosphate, for the synthesis of nucleotides and NADPH, which are key 
donors of reducing potential for GSH and TRXN enzymes that are essential for the 
recovery of oxidative stress and the reduction of oxidised cysteines (Mitsuishi et el, 
2012a; Ludtmann et al, 2013; Heiss et al, 2013). This pathway is especially 
important in high glucose environments, which is also associated with increased 
levels of oxidative stress and the tumour microenvironment, where the production of 
nucleotides and reducing equivalents fuels anabolic tumour growth (Hajnoczky et al, 
2015; Mitsuishi et al, 2012). The key rate-limiting enzymes in this process are 
glucose-6-phosphate dehydrogenase (G6PD), 6-phosphogluconate dehydrogenase 
(PGD), transketolase (TKT), malic enzyme-1 (ME-1) and isocitrate dehydrogenase-1 
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(IDH-1). All of which have are ubiquitous inducible Nrf2 gene-targets (Wu et al, 
2011; Pajarez et al, 2015; Timmlappa et al, 2002).  
 
1.1.7.5. Bach1  
 
Significantly, Nrf2 nuclear translocation is not the sole determinant of ARE-driven 
gene transcription, as other factors may also limit access to the promoters of these 
target genes.  For example, the availability of ARE binding sites may be restricted by 
the Bach1 protein, which like Nrf2, also belongs to the bZIP family of transcription 
factors and dimerises with sMaf proteins to bind to cis-acting sequences (Jyrkkanen 
et al, 2011). Unlike Nrf2, Bach1 lacks the leucine zipper transactivation domain 
(TD) necessary to initiate transcription, therefore its binding has a potent inhibitory 
role in ARE gene transcription, including NQO1 and HO-1 gene expression 
(Stepkowski et al, 2011; Kanezaki et al, 2001). Bach1 is also sensitive to increased 
levels of free radical species, which modulate oxidation of its reactive cysteine 
residues, thus promoting its nuclear export. Significantly, this process can also be 
triggered by the accumulation of free intracellular heme, thereby allowing Nrf2 to 
bind to previously occupied promoter ARE sequences. Interestingly, Bach1 contains 
an ARE site in its own promoter region and the application of Nrf2 inducing drugs 
leads to an increase in Bach1 mRNA, subsequently leading to dampening of Nrf2 
target gene expression (Jyrkkanen et al, 2011).    
 
1.1.8.  Intracellular Sources of ROS 	  
There are multiple oxygen and nitrogen species that act as redox signalling 
molecules, including hydrogen peroxide (H2O2), superoxide (O-2), singlet oxygen 
(O), hydroxyl radical (OH-) and nitric oxide (NO) and its by-products. H2O2 can 
readily act as a second messenger and is present within tissues at low concentrations, 
where it is able to freely pass through lipid membranes. The main generator of H2O2 
within cells is the NADPH oxidase enzyme, which is the main driver of intracellular 
oxidative stress (Bindoli et al, 2013). NADPH activity is vital in the generation of 
oxidative bursts in macrophages and neutrophils and serves as a potent weapon 
against phagocytised pathogens and therefore plays important roles in mediating 
inflammatory signalling (more on NADPH oxidase in Section 1.2.6).   
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Mitochondria are also a major source of cellular oxidative stress, due to the 
production of high levels of superoxide created during mitochondrial respiration. 
However, the net balance of ROS production is though to be smaller in healthy 
mitochondria than previously though (Bindoli et al, 2013; Pajarez et al, 2015). In 
addition, a considerable amount of redox stress is also generated as a response to 
unfolded proteins in the endoplasmic reticulum (Pajarez et al, 2015). 
 
Lipids, DNA and proteins are all prone to ROS induced damage, creating a risk of 
harmful mutations and further exacerbation of oxidative stress by the accumulation 
of dysfunctional proteins (Vargas & Johnson, 2009). The biggest changes in oxygen 
radical levels occurs as a result of drastic variation in the cellular environment, as 
experienced under conditions of hyperglycaemia, inflammation and damage from 
UV and ionising radiation (Takahashi et al, 2012). 	  
1.1.9. Pharmacological Inducers and Inhibitors of Nrf2 
 
1.1.9.1. Nrf2 Activating Compounds 
 
The induction of antioxidant genes by Nrf2 ameliorates the overproduction of ROS, 
however under conditions of persistently high levels of oxidative stress, as observed 
in chronic inflammatory disorders, pharmacological induction of Nrf2 could be 
necessary to boost protective responses. There are several well-characterised, plant 
derived and synthetic compounds that effectively trigger Nrf2 gene expression. In 
general, these act via electrophilic attack on the reactive thiol groups located in 
reactive cysteines in Keap1 (Baird et al, 2014; Suzuki & Yamamoto, 2015). The first 
described inducer of Nrf2 was an isothiocyanate molecule the sulforaphane (SFN), 
isolated from broccoli and described by Paul Talay’s lab in 1992 (Zhang et al, 1992). 
SFN is present in broccoli as a precursor glucosinolate, which becomes hydrolysed 
to the biologically active form (the glucosinolate glucoraphanin by β-thioglucosidase 
enzyme) upon chewing or plant damage. SFN acts by targeting C51 within Keap1 
thus blocking Nrf2 degradation, possibly by inducing the formation of the open 
complex, which then allows newly formed Nrf2 protein to enter the nucleus (Baird et 
al, 2014; Tufekci et al, 2011). The study by Clarke et al, demonstrated that within 3h 
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of ingesting 40g of broccoli sprouts, it was possible to detect a substantial increase in 
SFN concentration, reaching 2µmol/L in the blood plasma of study subjects (Clarke 
et al, 2011). Also, Zhou et al, demonstrated that broccoli soup made from 100g 
broccoli florets (cooked 90s at 700-W) yielded blood plasma concentrations between 
3.8 to 10.7µmol/L of SFN within 1.5h of ingestion (Zhou et al, 2015; Gasper et al, 
2015). SFN has also been shown to have potent anticancer properties and has also 
demonstrated promising neuroprotective action in a mouse model of Parkinson 
disease (Morroni et al, 2013; Clarke et al, 2011).  
 
To date, the most potent Nrf2 inducer characterised  is the CDDO-Me triterpenoid 
compound derived from oleanolic acid (found in olive oil), also known as 
Bardoxolone methyl and can induce antioxidant gene expression at nM 
concentrations (Suzuki & Yamamoto, 2015; Hayes & Dinkova-Kostova, 2014). The 
CDDO-Me also targets Keap1 Cys residues and exhibits potent neuroprotective 
properties and has been shown to delay the onset of ALS in a mouse model of this 
disease, extending the life of motor neurons by reducing inflammatory signalling 
(Danilov et al, 2009). Importantly, the neuroprotective effects of CDDO-Me are 
possible as it is able to pass the blood brain barrier (BBB) (Neymotin et al, 2011). 
CDDO-Me has been previously used in the clinics for the treatment of chronic 
kidney disease, however the trial was closed following the phase II stage due to the 
occurrence of deleterious adverse drug effects. Nevertheless, several other clinical 
trails have subsequently been initiated, focusing on pulmonary hypertension and 
diabetes associated chronic kidney disease (Suzuki & Yamamoto, 2015).  
Importantly the only available effective treatment accepted recently by the FDA for 
treatment of multiple sclerosis (MS) is dimethyl fumarate (DMF). Its neuroprotective 
activity has been attributed to the activation of the Nrf2 pathway possibly by 
modulating HDAC expression, although the exact mechanism of action of this drug 
is still unknown (Suzuki & Yamamoto, 2015; Sporn et al, 2012; Kalinin et al, 2013). 
Importantly many compounds that can activate Nrf2 signalling are present in dietary 
compounds, mostly plants and many inducers have been characterised, to date these 
include: reservatrol, from grapes; curcumin, from turmeric; SFN, from broccoli, 
cabbage, kale, broccoli sprouts; wasabi; honey; cinnamon; garlic; green tea and 
many more sources (Bryan et al, 2013; Tufekci et al, 2011; Pajares et al, 2015).  
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1.1.10. Brusatol –the Nrf2 Inhibitor 
 
Induction of Nrf2 is expected to yield protective cellular responses, however there is 
also an urgent need for the development of selective inhibitors of the Nrf2 pathway, 
for the treatment of cancers that evade treatment by hijacking the antioxidant 
activity. Brusatol is a plant-derived quasinoid from Brucea javanica, which has been 
shown to rapidly deplete Nrf2 levels, by decreasing its stability possibly via poly-
ubiquitination and clearance by an unidentified mechanism (Olayanju et al, 2015; 
Ren et al, 2011). Addition of the drug leads to reduced expression of Nrf2 target 
genes including γGCS, MRP1 and MRP2, without affecting Keap1 protein levels 
(Ren et al, 2011). Significantly, Ren et al, demonstrated that 40nM brusatol leads to 
the sensitisation of cancer xenographs to cisplatin, therefore showing promise in 
cancer treatment as an adjuvant to chemotherapy (Ren et al, 2011). 
 
1.1.11. Role of Nrf2 in Cancer 
 
 The antioxidant activity of Nrf2 is though to play a very important role in disease 
prevention, as demonstrated by the phenotype of Nrf2 knockout animals, which are 
hypersensitive to toxicity, inflammation and neurodegenerative disorders (Suzuki & 
Yamamoto, 2015; Bryan et al, 2013; Vargas & Johnson, 2009). However, Nrf2 acts 
as a double edge sword conferring beneficial effects during health, although in the 
event of tumourgenesis, elevated levels of Nrf2 contribute cancer cells resistant to 
therapeutic drugs and radiation (Hayes et al, 2006). Multiple cancers have been 
found to exhibit low expression or activity of Keap1 e.g. gastric, gallbladder, breast, 
ovary and liver cancers, which are frequently associated with poor prognosis (Sporn 
et al, 2012). The loss of function has been attributed to mutations of Keap1, 
especially in Nrf2 binding domains, as well as a reduction in Keap1 expression, due 
to methylation mediated inactivation of the Keap1 promoter (Suzuki et al, 2013; 
Sporn et al, 2012; Belleza et al, 2012). Other frequently detected mutations 
associated with cancer also occur in the ETDGE and DLG binding motifs within the 
Nrf2 protein (Figure 1.1), thus rendering it insensitive to negative regulation by 
Keap1. In addition, oncogenic activation of KRas, Braf and Myc signalling pathways 
in cancers have also been linked to increased antioxidant gene expression (Sporn et 
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al, 2012). On the other hand Nrf2 KO mice were found to be susceptible to 
development of cancers and when injected with Lewis lung carcinoma these mice 
exhibited a significant increase in the number and size of tumour nodules (Suzuki & 
Yamamoto, 2015). An important consequence of high Nrf2 activity in cancers is the 
activation of a genetic program designed to detoxify and reduce oxidative stress in 
response to ionising and gamma irradiation and the increased expression of drug 
metabolising enzymes, and export pumps, which collectively confer protection 
against chemotherapy (Ren et al, 2011; Rushworth et al, 2012; Hayes & Dinkova-
Kostova, 2013). Therefore, the status of Nrf2 activation should be determined prior 
to selection of optimal treatment regimes, in order to select an optimal therapeutic 
strategy, as the inhibition of Nrf2 could sensitise the cancer to the treatment routines. 
 
1.2. The Introduction to the NF-κB Pathway  
 
1.2.1. The NF-κB Cellular Function and Regulation  	  	  
The NF-κB transcription factor mediates immune responses to bacterial and viral 
infections, as well as initiates gene expression supporting inflammation, cell 
development, proliferation, anti-apoptotic pathways, oxidative metabolism and 
protection against UV radiation (Smale et al, 2011; Mauro et al, 2011; Kaltschmidt 
et al, 2005). The NF-κB pathway is evolutionarily conserved from the ancient 
horseshoe crab Carcinoscorpius rotindicauda to humans, suggesting an 
indispensable protective role through the animal kingdom (Wang et al, 2006). The 
Nobel Prize winner David Baltimore, first proved that the DNA enhancer element of 
the immunoglobin heavy chain enhancer sequence in the B-cell lymphocytes is 
driven by the NF-κB transcription factor (Sen et al, 1986). We now know that NF-
κB is actually a family of transcription factors including RelA (p65), RelB, c-rel, p50 
(105) and p52 (p100) subunits, which act as homo- or heterodimers (Heyden & 
Ghosh, 2008). Only the p65, RelB and c-rel contain the transactivation domain 
required to drive transcription. The p50 and p52 subunits are detected basally in the 
nucleus of unstimulated cells and are thought to have an inhibitory effect on gene 
expression, by blocking DNA sequence availability (Hayden & Ghosh, 2008; Zhong 
et al, 2002). NF-κB expression is universal in cells with the exception of the RelB 
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subunit, which is selectively expressed in the thymus, lymph nodes and Peyer’s 
patches (Li & Verma, 2002).  
 
1.2.2. The Regulation of NF-кB Signalling  
 
NF-κB signalling is mediated by a complex network of protein interactions usually 
initiated by en extracellular stimuli (Hayden & Ghosh, 2008).  The NF-κB subunits 
form homo and heterodimers through their Rel homology domains (RHD), which are 
also necessary for their dimerization, DNA binding and association with the IΚBα 
inhibitor (Perkins & Gilmore, 2006; Hayden & Ghosh, 2008). The p65/p50 
heterodimer is sequestered in the cytoplasm by association with IKBα, which 
obscures one out of two NLS and limits its nuclear entry (Hayden & Ghosh, 2008; 
Mincheva-Tascheva & Soler, 2013; Li & Verma, 2002). Importantly, NF-κB gene 
transcription is inducible by variety of stress stimuli and over 150 different factors 
have been identified as activators of NF-κB mediated gene expression e.g. LPS, 
exotoxin B, muramyl peptide, viruses e.g. Hepatitis B, Adenovirus, Herpex Simplex 
Virus-1, HIV, cytokines, but also physical stress, UV radiation, shear stress, 
ischemia oxidative stress and environmental hazards (Glass et al, 2010; Pahl, 1999). 
The NF-κB homo- and hetero-dimers associate specifically with the κB regulatory 
DNA consensus sequences: 5’GGGRNYYYCC-3’ (where “N” is unspecified 
nucleotide, “R” is an unspecified purine and “Y” is a pyrimidine residue) upstream 
of NF-κB target genes, (Chen et al, 1998; Sen et al, 1986). Even though the p50 
homodimer is inhibitory on gene expression, heterodimer formation with p65 greatly 
enhances the affinity of the p50/p65 transcription factor for DNA, with binding 
affinity estimated to be approximately 10-13 to 10-10M, stronger than a majority of 
other transcription factors (Chen et al, 1998). What is more, RelB, c-Rel, p50 and 
p52 also are regulated by the κB sequence and therefore the composition and 
quantity of NF-κB heterodimers can be adjusted to the inducing stimuli (Perkins & 
Gilmore, 2006). 
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1.2.3. Gene Targets 
 
NF-κB plays a central role in the maintenance of the immune responses by initiating 
the genetic program designed to modulate the local environment and to attract the 
immune cells to the site of infection or injury.  It mediates the expression of approx. 
300 genes, including numerous cytokines and their receptors, anti-apoptotic genes 
and adhesion molecules (Pahl, 1999; Turner et al, 2010). For the purpose of this 
chapter only selected gene targets will be discussed in more detail.   
 
1.2.3.1. Inflammatory Factors 
 
Cytokines are small signalling proteins that are secreted into the extracellular space, 
mediating inter-cellular signalling in response to environmental threats and can have 
both pro-inflammatory and anti-inflammatory properties (Zhang & An, 2007). The 
pro-inflammatory cytokines are mainly secreted by activated macrophages, however, 
they have also been shown to be secreted by many other immune and non-immune 
cells and have redundant roles in inflammatory signalling (Zhang & An, 2007; Liu & 
Chan, 2014). The cytokines described below are commonly expressed in response to 
NF-κB activation, during inflammatory stress (Scheller et al, 2011).  
 
IL-8 is a pro-inflammatory chemokine that conveys signalling through the CXRC2 
receptor and plays important role in attracting neutrophils to the site of inflammation 
(Zhang & An, 2007). It is commonly secreted by immune cells such as phagocytes, 
microglia and leukocytes in response to inflammation, infection, ischemia and 
trauma. IL-8 is produced by many cell-types and its expression can be activated by 
TNFα, IL-1 and other inflammatory stimuli, such as endotoxins. Apart from its 
chemoattractant properties it can trigger the release of granzymes and initiate 
oxidative bursts by augmenting the NADPH oxidase activity in neutrophils 
(Baggiolini et al, 1992). 
 
IL-1β and TNFα are other examples of inflammatory cytokines. Predominantly 
secreted by the monocytes and macrophages, but also by many other non-immune 
cells (Zhang & An, 2007). Interleukin-1β (IL-1β) is synthesised in an inactive form 
(pro-IL-1β) and it requires further cleavage by the multi-protein inflammasome 
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complex to yield mature, functional molecules. Its action depends largely on the cell 
type, but generally it leads to activation of the NF-κB pathway, thus amplifying 
inflammatory signals and driving production of other signalling molecules, such as 
IL-1β and IL-6. High IL-1β expression has been implicated in Alzheimer’s disease 
(AD) and leads to aggravation of the disease pathology (Liu & Chan, 2014). 
 
IL-6 has a very interesting function and mechanism of activation of downstream 
signalling pathways. It acts by binding to the IL-6 receptor, which then associates 
with the glycoprotein 130 (gp130) receptor associated protein. The membrane-bound 
IL-6R is present only on a handful of cells however most cells contain the type I 
signal transducer protein gp130 protein on their surface. Interestingly the IL-6 
receptor can exist also in a soluble form, and can transduce signalling by associating 
with the gp130 present on cellular membrane, effectively leading to activation of 
downstream JAK/STAT, PI3K and ERK kinases (Scheller et al, 2011). Aside from 
its well-established pro-inflammatory roles, IL-6 also has anti-inflammatory and 
regenerative functions, which distinguishes it from other cytokines described above. 
It also acts by attracting neutrophils and monocytes into to the site of infection. It can 
also have cell specific pro- and anti-apoptotic properties designed to resolve the 
inflammatory signalling of neutrophils, which otherwise create considerable local 
damage. IL-6 is involved in the production of chemoattractant molecules designed to 
lure monocytes into the site of infection and modulate the expression of adhesion 
molecules on endothelial cells, allowing leukocyte transmigration and cell 
differentiation. IL-6 mediated signalling orchestrates the local inflammatory 
environment by directing the sequential signalling in multiple cell types (Scheller et 
al, 2011). 
 
Tumour necrosis factor (TNFα) was first described over 40 years ago as an anti-
tumourgenic factor by Carswell et al, (Carswell et al, 1975).  Low basal TNFα 
concentrations are necessary to maintain normal physiological function and it is also 
thought to have neuroprotective properties (Figiel, 2008). TNFα is one of the best-
studied cytokines and it is also a potent activator of the NF-κΒ-mediated gene 
expression, playing an important role in systemic inflammation and the induction of 
fever (Liu & Chan, 2014; Lee et al, 2014). It has pleiotropic effects as it can induce a 
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range of cellular responses such as proliferation, chemotaxis, apoptosis and 
inflammation, as its downstream signalling triggers several molecular cascades (Liu 
et al, 2014). TNFα is produced as a monotrimeric transmembrane molecule and 
becomes solubilised by the TNFα converting enzyme (TACE), which is anchored to 
the plasma membrane. This cleavage results in the formation of monomeric form of 
TNFα (mTNFα), which remain associated with the membrane and a monotrimeric 
soluble form with higher affinity for the target receptors. The TNFα binding to the 
TNFR1 and TNFR2 receptors triggers their trimerization (Figure 1.4) and 
downstream signalling relay (Figiel, 2008). 
 
There are two receptors activated by the TNFα cytokine with TNFR1 (p55) and the 
TNFR2 (p75), which share extensive homology in their ligand binding, although the 
intracellular effector domains are largely unrelated (Baker & Reddy, 1998; Declerq 
et al, 1998). Despite that, they can both induce apoptosis and the NF-κB pathway by 
activating downstream signalling. The ligand-binding domain contains a cysteine 
rich domain (CRD), which serves as an anchor for receptor trimerisation by 
disulphide bonds between the individual monomers (Baker & Reddy, 1998).  
 
1.2.4. The Canonical Cascade 
 
Pro-inflammatory cytokines such as TNFα, IL-1β activate the canonical signalling 
cascade by engaging the extracellular receptors and initiating a relay of intracellular 
phosphorylation events, which co-ordinate signalling and conditional cell responses 
(Sakurai et al, 2003). Activation of the TNFR1 receptor initiates the TRADD/RIP 
signalling cascade, which removes the phosphate group from the IKK kinases 
complex, comprised of the IKKα and IKKβ catalytic subunits and IΚKγ (NF-κB 
essential modifier, NEMO) (Figure 1.4). IKK activation results in the 
phosphorylation of IΚBα on Ser32 and Ser36 and parallel activation of several 
kinases, such as MAPK p38, JNK (Liu et al, 2014; Hayden & Ghosh, 2008; Perkins 
& Gilmore, 2006). Phosphorylation primes IΚBα for interaction with the β-
TrCP/Skp1/Cullin1 complex, which drives IΚBα ubiquitination and proteasomal 
degradation, finally releasing the NF-κB subunits to the nucleus (Winston et al,  
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1999). It should be noted that the IΚBα/p65/p50 complex is though to basally shuttle 
through the nucleus, but is persistently recovered to the cytoplasm as a result of a 
strong IΚBα NES sequence, so its degradation skews subcellular distribution 
towards the nucleoplasm (Perkins & Gilmore, 2006; Kim et al, 2013). Several post-
translational modifications are necessary to enhance NF-κB transcriptional activity 
including multiple phosphorylation events and acetylation by p300/CBP (Huang & 
Hung, 2013; Heyden & Ghosh, 2008; Zhong et al, 2002). The entire signalling 
Figure 1.4 The Canonical and Non-Canonical NF-κB Pathways. The 
canonical/classical pathway of NF-κB activation involves TNFα that triggers a 
downstream cascade of TNFR1 ubiquitination and phosphorylation events 
leading to nuclear occupancy of p65/p50 heterodimers. The non-canocial 
pathway involves downstream NIK kinase signalling and activation of CD40, 
RANK or LT-βR receptors. The net result is processing of the p100 subunit 
precursor into functional p52 protein and association with RelB binding 
partner. The RelB/p52 then translocates to the nucleus and mediates 
transcription of κB driven genes. (Adapted from Kim et al, 2013; Buelna-
Chontal & Zazueta, 2013; Kaltschmidt et al, 2005). 	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process from the TNFR1 activation to the κB transcription is very rapid, taking place 
within minutes (Perkins & Gilmore, 2006). The activation of inflammatory gene 
transcription also initiates multiple negative feedback loops, which keep the 
inflammatory signalling at bay. The IΚBα protein is one of the earliest gene targets 
of NF-κB signalling, in response to TNFα cytokine. Shortly following translation it 
localises to the nucleus and removes p65 from the DNA, and sequesters it back into 
the cytoplasm (Bergquist et al, 2009). In addition, NF-κB also transcribes the de-
ubiquitinating enzyme (DUB) A20, which terminates the signalling cascade 
upstream of the IΚK complex by modification of the receptor interacting protein 
(RIP), which is essential for TNRF1 receptor signalling (Figure 1.4). The A20 
protein removes Lys-63 chains from the RIP protein leading to Lys-48 ubiquitination 
and targeting for proteasomal degradation, leading to inactivation of the downstream 
phosphor-relay signalling (Chen & Chen, 2013; Wertz et al, 2004). Therefore, both 
IΚΒα and A20 create safety loops terminate the signalling from the inflammatory 
signalling. 
 
1.2.5. The Non-canonical Cascade  
 
Non-canonical NF-κB signalling involves distinct receptors and ligands, such as e.g. 
the CD40 and RANK receptors, which initiate distinct molecular cascades by 
activating the NF-κB inducing kinase (NIK) which phosphorylates the IΚKα dimer 
leading to the processing of p100 precursor proteins into their mature p52 subunits. 
The most commonly detected partner for p52 interaction is RelB, and the p52/RelB 
complex detects slightly altered κB sequences to those recognised by canonical 
p50/p65 transcription factor (Figure 1.4) (Perkins & Gilmore, 2006). 
 
1.2.6. NF-κB and ROS  
 
The NF-κB activation triggers transcription of Manganese Superoxide Dismutase 
(MnSOD) enzyme, which swiftly reduces TNFα-induced ROS levels. In the absence 
of NF-κB activation the TNFα stimulus generates substantial intracellular ROS, 
which further triggers prolonged c-Jun N-terminal protein kinase (JNK) activation 
and finally apoptosis (Perkins & Gilmore, 2006; Liu et al, 2014). Therefore, the 
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activation of NF-κB gene transcription is critical to cell survival during prolonged 
TNFα signalling and its absence or malfunction can dramatically decrease cellular 
viability. 
 
 
 
 
 
 
 
The NADPH oxidase is a major source of intracellular ROS. First described in 
phagocyte cells, it is now appreciated that NADPH subunits are distributed in nearly 
all tissues and play important roles in immunological defence, protein modification, 
cellular signalling and differentiation. However, high expression aggravates 
neurodegenerative and cardiovascular disorders (Bedard & Krause, 2007).  The 
NADPH oxidase has several isoforms that differ in their subunit composition, but the 
Figure 1.5 The NADPH oxidase enzyme. The Schematic representation of 
the activated NADPH oxidase enzyme showing the subunits necessary for 
the assembly of the functional enzyme. The reduction of one NADPH 
equivalent results in net production of 2 superoxide anions. (Adapted from 
Gardiner et al, 2013). 
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canonical enzyme is composed of five subunits: the p22phox, the cytochrome b558 
containing gp91phox (NOX2) and cytoplasmic part with p40phox (NCF4), p47phox 
(NCF1), p67phox (NCF2) and a small GTPase Rac (Figure 1.5) (Manea et al, 2007; 
Bedard & Krause, 2007). The p22phox subunit is expressed in response to NF-κB 
signalling and is essential for functioning of the NADPH oxidase. The complete 
enzyme coordinates the transport of electrons across the plasma membrane or within 
the plasma of intracellular vesicles, generating superoxide from reduced oxygen, 
which is rapidly converted to H2O2 at low pH (spontaneously) or cleared away by 
superoxide dismutase , or stress caused by mechanical forces (Figure 1.5). High 
NADPH oxidase activity may act as a positive feedback loop, reinforcing 
inflammatory signalling, as NF-κB transcriptional activity is redox sensitive (Manea 
et al, 2007). 
 
1.2.6.1. SOD 
 
NF-κB regulates expression of several superoxide dismutase (SOD) enzymes 
including SOD1, SOD2, MnSOD and Cu/ZnSOD (Saleh et al, 2013). The 
importance of the protective function of SOD enzymes is highlighted by the 
phenotype of the MnSOD knockout mice, which have a life span of only a few days. 
MnSOD is a redox-active metalloenzyme located within the mitochondrial 
membrane. The active MnSOD homotetramer scavenges the superoxide (e.g. created 
by the NADPH oxidase) to produce H2O2 and dioxygen by reaction presented below. 
(Sheng et al, 2014). 
 2𝑂!! + 2𝐻! !"#   𝑂! + 𝐻!𝑂! 
 
With increasing expression of the SOD family of enzymes the half-life of superoxide 
dramatically changes. The half-life of 𝑂!! at 10-9M in the environment that does not 
contain SOD proteins can reach several hours. Whereas, the same concentration of 
superoxide in the presence of 10-9M SOD is reduced extremely fast, with a half-life 
of only 175ms (Sheng et al, 2014). Therefore, NF-κB mediated gene expression 
contributes to the increase of oxidative environment by upregulating the NADPH 
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oxidase but also to the clearance of ROS by increasing the availability of the 
powerful antioxidant SOD enzymes.  
 
1.2.6.2. iNOS 
 
NF-κB regulates the expression of the inducible nitric oxide synthase (iNOS) 
enzyme, which synthesises the gaseous second messenger nitric oxide (NO) (Vannini 
et al, 2015). NO participates in multiple processes in the body and can act to 
modulate the vascular tone and participate in multiple signalling cascades. NO 
interacts with the guanylate synthase enzyme yielding the cyclic guanosine 
monophosphate (cGMP) molecule, which further activates the cGMP dependant 
kinase (PKG). This leads to a cascade of events regulating the vasodilation of blood 
vessels. Importantly, the NO allows a post-translational modification called S-
nitrosilaiton, which alters the function of numerous proteins. The NO molecules also 
commonly participate in formation of free oxidative radicals, as interaction of NO 
with oxygen species yields peroxynitrites, which can damage lipids, nucleotides and 
proteins. The effect of NO depends on its concentration, with 100nM being 
protective and a threshold above 500nM leading to cytotoxicity and induction of 
apoptosis (Vannini et al, 2015; Bindoli & Rigobello, 2013).  
 
1.2.7. The NF-κB Dynamic Behaviour  
 
The spatio-temporal organisation of cellular networks fine-tunes the output of 
multiple signalling parameters into a functional response. A notable example of 
control of cell fate by the fluctuations in transcriptional activity has been shown 
during the differentiation of neural progenitor cells (NPCs) into astrocytes, neurons 
and oligodendrocytes in the brain. The frequency and persistence of oscillations of 
the Asc1/Mash1, Hes1 and Olig2 transcription factors drive the differentiation of 
NPCs by determining the temporal expression of the target genes, which commit the 
cells to the defined differentiation path (Imayoshi et al, 2013). Analogously, 
frequency in oscillations in intracellular Ca2+ concentration determines the strength 
of the cellular responses, therefore the temporal dynamics of protein and signalling 
molecules is fundamental in control of cellular function (Turner et al, 2010). 
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Computational simulation of NF-κB dynamics in response to inflammatory stimuli 
conducted by Hoffman et al was the first study to predict oscillatory nuclear 
shuttling of the NF-κB in cells. The mathematical modelling of NF-κB activity 
suggested that the rate of synthesis and degradation of IΚBα/β and IΚBε were likely 
to determine the oscillatory nuclear dynamics of p65. This hypothesis was partially 
confirmed by evidence of the fluctuations in NF-κB binding to target DNA 
sequences measured by electrophilic mobility assay (EMSA) in the IKBε-/- mouse 
fibroblasts (Hoffmann et al, 2002).   
 
Single-cell imaging experiments performed by Nelson et al, reinforced the prediction 
introduced by Hoffman et al, providing evidence for oscillatory nuclear dynamics of 
fluorescently labelled p65 in live-cells (Nelson et al, 2004). Interestingly, this 
unusual temporal behaviour was shown to be triggered by a pro-inflammatory TNFα 
stimulus, which following the initial peak of p65 nuclear accumulation, led to 
asynchronous nuclear cytoplasmic shuttling between cells (Nelson et al, 2004). The 
fluorescently labelled p65-dsRedXP oscillations occurred every 100min for about 
20hrs in the continuous presence of TNFα (10ng/ml), whereas a 5min pulse of TNFα 
cytokine led to a synchronous single peak in SK-N-AS and HELA cells. This 
phenotype is driven by the delayed feedback loop of IΚBα gene transcription and 
with time the gradual increase in its expression dampens the temporal behaviour of 
NF-κB. The negative regulation initiated by fast IΚBα expression (30min peak) 
leads to augmented temporal oscillatory dynamics, whereas expression of the IΚBε 
subunit results in their dampening (120min peak expression) (Hoffmann et al, 2002; 
Nelson et al, 2004). IΚBα is an excellent regulator of NF-κB as it is very sensitive to 
transcriptional activation, due to the unusually high number of 6xκB repeats in the 
IKBA promoter region (the average is 2-3) (Zambrano et al, 2014). The role of the 
IKB proteins is redundant in regulation of NF-κB but the timing of their subsequent 
expression is detrimental to the frequency and the amplitude of the NF-κB nuclear 
oscillations e.g. the IΚBα-/- mice are prenatally lethal however the insertion of IΚBα 
promoter upstream of the IΚBΕ  (encoding IΚBε) rescued this phenotype (Hoffmann 
et al, 2002). 
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The NF-κB gene expression profile was monitored in response to varying durations 
of inflammatory signals by luciferase transcriptional reporter assays, demonstrating 
that a pulsatile stimulation results in a lower magnitude of induction and faster peak 
in transcription as compared to continuous application of TNFα. This suggested that 
the persistence of inflammatory stimulus greatly alters the expression pattern of 
target genes (Nelson et al, 2004). The tenacity of the NF-κB signalling is though to 
be maintained by the IΚBβ activity, which is more resistant to degradation evoked 
by the inflammatory stimuli (Li & Verma, 2002).  
 
Variations in the frequency of p65 oscillations have different effects on NF-κB target 
gene transcription, therefore the dynamic parameters of p65 cytoplasmic: nuclear 
shuttling act as a code, which enables calibration of the expression of genes 
necessary to handle the stress response (Turner et al, 2010). What is more, the 
duration of the inflammatory signalling has been shown to modulate the portfolio of 
activated gene targets, which can be divided into early, middle and late genes e.g. 
IΚBα is an early gene, whereas RANTES is an example of a late gene target (Ashall 
et al, 2002). 
 
The study by Ashall et al, demonstrated that synchronicity of NF-κB oscillations 
between cells is augmented by 5min pulsatile application of TNFα at 200min 
intervals, whereas shorter pulses (60-100min) diminished the magnitude of p65 
nuclear translocation leading to a smaller number of cells responding to the stimuli. 
This result suggested that in order to allow subsequent NF-κB translocations, the 
system needs to be reinstated, before it can again be sensitive to the cytokine 
activation (Ashall et al, 2002). The heterogeneity of NF-κB oscillatory behaviour is 
determined by the levels of the IKBε expression, which is slightly delayed in 
comparison to IKBα, and knockdown of IKBε leads to synchronised nuclear 
shuttling of fluorescently labelled p65 in live cells. Heterogeneity is an important 
inherent characteristic of cellular behaviour, which ensures robustness of the 
signalling output. It minimises the risk of augmented synchronous pro-inflammatory 
gene expression, which could lead to uncontrolled tissue inflammation. Interestingly, 
the protective character of cellular heterogeneity is demonstrated by the 
asynchronous pattern of apoptosis and cell division processes (Paszek et al, 2010).  
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1.3. The NF-κB and Nrf2 Pathways in the CNS 
 
Chronic oxidative stress has been associated with neurodegeneration and it is 
becoming increasingly recognized that a better understanding of the control of 
antioxidant and inflammatory response pathways in the CNS could improve patient 
outlook, as well as, reinforce disease prevention. The different cell-types that 
constitute the central nervous system are briefly described below, followed by a 
discussion of the role of NF-κB and Nrf2 signalling in the central nervous system in 
a cell specific context. 
 
1.3.1. Cell Types in the Nervous System 
 
1.3.1.1. Neurons 
 
Neurons are unique cells that process information by electrical or chemical 
signalling. In the CNS there are about 100 billion neurons composed of 
subpopulations of cells specializing in secreting specific neurotransmitters, such as 
glutamate, dopamine, acetylcholine, gamma-aminobutyric acid (GABA) and others, 
which convey a specific message (Liu et al, 2014). They are highly complex cells 
that form thousands of neurite processes interconnecting with other neurons and glial 
cells. The neurons have a very high oxidative metabolic rate and therefore are highly 
susceptible to generated intracellular ROS, especially as they are required to 
withstand the environmental challenges in order to remain viable for many years 
(Bell et al, 2011). Due to their highly specialized role they rely largely on functional 
support from surrounding glial cells. This is especially evident as they depend on 
astrocyte cells to secrete metabolic compounds such as lactate, which is then used by 
neuronal cells as a primarily energy source to fuel the tricarboxylic acid (TCA) cycle 
(Tsacopoulos et al, 1996).  
 
1.3.1.2. Astrocytes 
 
Astrocytes (also called astroglia) are glial cells characterized by the formation of 
multiple star-like processes. The name glia means glue in Greek, the name originated 
from the assumption that they were playing solely a structural role in the brain. 
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However, research into astrocyte physiology has intensified recently, because they 
were recognised as playing a key role in protective cellular responses, cognitive 
behaviour, inflammatory and antioxidant signalling, learning, memory and brain 
metabolism (Wang et al, 2012b). Astrocyte end-feet processes wrap around synaptic 
connections forming a “tripartite synapse” allowing them to modulate the synaptic 
activity and ensuring the appropriate synapse maintenance and protection. The 
metabolism of these cells is tightly coupled with the neuronal activity, which has 
been shown to trigger an increase in astrocyte glucose uptake and aerobic glycolysis, 
and to enhance the lactate shuttle for neuronal consumption (Tsacopoulos et al, 
1996; Zonta et al, 2002; Pellerin et al, 1994). They also play a vital role in 
maintaining the ion balance and water content and in the clearance of glutamate 
neurotransmitter to prevent its excitotoxicity (Losi et al, 2012). Importantly, 
astrocyte processes are in direct contact with the arterioles and form the BBB 
therefore they are able to take up compounds from the blood and process them for 
secretion into neurons and the extracellular fluid. The interaction of astrocytes with 
the blood vessels can dynamically regulate vascular tone, depending on brain energy 
needs, coupling its function with increased oxygen and nutrient use (Zonta et al, 
2002). Astrocytes are also an important energy source in the brain, as they are able to 
store and mobilise energy in the form of glycogen. It is thought that a single 
astrocyte cell is in contact with over 100,000 neuronal synapses and up to 600 
dendrites forming a functional syncytium, which can reach up to 80,000µm3 
(Pfreiger & Slezak, 2012). What is more they can modulate inter-astrocyte signalling 
through connexins (gap junctions), which permit diffusion of ions and propagation of 
calcium waves, synchronizing their local signalling (Stobart & Anderson, 2013). 
Astrocyte cells, together with microglia (discussed below) play central role in 
modulating the immune signalling within the CNS and respond to multiple stress 
stimuli such as cytokines extracellular protein aggregates, lipopolysaccharide (LPS), 
extracellular ATP, glutamate and chemokines.  They are also key players in 
maintaining the antioxidant protection of the brain as astrocytes secrete high quantity 
of the GSH for utilisation in neuronal cells that are unable to synthesize it and 
therefore rely exclusively on astrocyte specific production of this antioxidant (Vargas 
& Johnson, 2009). Due to the incredible multi-functionality and protective roles of 
49	  	  
astrocytes they become increasingly important as pharmacological targets to tackle a 
range of brain disorders. 
 
1.3.1.3. Microglia 
 
Microglia are the brain’s resident macrophages, modulating immune signalling 
processes and they constitute around 10% of cells in the CNS (Liu & Chan, 2014). 
They exist in the resting state when they secrete anti-inflammatory signals and 
neurotropic factors. They constantly inspect the surrounding environment and 
influence astrocyte and neuronal inflammatory signalling (Brown et al, 2010). The 
microglia abandon their resting status as a result of an injury or infection and switch 
to an activated mode, during which they secrete factors such as pro-inflammatory 
cytokines and chemokines in order to mobilize immune cells from the blood, which 
migrate to the site of injury (Hoing et al, 2012; Liu & Chan, 2014). This is especially 
relevant, as the immune cells from the circulation normally do not cross through the 
blood brain barrier, they can only enter as a result of astrocytic and microglial 
chemokine secretion and inflammatory cues (Glass et al, 2010).  The microglia are 
also able to engulf bacteria, viruses and toxic protein aggregates, which are then 
destroyed by oxidative burst within the phagosome (Lee et al, 2003). Continuous 
activation of microglia causes significant damage from ROS and is associated with 
progression of neurodegenerative disorders (Bedard & Krause, 2007). 
 
1.3.1.4. Oligodendrocytes 
 
Oligodendrocytes are also a type of glial cells that form myelin sheets protecting the 
neuronal axons from environmental stress in the brain and in the spinal cord 
(Pfreiger & Slezak, 2012). They migrate towards electrically active neuronal 
processes and insulate them and have an important regulatory role in maintaining 
appropriate neuronal physiology. They are able to control the local environment of 
axons by secreting neurotrophic factors ultimately leading to an increase in neuronal 
viability and protection against the harmful effects of inflammation. The 
oligodendrocytes are particularly sensitive to ROS damage and TNFα induced 
apoptosis, but the restoration of myelin sheets can take place from oligodendrocyte 
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precursor cells, which can further differentiate into myelin forming oligodendrocyte 
(Bradl & Lassman, 2010). 
 
1.3.2. Neuroinflammation 
 
Lipids are the most sensitive cellular components to free-radical damage and since 
the brain is a very lipid rich tissue it is very prone to oxidative stress (Vargas & 
Johnson, 2009). With aging the balance between the oxidative stress and 
inflammation changes in favour of higher ROS production and altered metabolism, 
which supports the inflammatory signalling. For example, the antioxidant activity of 
Nrf2 is though to be diminished, leading to decreased GSH content, possibly caused 
by a parallel increase in GSK-3 activity (Vargas & Johnson, 2009; Suh et al, 2004). 
It is argued that aging is not directly caused by increased ROS but by the decline in 
mitochondrial function and oxidative metabolism. A further hallmark of the aging 
brain is an increased level of lactate, which indicates alterations in the brain’s 
bioenergetics (Ross et al, 2010). What is more, microglial and astrocyte cells are the 
main drivers of inflammatory signalling, which is expected to aggravate age related 
neurodegeneration (L’Episcopo et al, 2013). With an increase of the average age of 
the population, the risk of neurodegenerative disease rises sharply and they pose 
catastrophic effects on patient’s quality of life, and a burden to the public health 
sector. Significantly, brain diseases (including neurodegeneration, psychiatric 
disorders and stroke) comprise 35% of the total disease burden in Europe, and it is 
predicted to rise further (Olesen & Leonardi, 2003). Although, the pathophysiology 
of neurodegenerative disorders varies greatly, a common denominator of 
neurodegeneration is chronic inflammation associated with the widespread presence 
of activated microglia and increased levels of cytokines in the cerebrospinal fluid 
(CSF), which can be found in amyotrophic lateral sclerosis (ALS), Parkinson’s 
disease (PD), Alzheimer’s disease (AD), multiple sclerosis (MS) and HIV-associated 
dementia patients (Cuadrado et al, 2009; Liu & Chan, 2014; Cartier et al, 2005). 
Neuroinflammation is a very complex process involving multiple cell-types, which 
initially act in favour of protection, but eventually become increasingly entangled in 
a vicious cycle of inflammation-induced damage. The Nrf2 and NF-κB transcription 
factors are functionally closely linked in prevention, amplification and resolution of 
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the inflammation, therefore understanding how they contribute to various 
inflammatory brain diseases is essential in designing better treatment strategies. 
 
1.3.3. The Role of NF-κB and Nrf2 in the CNS 
 
1.3.3.1. NF-κB  
 
The NF-κB plays multiple roles in the nervous system and has been implicated in 
learning and memory, neuronal development, neurite outgrowth, calcium 
homeostasis, metabolism, anti-apoptotic signalling and secretion of growth factors 
that support neuronal viability (Ghosh et al, 2011; Mincheva-Tascheva & Soler, 
2013; Kaldtschmidt et al, 2005; Figiel, 2008; Gutierrez & Davies, 2011). 
Importantly, as NF-κB function is cell specific, its activity is though to promote 
different cellular outcomes, depending on the cell type investigated. There are 
conflicting reports on the status of NF-κB inducible and basal activity in the neurons, 
as it is difficult to discriminate its cell-specific contribution (O’Neil & Kaltschmidt, 
1997; Memet, 2006; Meffert & Baltimore, 2005). The resting, low level NF-κB 
activity in microglia and astrocytes is essential in the maintenance of robust anti-
inflammatory signals, proliferation and cellular viability, however chronic 
inflammatory activity as a result of damage, infection or neurotransmitter 
extitotoxicity leads to a concatenation of the brain’s inflammatory status. This 
eventually results in damage to the mitochondria and to formation of protein 
aggregates, proteasomal and autophagic dysfunction and neuronal apoptosis, which 
further fuels chronic inflammation (Calkins et al, 2009; Liu & Chan, 2014). Also, 
activated microglia produce large concentrations of NO, due to increased expression 
of iNOS, contributing to further ROS production, which is additionally augmented 
by an increase in NADPH oxidase activity (Bedard & Krause, 2007). The resulting 
high oxidative environment enhances mitochondrial damage, leading to chronic 
inflammation and abnormal protein deposits in neurons (Caccamo et al, 2005; Glass 
et al, 2010, Brown et al, 2010). What is more, the production of chemotactic signals 
by microglial and astroglial cells direct the leukocyte migration across the BBB 
leading to further amplification of the inflammatory burden (Brown et al, 2010; Liu 
& Chan, 2014). However it should be noted that low levels of TNFα are protective 
and can stimulate Nrf2 gene expression, as well as MnSOD and anti-apoptotic 
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signalling (Correa et al, 2012). The NF-κB activity is detrimental in cell survival 
during inflammation and therefore the inhibition of inflammatory signalling could 
affect normal brain function. 
 
To conclude, the acute inflammatory signalling designed to defend the brain tissue 
from infection and damage, becomes compromised and hijacked during chronic 
inflammation and threatens the neuronal viability by fuelling progressive damage 
and deterioration.  
 
1.3.3.2. The Nrf2 Pathway in the Nervous System 
 
Neurons rely heavily on astrocytic protection against ROS, as they do not posses the 
ability for de novo synthesis of the GSH, which is necessary to maintain the correct 
reducing environment. The GSH is secreted to the extracellular space before being 
taken up as a cysteine precursor by the gamma-glytamyl transpeptidase (GGT). Once 
inside the neurons it can be incorporated into GSH biosynthesis for intracellular 
utilisation (Vargas & Johnson, 2009). The microarray studies on neuronal and 
astrocytic Nrf2 gene targets highlighted the differences in cell-specific Nrf2- 
mediated responses. The neuronal Nrf2 activity was shown to be important primarily 
in calcium homeostasis, ion channel and neurotransmitter receptor signalling, 
whereas the astrocytic ARE regulated genes are mainly involved in antioxidant 
responses, iron metabolism and the PPP (Lee et al, 2003a; Lee et al, 2003b). In 
addition, Nrf2 activation in response to H2O2, neuronal activity, CDDO-TFEA and 
tBHQ have been observed exclusively in astrocytes (Habas et al, 2013; Bell et al, 
2011; Gupta et al, 2012), in agreement to the observation that the wild-type 
astrocytes were shown to rescue Nrf2 knockout neurons from mitochondrial toxin I 
induced apoptosis, suggesting that glial antioxidant activity is sufficient to ensure 
protection of the neuronal cells (Lee et al, 2003b). This evidence cast doubts on the 
existence of effective Nrf2 neuronal activity and prompted a more rigorous 
investigation.  The study by Bell et al, demonstrated that the Nrf2 expression in 
mature neurons is inhibited by extensive promoter methylation, and therefore Nrf2 
activity is not present in adult neurons. The reason for neuronal Nrf2 inactivation 
emerged as the high levels of ectopic Nrf2 expression inhibits neurite outgrowth. It 
seems like mild oxidative stress favours neuronal development and hence high 
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intracellular antioxidative activity could interfere with this process (Bell et al, 2015). 
Therefore, the main antioxidant potential seems to lie within astrocytes, thus 
highlighting the need for therapeutic compounds that are able to modulate glial 
activity. This is especially relevant, as the current pharmacological compounds used 
in the treatment of neurodegenerative disorders target neuronal physiology or 
neuronal-specific receptors (Calkins et al, 2009). What is more, astrocytes can be 
accessed more readily as they form direct contacts with blood vessels. Drugs such as 
SFN, CDDO-Me can pass the BBB and shown promise in reducing brain 
inflammation (Danilov et al, 2009; Neymotin et al, 2011). Neurodegeneration is 
frequently coupled with several pathological phenotypes linked to the inhibition of 
Nrf2 activity such as: the inhibition of autophagy, which is necessary to clear away 
the harmful inclusion bodies (Hara et al, 2006), the increase in free Fe2+ which 
contributes to alpha synuclein aggregation and the amyloid formation (Gan & 
Johnson, 2014), mitochondrial dysfunction and toxicity presence of the reactive 
astrocytes and microglial cells leading to high ROS levels, increased protein 
oxidation and the proliferation of microglia (Oberheim et al, 2009; Petri et al, 2012). 
It is likely that these pathological cellular phenotypes could be diminished by the 
reestablishment of Nrf2 gene expression by pharmacological activation of the 
antioxidant protection.   
 
1.3.4. Conclusions 
 
The inflammatory signalling that underlies aging and disease progression is a very 
complex process resulting from the interplay between multiple different cell types 
and is extremely difficult to target pharmacologically. However, the accessibility of 
astrocytes and their pronounced role in the protection of the brain against 
inflammation could facilitate the treatment of neurodegenerative disorders. In order 
to effectively ameliorate the chronic inflammation it is essential to understand the 
molecular cross talk between the Nrf2 and NF-κB pathways, which is discussed in 
more detail in the next section. 
 
1.4. The Molecular Crosstalk Between NF-κB and Nrf2 
 
1.4.1. Are the Protective Roles of p65 and Nrf2 Redundant? 
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The NF-κB and Nrf2 pathways are at the core of protective cellular signalling and 
the imbalance between their activities has been linked to many inflammatory 
diseases, cancer and neurodegeneration (Ben-Neriah et al, 2011). Nrf2 induction 
normally occurs in a low oxidative stress environment, thus preventing a further 
increase in ROS levels and to restore oxidative modifications of affected proteins. 
However, at a certain threshold at which ROS levels threaten cellular viability, the 
NF-κB responses become activated (Belleza et al, 2010). The NF-κB activity is also 
redox sensitive and has been demonstrated to respond to increase in intracellular 
H2O2 leading to the induction of the MnSOD and the anti-apoptotic genes (Vannini et 
al, 2015; Sheng et al, 2014; Belleza et al, 2010). The double knockdown of p65 and 
Nrf2 in mouse hepatocytes leads to severe chronic inflammation, whereas animals 
with single deletions exhibit much milder phenotypes (Kohler et al, 2013). 
Therefore, the balance between the Nrf2 and NF-κB activation may dictate the 
cellular responses, fine-tuning gene expression to resolve stress signalling (Chia et 
al, 2010). 
 
The interplay between antioxidant and inflammatory signalling is complex and the 
consequences are currently not very well understood. Potential points of molecular 
crosstalk between Nrf2 and NF-κB are described next.  
 
1.4.2. Nrf2 Activity is Modulated by p65 
 
The NF-κB itself modulates the Nrf2 mediated gene expression and has pleiotropic 
effects on the cellular antioxidant protection. The study by Yu et al, demonstrated 
that p65 activity leads to a reduction in ARE-target gene expression by assisting in 
increase of nuclear Keap1 levels, subsequently targeting Nrf2 protein for degradation 
(Yu et al, 2011). Overexpression of the nuclear import facilitating protein 
karyopherin alpha 6 (KPNA6) leads to augmented levels of Keap1 and prompts 
decrease in NQO1 and HO-1 gene expression (Sun et al, 2011). However the exact 
mechanism of how p65 mediates this process has not been well defined.  The best 
understood mechanism of NF-κB-imposed reduction in Nrf2 transcriptional activity 
occurs by competitive binding of the p300/CBP acetyl transferase protein, as both 
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the Nrf2 and NF-κB transcription factors require acetylation for efficient assembly of 
the transcriptional apparatus on the gene target promoters (Sun et al, 2009). Nrf2 
interacts with CBP/p300 by the Neh4 and Neh5 domains, which leads to subsequent 
acetylation of the DNA binding Neh1 fragment. What is more, the p65 
phosphorylation at its Ser276 residue is a pre-requisite to acetylation by CBP/p300 
and overexpression of p65 its thought to impose preferential binding of the acetylase 
enzyme, prioritizing the expression of NF-κB target genes. Consequently, the 
depletion of p65 by siRNA has been shown to increase Nrf2 DNA binding by 
augmenting the Nrf2/CBP interaction (Liu et al, 2008). This competitive HAT 
binding can work both ways and stimulation of Nrf2 by ethyl pyruvate was shown to 
shift the CBP/p300 binding in favour of the ARE expression and decrease the in κB-
mediated genes such as iNOS (Kim et al, 2013).  
In addition, to competition for acetylation, the p65 has been reported to decrease the 
MafK acetylation by promoting HDAC3 and MafK binding, which consequently 
prevents it from forming a transcriptional dimer with Nrf2, which is required for 
antioxidant gene transcription (Liu et al, 2008). The well-characterised molecular 
crosstalk points are presented in Figure 1.6. 
However regulation of the antioxidant signalling by NF-κB is far form simple and 
unidirectional, as certain cell types demonstrate increase of Nrf2 protein levels in 
response to pro-inflammatory TNFα cytokine. The study by Rushworth et al, 
established that NRF2 gene transcription is itself regulated by NF-κB transcriptional 
activity and the promoter of NRF2 gene contains functional κB sites that enable 
inflammatory-inducted expression. Interestingly, p65 mediated Nrf2 transcription is 
an underlying cause for resistance of acute myeloid leukaemia to the proteasome 
inhibitor bortezomib, protecting the cancer cells from effective treatment (Rushworth 
et al, 2012). What is more, a study conducted in Cuadrado’s lab established that LPS 
treatment results in Nrf2 activation and the induction of gene expression is mediated 
by the small RAC1 GTPase. As a result, the increase of HO-1 expression inhibits the 
pro-inflammatory signalling and leads to the restoration of a more reducing 
environment (Cuadrado et al, 2014). 
The recent study by Zhou et al, demonstrated an interesting mode of regulation of 
Keap1 mRNA levels by the micro RNA miR-29, which blocks its translation 
process. Interestingly, the NF-κB has been shown to regulate miR-29 expression in a 
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diabetic rat model. During high glucose conditions the NF-κB activity is 
downregulated by activation of the Sirt1 deacetylase, leading subsequently to 
increased levels of Keap1 coupled with reduction in NQO1 and GCLC mRNA levels 
(Zhou et al, 2015).  
 
1.4.3. The Proteins Linking the Nrf2 and NF-кB Pathways 
 
The Keap1 E3 ligase alongside its canonical role in regulating the Nrf2 protein has 
been shown in addition to trigger IΚKβ degradation through autophagy. Keap1 acts 
by preventing the TNFα-induced IΚKβ phosphorylation, by obscuring the target 
residues on IΚKβ and augmenting its autophagy dependent degradation. 
Subsequently this leads to stabilization of IΚKα and inhibition of NF-κB signalling 
(Kim et al, 2010). As discussed in before the Nrf2 protein is degraded as a result of 
GSK-3 phosphorylation, which directs it to the Skp1/Cullin1/β-TrCP E3 ligase 
complex (Rada et al, 2011).  
The GSK-3 has also been shown to modulate the p65 DNA binding and can have 
Figure 1.6  The known regulators of the Nrf2 and NF-κB molecular 
crosstalk. The schematic representation of some of the described common 
regulatory mechanisms involved in modulation of antioxidant and the 
inflammatory signalling. (Adapted from Wardyn et al, 2015)   	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both positive and negative effect on the κB gene expression, largely dependent on 
the cell type and the environment (Park et al, 2011). It should be noted that 
degradation of IΚBα is also mediated by the β-TrCP adaptor protein, which 
highlights its dual role in potentiating NF-κB signalling and the reduction of 
antioxidant protection (Winston et al, 1999). What is more, the p62 protein aside 
from mediating the autophagosome dependent Keap1 depletion can prompt ubiquitin 
attachment on the TNFα receptor associated factor 6 (TRAF6) and augment NF-κB 
gene expression as a result of nerve growth factors (NGF) signalling (Wooten et al, 
2005). Figure 1.7 below presents the validated, common interactors of Nrf2 and p65. 
 
 
 
1.5. Summary: 
 
 
The Nrf2 and NF-κB pathways are key regulators of protective cellular 
responses against a wide range of stress stimuli. Crosstalk between these processes 
may be very complex, involving common protein partners, as well as transcriptional 
regulation. The mechanisms of molecular interplay provide fine-tuning points of 
balance between the inflammation and antioxidant signalling, ensuring effective 
genetic program is activated and assisting in remission into the resting state.  
 
 
 
 
Figure 1.7 The proteins 
linking the antioxidant and 
inflammatory pathways. Data 
processed by Amy Ponsford 
(Sanderson lab) using BioGRID 
database. The purple nodes 
represent direct protein 
interactions. Taken from 
Wardyn et al. 	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1.6. THESIS AIMS 
 
The activity of Nrf2 and NF-κB transcription factors is intrinsically linked with their 
nuclear occupancy status. Surprisingly, even though pharmacological interventions 
targeting the Nrf2 pathway are already present in the clinic, the temporal Nrf2 
behaviour has not been extensively studied and this contributes to the current lack of 
comprehensive understanding of Nrf2 regulation. Both the Nrf2 and NF-κB 
transcription factors have been implicated in the progression of inflammatory 
disorders, cancer and immune diseases however the cell type specific responses of 
those transcription factors, especially in mixed cells population have not been studied 
in detail. Lastly, the two pathways are functionally linked, however the exact 
mechanism of the interplay between the inflammatory and antioxidant gene 
expression has not been confirmed. This aim of this thesis is to generate fluorescent 
molecular tools to enable the tracking and dynamic localisation of the p65 subunit 
and Nrf2 in single cells from the mouse hippocampus and human neuroblastoma SK-
N-AS models. The highlighted areas of data paucity are then addressed by using 
cutting edge confocal microscopy techniques providing single-cell resolution of 
antioxidant and inflammatory activities, coupled with functional studies of cell 
populations. The main focus of this thesis is to investigate the cellular responses to 
acute inflammatory cytokine signalling and plant derived antioxidant compounds, in 
order to determine how these stimuli lead to the modulation of Nrf2 and NF-κB 
crosstalk and provide information about the layers of molecular interplay involved in 
maintaining the balance between them.  
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2. METHODS 
 
2.1. Generation of Fluorescent Expression Plasmids 
 
2.1.1. Gateway Recombination Cloning 
 
Gateway Recombination Cloning Technology (Invitrogen) was used according to 
manufacturer’s instructions to generate plasmids for expression of fluorescent 
proteins fusions. Gateway cloning system allows a rapid, site-specific recombination 
of gene targets into multiple expression vectors (Hartley et al, 2000). First, the 
desired gene targets were amplified using high-fidelity Hot Start KOD polymerase 
(Merck Millipore, 71086) from plasmids encoding the genes of interest or from a 
cDNA library using reaction conditions and PCR program as stated in Table 2.1. 
The gene specific primers used to amplify the inserts were contained the flanking 
attB recombination sequences allowing insertion into specific sites of Gateway 
compatible vectors (Table 2.2). The amplified PCR products of correct size were 
recombined into pDONR223 donor vectors using Gateway BP Clonase II kit 
(Invitrogen, 11789-020). Briefly, 2-3µl of the PCR amplified product (~200ng) and 
200ng of the pDONR223 plasmid were mixed with 2µl 5x BP ClonaseTM reaction 
buffer and topped up with ddH2O to 10µl, mixed and incubated overnight at 25oC 
(~16h). The following morning 0.5µl of Proteinase K was added to terminate the 
reaction and sample was further incubated at 37oC for 10min and placed on ice until 
bacterial transformation or stored at -20oC.  
 
KOD Reaction Mix [25ul] KOD PCR Cycle 
 
• Template: 10ng plasmid DNA 
template (or up to 200ng cDNA 
library) 
• 2.5µl dNTP (2mM stock) 
• 1.5µl MGSO4 (25mM stock),  
• 0.5µl KOD Polymerase (1U/µl)  
• 0.5µl Forwards primer (10µM 
stock) 
	  
1. 95oC 2min 
2. 95oC 30sec 
3. 58-65oC 1min 
4. 70oC 0.5-2min (extension speed 
5sec/1kbp) 
5. Repeat step 2 to 4, (29x) 
6. 4oC storage 	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• 0.5µl Reverse primer (10µM 
stock) 
• 2.5µl of 10x Reaction buffer 
 
Table 2.1 The KOD PCR reaction conditions and cycling parameters. 
 
 
 
Table 2.2 PCR primers used for amplification of genes of interest and 
incorporation using Gateway cloning system.  
 
 
 
 
 
 
Target Forward Primer Reverse Primer 
GFAP 
(promoter) 
ATCCAGTTTGGTTAAT 
GTCTGTAAGCTGAAGACCT
G 
TCGACTGCAGAATTCG 
GGTGCCCTGCCTCTGCGT  
 
NRF2 promoter ATCCAGTTTGGTTAATTTT
TCGGTGCTCCAGAGAAC 
 
AGC GCT AGC GTC TAG 
GCT GAG GGC GGA CGC 
TGT GGT A 
(hm)p65 gaattcacaagtttgtacaaaaaagcaggct
ggATG GAC GAT CTG TTT 
CCC CTC 
 
 
 
 
gtcgaccactttgtacaagaaagctggGT
G   TTA GGA GCT GAT CTG 
ACT C 
(with STOP) 
gtcgaccactttgtacaagaaagctggGT
G   GGA GCT GAT CTG ACT 
CAA AAG 
(w/o STOP) 
5κB ATCCAGTTTGGTTAAT CTA 
GGG GAC TTT CCG CTT G    
TCG ACT GCA GAA TTCG 
TTTACCAACAGTACCGGAA
TGC  
LaminB1 gaattcacaagtttgtacaaaaaagcaggct
ggATG  
GCGACTGCGACCCCCGTGC 
 
gtcgaccactttgtacaagaaagctggGT
G  
CATAATTGCACAGCTTCTA 
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2.1.2. Bacterial Transformation 
 
The Gateway BP reaction mixture was then transformed into an appropriate bacterial 
strain (Table 2.3). The chemically competent bacterial stocks were maintained at -
80oC as aliquots and were thawed on ice shortly before the transformation procedure. 
The appropriate amounts of reactions were added into the bacterial suspension, 
gently mixed and incubated on ice for 30min. The reaction was placed for 45sec at 
42oC water bath to heat shock bacterial cells and then placed back on ice for 2min. 
Next, 250µl of SOC media (Invitrogen) was added and sample was then placed at 
37oC into horizontal orbital shaker at 220rpm for 1h. The transformation reaction 
was plated onto appropriate solid selection media (Table 2.5 and 2.6) and cultured at 
37oC overnight to allow growth of bacterial colonies. 
 
 
 
Transformation 
Substrate 
Quantity 
Required 
Bacterial 
Strain 
Vol of 
bacterial 
suspension 
Solid media and 
the volume of the 
reaction plated 
BP reaction 
product 
2µl (40ng) Alpha-Select 
(Bioline, 
BIO-85027) 
30µl 2xTY agar, 200µl 
LR reaction 
product 
2µl 
(~20ng) 
DH5αTM 
(Invitrogen, 
18265017) 
30µl 2xTY agar, 200µl 
In-Fusion reaction 
product 
1-2ng One shot® 
Stbl3TM 
(Invitrogen, 
C7373-03) 
50µl LB agar, plated 
100µl 
Empty 
pDONR223 
vectors (no insert) 
50ng One shot 
ccdB 
SurvivalTM 
T1R E.coli 
(Invitrogen, 
#A10460 ) 
50µl 2xTY agar 
(+Spectinomycyn) 
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Fluorescent 
expression 
plasmids  
10ng DH5α or 
Stbl3 
30µl or 
50µl 
2xTY or LB agar, 
plated 50-100µl 
Table 2.3 Bacterial strains and reaction conditions used for transformation of 
target constructs. 
 
 
2.1.3. Bacterial Colony PCR (BCPCR) 
 	  
The bacteria transformed with generated clones were grown on solid selective media 
and screened for successful insertion of the desired DNA fragment by bacterial 
colony PCR (BCPCR) using BIOTAQTM Polymerase kit (Bioline, BIO-21040) 
according to manufacturer’s instructions and applying aseptic technique. The 
colonies were picked with a sterile toothpick, which was sequentially immersed in 
the PCR reaction mix and then in the 25µl of Luria-Bertani (LB) media containing 
appropriate selection antibiotic for subculture. The PCR was then run as stated in 
Table 2.4. 
 
BIOTAQ Polymerase Reaction 
[10µ l]  
BIOTAQ Polymerase PCR Cycle 
• Template: bacterial colony 
• 0.7µl Forward primer 
(10µMstock) 
• 0.7µl Reverse primer (10µM  
stock) 
• 0.25µl dNTP (25mM stock) 
• 0.4µl MgCl2 (50mM stock) 
• 1µl 10x NH4 reaction buffer  
• 0.05µl BIOTAQ polymerase 
• 6.9µl ddH2O 
 
1. 98oC for 5min 
2. 95oC 1min 
3. 55oC 1min 
4. 72oC 1-2min (30s/1kb extension 
speed) 
5. Repeat steps 2-4, (34x) 
6. 15oC to finish 
 
Table 2.4 BIOTAQ PCR reaction conditions and cycling parameters. 
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The PCR products were then combined with Orange G stain and run on 1% agarose 
gel (the concentration of agarose was adjusted to the size of expected product bands) 
containing 1:20000 SYBRsafe DNA stain (Life Technologies, #S33102) alongside 
Hyperladder 1kb (Bioline, BIO-33053), in 0.5xTBE buffer (Fisher Scientific, 
#10031223) at 110V for ~45min. The bacterial colony stocks from which band of 
correct size was amplified by PCR were propagated for further DNA amplification 
and DNA purification using PureYieldTM Plasmid Miniprep kit (Promega, A1223) 
according to manufacturers instructions. The purified DNA was then sent off for 
sequence verification.	  
 
2.1.4. Verification of Plasmid Quality 
 
The plasmid concentration of all obtained DNA stocks were verified using 
NanoDrop Lite Spectrophotometer (Thermo Fisher Scientific) at 260nm excitation. 
The ratio between the DNA and protein contaminants at 260nm to 280nm emissions 
respectively, was usually around 1.8 value indicating high plasmid purity. 
 
2.1.5. Sequencing 
 
Generated vectors containing desired inserted sequences were sequence verified 
using GATC sequencing service (GATC Biotech, Germany) using forward and 
reverse primers (designed to anneal 100bp upstream of gene insertion). The correct 
open reading frame of the insert was and aligned with known gene sequence using 
Nucleotide BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and Clustal Omega 
alignment tool online (http://www.ebi.ac.uk/Tools/msa/clustalo/). 
Sequence verified clones were then amplified from a single bacterial colony and their 
DNA purified using HiSpeed Plasmid Maxi Kit (Qjagen, 12662) according to 
manufacturer’s instructions.  
 
2.1.6. Preparation of Glycerol Stocks 
 
The stocks of sequence verified clones were stored in form of purified DNA and 
additionally as bacterial glycerol stocks made using 80µl of 80% sterile glycerol and 
200µl of appropriate bacterial suspension (aliquoted from bacteria used for DNA 
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extraction previously). These were briefly vortexed and kept at -80oC. When more 
plasmid DNA was needed the glycerol stocks were thawed on ice and streaked out 
on selective solid media to obtain single colony, which was further propagated for 
DNA purification.  
 
2.1.7. LR Reaction 
 
The Entry vectors generated as a result of BP cloning contained gene targets flanked 
with attL recombination sites that could be easily flipped into the Destination 
expression vectors containing the attR sites during LR cloning reaction. For the 
purpose of this study Gateway compatible fluorescent Destination expression 
plasmids were chosen in to visualize the distribution of the proteins of interest in live 
cells. The Entry vectors used were either conventional mammalian expression 
systems (Gateway, Invitrogen) or plasmids allowing production of lentiviral particles 
for stable gene expression as stated in Table 2.8. The construction of Gateway 
compatible lentiviral transfer fluorescent plasmid backbones was described 
previously (Bagnall et al, 2015) and the empty Entry clones were kindly gifted by 
Dr. James Bagnall (Paszek lab, University of Manchester). The LR reaction was 
performed using Gateway LR clonase II kit (Invitrogen, 11791-100) by combining 
100ng of generated pDONR223(+appropriate insert) with 100ng of appropriate 
fluorescent entry vector e.g. EGFP-Entry and 1µl of the LR clonase II mix 
(Invitrogen) and topped up with ddH2O to 5µl of the final reaction volume. The 
mixture was then briefly mixed and incubated at 25oC overnight and the next 
morning 0.5µl of Proteinase K was added and tube placed at 37oC for 10min to 
terminate the reaction and deactivate the enzymes.  Then the reaction mix was 
transformed as stated in Table 2.3 and processed as previously (Section 2.1.2) with 
BCPCR (Section 2.1.3) and insert sequencing (Section 2.1.5). The lentivirus 
compatible vectors contain LTR regions, which are highly unstable, were amplified 
in E.coli Stbl3 cells (Invitrogen), which reduce the occurrence of viral plasmid 
recombination events. 
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2.1.8. Bacterial Media 
 
Media for culture of bacterial trains for DNA plasmid cloning and purification were 
prepared using aseptic technique and prepared using components stated in Table 2.5 
and when necessary using appropriate selection antibiotic at concentration stated in 
Table 2.6. 
 
 
 
 
Media 
 
Components 
 
Purpose 
LB (liquid) 5g Tryptone 
2.5g Yeast Extract 
5g NaCl 
Top up with ddH2O up 
to 500ml 
 
Culture of bacteria transformed with viral 
transfer vectors 
2xTY (liquid) 10g Tryptone 
5g Yeast Extract 
5g NaCl 
Top up with ddH2O up 
to 500ml 
 
Culture of bacteria transformed with 
Gateway compatible vectors 
LB (solid) 5g Tryptone 
2.5g Yeast Extract 
5g NaCl 
10g Agar  
Top up with ddH2O up 
to 500ml 
 
Selection of bacteria containing viral 
transfer vectors, following appropriate 
supplementation with antibiotics 
2xTY (solid) 10g Tryptone 
5g Yeast Extract 
5g NaCl 
10g Agar 
Top up with ddH2O up 
Selection of bacteria transformed with 
Gateway compatible vectors 
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to 500ml 
 
Table 2.5 Growth media used for bacterial culture. 
 
 
 
Antibiotic (stock) Final concentration in 
media 
Spectinomycin (50mg/ml in 
ddH2O) 
50µg/ml 
Kanamycin (50mg/ml) 
 in ddH2O) 
50µg/ml 
Ampicillin (100mg/ml in 
ddH2O) 
100µg/ml 
Table 2.6 The concentration of antibiotics used in selective bacterial growth 
media. 
 
 
2.1.9. Genomic DNA Extraction  
 	  
The fluorescent protein fusions encoded in lentiviral fluorescent Entry vectors were 
driven by high expression Human Ubiquitin C (UBC) promoter. For designing 
endogenous promoter driven mouse Nrf2 protein fusions it was necessary to amplify 
the NRF2 gene promoter from the mouse genomic DNA template. The genomic 
DNA was extracted from primary cortical astrocytes cultured as described in Section 
2.4.3, using ZR-DuetTM DNA/RNA MiniPrep kit (Zymogen, D7001) according to 
manufacturers instructions. The 70% confluent monolayer of astrocytes was briefly 
washed twice with warm DPBS and lysed in 100µl DNA/RNA lysis buffer and 
preceded as described in manufacturer’s protocol with spin column purification 
steps. The genomic DNA was eluted twice using 50µl in RNAse/DNAse free water 
with yielding 20ng/µl (~2µg total) genomic DNA. 
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2.2. In-Fusion Cloning 
 
2.2.1. Insert Amplification 
 
The In-Fusion cloning technology was primarily used to insert specific promoter 
sequences into fluorescent lentiviral Entry vector backbones to report on changes in 
the transcriptional regulation of Nrf2 protein (2kb-Venus-msNrf2) or κB repeats 
(5xκb-Venus) or to label specifically astrocyte cell populations using glial fibrillary 
acidic protein (GFAP) promoter-driven fluorescent protein fusions (GFAP-Cyan, 
GFAP-LaminB1-Cyan) (see Supplementary Section Figure 8.2 for Maps).  The 
insertion of promoter sequences into the 2kB-Venus-msNrf2 and the GFAP-Cyan 
and GFAP-LaminB1-Cyan and 5xκB-Venus was performed by directional, seamless 
In-Fusion cloning technique according to the Clontech manual (Takara Bio). The 
NRF2 promoter sequence was amplified from the mouse genomic DNA (genomic 
DNA extraction described in Section 2.1.9) to create the 2kB-Venus-msNrf2. To 
amplify the GFAP promoter sequence the pDRIVE-msGFAP plasmid was purchased 
from Invivogen Europe, using custom-designed primers (primer sequences in Table 
2.1) and the NF-κB-Luc construct (Table 2.8) was used as a template to amplify the 
5xκB repeats. The insert sequences were amplified using the Clone Amp HiFi PCR 
Premix (Clontech, Cat. No. 639298)	  using	  the	  reaction	  mixture	  and	  the	  PCR	  cycle	  as	  stated	  in	  Table	  2.7	  below.	  	  	  
HiFi PCR Reaction Mix [25ml]	   HiFi PCR Cycle	  
• Template: 1ng plasmid or 
10ng murine genomic DNA 
• 12.5µl HiFi PCR Premix (Clontech) 
• F primer 0.75µl [10µM stock] 
• R primer 0.75µl [10µM stock] 
• Top up with ddH2O 	  
 
1. 98oC for 2min (denaturation) 
7. 98oC for 10sec (denaturation) 
8. 58-62oC for 15sec(annealing) 
9. 71oC for 5-30sec (extension, HiFi 
speed 1kB/5sec) 
10. Repeat step 2 to 4, (34x) 
11. 72oC 5min 12. 4oC	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Table 2.7 The HiFi PCR reaction conditions and cycling parameters. 
 
 
The amplified PCR products were analysed on an agarose gel (Section 2.1.3) and 
obtained DNA bands of correct size (2kb for NRF2 promoter, 1.6kb for the GFAP 
promoter, 120bp for 5κB repeats) were then purified directly from the PCR reaction 
mixture using the Nucleospin Gel & PCR Cleanup (Macherey-Nagel, #740609.50) 
kit accordingly to the manufacturer’s protocol. The purified PCR product was then 
eluted in 30µl of DNAse free ddH2O and the obtained concentration was measured 
using the Nanodrop spectrophotometer (Section 2.1.4).  
 
2.2.2. Vector Linearization 
 
The fluorescent, lentiviral transfer Entry vectors used to insert the promoter 
sequences were first linearized at desired sites using NEB restriction enzymes PacI 
and BstBI to remove the ccdB cassette and the UBC promoter (see Figure 8.2 in the 
Supplementary). The double digest was performed on 50µg of purified plasmid using 
5µl PacI, and 8µl of the 10x Smart Cut buffer (NEB, B7204S) in total reaction 
volume of 80µl. The PacI digestion was performed for 1h at 37oC and then 5µl of 
BstBI restriction enzyme was added and the temperature of incubation increased to 
65oC for another 1h. To purify the linearized vector, the entire reaction volume was 
run on 0.8% agarose gel and the obtained restriction products were illuminated in the 
dark room using UV platform at long wavelengths settings to minimize UV-induced 
DNA mutations. The band representing the correct linearized vector template was 
then cut out from the gel using scalpel and placed into a pre-weighted Eppendorf 
tube. The DNA was extracted using Nucleospin Gel & PCR Cleanup kit and the 
concentration of purified sample was measured using NanoDrop Lite 
Spectrophotometer. 	  
2.2.3. The In-Fusion Reaction  
 
The molar ratios of insert to vector used for the In-Fusion reaction were estimated 
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using In-Fusion Molar Ratio Calculator tool online: 
http://bioinfo.clontech.com/infusion/molarRatio.do and appropriate quantities of the 
purified insert and the target vector were then combined with 2µl In-Fusion HD 
Enzyme Premix (Clontech, 638917) in a total reaction volume of 10µl. The tube with 
the reaction was placed at 50oC for 15min and then cooled on ice and used for 
bacterial transformation (Table 2.3), sequencing (Section 2.1.5) and DNA 
amplification and purification using Maxi/MiniPrep (Qjagen) according to the 
manufacturer’s protocol.  
 
2.3. List of Plasmids Used 
 
 
The Table 2.8 below provides a list of generated fluorescent protein expression 
plasmids using Gateway and In-Fusion cloning techniques described below. The 
maps main vector maps generated in this project are attached in the Supplementary 
Section 8.3. 
 
Plasmids Used LENTIVIRAL 
(Y/N)? 
Purpose Source/Generated By 
RFP-(ms)p65 Y Imaging Gateway cloning 
RFP-(hm)p65 Y Imaging Gateway cloning 
Venus-(ms)Nrf2 Y Imaging Gateway cloning 
2kb-
Venus(ms)Nrf2 
Y Imaging Gateway and In-Fusion 
cloning 
Cyan-(ms)Keap1 Y Imaging Gateway cloning 
5xκb-Venus Y Imaging In-Fusion cloning 
GFAP-Cyan Y Imaging In-Fusion cloning 
GFAP-LaminB1-
Cyan 
Y Imaging In-Fusion and Gateway 
cloning 
mCherry-Keap1 N Imaging Amy Ponsford/Gateway 
cloning 
p65-DsReDXP N Imaging White lab (Ashall et al, 
2002) 
Venus-Nrf2 N Imaging Dr. Karen Dunn 
(previously 
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Sanderson/White labs) 
NF-κB-Luc N Luciferase 
assay 
Stratagene (USA) 
8xARE-Luc 
(pGL4.11) 
N Luciferase 
assay 
Dr. Joanne Walsh, 
Pharmacology 
(Kratschmar et al, 2012) 
pNRF2-luciferase N Luciferase 
assay 
MacEwan’s lab 
(Rushworth et al, 2012) 
ΔκB2-luciferase N Luciferase 
assay 
MacEwan’s lab 
(Rushworth et al, 2012) 
pDendra2-Nrf2 N Protein stability 
imaging 
Gateway cloning 
pDendra2-
MARCH5 
N Protein stability 
imaging 
Dr. Robert Jenn 
pGL4.0-
Luciferase 
N Luciferase 
assay (control) 
MacEwan’s lab 
FUW-EGFP-p65 
(mouse p65 
promoter, human 
p65 gene) 
 
Y Imaging Dr. James Bagnall (Paszek 
lab) University of 
Manchester 
(Bagnall et al, 2015) 
Table 2.8 List of plasmid used for imaging and dual luciferase experiments.  	  	  
2.4. Primary Cell Culture 	  	  
2.4.1. Preparing Glass Coverslips for Neuronal Culture 
 
The immunocytochemistry of neuronal cultures required culture of cells on specially 
prepared glass coverslips. The coverslips used for primary culture were made by 
Thermo Scientific Gerhard Menzel, 16mm diameter, 0.13-0.17mm thick (Fisher 
Scientific, 12332138). They were extensively cleaned in concentrated 70% nitric 
acid (Sigma-Aldrich, 438073-500ML) in 100ml glass Duran® bottle placed 
overnight on a rocking platform. The next day the coverslips were transferred to 
ddH2O and rinsed thoroughly until the solution reached neutral pH. The coverslips 
were then placed in 70% EtOH and sonicated in a plastic sterile beaker in a sonicator 
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water bath for 15min and stored in the fridge for up to a month. Before use they were 
extensively washed individually in sterile ddH2O in a Petri dish and then placed in a 
second Petri dish to air dry, ready for coating with a Poly-D-lysine (PDL) substrate. 
The coating was performed using sterile 0.1mg/ml PDL (Sigma-Aldrich, P0899) in 
50mM borate buffer (Fisher Scientific, 10638294) for 1.5h at RT (or 16h in the tissue 
culture (TC) incubator), about 120µl of this solution was enough to cover the surface 
of 16mm diameter coverslip. The coverslips were then washed four times in sterile 
ddH2O and placed in 6-well plate (2 coverslips p/well) with remaining water 
aspirated from around the coverslip and covered with 120µl of plating medium 
(Table 2.11) and placed in the tissue culture (TC) incubator, ready for cell plating 
the next day. 
The 35mm dishes used for live cell imaging did not need to be cleaned with nitric 
acid, but required coating with PDL (2ml of 0.1mg/ml per dish) and washing 
afterwards as described, the same applied to 6cm dishes used for culture of cells for 
Western Blot analysis. 
 
2.4.2. Neuron-Astrocyte Cultures 
 
Mixed hippocampal astrocyte-neuron cultures were prepared from embryonic E19 to 
postnatal P1 pups from C57BL6J mice as described by Kaech & Banker, with minor 
modifications (Kaech & Banker, 2006). The hippocampi were collected under light 
microscope into ice-cold Dissection medium (Table 2.11), the procedure did not 
usually take longer than 1h. The tissue was then placed in Dissection media 
containing 0.25% Trypsin (Table 2.11) (Life Technologies, 15090046) for up to 
10min at 37oC. The trypsin was decanted and tissue was gently washed in cold 10ml 
Plating medium (Table 2.11). The hippocampi were then transferred to 3ml of cold 
Plating medium and triturated with glass Pasteur pipettes with two different bore 
sizes. The cell suspension was passed through 100µm nylon mesh (Fisher Scientific, 
11517532) to remove any cells clumps. The cell viability was assessed by trypan 
blue staining by mixing cell suspension with 0.4% (w/v) trypan blue dye (in PBS) at 
1:1 ratio (cells to 0.4% trypan blue). Only cells that did not take up the dye were 
counted and the suspension was plated onto previously prepared glass or plastic 
surfaces. For imaging purposes the isolated cells were plated at 0.35-0.45x106 cell 
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p/ml in 35mm CELLviewTM imaging dish (Greiner Bio-One, 627870 or 627860), or 
120 µl (250,000 c/ml density) directly onto 16mm glass coverslip. 
The cells were then allowed to attach in Plating medium containing serum (Table 
2.11) for 16-24h to encourage some astrocyte growth. All media was always pre-
equilibrated in the TC incubator to contain the right amount of CO2 and the 
temperature before it was applied to primary cells. The next day the Plating media 
was changed to Neurobasal media (Table 2.11) and the cultures were fed every 4-5 
days by changing half of the media following next two weeks of culture and then fed 
once a week with 30% media change. The imaging experiments were performed on 
mature neurons around 14th-17th day in vitro (DIV14-17). 
For neuronal cultures with smaller astrocyte numbers, the cultures were prepared 
from earlier E16 embryos and the plating step with serum was shortened to only two 
hours. 
 
2.4.3. Culture of Primary Astrocytes  
 
To obtain enriched hippocampal and cortical astrocyte cultures it was important to 
appropriately coat all the plastic or glass surfaces in advance of the dissection or 
passaging procedures. The coating was performed using sterile filtered PDL stock at 
0.1mg/ml as described in Section 2.4.1. 
Hippocampal and cortical astrocyte cultures were obtained from C57BL6J mice or 
Nrf2-/- knockout mice at postnatal day 1-2 (P1-P2) using hippocampi or cortices as 
previously described by Kaech & Banker with some modifications. The Nrf2 
knockout mice were kindly provided by Dr. Kitteringham’s group in the 
Pharmacology Department (University of Liverpool); being previously generated by 
M. Yamamoto (Itoh et al, 1997). The dissection procedure was performed as 
described previously (Section 2.4.2). Following the digestion of isolated tissue 
samples in Dissection media, the tissue was placed in cold Astrofood media (Table 
2.11) and gently rinsed by inverting the tube several times to inactivate trypsin 
activity. To obtain single cell suspension the tissue was further triturated 15 times 
using flame polished glass Pasteur pipettes and passed through 100µm nylon mesh 
tissue strainer. The cell suspension was then spun down at 1500rpm for 5min and re-
suspended in cold 5ml Astrofood media and viable cells were counted using trypan 
blue staining and plated onto PDL-coated T75 flask immersed with 20ml Astrofood. 
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The next day, media was exchanged following vigorous tapping of the flask to 
remove any adherent microglial cells that usually grow on top of astrocytes and fed 
every 3-4 days by changing the media completely, every-time following vigorous 
shaking. The flask was usually fully confluent within 7-9 days. 
Astrocyte culture was passaged after the cell monolayer reached about 80% 
confluence, up to two times for subculture for experiments. For passaging, the 
astrocytes were washed twice with pre-warmed DBPS (w/o Ca2+ and Mg2+) and then 
the flask was filled with 10ml 0.05% Trypsin-EDTA (Invitrogen, 25300054) and 8ml 
was rapidly removed and the flask placed for ~5min to the TC incubator. When the 
cells rounded up as a result of trypsin activity, they were removed using cell scraper 
(Greiner Bio-One). The astrocytes attached firmly to coated surfaces and scraping 
dramatically increased the cell yield after passaging. The astrocytes were seeded 
usually at 0.5x106 p/6cm dish for western blotting or directly onto glass surface of 
35mm imaging dish at 0.12x106 cells. 
 
2.4.4. Viability Assay 
 
To assess the toxicity of drug treatments on primary and cancer cell lines the cellular 
viability was measured using CellTiter-Glo (Promega) ATP based assay according to 
manufacturer’s instructions. The cells were plated onto 96-well tissue culture treated 
white walled plate (Table 2.12) and cultured for at least a day before treatment with 
pharmacological compounds. Following desired incubation time the plate was 
equilibrated at RT for 30min and 120µl of CellTiter-Glo Buffer (1: 1 (v/v) reagent to 
cell media ratio) was added to each well using multichannel pipette and the sealed 
plate was shaken vigorously in an orbital shaker for 2min. The luminescence 
readings were then taken using GloMax-Multi Detection System (Promega) at RT 
and results were compared to untreated and positive control samples (0.1% Triton-X 
treated cells). 
 
2.4.5. Transfection of Primary Cells 
 
The primary astrocyte cells were transfected for live-cell imaging or for dual 
luciferase assays using purified plasmid stocks. For live cell imaging experiments the 
cells were seeded at 0.1x106 cells p/35mm imaging dish and transfected when they 
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reached 60% confluence. The Astrofood media was changed to serum free Astrofood 
about 1h before the transfection, as serum was found to inhibit effective transfection 
in primary astrocytes (personal observations). The transfection was performed by 
placing desired amount of Lipofectamine2000 according to manufacturer’s protocol 
at 1µl of reagent per 1µg of plasmid DNA into tube containing Opti-MEM medium 
(Invitrogen, 11058021) for 5min, then the required plasmid DNA was added and 
incubated for further 15min at RT. The transfection reaction was then dropped onto 
cells and incubated for 2h, and following the incubation period the media was 
changed back to full Astrofood and incubated for another 24h. 
 
Plasmid Purpose Concentration 
mCherry-msNrf2 Live cell imaging 2µg/ml 
mCherry-UBE2D2 Live cell imaging 2µg/ml 
RFP-p65 (mouse variant) Live cell imaging 2µg/35mm dish 
EGFP-p65 (mouse 
variant) 
Live cell imaging 2µg/35mm dish 
pGL4.11 ARE-Luc/NF-
κB-Luc 
Dual luciferase 0.5µg/well (24well 
format) 
SV40-Renilla Dual luciferase 0.025µg/well (24well 
format) 
Fluorescent fusion 
proteins 
Dual luciferase 0.5µg/well (24well 
format) 
Table 2.9 The quantity of plasmids used for imaging and dual luciferase studies 
on primary cells. 
 
 
2.4.6. Dual Luciferase Assay 	  	  
The Dual-Luciferase Reporter assay (Promega, E1960) was used to monitor the 
transcriptional activity of selected gene sequences driving the expression of firefly 
luciferase following pharmacological treatments or transient expressions of plasmid 
encoding proteins, in accordance to the manufacturer’s instructions. 
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The luciferase-based reporter plasmid expressing Firefly luciferase and Renilla 
luciferase (SV40-Renilla) transfection control were transfected as stated in Table 2.9. 
Following 24h and after desired drug incubation time the cells were processed for 
dual luciferase assays. The cells were gently washed twice using warm DPBS and 
then lysed in 100µl of 1x passive lysis buffer (PLB) and mixed at RT for 15min. The 
collected cell lysates were placed in Eppendorf tubes and spun down at 12,000rpm 
for 1min at RT. The supernatant was then transferred to a 96-well plate, sealed and 
frozen at -20oC for up to a week. Before, the luciferase assay, the Luciferase Assay 
Reagent II (LARII) and Stop & Glo (S&G) reagents were defrosted in the dark until 
they reached RT (for ~1,5h) and appropriate amounts were transferred to 15ml 
Falcon tubes to be used in the assay. The cell lysates were also equilibrated at RT 
and 20µl was transferred to 96-well white plate for luminescence reading. The assay 
was performed in GloMax machine following cleaning of the inlet tubing that was 
used for dispensing the LARII and the S&G reagents. The 100µl of reagents was 
added p/well and the reading taken following 10s of reagent addition.  
 
2.4.6.1. Dual Luciferase Data Analysis 	  
 
The Luciferase luminescence signal was normalized to Renilla luminescence 
readings (from the same sample) and the average ratio from the technical triplicate 
measurements was then obtained, the fold change was calculated by comparing each 
sample to the untreated control. The mean values were then plotted using GraphPad 
Prizm 5 with error bars representing the standard deviation of the mean and 
compared using student t-test (for comparison of two means) or One-Way Anova 
with Tukey’s post-hoc analysis (for comparison three and more means). The 
statistical significance of the P-values were denoted as follows: 0.01-0.05=*; 0.01-
0.001=**, 0.001-0.0001=*** and P value< 0.0001=****. 
  
2.5. Immunocytochemistry 
 	  
The primary neuron-astrocyte or pure neuronal cultures were grown on glass 
coverslips in a 12-well or 6-well plates as described before (Section 2.4.1, 2.4.2). To 
visualize the cell-specific markers or the localisation of proteins of interest the 
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primary cells were immunostained following at least 14 days in vitro (DIV). The 
cells were gently washed twice in warm PBS (with Ca2+ and Mg2+) and then fixed 
using the paraformaldehyde fixing solution (4% fresh paraformaldehyde, 3% sucrose 
in PBS) for 10min. Cells were briefly washed 2x with PBS and permeabilised using 
0.15% Triton-X in PBS for 15min and the permeabilising solution was replaced with 
fresh PBS and washed three times and incubated in serum from the host of the 
secondary antibody to minimize the non-specific staining. The 5% goat serum was 
used (GIBCO) in PBS for 30-60min to block the non-specific interactions and then 
the primary antibody of choice was applied (Table 2.10) in 5% goat serum/PBS for 
1h at room temperature (RT) or overnight at 4oC in a humidified box. This was 
usually performed on coverslips placed on a parafilm in a sealed box with the 
antibody solution placed directly on top of cells (usually 80µl of diluted antibody is 
enough to cover 16mm diameter coverslip) in a humidified atmosphere.  The primary 
antibody was then washed away by placing the coverslips back into the 12-well plate 
and replacing the PBS solution three times. The fluorescence-labelled secondary 
antibodies (Table 2.7) (Jackson ImmunoResearch) were used to visualize the 
primary antibody staining at 1:1000 concentration in 5% goat serum in PBS, in the 
dark for 45min at RT. Following the incubation, the coverslips were gently washed 
with fresh PBS three times and then briefly dipped into the ddH2O and left to dry in 
the dark for about 20min. The coverslips were then mounted in ProLong Gold 
Antifade with DAPI (Invitrogen, P36931) on glass slides and left to set in the dark 
overnight at RT and then placed in a storage box at 4oC until the imaging (usually 
within a week). 
  
 
Antibody 
 
Species/Company 
 
Dilution 
 
Purpose 
CD11b Rat, AbCam Ab7260, Pn 
 
1:300 Microglial marker 
GFAP Rabbit , AbCam Ab8878, Pn    1:300 Astrocyte marker 
β Tubulin III Mouse, Promega G7121, Mn 1:1000 Neuronal marker 
α Tubulin Mouse, AbCam, ab7291, Mn 1:500 Visualization of tubulin 
filaments 
p65/RelA Rabbit, Santa Cruz sc-372, Pn 1:300 Visualization of p65 
PML Rabbit, Santa Cruz, sc-766, Pn 1:200 Visualization of PML 
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Secondary 
antibodies 
Anti-Goat (Jackson 
ImmunoResearch) 
1:1000 Visualisaiton of 
primary antibody 
staining 
Table 2.10 The list of antibodies and their concentrations used in 
immunocytochemistry.  
 
2.6. Production of Lentivial Particles 
 	  
The lentiviral transfer vectors containing fluorescent protein fusions were generated 
using Gateway and In-Fusion cloning approaches as described previously (Section 
2.2. & 2.1). All practices were carried out according to detailed health and safety 
rules and established standard operating procedures. The 3rd generation lentivirus 
packaging system was used with compatible transfer vector expressing the protein 
fusion of interest as described previously by Tiscornia et al, 2006; with minor 
modifications. The HEK293 cells were used for producing the lentiviral particles and 
for this purpose they were maintained in DMEM supplemented with P/S, sodium 
pyruvate, 10% FBS, GlutamaX (not older than passage 15) (Table 2.11).  The 6x106 
HEK293 cells were seeded onto 15cm dishes in the late afternoon and the next day 
(late afternoon) the cell media was exchanged 2h before the transfection (the 
confluence should be around 40-50%, but for each construct should be determined 
empirically) The transfection reaction was made up for 5x 15cm dishes (or scaled-up 
equivalently) into 50ml falcon tube in the following order: 112.5µg of fluorescent 
transfer vector (e.g. 2kb-Venus-msNrf2) and packaging plasmids 39.5µg VSVG 
plasmid, 73µg REV plasmid, and 73µg RRE plasmids dropped into 3.3ml 0.1x TE 
buffer; then added 1.75ml buffered water (50ml ddH2O with 125µl of 1M HEPES, 
pH 7.3, filter sterilised). Next, added 565µl of 2.5M CaCl2 (9.8g CaCl2*2H2O in 
25ml ddH2O, filter sterile, store -20oC) and mixed by pipetting. The 5.7ml 2xHeBS 
(Sigma) buffer was added last and the transfection reaction vortexed thoroughly, 
until fine precipitate was visible. This reaction mixture was incubated at RT for 
15min and 2.25ml dropped into HEK293 culture and gently mixed until the medium 
achieved uniform colour.  
The media was collected early the next morning and replaced with 17ml of fresh 
DMEM, discarding the old media. The first batches of lentiviral particles were 
collected at ~40h post-transfection, and then second and final collection took place 
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again after 64h post-transfection. The media containing lentivirus was spun down at 
1500rpm for 5min to remove any detached cells and additionally filtered through 
0.22µm PES filter. The lentiviral media was further concentrated using 
ultracentrifugation so that only small volumes of stocks were used during 
transduction of primary cells to avoid changes in the growth medium composition. 
The medium containing lentiviral particles was concentrated in capped, 
polycarbonate thickwall ultracentrifugation tubes (Beckman Coulter, 355618), which 
were filled with minimum 16ml of media (capacity 26.3ml). The tubes were then 
balanced, as accurately as possible (within 10mg) using fine balance and next 
centrifuged in ultracentrifuge (Beckman Coulter) in Ti50.2 fixed angle rotor at 
56,000g (25krpm) at 4oC for 2h. The ultracentrifugation resulted in assembly of the 
viral particles in form of a pellet that could be harvested and re-suspended in small 
amount of PBS. For this purpose the media was aspirated using vacuum pump and 
the pellet obtained was washed off the tubes by adding 100µl sterile DPBS and 
gently pipetting and the tubes were gently rocked in the cold room overnight. The 
next morning the concentrated virus was aliquoted (5µl aliquots) flash frozen in 
liquid nitrogen and kept at -80oC in sealed plastic bags, in cardboard storage boxes.  
Polycarbonate tubes are sensitive to UV light, EtOH, detergents and autoclaving 
therefore to sterilize them they were soaked in 10% H2O2 (Sigma-Aldrich) for 10 min 
and vortexed for 1min, and washed with plenty of sterile ddH2O water, which was 
further aspirated and the tubes and caps were left to dry in the TC hood.  
 
2.6.1. Transduction  
 
The lentiviral infection took place around 5 days before (~DIV9-10) the imaging 
experiments (~DIV14-17), as the expression of lentivirally-transferred genes peaks 
following 64h from the transduction (Tiscornia et al, 2006), additionally this timing 
allowed the cells enough recovery from infection. Before the transduction procedure, 
the cells were fed by changing 50% media (saving the condition media in the fridge), 
and at the end of the day the concentrated virus (in PBS) was gently diluted in cell 
media and added to cells. The next morning the viral and plasmid DNA was digested 
using 10U of DNAse enzyme p/1µg of transfected DNA (Calbiochem, 260913) 
added to the cell media and incubated for 30min in the TC incubator to deactivate 
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any viral particles. The media was then changed to pre-conditioned media and cells 
cultured as previously stated.  
 
2.7. Cell Culture Growth Media  
 	  
 
Media name 
 
Components 
 
Purpose 
 
Neurobasal 
(made up only 100ml at the 
time, kept up to 1month in 
the fridge) 
Neurobasal (12348017) 
2% (v/v) B27 Supplement 
(17504044) 
0.5mM Glutamax (35050-
061) 
1x P/S (15140122) 
1. Pure neuronal culture 
2. Mixed astrocyte-
neuronal culture 
Astrofood MEM (51200046) 
10% Horse Serum, heat 
inactivated (26050-088) 
Glutamax 2mM 
P/S 1% 
0.6% D-Glucose (20% stock 
in MEM stored -20oC) 
Culturing primary 
astrocytes WT and Nrf2 KO 
Plating Media Neurobasal media 
supplemented with 10% 
Horse serum 
Plating neurons 
Dissection Media EBSS (w/o Ca2+ and Mg2+) 
(14155048) 
1% P/S 
1% NaPyruvate (S8636-
100ML) 
10mM HEPES (15630056) 
Dissection of hippocampus 
and Cortex 
Trypsin Solution 
(Dissection) 
1.5ml of 2.5% Trypsin 
13.5ml of Dissection Media 
Tissue digestion for single 
cell separation 
BACNrf2-Venus/SK-N-AS 
media 
MEM 
1% P/S 
10% FBS (10270106) 
1% Glutamax (2mM) 
1% NEAA (11140035) 
Culture of SKNAS and 
BACNrf2-Venus cells 
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HEK293T Medium High glucose DMEM + 
NaPruvate, +Glutamax 
(31966047) 
10% FBS 
1% P/S 
Culture of HEK293T cells 
for lentiviral production 
Hepa1c7 Medium DMEM 
10% FBS 
1% P/S 
Culture of Hepa1c7 cells for 
testing anti-Nrf2 antibodies 
specificity 
Table 2.11 Cell culture media components used for maintenance of primary and 
immortalized cells (all components from Invitrogen). 
 
 
2.8. Cell Culture of SK-N-AS and BACNrf2-Venus Neuroblastoma Cell Lines 	  
 
BACNrf2-Venus cells were generated previously by Dr. Karen Dunn (Sanderson and 
White lab) by stable integration of bacterial artificial chromosome (BAC) encoding 
Nrf2-Venus fluorescent protein fusion into neuroblastoma SK-N-AS cells, at 2 
copies per cell. The wild-type SK-N-AS and BACNrf2-Venus were maintained in 
supplemented MEM medium (Table 2.11) in a humidified atmosphere at 37oC, 5% 
CO2 and passaged every 3-4 days when the cell monolayer reached 80-90% 
confluence. For subculture, the cells were washed twice with pre-warmed DPBS 
(w/o Ca2+ and Mg2+) and 2ml of 0.25% Trypsin-EDTA (Life Technologies, 
15090046) was added onto cells and placed to TC incubator ~2min to allow the cells 
to detach. The cells were collected by adding 8ml pre-warmed media and spun down 
for 3min at 200G. Cell media was then removed and pellet re-suspended in 10ml of 
fresh cell culture media and seeded onto desired flask/plate for further culture. The 
BACNrf2-Venus cells were used for up to 25 passages. The amounts of BACNrf2-Venus cells 
and vessels used for experiments are presented in Table 2.12, the SK-N-AS cells 
were scaled down by ~50% due to a higher growth rate.  
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Experiment 
 
Vessel 
 
Cell number 
 
Experiment 
 
Live cell imaging 
 
35mm dish with 
glass bottom 
(Greiner Bio-one) 
350,000 (for 
transfection) 
500,000 (for 
imaging the next 
day) 
 
Transfection or 
imaging following 
24h 
siRNA Live cell 
imaging 
35mm dish with 
glass bottom 
(Greiner Bio-one) 
 
200,000 
 
Transfection 
following 24h 
Immunocytochemistry 
 
12 well plates  
250,000 
Fixing 24-48h later 
Dual Luciferase 24 well plate  
140,000 
Transfection 24h 
later 
Western Blot 6 or10cm plate  
1.2-2.4x106 
Drug treatment 48h 
later 
Subculture 
 
10 or 15cm plate  
1.5-3x106 
Passaging 64h later 
Viability assay 96 well plate 90,000 Drug treatment next 
day 
Table 2.12 The BACNrf2-Venus cell seeding densities used for experiments. 
 
 
2.8.1. Transfections of Plasmids Encoding Fluorescent Fusion Proteins 
 
Transient transfections were carried to introduce fluorescent protein fusions into 
target cells using Lipofectamine 2000 (Invitrogen) according to manufacturer’s 
protocol. For transient expression of p65-DsRedXP construct of cells cultured in 
35mm dish, 0.5µg of Maxi-prepped DNA stock was used alongside 0.5µl of 
Lipofectamine 2000 for imaging the next day. 
 
2.8.2. Keap1 Gene Silencing Using siRNA 
82	  	  
 
To silence the expression of the Keap1 protein, short interfering RNA (siRNA) 
duplexes targeting human Keap1 (siKeap1) (SMARTpool ON-TARGETplus Keap2 
siRNA, Darmacon, L-012453-00-000) were transfected at 10nM final concentration  
alongside a scrambled control (siCTR) siGENOME Non-Targeting siRNA Pool no 1 
(Dharmacon, D-001206-13-05). For imaging experiments using 4-compartment 
35mm glass bottom dishes (Greiner Bio-One, 627870) two reactions were prepared 
each with 50µl Optimem, 1µl of RNAiMax Lipofectamine (Invitrogen, 13778-100) 
and then 1µl of 10µM siRNA (siCTR or siKeap1) and incubated 5min at RT. 
Dropped 25µl p/chamber (each with 500µl media, feed just before the transfection) 
and incubated for 48h before the live cell imaging experiments.	  
 
2.8.3. Cryogenic Storage of SK-N-AS and BACNrf2-Venus Cells 
 
To prepare frozen cell stocks, the cells were cultured in 15cm dishes to achieve 80-
90% confluence and collected as described before (Section 2.8). The cell pellet was 
then resuspended in 7ml SK-N-AS media containing 10% dimethyl sulfoxide 
(DMSO) (Sigma-Aldrich, D8418-50ML) and 0.7ml of cell solution was aliquoted 
(1.5x106 cells) into externally threaded cryotubes (Alpha Labs, LW3532) and frozen 
in NAGLENETM Cryo freezing container filled with 100% isopropanol and placed at 
-80oC. Following at least 16h the cryotubes were transferred to gas phase liquid 
nitrogen crystore.	  
 
2.8.4. Thawing Cell Stocks 
 
To defrost the stocks cells the cryotube with cells was placed on briefly on ice and 
then immersed into the water bath at 33oC until for 1-2min (until only small ice 
clump was visible in the tube). The cell suspension was then gently transferred into 
9ml of pre-warmed cell media and spun down at 220G for 4min. The cell pellet was 
then resuspended in fresh media and plated into 6cm dish. Following the 24h the cell 
media was then replaced with fresh media solution.  
 
 
 
83	  	  
2.9. Q-PCR 	  	  
2.9.1. Q-PCR Primer Preparation 
 
The gene specific primers used for quantitative polymerase chain reaction (Q-PCR) 
analysis were designed using Vector NTI based on the coding sequence of the gene 
targets (Table 2.13). The following primers were generated and synthesized by 
Invitrogen, and kept at stock concentration of 100µM in RNAse and DNAse free 
diethylpyrocarbonate (DEPC)-treated and UV-treated (30min) water. The efficiency 
of target amplification of each primer pair was measured by Q-PCR by plotting 
standard curve of the Ct threshold from cDNA sample serial dilutions (1:1, 1:10, 
1:100, 1:1000, 1:10000 and no-template control (NTC) and calculating the reaction 
efficiency from the slope of obtained standard curve. Only primer pairs with reaction 
efficiency of target amplification of 100% (+/-15%) were used in this study. 
 
Target/gene 
bank name 
 
F sequence (5’-3’) 
 
R sequence (5’-3’) 
Nrf2 GAGAGCCCAGTCTTCATTG
C 
TGCTCAATGTCCTGTTGC
AT 
HMOX-1 CCCACGCCTACACCCGCTA
C 
GGTGGCACTGGCAATGTT
GG 
NQO1 GGGCAAGTCCATCCCAACT
G 
GCAAGTCAGGGAAGCCT
GGA 
GCLC GTCTTCAGGTGACATTCCA
AGC 
TGTTCTTCAATGGCTCCA
GTC  
SOD-2 TGCACTGAAGTTCAATGGT
GG 
CTTCCAGCAACTCCCCTT
TG 
IL-6 TGAACTCCTTCTCCACAAG
CG 
ATCTTCTCCTGGGGGTAC
TGG 
IKBα GATCCGCCAGGTGAAGGG GCAATTTCTGGCTGGTTG
G 
IL-8 AGTGGACCACACTGCGCCA
A 
TCCACAACCCTCTGCACC
CA 
TRXDN ATGTCATGTGAGGACGGTC
GG 
GGCCCCTATCTTTCTCTGT
T 
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SFXN GATCCGGGAGGACCCAGA
CA 
CAAGGAGGCTGCTACTGC
AA 
BACH1 GGACACTCCTTGCCAAATG
CAG 
TGACCTGGTTCTGGGCTC
TCAC 
msNQO1 CGGCGAGAAGAGCCCTGA GCAGCCTCCTTCATGGCG
TA 
msHMOX-1 CACGCCAGCCACACAGCA ATATGCGTGGGCCACCAG
CA 
PML CGCCCTGGATAACGTCTTT
TT 
CTCGCACTCAAAGCACCA
GA 
KEAP1 TACGATGTGGAAACAGAG
ACGTGGA 
TCAACAGGTACAFTTCTG
GTCAATCT 
β-Actin AGGCTGTGCTATCCCTGTA
CGC 
ATGGGCACAGTGTGGGTG
AC 
Table 2.13 Primers used for Q-PCR expression measurements of selected, 
representative target genes 
 
2.9.2. mRNA Extraction  
 
The mRNA extraction was performed using RNAeasy (Qjagen) mRNA extraction 
kit. The cells (around 6x106 cells) were collected as described previously (Section 
2.8) the cell pellet was stored at -80oC overnight. The pellets were placed on ice and 
re-suspended in 350µl RLT buffer and passed through a 21G syringe around 10 
times. Next, 350µl of 70% EtOH was added (made up with RNAse and DNAse free 
water) and mixed by pipetting. The homogenate was transferred to a spin column and 
centrifuged at full speed for 30s. The column was washed with 350µl RW1 buffer 
and spun for 15sec at full speed, following this step the on-column DNAse was 
performed. The 80µl of the DNAse solution made of 10µl DNAse and 70µl RDD 
buffer (Qjagen) was dropped on top of the column and incubated for 15min at RT, 
then 350µl RW1 buffer was added and sample was centrifuged for 15sec at 
9000rpm. The columns were washed twice with 500µl buffer RPE for 1min. The 
mRNA was eluted in 15µl RNAse and DNAse free water twice for 1min at max 
speed, the yield quantified using NanoDrop spectrophotometer and stored at -20oC 
until the cDNA conversion step.  
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2.9.3. Converting mRNA into cDNA   
 
The extracted mRNA was converted into cDNA using GoScriptTM Reverse 
Transcription kit (Promega, A5000) according to manufacturer’s instructions. The 
procedure was initiated by primer annealing using (1ul) OligodT primers and 2.5µg 
of mRNA sample in reaction volume of 4µl, which was further placed at 70oC for 
5min and then cooled on ice for 10min. The mRNA-OligodT primer mixture was 
then mixed with 15µl of GoScript reaction mix (4µl GoScript 5x Reaction Buffer, 
4µl MgCl2, 1µl PCR mix Nucleotide, RNAsin 0.5µl, GoScript RT 1µl and nuclease 
free water 4.5µl) and placed in the PCR block for the following cycles: 25oC 5min, 
42oC 1h, 70oC 15min. The reaction was diluted with 40µl of RNAse free water (final 
concentration ~320ng/µl), aliquoted (~8-10µl p/tube) and stored at -20oC until the Q-
PCR analysis. 
 
2.9.4. Setting up Q-PCR Reaction 
 
The Q-PCR reaction set-up was performed in specially designated Q-PCR hood with 
all the consumables UV-treated for 30min before the experiment. Each primer pair 
had a corresponding no-template control (NTC in triplicates) to test for DNA 
contamination of reagents. The reaction was set up using 20µl Precision MasterMix 
SYBR green (Primerdesign, PrecisionBlue-iC-SY), 0.8µM forward and reverse 
target-specific primers (2µl of 2µM stock), 2µl of target sample cDNA or 2µl of 
DEPC treated water (NTC) was added and topped up to a total volume of 40µl with 
DEPC treated ddH2O. The reaction was performed in triplicated by aliquoting 10µl 
p/well of 96-well QPCR plate (BIO-RAD, HSP9645) using Bio-RAD (CFXconnect) 
realt-time PCR detection system. Cycling parameters are described in the Table 
2.14. 
 
Step Temperature 
[oC] 
Duration [s] Cycles 
Denaturation 95 120 1 
Amplification 95 15 2x39 
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(Denaturation/Annealing/ 
Extension) 
60 60  
Denaturation 95 10 1 
Annealing 65 5 1 
Denaturation 95 5 1 
Table 2.14 The Q-PCR cycling parameters. 
 
 
2.9.5. Q-PCR Data Analysis 
 
The Ct values obtained from Q-PCR experiment were analysed in Excel (Microsoft) 
using ddCT method, the data was then plotted and analysed in GraphPad Prism to 
measure the statistical significance. To compare the means of two groups of data the 
paired t-test was performed; when comparing more than two means the data One-
Way Anova analysis with Tukey’s Post-hoc test for pair-wise comparisons was used. 
The error bars were calculated using STDEV of the mean. The statistical significance 
of the P-values were denoted as follows: 0.01-0.05=*; 0.01-0.001=**, 0.001-
0.0001=*** and P value< 0.0001=****. 
 
2.10. Preparation of Whole Cell Lysates for Western Blotting Analysis 
 	  
The cells were seeded according to Table 2.12 and cultured until 90-100% 
confluence and treated with pharmacological compounds as required. The cells were 
washed twice with warm DPBS and placed on ice, then cold 100-120µl 1x RIPA 
buffer (Pierce, 8990) supplemented with 1% protease and 1% phosphatase inhibitors 
(Sigma-Aldrich) was dropped on the petri dish and cells were scraped thoroughly on 
ice using cell scraper (Greiner Bio-One).  
The cell suspension was mixed by pipetting and kept on ice for 20min, during this 
time the samples were sonicated in icy water bath in Ultrasonic bath sonicator for 
1min (to fragment the nuclear membrane and the genomic DNA) and spun down at 
4oC at 13krpm 15min, next the supernanant was transferred to a fresh, pre-cooled 
Eppendorf tube. The concentration of obtained samples was measured using the 
bicinchoninic acid (BCA) protein assay kit (Pierce, Thermo Scientific) according to 
manufacturer’s instructions. The BCA assay was performed in 96-well plate using 
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10µl of sample to 200µl of working reagent. The samples were incubated at 37oC for 
30min and then left to equilibrate at RT for around 20min. The absorbance was 
measured at 560nm wavelength using GloMax plate reader (Promega). The 
background absorbance was deduced from all readings and a standard curve of BSA 
samples of known concentrations (25mg/ml-2000mg/ml) was plotted, next the 
concentration of the sample protein lysates was calculated from the slope of the 
obtained standard curve. The protein lysates were denatured in Novex loading buffer 
(70% (v/v) of 4x Novex NuPAGE LDS Sample Buffer to 30% (v/v) NuPAGE 
Reducing Agent, (both from Invitrogen) at 1:2 buffer to sample ratio and boiled at 
95oC for 10min. Boiled lysates were then stored at -20oC until Western Blot analysis 
and spun at 13,000rpm at RT for 5min before being run on a protein gel. 
	  
2.10.1. Nuclear and Cytoplasmic Extraction 	  
 
The nuclear and cytoplasmic protein samples from cultured cells were prepared for 
Western blot analysis using NE-PERTM Nuclear and Cytoplasmic Extraction Reagent 
(Pierce, Thermo Fisher Scientific) and scaled up appropriately to the collected cell 
pellet volumes. The cell pellet of around 15µl packed volume was usually obtained 
from confluent 6cm dish of BACNrf2-Venus, was mixed with 150µl of cold buffer CERI 
(supplemented with 1% protease and 1% phosphatase inhibitor cocktail (Sigma-
Aldrich) and mixed by pipetting and vigorously for 15sec and then incubated on ice 
for 10min. Following the incubation 8.25µl of cold CERII buffer was added and 
sample vortexed for 5sec and incubated on ice for further 1min. The sample was then 
vortexed briefly once more and spun down at 4oC for 10min at max speed. The 
supernatant containing the cytoplasmic fraction was transferred to a fresh, pre-chilled 
Eppendorf tube and kept on ice until denaturation step. The pellet was then gently 
washed in ice-cold PBS to remove any cytoplasmic contaminants, with as much PBS 
as possible removed from the tube. The pellet containing the nuclear and insoluble 
protein fractions was then resuspended in 75µl of cold NER solution (with 1% 
proteases and phosphatases inhibitors) and pipetted until considerable fraction of 
pellet was dissolved. The sample was vortexed at the highest speed for 15sec and 
incubated on ice for 10min, these steps were repeated 4 times. During the incubation 
time, nuclear lysates were sonicated in icy water in Ultrasonic bath sonicator for 
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1min. Following the incubation and vortexing steps, the sample was spun down at 
16,000rpm at 4oC for 10min and the supernatant containing the nuclear fraction was 
transferred to new tube and the protein concentration quantified as described 
(Section 2.10). 
 
2.11. Western Immunoblotting  
 	  
Equal quantities (usually 40µg, or as stated) of whole cell lysates, cytoplasmic or 
nuclear fraction samples were run on 10well pre-cast NuPAGE Novex bis-tris gels 
(Invitrogen) alongside a BenchMarkTM protein pre-stained protein ladder (Invitrogen, 
10748-010). Samples were resolved in a gel tank in 1x 3-(N-morpholino) 
propanesulfonic acid (MOPS) buffer (Invitrogen) at 90V for 20min, followed by 
160V for 70min. Separated protein samples were then transferred onto a 
nitrocellulose membrane (pore size 0.45µm, Gene Flow Limited, B3-0058) for 1h at 
300mAmp. Once transfer was completed, the nitrocellulose membrane was briefly 
washed in ddH2O and stained with Ponceou S to verify equal loading. The membrane 
was then washed briefly in PBS and blocked in 8% Blotting grade milk (Bio-Rad, 
170-6404) in PBS-T (PBS with 0.1% Tween detergent (v/v), Sigma) for 1h at RT 
while gently agitating. The primary antibody (for antibodies used and dilutions see 
Table 2.15) was subsequently applied in 5% Blotting grade milk in the cold room, 
overnight. The next morning the nitrocellulose membrane was washed several times 
in PBS-Tween (PBS-T) and probed with horse radish (HRP) conjugated  (1:5000) 
(AbCam) or fluorescently conjugated secondary antibodies (1:20,000) (LI-COR) in 
5% Milk in PBS-T for 1h. Following washing in PBS-T the last wash was performed 
in PBS and the nitrocellulose membrane was imaged by X-ray film exposure 
(Section 2.11.1) (for HRP conjugated antibodies) or using infrared radiation using 
Odyssey (LI-COR Sa) imaging system (for fluorescently conjugated antibodies). 
 
2.11.1. X-Ray Film for Western Blot Detection 
 
The immunoblots probed with HRP-conjugated secondary antibodies were visualised 
using Clarity Western enhanced chemiluminescence substrate (Bio-Rad) for 
detection of HRP activity.  The nitrocellulose membrane was then exposed on 
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Amersham Hyperfilm ECL (GE Healthcarse Life Science) and developed using 
Kodak developer and fixer solutions under dark room conditions. 
 
 
Antibody target Host/Dilution Company 
Nrf2 (H-300) Rabbit/1:500 Santa Cruz (sc-13032) 
Nrf2 (Proteintech) Rabbit/1:1000 Proteintech (16396-1-AP) 
RelA/p65 Rabbit/1:1000 Santa Cruz (sc-372) 
Keap1 Rabbit/1:2000 Proteintech (10503-2-AP) 
eGFP/Venus Sheep/1:1000 from Prof. Ian Prior’s 
Laboratory 
Lamin B1 (H-90) Rabbit/1:500 Santa Cruz (20682) 
β-Tubulin Mouse/1:10,000 AbCam DM1A (ab7291) 
Table 2.15 Primary antibodies used for Western blotting.  
 
 
 
2.11.2. Cytokine Stocks 
 	  
The human recombinant IL-1β (Merck Millipore, IL038) and human and mouse 
recombinant TNFα (Merck Millipore, 654205 and GF027 respectively) stocks were 
made by dissolving 10µg of lyophilized proteins in sterile 1000ul PBS containing 
0.1% BSA (w/v) to a stock concentration of 10µg/ml and the further diluted 1:1000 
in cell media to a 10ng/ml concentration. The small aliquots were then made 10-20µl 
and stored at -80oC. 
 
2.12. Stock and Working Concentrations of Compounds Used 	  
*Viability data for the commonlu used drugs is presented in Figure 8.2 in the 
Supplementary Section. 
 
Compound Mechanism of 
Action 
Stock 
Conc. 
Workin
g Conc. 
Diluent Source 
Sulforaphane Nrf2 induction 2mM 2µM DMSO Sigma-Aldrich 
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CDDO-Me Nrf2 induction 200µM 50-
100nM 
DMSO Goldring lab 
Brusatol Nrf2 100µM 100nM DMSO Goldring lab 
CHIR99021 GSK-3 
inhibitor 
10mM 5-10µM DMSO Signal-Chem 
MG132 Proteasome 
inhibitor 
10mM 10µM DMSO Sigma-Aldrich 
Leptomycin B Nuclear export 
inhibitor 
5.55µg/ml 10ng/ml 70% 
MeOH 
Sigma-Aldrich 
SB203580 p38 MAPK 
inhibitor 
10mM 5-10µM DMSO Cell Signaling 
Technology 
 
Trichostatin A 
(TSA) 
 
HDAC 
inhibitor 
 
5mM 
 
3.3µM 
 
DMSO 
 
Sigma-Aldrich 
C646 P300 inhibitor 10mM 10 µM DMSO Selleck Chemicals 
MC1568 Class II 
HDAC 
inhibitor 
20mM 2 µM DMSO Coulson lab 
Mocetinostat Class I HDAC 
inhibitor 
20mM 1 µM DMSO Coulson lab 
 
Cycloheximide 
 
Translation 
inhibitor 
 
10mg/ml 
 
5 µg/ml 
 
DMSO 
Sigma-Aldrich 
 
CNQX Glutamate 
receptor 
blocker 
10mM 10 µM DMSO Sigma-Aldrich 
DL-APV Glutamate 
receptor 
blocker 
25mM 50µM DMSO Sigma-Aldrich 
Table 2.16 List of compounds used in this project alongside their stock and 
working concentrations.  
 
 
2.13. Live Cell Imaging 
 	  
For real-time imaging of live cells, cells were seeded onto the 1 or 4 compartment 
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35mm glass bottom dishes (Greiner Bio-One). The 4 compartments allowed imaging 
of 4 different experimental conditions in parallel. The imaging experiments were 
performed under humidified atmosphere, at 5% CO2 and 37oC on two imaging 
systems. The primary cells expressing plasmid encoded fluorescent protein fusions 
were imaged on the Zeiss Axiovert 5.10 (Zeiss Germany) confocal microscope using 
40x oil immersion objective with numerical aperture (NA) of 1.4. The image 
acquisition on this system was coupled with autofocus Marco (Ellenberg lab, 
EMBL), which enabled maintenance of stable Z-plane position of the imaged cells, 
avoiding the problems of focal drifts that can occur during the long acquisition times. 
The LSM 7.80 (Zeiss, Germany) system was used for monitoring low expression of 
fluorescent proteins, as it has superior resolution and sensitivity of detection, using 
40xoil immersion objective (1.4 NA) and LSM ZEN 2010 image acquisition 
software (Zeiss). In both systems the image acquisition was performed, using 
512x512 pixel resolution, 7 scanning speed with the pinhole diameter adjusted to the 
fluorescence intensity of imaged samples. The table below shows the filter and laser 
set up for imaging of the fluorescent proteins used in this study. The image 
acquisition of single fluorophore was performed by taking one acquisition frame at 
8min interval in 1-20 imaging locations, and the time taken to acquire image at all 
selected positions did not exceed the 8min interval. When imaging two separate 
channels (or fluorescent probes) the image acquisition was performed every 7min at 
up to 16 locations. The drug treatment was usually performed following initial three 
fames were acquired, which served as a baseline fluorescence measurement. Both 
imaging protocols were carried out at various lengths of time between 2-14h, and the 
drug of interest was added following 3 initial frames, which were taken to establish a 
signal baseline.  
 
 
Fluorophore Laser Filter Set 
TagBFP 405nm Laser diode 420-470nm 
EGFP 488nm Argon laser 490-554nm 
Venus 514nm laser 529-539nm 
AmCyan 488nm Argon laser 480-520nm 
TagRFP 561nm DPSS diode 560-610nm 
mCherry 561nm DPSS diode 570-630nm 
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dsRedXP 561nm DPSS diode 560-610nm 
pDendra2 488nm Argon laser and 
561nm DPSS diode 
490-550nm 
560-667nm 
Table 2.17 List of fluorescent protein fusions imaged throughout this project 
alongside their excitation source and filter settings for collection of the emission 
signal. 
 
 
2.13.1. Lambda Scan 
 
Lambda Scan imaging mode was used for spectral unmixing of fluorophores with 
overlapping fluorescence emission peaks. This mode was predominantly used to 
image cells exhibiting very low expression of fluorescent protein fusions such as 
BACNrf2-Venus or primary astrocytes transduced with 2kb-Venus-msNrf2. The levels of 
Venus fluorescence in those models was close to autoflourescent signal and therefore 
there was a considerable autofluorescent noise being detected. The lambda scan 
allows collecting emission of Venus fluorophore with 514nm laser and collecting the 
emission at sequentially increasing (10nm interval) band-pass width such as 522nm, 
531nm, 540nm, 548nm, 557nm, 565nm, 574nm, 583nm, 591nm and 600 using 
arsenide phosphate quasar detector. The spectral images were then combined using 
LSM ZEN 2010 software (Zeiss). 
 
2.13.2. pDendra2 Imaging 
 
The photoswitchable fluorescent protein pDendra2 was isolated from Octocoral 
Dendronephthya (Gurskaya et al, 2005).  It was previously characterized and 
optimized for imaging stability and redistribution of molecules and organelles 
(Chudakov et al, 2007). It matures completely at 37oC, its pH stable and monomeric. 
The pDendra2 emits naturally in a green light spectrum, however UV irradiation 
results in irreversible transition in emission to bright and photostable red fluorescent 
protein (RFP) spectrum (Baker et al, 2010). The pDendra2-Nrf2 fusion was 
transiently expressed in SK-N-AS cells (3µg of plasmid p/35mm dish) 24h before 
the experiment as described previously (Section 2.8.1). The following parameters 
were used during image acquisition: Line averaging 1, scanning speed: 7, zoom 1.3x, 
40x oil, 512x512 pixel resolution. To image turnover of Nrf2, four locations were 
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selected with each localisation treated with different compound (4 compartment 
dishes) and the 2 regions of interest (ROIs) were selected, each of 13x13 pixel size. 
The fluorescent signal was collected for the Green and the Red channels (Table 
2.17) and following acquisition of three imaging frames, the drug was added and one 
more frame was collected (3min interval between acquisition). Then the 
photoconversion of pDendra2 was performed either by a UV lamp at 75% power for 
45s and image taken following the irradiation and photoswitching the entire imaging 
localisation e.g. for imaging Nrf2 stability following pharmacological treatment. 
Local pDendra photoconversion was used to monitor nuclear import and export rates 
of pDendra2-Nrf2 and for this purpose the 405nm laser was used (400Hz, 100%, 
continuous wave mode) for 20x iterations, speed: 177.32µsec/pixel in the ROI1 and 
the collection of signal was measured in both the photoconverted ROI1 and the 
ROI2. The data measurements were performed using ZEN 2010 and exported and 
averaged using Microsoft Excel, the averaged data was exported to GraphPad Prism 
5. The for calculating the protein turnover half-life and the fluorescence increase 
rates the changes in red fluorescence signal was analysed using nonlinear regression 
and using One phase association to measure the rate of fluorescent signal change. 
The obtained values were –t1/2 is a measure of time it takes to achieve half maximal 
fluorescence change and therefore measure of equivalent import and export rates 
between nuclear and cytoplasmic compartments, tau (τ)- describes the time constant, 
and R2 is the fit of the obtained data to the calculated curve. 
 
2.13.3. Image Analysis 
 
Image analysis was performed using Cell Tracker software Version 6.0 
(www.dbbkgroup.org/celltracker/) (Shen et al, 2006). In order to select the 
representative cells of target cells for analysis on Cell Tracker the target cells had to 
fulfil several requirements such as: remain in the field of view, not undergo mitosis 
or apoptosis throughout the experiment, and where required, express second 
fluorescent protein fusion of interest. The nucleus was drawn manually and the 
changes in the nuclear shape adjusted on every acquired image (usually 100 per each 
location), either manually or automatically by cell tracker software. The data was 
averaged and exported as an Excel file format. It was normalized to the initial 
fluorescence levels and the noise was reduced by averaging the values using 3rd order 
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moving average (three frame smoothing). The data from cell populations was 
averaged between independent experiments and error bars were plotted using 
standard deviation of the mean. The legends of the figures contain information about 
the biological replicated “n” and the total cell numbers analysed “c”. Please note 
some representative imaging experiments are recorded as an avi. file in the enclosed 
DVD at the back of this thesis.  
 
2.13.4. Fluorescence Cross Correlation Spectroscopy (FCCS) 
 
The FCCS experiments were performed at University of Manchester with kind help 
from Dr. James Boyd (White lab). The data collection was performed using LSM 
780 with confocor 3 mounted on Axio observer Z1 microscope using oil immersion 
100x lens (N.A. 1.46) and using ZEN2010 software (Zeiss). The Venus and the 
mCherry fluorescence were excited as stated in Table 2.17. The pinhole was set to 1 
airy unit and the laser power was typically set to 1% laser power, adjusted to avoid 
photobleaching and to maximize the count per minute (cpm) fluorescent signal to 
minimum 0.5 kHz value. The data collection protocols were previously described by 
Bacia et al, 2006; and were carried out 10x for 10s each and the fluorescence signal 
of mCherry and the Venus channels was then compared using first correlation and 
then cross-correlation logarithms using LSM ZEN 2010B FCS function. The data 
was then exported to MATLAB (Mathworks) and processed by Dr. Boyd (White 
lab). 
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RESULTS CHAPTER 1:  
 
3. Construction and Characterisation of Expression 
Systems to Study Dynamic Nrf2 and NF-κB Responses in 
Primary Mouse Neurons, Astrocytes and Human SK-N-
AS Neuroblastoma Cells 
 
3.1. CHAPTER 1 AIMS: 	  
• Construction of molecular tools for live cell imaging of NF-κB and Nrf2 
protein localisation and activation 
• Characterisation of inflammatory and antioxidant responses in the 
neurons and astrocytes from the CNS 
• Characterisation of low expression model of Nrf2 in neuroblastoma SK-
N-AS cell model under basal and stimulated conditions 
 
3.2. Introduction 
 
The balance between the antioxidant and inflammatory pathways is essential for 
maintaining appropriate levels of protection against neurodegeneration. Neuronal 
cells have been at the centre of recent efforts to designing targeted therapeutic 
strategies to protect against neurodegeneration, however in recent years, the role of 
glial cells in mediating anti-oxidant defence and inflammatory responses has become 
increasingly more evident (Vargas & Johnson, 2009).  
Both the NF-κB and the Nrf2 pathways have been highlighted as potential targets for 
therapeutic intervention, however there is limited comparative information on cell-
type specific basal or induced dynamic responses due to the inherent limitations of 
traditional population level biochemical methods.   
This study was designed to facilitate a comparative cell-type specific investigation of 
signalling responses in each pathway, using near-endogenous levels of fluorescently 
tagged p65/RelA (used here as a representative of the canonical NF-κB pathway 
activity) and Nrf2 proteins and corresponding reporters of transcriptional activity in 
cultured hippocampal neurons and astrocytes, either in mixed or pure culture 
settings. There are several types of glial cells in the brain including astrocytes, 
96	  	  
microglia and oligodendrocytes (Section 1.3.1), however for this study, astrocytes 
were selected for detailed investigation since they are though to play an important 
role in mediating anti-inflammatory signalling.  
Primary cell culture models present several challenges including detailed isolation 
and maintenance protocols. Previous research in the Sanderson and White labs lead 
to the generation of an SK-N-AS neuroblastoma cell line, which stably expresses 
Nrf2-Venus from a Bacterial Artificial Chromosome (BACNrf2-Venus), however this cell 
line had not been fully validated as a model for studying Nrf2 protein dynamics. 
Therefore, the first aim of this study was to generate a suite of molecular tools to 
enable visualisation and tracking of the dynamic abundance and localisation of Nrf2 
and p65 in primary astrocytes and neurons in response to acute TNFα-mediated 
inflammatory signalling and/or pharmacological induction of Nrf2 with CDDO-Me 
and SFN. 
Secondly, the neuroblastoma BACNrf2-Venus cell line was further investigated to 
establish if the Nrf2-Venus fusion exhibits equivalent dynamic or conditional 
responses as observed for endogenous proteins. In order to confirm that this cell line 
is a suitable model for use in further live cell imaging studies.	  
 
3.3. RESULTS 
 	  
3.3.1. Characterisation of dynamic NF-κB responses in Murine Neurons and        
Astrocytes 
 
3.3.1.1. Primary Cell Culture Characterisation 
 
To investigate the dynamics distribution, abundance and transcriptional activity of 
Nrf2 and NF-κB pathways in primary neurons and astrocytes it was necessary to 
establish primary, mixed neuron-astrocytes cultures. The isolation of cells was 
carried out as described in methods (Sections 2.4.2 & 2.4.3). To validate the cellular 
composition of enriched neuronal and astrocyte cultures immunostaining was 
performed to detect cell-type specific markers. In brief, neuronal and astrocyte 
cultures were fixed following 14 days in vitro culture (14DIV) and labelled by 
indirect-immunofluorescent staining for glial (GFAP), neuronal (β-Tubulin III) and 
microglial (CD11b) markers (Figure 3.1). Enriched hippocampal neuronal cultures 
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Figure 3.1 Characterisation of neural hippocampal cultures. A) Mixed 
neuronal/astrocyte cultures were fixed after 14 days of in vitro culture (14DIV), 
prior to staining for the astrocyte marker GFAP-488 (green) and neuronal β-
tubulin III-Cy3 (red) (Methods 2.5). B) Enriched astrocyte culture showing the 
presence of a microglial cell, expressing the microglial marker CD11b-Cy3 (red). 
C) Brighfield micrograph showing phase-bright neuronal cell bodies (14DIV). 
Scale bar = 10µm. 	  
A) 
B) 
C) 
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showed characteristic positive staining with β-tubulin III, and exhibited densely 
packed neuronal connections, which were commonly wrapped around cell bodies 
(Figure 3.1A & C). Star-shaped astrocytes grown in the underlying layer showed 
strong expression of the glial marker GFAP-488 (Figure 3.1A & B). As astrocytes 
are essential for maintaining healthy synaptic connections, some low-level glial cell 
presence was allowed in neuronal cultures, in order to ensure robust neuronal growth 
and function. In these in vitro culture models, the health of neurons can easily be 
assessed by monitoring the shape and brightness of the cell body, which appears as a 
phase-bright structure, resting on top of a dense network of smooth, inter-neuronal 
connections (Figure 3.1C).  
To compare astrocytic responses to inflammatory and antioxidant signalling in the 
presence or absence of neurons. Enriched astrocyte cultures isolated from either the 
hippocampi or cortex of P1-3 pups were grown in Astrofood media (Methods, 
Section 2.4.2). Indirect immunofluorescence analysis confirmed that glial cultures 
were predominantly composed of GFAP positive astrocytes (Figure 3.1B), with the 
occasional presence of low levels of microglial cells (normally less than 1% of the 
total cell population, as assessed by visual examination). In the absence of neurons 
the shape of astrocytes was observed to be generally more uniform with fewer 
branched protrusions, as can be seen by comparing  Figure 3.1A & 3.1B.  
 
3.3.1.2. Measuring TNFα-induced NF-κB Responses in Neural Cells 	  	  
In order to define cell-specific NF-κB responses to TNFα mediated inflammatory 
stimulation, population level biochemical studies were first performed on pure 
neuronal or pure astrocyte cultures (Figure 3.2). Following treatment with murine 
recombinant TNFα (10ng/ml), lysates were prepared from hippocampal cell cultures 
at indicated time points, before being fractionated into nuclear and cytoplasmic 
fractions (Methods Section 2.10.1), which were then analysed by western blot to 
define the relative nuclear/cytoplasmic distribution of p65 (Figure 3.2A & B). 
Consistent with previous reports (Listwak et al, 2013), pure neuronal cultures did not 
exhibit nuclear translocation of p65 in response to TNFα, even after prolonged (16h) 
stimulation (Figure 3.2A). Interestingly, we observed a difference in the apparent  
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Figure 3.2  TNFα  induces nuclear translocation of p65 in astrocytes. 
Nuclear and cytoplasmic fractions were prepared from cultures of pure 
neuronal cells (A), or astrocyte-enriched cultures (B), following treatment with 
either 10ng/ml murine TNFα alone, or 10ng/ml murine TNFα in combination 
with 100nM CDDO-Me, n=1.  In each case western blots were performed to 
assess conditional changes in p65 sub-cellular distribution. TNFα induced 
nuclear accumulation of p65 (grey triangles) is clearly observed in astrocytes 
but not in neurons. 	  
A) 
B) 
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molecular weights (MW) of p65 between cytoplasmic and nuclear fractions of 
neuronal cells. While nuclear fractions of primary neurons contained a single 80kDa 
form of p65, corresponding cytoplasmic fractions also contained a higher molecular 
weight (~150kDa) form of p65. Significantly both forms of p65 fail do demonstrate 
significant responses to stimulation with TNFα or CDDO-Me.  
 
In contrast to conditional responses observed in neurons, astrocytes displayed a 
pronounced TNFα induced nuclear accumulation of the 80kDa form of p65 within 
30min. However, nuclear levels of p65 had declined by 3hrs post stimulation (Figure 
3.2B). Co-stimulation with TNFα (10ng/ml) and the antioxidant inducer CDDO-Me 
(100nM) for 16h did not inhibit TNFα induced p65 nuclear translocation of p65 as a 
result of cytokine treatment.  
 
3.3.1.3. Quantitative Analysis of Conditional NF-κB Transcriptional 
Activity in Primary Neurons, Astrocytes  
 
To measure the degree of TNFα mediated NF-κB transcriptional activation in pure 
astrocyte or neuronal cultures, a quantitative dual luciferase transcription activity 
assay was performed, using an NF-κB-Luc plasmid in which expression of firefly 
luciferase is driven by 5xκB repeats, each containing a consensus NF-κB binding 
sequence (Nelson et al, 2004) (Methods 2.4.6). Using this surrogate reporter system, 
any increase in luciferase signal compared to control indicates a general increase in 
NF-κB transcriptional activity. Consistent with data from biochemical analysis of 
p65 nuclear/cytoplasmic distribution, 10ng/ml TNFα stimulation of astrocytes 
conferred a correlated conditional increase in NF-κB transcriptional activity (Figure 
3.3A). 
 
To further confirm the lack of TNFα mediated transcriptional responses in primary 
mouse neurons, indirect immunohistochemistry was performed on enriched neuronal 
cultures to investigate conditional changes in the subcellular distribution of 
endogenous p65 (Figure 3.3B). These studies confirmed results from our 
biochemical analysis showing no detectable increase in p65 nuclear translocation in 
response to TNFα stimulation, even after prolonged stimulation. 
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Figure 3.3 Astrocytes exhibit NF-κB activation in response to TNFα. A) 
Temporal changes in NF-κB transcriptional activity were measured in primary 
murine astrocytes following stimulation with TNFα (10ng/ml) at times 
specified. Increases in NF-κΒ−Luc luciferase reporter activity reflect temporal 
trends in NF-κB transcriptional activity, n=1. B) Immunofluorescent staining 
of p65 following TNFα treatment of mixed neuron-astrocyte cultures. It is 
important to note the lack of nuclear p65 accumulation in neurons compared to 
the positive accumulation of nuclear p65 seen in astrocytes. Error 
bars=STDEV, scale bar=10µm. 	  
A) 
B) 
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Figure 3.4. Lentiviral transduction provides an efficient method for gene 
delivery into primary neurons and astrocytes. A) Diagram depicting the 
process of lentiviral particles production. B) Optimisation of transduction of 
mixed cultures with tagRFP-p65 lentivirus. Transduction of cultures at 
earlier DIV resulted in more fluorescent protein aggregates. C) Comparative 
distribution of basal EGFP-p65 fusion and endogenous p65 protein showing 
a high degree of co-localisation in all cells. Scale bar 20µm. 	  
A) B) 
C) 
103	  	  
In order to obtain a more detailed insight into the spatiotemporal dynamics of 
conditional p65 responses, a collection of molecular tools had to be developed, in 
order to correlate the dynamic behaviour of p65, expressed at near endogenous 
levels, with NF-κB transcriptional activity, in primary neuronal and astrocyte 
cultures. This was achieved by developing a collection of lentiviral expression 
vectors, which facilitate efficient delivery and low-level expression of fluorescent 
p65 fusions proteins and transcriptional reporter systems. The basic workflow of the 
lentiviral production process is shown in Figure 3.4A. In brief, the mouse p65 coding 
sequence was inserted into the gateway compatible lentiviral transfer vector allowing 
in-frame expression of p65 downstream of an N-terminal fluorescent tagRFP tag 
(Map in Supplementary Section 8.3) (Methods Section 2.1). A comparable EGFP-
p65 plasmid encoding human p65 driven by a mouse endogenous promoter sequence 
was kindly provided by Dr James Bagnall (Dr Pawel Paszek group, University of 
Manchester). The EGFP-p65 and tagRFP-p65 lentiviral systems were found to 
function identically and were therefore used interchangeably throughout imaging 
experiments in this study. Stocks of viral particles were generated by co-transfecting 
fluorescent lentiviral transfer vectors with third generation lentiviral packaging 
vectors into HEK293T cells by MgCl2 transfection (Methods Section 2.6), and the 
lentiviral particles were harvested after 64h.  
 
Optimal lentiviral transduction was found to be highly dependant on the DIV stage 
of neuronal cultures. As later stage cultures of primary cells were found to be more 
optimal for transduction (Figure 3.4B). 
Increased numbers of tagRFP-positive inclusions/aggregates were observed when 
cells were transformed at early stages of culture in vitro (Figure 3.4B).  Therefore, 
DIV9 was chosen as an optimal day for lentiviral infection (Methods 2.6.1), in order 
to minimize the presence of fluorescent aggregates and avoid infection related stress 
responses when imaging at DIV14. To determine if the subcellular distribution of 
fluorescently labelled p65 fusion proteins appropriately mirrored that of endogenous 
p65 in these cells, the relative co-localisation of fluorescent constructs and 
endogenous p65 protein was directly compared (Figure 3.4C). Significantly, these 
studies also show that the process of lentiviral transduction did not confer any NF-
κB activation at DIV14 when all subsequent studies were performed. Extensive co- 
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Figure 3.5 Lentivirally transduced tagRFP-p65 as a tool for monitoring 
p65 dynamics in primary neural cells. Mixed hippocampal cultures of 
neurons and astrocytes lentivirally transduced at DIV9 with tagRFP-p65 (red) 
virus (fixed at DIV14), show similarity with labelled endogenous p65-488 
(green) protein under basal and TNFα activated conditions, n=2. Scale bar 
10µm. 	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localisation of EGFP-p65 and p65-Cy3 (Figure 3.4C) and EGFP-p65 tagRFP-p65 
(Figure 3.5), with no nuclear p65 accumulation under basal conditions indicating that 
the infection process itself did not elicit NF-κB activation or cell death. Prior to use 
in live cell imaging studies, the tagRFP-p65 construct expressed in lentivirus-
transformed cells was also tested to confirm responsiveness to TNFα stimulation and 
co-localisation with endogenous p65 (Figure 3.5). As previously observed tagRFP-
p65 fusion protein accumulated in the nucleus of astrocytes following 30min TNFα 
stimulation, although as in previous experiments, no nuclear accumulation of 
tagRFP-p65 was observed in neuronal nuclei. 
 
3.3.1.4. Investigating Dynamic p65 Responses in Primary Mouse Neurons 
and Astrocytes 
  
To gain insight into the real-time dynamics of p65 responses to TNFα stimulation in 
mixed neuron/astrocyte or pure astrocyte cultures, primary cells were infected with 
virus encoding EGFP-p65 (Methods 2.6.1) and imaged using Zeiss 7.80 confocal 
microscope (Figure 3.6). All cultures were maintained at 37oC, under 5% CO2 in a 
humidified atmosphere during image acquisition, which took up to 14 hours 
(Methods 2.13). Temporal measurements of nuclear EGFP-p65 levels showed that 
astrocytes display clear oscillatory nuclear shuttling in response to TNFα stimulation 
as measured by the normalised nuclear fluorescence (NNF) (Data normalised as 
described in 2.13.3) (Figure 3.6B & E). Although in this study, there also seemed to 
be some increase in nuclear levels of p65 in neurons (Figure 3.6C), closer inspection 
of these images suggest that this phenotype may simply be due to gradual shape 
change in the neuronal cell body, rather than a genuine nuclear accumulation (Figure 
3.6G and Movie 1b). Interestingly, the dynamic profile of TNFα (10ng/ml) induced 
p65 oscillations was found to be dependant on whether astrocytes were cultured in 
the presence or absence of neurons (Figure 3.6A vs. 3.6D). Comparison of mean 
nuclear fluorescence levels show that pure astrocyte cultures (Figure 3.6A and Movie 
2) maintained persistently higher amplitude of nuclear p65 oscillation in response to 
cytokine application, with less damping of peak amplitude after the first peak, when 
compared to profiles obtained when astrocytes are co-cultured in the presence of 
neurons.  
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Figure 3.6 Astrocytes exhibit neuron-induced changes in EGFP-p65 
nuclear oscillations in response to TNFα. The nuclear fluorescence 
measurements were analysed in Cell Tracker by manual labelling of the 
nuclear compartment throughout the acquired imaging frames (1 frame per 
7min, Methods Section 2.1). A) Averaged and B) single-cell trends in nuclear 
EGFP-p65 levels following stimulation with 10ng/ml TNFα in pure astrocyte 
cultures, n=2, c=30 (Movie 2). C) Apparent changes in nuclear EGFP-p65 
levels in response to TNFα stimulation in neurons, n=2, c=10 (Movie 1b). D) 
Averaged and E) single-cell nuclear trend in astrocytes co-cultured with 
neurons, n=3, c=32 (Movie 1a). F) Comparison of averaged patterns of 
nuclear EGFP-p65 fluorescence in astrocytes, grown in the presence and 
absence of neurons. G) Representative time-lapse images showing EGFP-p65 
localisation in response to TNFα stimulation. NNF= Normalised Nuclear 
Fluorescence, Error bars=SEM, scale bar=10µm, n= independent experimental 
repeats, c=total cell number analysed.  	  
A) B) C) 
D) E) F) 
G) 
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Astrocytes that are co-cultured with neurons responded to TNFα with a pronounced 
initial accumulation of p65, followed by sustained low amplitude nuclear oscillations 
(Figure 3.6B, Movie 1a & 1b). 
 
However, the apparent lack of TNFα  p65 nuclear translocation in neurons, does not 
eliminate the possibility that other NF-κB family members could mediate a response 
to TNFα stimulation. To test this, hypothesis and investigate the consequences of 
p65 activation in more detail, a new fluorescent reporter of NF-κB transcriptional 
activity was developed. This reporter, which was based on the widely used NF-κB-
luc reporter plasmid also encodes the 5xκB consensus repeats upstream of a 
TATAbox element, which was designed to drive expression of a Venus fluorescent 
protein sequence (Figure 3.7A, Map in Supplementary 8.3). Therefore, using this 
reporter system, an increase in Venus fluorescence is indicative of an increase in NF-
κB transcriptional activity. The practical advantage of using this new lentiviral 
encoded reporter is the ability to investigate both tagRFP-p65 dynamics and relative 
conditional transcriptional activity in parallel in real time in primary cell cultures.  
The mean changes in the nuclear fluorescent signal of tagRFP-p65 and 5xκB driven 
Venus expression following TNFα stimulation are shown in Figure 3.7B. The Venus 
fluorescence accumulated gradually in parallel to tagRFP-p65 oscillations, indicating 
that the fluorescent reporter does respond to the cytokine induction (Figure 3.7B & 
C). The application of this powerful imaging tool definitively shows that in 
comparison to astrocytes primary mouse neuronal cells are insensitive to TNFα 
stimulation (Figure 3.7D, Movie 3a). As evidenced by the lack of p65 nuclear 
accumulation and the failure to increase by any means NF-κB transcriptional activity 
(Figure 3.7D). In contrast, astrocytes consistently responded to TNFα stimulation 
showing significant increases in 5xκB driven Venus expression, which was observed 
to gradually appear in the background of neuronal cells over time (Figure 3.7E, 
Movie 3a). 
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Figure 3.7 The new 5xκB-Venus reporter acts as a fluorescent activity 
reporter of NF-κB activity. A) Schematic representation of the 5xκB-
Venus reporter of NF-κB transcriptional activity. B) Averaged levels of 
nuclear tagRFP-p65 and 5xκB-Venus fluorescence in astrocytes grown in 
mixed cultures, following stimulation with 10ng/ml TNFα (n=2, c=6). C) 
Representative single-cell temporal trends in p65 nuclear occupancy and 
NF-κB transcriptional activity. D) Time-lapse images showing mixed 
neuron/astrocyte co-cultures transduced with tagRFP-p65 and 5xκB-Venus 
following stimulation with TNFα (10ng/ml) (Movies 3a)). D) 5xκB-Venus 
signal remains unchanged in neurons, whereas in E) astrocytes show Venus 
increase in conjunction with tagRFP-p65 nuclear shuttling. Error 
bars=SEM, scale bar=20µm. 
A) 
B) C) 
D) 
E) 
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3.3.1.5. Astrocytes Exhibit Inherent Basal NF-κB Activity 
 
The mixed primary culture system of neurons and astrocytes is a complex yet 
informative experimental model, which has the potential to provide mechanistic 
insight into brain physiology or potential conditional inflammatory responses in vivo. 
Having established that there are clear differences in cell-type responses to TNFα, it 
was necessary to determine if the basal activity of the NF-κB pathway was 
inherently variable in astrocyte enriched or neuron/astrocyte co-cultures. 
Interestingly, data from these studies show that astrocytes display spontaneous p65 
nuclear translocation events, which were demonstrated by characteristic oscillatory 
activity in neighbouring cells (Figure 3.8, Movies 5b). To establish if these 
autonomous p65 oscillations correlate with an increase in transcriptional activity, the 
5xκB-Venus reporter was imaged in parallel with tagRFP-p65 fluorescence (Figure 
3.8C, Movie 4 & 5a). Results from these studies clearly show that autonomous 
nuclear translocations of tagRFP-p65 in astrocytes (grown in mixed culture) were 
associated with increased NF-κB transcriptional activity as demonstrated by the 
increase in 5xκB-Venus expression (Figure 3.8C). However, it was not clear if the 
observed spontaneous induction of NF-κB occurred as a result of autocrine or 
paracrine communication between astrocytes, or between astrocytes and neurons. 
The pyramidal neurons present in hippocampal cultures are known to exhibit 
spontaneous electrical activity as a result of glutamate signalling (Caech & Banker, 
2006), and astrocytes grown in mixed cultures with neurons occasionally exhibited 
nuclear p65 staining detected by immunofluorescence (Figure 3.9A). To investigate 
the possibility that glutamate may act as an inducer of NF-κB oscillations and 
associated increases in transcriptional activity, mixed cultures were treated with two 
glutamate receptor antagonists DVLAP and CNQX (Figure 3.9B). However, 
blocking glutamate signalling did not prevent the spontaneous NF-κB activity as 
measured by nuclear fluorescence changes (NNF) of EGFP-p65. Equally, addition of 
0.5mM L-Glutamate did not enhance NF-κB-luc activity in primary astrocytes 
(Figure 3.9C), leading instead to a reduction of luminescent signal over time. To 
exclude the possibility that the observed spontaneous NF-κB activity is mediated by 
neuronal inputs, pure astrocyte cultures infected with EGFP-p65 lentivirus were 
imaged in Neurobasal medium (instead of Astrofood usually used for 
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Figure 3.8 Astrocytes exhibit autonomous p65 oscillations. Panels A) & B) 
show example temporal traces of nuclear EGFP-p65 levels, demonstrating 
oscillations in nuclear p65 levels in unstimulated cells. C) Time-lapse images 
from astrocyte-neuron culture transduced with tagRFP-p65 and 5xκB-Venus 
under basal conditions. Significantly the Venus reporter signal increases in the 
cell showing spontaneous oscillations in nuclear tagRFP-p65 levels (Movie 4 
and Movie 5b). D) Neighbouring astrocytes showing evidence of spontaneous 
nuclear EGFP-p65 shuttling (Movie 5a), n=3. Scale bar 20µm.  	  
A) 
C) 
B) 
D) 
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Figure 3.9 Spontaneous astrocyte p65 activity is independent of 
neuronal inputs. A) Indirect immunofluorescent staining of mixed 
neuron/astrocyte co-cultures shows evidence of p65-488 nuclear 
accumulation in unstimulated astrocytes. B) Spontaneous changes in nuclear 
EGFP-p65 fluorescence levels in mixed neuronal-astrocyte cultures imaged 
in the presence of glutamate receptor antagonists DVLAP (50µM) and 
CQNX (10µM). C) 0.5mM L-Glutamate has an inhibitory effect on NF-кB-
Luc activity in pure astrocytes (n=1, in triplicates). D) Spontaneous nuclear 
EGFP-p65 oscillations in 5% Horse Serm (Movie 6a) are amplified and more 
frequent in serum-free conditions (Movie 6b) (n=1). Scale bar=10µm. 	  
A) 
B) 
D) 
C) 
E) 
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maintenance of pure astrocyte culture) with or without supplementation with horse 
serum (Figure 3.9D & 3.9E respectively). Although spontaneous p65 oscillations 
were observed in both culture conditions, they were found to be amplified and more 
frequent in the absence of serum (Figure 3.9E, Movie 6b vs. 6a). Therefore neurons 
are not necessary to induce the voluntary p65 activation, but the lack of serum in the 
Neurobasal media seems to amplify inherent NF-κB activity.  
 
3.3.2. Constructing Molecular Tools to Image Dynamic Nrf2 Responses in 
Primary Hippocampal Astrocytes and Neurons. 
 
3.3.2.1. Characterisation of Nrf2 Responses in Astrocytes and Neurons 
 
As Nrf2 appears to be constitutively expressed at low level a broad range of cells 
quantification and dynamic profiling of Nrf2 by western blotting or 
immunofluorescence has proved challenging, in part due to the relatively poor 
quality of most commercially available antibodies. 
To validate the tools used for detection of Nrf2 protein by western blotting (Methods 
Sections 2.11 & 2.15), several antibodies were tested  (R&D Systems clone 383727; 
Santa Cruz C20 and T19, Abcam ab62352; Everest EB11042), however, in our 
hands only the polyclonal rabbit anti-Nrf2 (H300, Santa Cruz) successfully detected 
the Nrf2 protein in primary mouse cells (Figure 3.10A). However, although a 
specific Nrf2 band was detected with this antisera considerable levels of non-specific 
staining was observed in western blots. As such the anti sera was thought to be 
unsuitable for use in immunocytochemistry studies. Figure 3.10A presents data from 
western blot analysis of hippocampal astrocytes isolated from WT or Nrf2-/- mice. 
The band of about 100kDa represents Nrf2 as it was detected only in WT cells and 
not in cells derived from Nrf2-/- mice. 
 
In addition, the identified Nrf2 specific band was shown to increase in response to 
induction by a single treatment with 100nM CDDO-Me, or co-treatment with 
CDDO-Me and the proteasome inhibitor MG132 (10μM) (Figure 3.10A). A band of 
the same molecular weight was also detected by western blotting in mouse 
hepatocellular carcinoma cells (Hepa-1c7) shown in Figure 3.10B. Therefore, we 
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Figure 3.10 Comparison of conditional Nrf2 protein expression and 
transcriptional activity in astrocytes from WT or Nrf2-/- KO mice.  
A) Western blot showing anti-Nrf2 specific staining represented by a band of 
~100kDa, which is only observed in lysates prepared from WT astrocytes.  B) 
Western blot showing changes in Nrf2 protein abundance following addition 
of 100nM CDDO-Me and 10µM MG132 to Hepa-1c cells. C) Relative Nrf2 
transcriptional activity in WT astrocytes following addition of SFN or CDDO-
Me measured in primary astrocytes using the dual luciferase assay and a 
reporter plasmid in which luciferase expression is driven by an 8xARE 
sequence in the luciferase promoter region sensitive to 2µM SFN and 100nM 
CDDO-Me treatment (n=1, triplicates). D) mCherry-Nrf2 protein fusion 
expression dramatically increases ARE-Luc activity in Nrf2 KO primary 
astrocytes (n=1, triplicates). Error bars=STDEV. 	  
A) B) 
C) D) 
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were confident that the H300 anti-Nrf2 antibody was suitable for use in further 
experiments to investigate conditional changes in Nrf2 protein levels. 
In order to correlate observed trends in Nrf2 protein abundance with functional 
studies, with measurements of Nrf2 transcriptional activity, an ARE-Luc reporter 
construct (kindly provided by Dr. Joanne Walsh, University of Liverpool) was used 
in conjunction with the dual luciferase method (Figure 3.10C & D) to quantify 
conditional levels of Nrf2 transcription. Expression of luciferase in the ARE-Luc 
plasmid is driven by 8xARE consensus sequences based on mouse GCLC sequence 
(Kratschmar et al, 2012). All luciferase assays were performed as described in 
Methods Section 2.4.6.  
 
The ARE-Luc expression was measured following addition of either 100nM CDDO-
Me or 2µM SFN at indicated time points. The ARE driven luciferase activity was 
seen to increase in response to both Nrf2 inducing drugs (Figure 3.10C), with the 
CDDO-Me evoking more pro-longed activation of Nrf2 transcriptional activity. To 
examine the specificity of the ARE-Luc construct as a reporter for Nrf2 mediated 
transcriptional activity, the activity of the ARE-Luc reporter in response to CDDO-
Me was also assessed in astrocytes derived from Nrf2-/- mice (Figure 3.10D). 
Significantly no increase in ARE-driven luciferase activity was observed in 
astrocytes derived from Nrf2-/- mice. Co-expression of a fluorescent mCherry-Nrf2 
fusion protein restored Nrf2 activity in Nrf2-/- astrocytes, significantly increasing the 
ARE-Luc signal, however in this case addition of CDDO-Me (100nM) failed to 
further amplify the ARE-Luc signal.  
   
To visualize Nrf2 dynamic responses in live cells, the mouse NRF2 cDNA coding 
sequence was inserted downstream of the mCherry fluorescent tag to form a 
mCherry-Nrf2 protein fusion (Methods 2.1). In this vector relatively high levels of 
expression are driven by the human UBC promoter sequence. Initially, the plasmid 
was transiently expressed in astrocytes using Lipofectamine2000 (Methods 2.4.5) 
and imaged using Zeiss 5.10 confocal imaging system (Methods 2.13) (Figure 
3.11A, B & D). Although transfection efficiency in primary astrocytes was found to 
be very low, sufficient numbers of transfected cells were obtained to perform  
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A) 
Figure 3.11 Transient expression of Nrf2 and p65 from a plasmid is 
associated with aberrant nuclear behaviour. A) Measuring mCherry-Nrf2 
fluorescence in primary astrocytes shows no response to 100nM CDDO-Me 
(addition marked by a dashed line) (n=1, c=6). B) Representative trace of basal 
mCherry-Nrf2 levels shows nuclear oscillatory dynamics under basal 
conditions in astrocytes, n=3. C) Fluctuating nuclear levels of unrelated 
nuclear protein mCherry-UBE2D2 can also be observed under basal 
conditions, n=1. D) Representative images from time-lapse imaging showing 
nuclear breakdown events and apoptosis of astrocytes expressing mCherry-
Nrf2 (Movie 7 and Movie 8). E) The transiently expressed EGFP-p65 shows 
appropriate oscillatory dynamics in astrocytes following TNFα. F) Transient 
expression of tagRFP-p65 is frequently associated with atypical nuclear 
morphology. Error bars=STDEV, scale bar=10µm. 	  
B) C) 
D) 
E) F) 
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planned imaging experiments. Initial time-lapse imaging studies using the mCherry-
Nrf2 vector in primary astrocytes (1 image p/8min) unveiled an irregular pattern of 
Nrf2 nuclear fluorescence under basal conditions (Figure 3.11A & B, Movies 7 & 8), 
showing periodic deceases and increases in levels of mCherry-Nrf2 fluorescence 
(Figure 3.11B), with little or no response to the addition of CDDO-Me (Figure 3.11A 
& 3.10D). To test whether the observed oscillatory phenotype was specific to 
mCherry-Nrf2 or resulted of some deleterious artefact, another resident nuclear 
protein mCherry-UBE2D2 was investigated. Surprisingly the mCherry-UBE2D2 also 
demonstrated similar oscillatory nuclear dynamics (Figure 3.11C). As a result we 
concluded that the apparent oscillatory dynamics initially observed for mCherry-
Nrf2 were most likely an artefact resulting from a non-specific instability, or periodic 
rupturing, of the nuclear membrane, as reported in other cell types (De Vos et al, 
2011). To support this conclusion, Figure 3.11D (Movie 7) shows representative 
images from live cell imaging studies where high levels of mCherry-Nrf2 expression 
were frequently accompanied with irregular nuclear morphology characterized by the 
presence of a small satellite nuclear blebs (indicated by an arrow in Figure 3.11D), 
which are characteristic of transient nuclear rupture events. Similarly imaging p65 
responses to TNFα by transient expression of EGFP-p65 plasmid demonstrated 
expected oscillatory behaviour (Figure 3.11F). However overexpression of p65 was 
associated with increased apoptosis during imaging and observation of irregularities 
in the nuclear shape (Figure 3.11G). Given these phenotypes we concluded that 
transient expression methods that result in expression of high levels of Nrf2 (or other 
nuclear proteins) are an inappropriate experimental system to study conditional Nrf2 
dynamics as they are highly prone to experimental artefacts, which could seriously 
jeopardise meaningful interpretation of physiologically relevant Nrf2 responses. For 
this reason we developed alternate lentivirus mediated expression systems, which 
allow fluorescently tagged Nrf2 proteins to be expressed at near endogenous levels 
without the use of stress inducing transfection reagents.    
 
3.3.2.2. Development of Lentiviral Expression System for Imaging of 
Dynamic Nrf2 Responses 
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in  
Figure 3.12 Imaging low-level expression of 2kb-Venus-Nrf2 in primary 
murine astrocytes. A) Spectral profile of astrocytes stably expressing Venus-
Nrf2, under control of the endogenous 2kb Nrf2 promoter region (2kb-Venus-
Nrf2) obtained by Lambda scanning; characteristic Venus emission maxima 
peak is highlighted in green. B) Results of Linear unmixing showing signal 
from Venus the fluorescence channel (green) compared to the background 
autofluorescence/noise signal removed by spectral unmixing (Auto*, yellow). 
C) Representative time-lapse images of 2kb-Venus-Nrf2 in primary astrocytes 
in response to addition of 50nM CDDO-Me or D) 2µM SFN. E) Mean nuclear 
fluorescence levels of 2kb-Venus-Nrf2 in response to addition of DMSO 
(control) (Movie 9), 50nM CDDO-Me (Movie 11) or 2µM SFN (Movie 10) 
(n=2, c=4-13). Error bars=SEM, scale bar=20µm. 	  
C) 
E) 
A) B) 
D) 
D) 
118	  	  
To address the problems encountered during plasmid Nrf2 expression, a lentiviral 
expression system was employed to allow low-level expression of the Nrf2 protein. 
To achieve near endogenous levels of Nrf2 expression, the UBC promoter sequence  
the UBC-Venus-(insert) vector was replaced by the murine proximal Nrf2 promoter 
sequence, including the 2kb region directly upstream of the NRF2 START codon 
(Figure 3.12D) (Methods 2.2, Map in Supplementary Section 8.3). Reassuringly, 
astrocytes infected with the resulting Venus-Nrf2 encoding lentivirus exhibited very 
low levels of 2kb-Venus-Nrf2 fluorescence (Figure 3.12B), which was similar in 
intensity to levels of cellular autofluorescence. To separate the background 
autoflourescence signal from the 2kb-Venus-Nrf2 fluorescence, astrocytes were 
imaged using the lambda scan mode on the Zeiss 7.80 confocal microscope 
(Methods 2.13.1). Lambda scanning allows a sequence of images to betaken by 
gradually increasing the wavelengths allowed to pass through the emission filter sets, 
while illuminating with the 514nm laser beam. It then combines the images 
generated and the specific fluorescence emission profile can be selected (Figure 
3.12A). The astrocyte cells expressing Venus-Nrf2 showed characteristic Venus 
emission peak (highlighted in green Figure 3.12A), which could then be easily 
distinguished from background autoflourescence or noise. This approach also 
allowed selection of the optimal emission peak for imaging of Venus fluorescence 
alongside other fluorescent protein fusions. 
 
To test whether the lentivirally expressed 2kb-Venus-Nrf2 responds to canonical 
Nrf2 inducing drugs, astrocytes were imaged every 8min for at least 8hrs and the 
dynamic profile of the Nrf2 fusion in response to 2μM SFN, 100nM CDDO-me or 
the DMSO control was obtained. Representative images from this experiment are 
shown in Figure 3.12C & D (Movies 9, 10, 11). Measurement of Venus-Nrf2 
normalised nuclear fluorescence levels (NNF), displayed clear induction profiles in 
response to both CDDO-Me and SFN stimulation, but remained unchanged as a 
result of DMSO control treatment (Figure 3.12E, Movie 9). 
 
Finally, tagRFP-p65 and 2kb-Venus-Nrf2 were co-transduced into mixed 
hippocampal neuron-astrocyte cultures in order to monitor dynamic responses to 
stimulation with 50nM CDDO-Me in both cell-types (Figure 3.13 and Movie 12). 
The experiment provided clear evidence that both astrocytes and neurons show clear 
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CDDO-Me induction of nuclear Venus-Nrf2. Significantly, addition of CDDO-Me 
did not induce nuclear translocation of tagRFP-p65 in either cell type.	  	  	  
 
 
3.3.3. Development of an Astrocyte Specific Nuclear Marker 
 
Unfortunately, analysis of data obtained from p65 and Nrf2 imaging experiments 
required tedious manual cell-by-cell analysis to define nuclear boundaries when 
quantifying nuclear fluorescence intensities (Methods 2.13.3). However, there was a 
potential that this process could be significantly automated by labelling the nuclear 
compartment with a stable fluorescent marker. There are several proteins that could 
act as a nuclear marker, however LaminB1 structural nuclear protein has frequently 
been used for this purpose. To avoid spectral overlap between the LaminB1 protein 
and tagRFP and Venus signals, a Cyan fluorescent protein was chosen to generate a 
fluorescent LaminB1 fusion construct for nuclear labelling. Additionally, to ensure 
that the measurement is indeed carried out in astrocyte cells of interest, as opposed to 
oligodendrocytes, microglia, neurons or epithelial cells, the LamninB1-Cyan fusion-
protein was expressed under an astrocyte specific GFAP promoter (Figure 3.14A & 
C) (Map in Supplrmrntary Section 8.3). Initially, the GFAP-Cyan construct was 
tested to verify the GFAP-driven expression was possible in SK-N-AS and astrocytes  
Figure 3.13 Combined temporal imaging of tagRFP-p65 and 2kb-Venus-
Nrf2 in co-cultured mouse neurons and astrocytes. Representative images 
taken from a mixed culture of neurons and astrocytes transduced with tagRFP-
p65 and 2kb-Venus-Nrf2. Times indicate elapsed period after addition of 50nM 
CDDO-Me (Movie 12), n=2. Highlighted neuronal cell shows increasing levels 
of nuclear 2kb-Venus-Nrf2 expression in response to CDDO-Me treatment. 
Scale bar =20µm. 	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Figure 3.14 Construction of an astrocyte specific fluorescent nuclear 
marker GFAP-LaminB1-Cyan. A) Diagram showing the design of the 
Cyan fluorescent reporter under astrocyte specific GFAP promoter. B) 
Representative images of SK-N-AS neuroblastoma and primary astrocyte 
cells transiently transfected with GFAP-Cyan. C) Diagram depicting the 
design of GFAP-LaminB1-Cyan plasmid. E) Representative images of 
mixed astrocyte-neuronal culture showing astrocyte specific LaminB1-
Cyan nuclear labelling as a result of GFAP-LaminB1-Cyan transduction. 
Scale bar=20µm. 	  
A) 
B) 
C) 
D) 
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cells (Figure 3.14 B & C). Subsequently, the laminB1 sequence (isoform 1) was 
inserted downstream of the GFAP promoter using Gateway cloning approach 
(Methods 2.1) (Figure 3.14D). The mixed culture infected with GFAP-LaminB1-
Cyan displayed nuclear staining of astrocytes, whereas phase bright neurons did not 
show any fluorescence (Figure 3.14E). Therefore the GFAP-LaminB1-Cyan 
lentiviral construct could be used for future studies to facilitate the automation of 
nuclear fluorescence intensity measurements in astrocytes.  This tool has proved 
especially helpful in studying Nrf2 responses in astrocytes grown in mixed culture 
systems. 
 
3.3.4. Characterisation of Nrf2 Dynamic Responses Using a Stable Nrf2-Venus 
Expressing BACNrf2-Venus Neuroblastoma Model for Live Cell Imaging 
 
3.3.4.1. Comparison of Endogenous Nrf2 and BAC-derived Nrf2-Venus 
Dynamic Responses 
 
Imaging primary neuronal and astrocyte cells is an excellent source of information 
about the physiological responses of cells originated form the CNS. However, 
limited cell numbers and the demanding nature of primary neuronal cell culture 
impose restrictions on large-scale multi-modal analysis of dynamic conditional 
signalling responses. To first establish the fundamental principles of pathway 
regulation and the interplay between NF-κB and Nrf2 signalling responses we chose 
to utilise a recently generated neuroblastoma SK-N-AS cell line, which had been 
engineered to stably express Nrf2-Venus in an endogenous genomic context from an 
integrated Bacterial Artificial Chromosome (BAC).  To initiate this work it was first 
necessary to validate that the Nrf2-Venus BAC cells (BACNrf2-Venus) were a suitable 
model system to use to investigate dynamic Nrf2 responses in live cells. In 
particular, it was important to first establish if dynamic or conditional changes in 
Nrf2-Venus distribution or accurately reflect expression levels and dynamic changes 
seen for the endogenous Nrf2 protein. 
The Nrf2-Venus BAC cell line was previously generated by Dr Karen Dunn under 
the supervision of C.M. Sanderson (University of Liverpool) and M.White 
(University of Manchester). Initial fluorescence in situ hybridisation (FISH) 
established that the fragment of BAC expressing the Nrf2-Venus fluorescent protein  
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Figure 3.15 Characterisation of a neuroblastoma SK-N-AS BACNrf2-Venus 
cell line as model for studying dynamic Nrf2 responses at a near-
endogenous level. A) Representative image from FISH analysis of BACNrf2-
Venus cells (image provided by Dr Karen Dunn) showing only two sites of 
Nrf2-Venus encoding BAC integration in the SK-N-AS genome. B) Western 
blot analysis of WT SK-N-AS and SK-N-AS BACNrf2-Venus lysates showing 
relative levels of Nrf2 and Nrf2-Venus expression in each cell type under 
basal and induced conditions, n=1. C) Western blot of BACNrf2-Venus nuclear 
lysates, showing correlated time dependent accumulation of both 
endogenous Nrf2 and the BAC-encoded Nrf2-Venus protein following 
addition of 2µM SFN, n=2. D) Quantification of total protein levels 
normalised to Lamin Β1 nuclear loading control, performed on ImageJ. 
Scale bar=20µm.  	  
A) 
C) 
B) 
D) 
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was incorporated into the SK-N-AS cells at two copies per cell (from now being 
referred to as BACNrf2-Venus) (Figure 3.15A). A western blot analysis was then 
performed to assess the relative level of expression of the endogenous Nrf2 protein 
and Nrf2-Venus between SKNAS and BACNrf2-Venus (Figure 3.15B). As expected the 
higher MW band representing the Nrf2-Venus fusion protein was only observed in 
the BACNrf2-Venus cells (~130kDa). Importantly, the Nrf2-Venus protein and 
endogenous Nrf2 (100kDa) exhibited similar increases in expression levels following 
addition of the proteasomal inhibitor MG132 (10μM) or the Nrf2 inducer SFN 
(2μM) (Figure 3.15B). The western blot analysis of Nrf2 induction following time 
course addition of 2μM SFN displays similarity of Nrf2-Venus and endogenous Nrf2 
responses and stability over 24h (Figure 3.15C & D)    
 
Although the low levels of Nrf2-Venus are optimal, as they closely resemble levels 
of the endogenous protein, this poses a technical problem for live cell imaging 
studies. As with our previous studies using lentivirus mediated expression systems in 
neurons and astrocytes, visualisation of the BACNrf2-Venus cells required the use and 
optimisation of state of the art imaging techniques available on the 7.80 confocal 
system. Use of the lambda scan mode confirmed that the nuclear fluorescent signal 
was indeed the Venus fluorescence. The range of emission profiles acquired by 
514nm illumination and the combined emission spectrum profile of Nrf2-Venus and 
the SK-N-AS autofluorescence are shown in Figure 3.16A & B respectively 
(Methods 2.13.1). From this data it is clear that imaging of the Nrf2-Venus 
fluorescence could be performed in two ways. Either by using the lambda scan 
mode, which would maximize the Venus fluorescent signal (Figure 3.16D), or by 
selecting the narrow Venus emission maximum (522nm-540nm), which may be 
preferable when imaging Nrf2 alongside other fluorescent proteins. Comparison of 
both methods shows the Nrf2-Venus signal is much clearer when using the linear 
unmixing method (Figure 3.16C). 
 
The utility of the BACNrf2-Venus cells was further assessed by imaging live cell 
responses to canonical inducers of Nrf2, including 2μM SFN, 100nM CDDO-Me 
and 10μM MG132 (Figure 3.17A, Movies 13, 14, 15).  
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Figure 3.16 Imaging near-endogenous levels of Nrf2-Venus expression in 
the SK-N-AS BACNrf2-Venus cell-line using 7.80 Zeiss confocal microscope. A) 
Low-levels of Nrf2-Venus expression were spectrally unmixed using lambda 
scan mode on a 7.80 Zeiss confocal microscope. The figure shows sequential 
image series taken by narrow spectrum band pass filters show differences in 
fluorescent signal, which are dependent on detector bandwidth sensitivity. B) 
The emission profile of SK-N-AS BACNrf2-Venus cells following spectral 
unmixing to separate Venus and autofluorescence specific emission spectrum. 
C) Comparison of Nrf2-Venus signal taken by setting narrow detection limits 
on band-pass filters (set to Venus emission maximum), or by spectrally 
unmixing using the lambda scan method. D) Spectrally unmixed fluorescence 
signals of Nrf2-Venus (green) and the autofluorescence (yellow). Scale 
bar=20µm. 
 
A) 
B) 
C) 
D) 
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Figure 3.17 Co-expression of mCherry-Keap1 induces redistribution of   
Nrf2-Venus in BACNrf2-Venus cells. A) Temporal changes in Nrf2-Venus 
expression levels following treatments of BACNrf2-Venus cells with 10µM 
MG132 proteasome inhibitor (Movie 13), 2µM SFP (Movie 14) or 100nM 
CDDO-Me (Movie 15). B) Co-expression of mCherry-Keap1 plasmid in 
BACNrf2-Venus cells leads to a reduction in Nrf2-Venus expression and enhanced 
sequestration of Nrf2-Venus in the cytoplasm of transfected cells. Scale 
bar=20µm. 	  
A) 
B) 
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3.3.4.2. Measuring Keap1 and Nrf2 Interaction in Live Cells 
 
In order to further establish that the Nrf2-Venus fusion protein was an appropriate 
tool to investigate functional responses in the Nrf2 pathway, it was essential to 
establish if the Nrf2-Venus fusion protein could associate with its primary negative 
regulator Keap1, in live cells. To address this point, the mCherry-Keap1 plasmid was 
transiently expressed in BACNrf2-Venus cells in order to define the effects of Keap1 
expression on the abundance and distribution of Nrf2-Venus (Figure 3.17B). 
Transient over-expression of mCherry-Keap1 resulted in a dramatic depletion of 
nuclear Nrf2-Venus levels, with a commensurate accumulation of both mCherry-
Keap1 and Nrf2-Venus in the cytoplasm of transfected cells. In contrast, Nrf2-Venus 
remained almost totally nuclear in neighbouring non-transfected cells (Figure 
3.17B). This encouraging result prompted a more detailed study of mCherry-
Keap1/Nrf2-Venus complex formation in live cells, utilising the cutting edge 
Fluorescence Cross-Correlation Spectroscopy technique (for which help and training 
were kindly provided by Dr James Boyd, Prof. M. White’s group, University of 
Manchester). The principles of FCS and FCCS are depicted in Figure 3.18A & B and 
explained in Methods 2.13.4. FCCS measurements are only possible between 
fluorophore pairs that are spectrally well separated, and relatively photostable. 
However, the advantage of this technique over FRET based assays is that the two 
fluorescent proteins do not have to be in close proximity, they simply have to be part 
of the same molecular complex.  The fluorescent signal of mCherry-Keap1 and Nrf2-
Venus measured by the Autocorrelation function followed a steady one-phase decay, 
as illustrated by the FCS curves in Figure 3.18C, with the magnitude of decline being 
indicative of the reproducibility of diffusion behaviour. This shows that the diffusion 
of Nrf2 and Keap1 proteins (separately) follow a consistent pattern, e.g. the 
movement of molecules was comparable over the acquisition time. To further 
measure this interaction the similarity between the mCherry and Venus fluorescence 
signals was compared by FCCS analysis. It was expected that bound proteins would 
achieve a cross-correlation value greater than zero. The FCCS curve has a one-phase 
decay shape (as opposed to a straight line, which would signify no interaction), 
starting from a relatively high value of approximately 0.015 G(τ), which is indicative 
of the formation od a stable complex between the Nrf2-Venus and mCherry-Keap1  
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Figure 3.18 Use of FCCS microscopy to investigate the formation of Nrf2-
Venus/mCherry-Keap1 complexes in cytoplasm in real-time. A & B) 
Diagram depicting the principles of the FCCS technique. C) Auto-correlation 
curves of Nrf2-Venus (yellow) and mCherry-Keap1 (red). D) Cross-correlation 
curves of Nrf2-Venus and mCherry-Keap1, the high correlation value indicates 
strong binding between the two proteins. E) The KD constant obtained by 
plotting the free Nrf2-Venus [G] and mCherry-Keap1 [R] signals against Nrf2-
Venus and mCherry-Keap1 complexes ([GR]), indicates strong binding between 
the two proteins. F) Graph showing the relative proportions of free and 
complexed Nrf2-Venus and mCherry-Keap1 molecules. Error bars= STDEV, 
n=2, c=9. 	  
A) B) 
C) D) 
E) F) 
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proteins (Figure 3.18D). The data obtained from FCS and FCCS measurements could 
be further used to assess the strength of complex formation by plotting the amount of 
free Venus and mCherry proteins, which diffuse much faster than proteins in larger 
complexes, against the values for mCherry-Venus complexes, in order to calculate a 
predicted dissociation constant (KD) (Figure 3.18E). The dissociation constant 
calculated for the Nrf2-Venus and mCherry-Keap1 = 358.82nM KD, representing a 
very strong binding.  The number of free molecules in the confocal volume was 
calculated by substracting the amount of mCherry-Venus complexes from the total 
amount of Venus and mCherry proteins respectively (Figure 3.18F). As the Nrf2-
Venus is expressed at near-physiological levels in BACNrf2-Venus cells, the Nrf2 
molecules are out-titrated by the expression level of the transiently overexpressed 
mCherry-Keap1 protein, and a large proportion of Nrf2-Venus is bound in a complex 
with mCherry-Keap1. 
 
3.3.4.3. Basal Nrf2 Dynamics 
 
While it has been established that Nrf2-Venus protein responds to induction with 
SFN, CDDO-Me and MG132 (Figure 3.17A), it is important to note that the basal 
Nrf2-Venus nuclear fluorescence remained stable throughout most imaging 
experiments in this study (Figure 3.19A). However, there is one notable exception. 
There appeared to be a well-defined time-point during unstimulated imaging 
conditions when the Nrf2-Venus protein levels first decrease then increased in 
synchronised pattern in both daughter cells (Figure 3.19B & C, Movie 16). This 
phenotype is shown in the representative images taken during extended 14 or 24h 
time-lapse experiments (Figure 3.19B), showing the cell division process, which 
results in two, bright daughter cells. Interestingly, the Nrf2-Venus increase occurs 
every time cell division takes place suggesting that levels of Nrf2 expression is under 
cell-cycle dependent control. 
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Figure 3.19 Levels of Nrf2-Venus are regulated in a cell-cycle dependent 
manner. A) Averaged nuclear Nrf2-Venus fluorescence under unstimulated 
conditions (n=2, c=6). B) Representative Nrf2-Venus fluorescence traces 
showing a co-ordinated dip and subsequent increase in nuclear Nrf2 levels in 
daughter cells following cell-division. C) Representative time-lapse images 
from unstimulated BACNrf2-Venus  neuroblastoma cells showing a clear increase 
of Nrf2-Venus signals in both daughter cells following cell division (Movie 
16). Scale bar 20µm.  	  
C) 
A) B) 
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3.4. DISCUSSION 
 
Glial cells perform a wide array of cellular tasks in support of neighbouring neuronal 
cells, and are believed to be the main players involved in antioxidant protection 
within the brain (Vargas & Johnson, 2009). The antioxidant responses ensure 
appropriate resolution of acute inflammatory episodes and play a major role in the 
prevention of neurodegeneration (Gupta et al, 2012). Cellular responses to 
antioxidant and inflammatory stimulation are primarily mediated by the Nrf2 and 
NF-κB signalling cascades respectively, however their dynamic responses to 
physiological and pharmacological modulators in primary astrocytes and neurons 
have not been extensively researched. This study aimed to generate sophisticated 
imaging tolls to enable investigation of Nrf2 and p65 responses to TNFα, SFN 
and/or CDDO-Me, and to gain more insight into cellular responses that are likely to 
take place within the CNS. 
 
The investigation of mixed neuronal and astrocyte cultures by live cell imaging 
provided an excellent approach for exploration of cell specific responses without the 
need to utilise large cell numbers and labour intensive biochemical studies. 
 
3.4.1. Astrocytes Exhibit Strong Basal and TNFα-Induced NF-κB Responses 
 
There have been mixed reports on the cell specific nature of NF-κB responses in the 
brain. Historically, agreement on this point was hindered by the poor quality of 
available antibodies used in immunofluorescent staining and western blot studies 
(Slotta et al, 2014). In this study, western blot analysis of the cytoplasmic and 
nuclear fractions from both astrocytes and neurons highlighted the differences in 
cell-type specific responses to TNFα, with neurons failing to induce nuclear p65 
accumulation following cytokine treatment (Figure 3.2). Interestingly, the molecular 
weight of p65 detected in neurons was different between cytoplasmic and nuclear 
fractions. Our data shows that the quantity of nuclear p65 did not change over the 
time-course of TNFα treatment, and only one 82kDa band was detected (slightly 
higher than the predicted MW of ~69kDa, whereas two bands (82kD and ~150kDa) 
were detected in the cytoplasm (Figure 3.2A), to validate if the upper band represents 
genuine p65 staining siRNA knockdown of p65 should be performed in the future.  
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Lentiviral expression of the p65 subunit at near-endogenous levels as either 
fluorescent tagRFP-p65 or EGFP-p65 fusion proteins (Figure 3.4C and 5), allowed 
real-time imaging of NF-κB temporal behaviour in primary cells under basal activity 
(Figure 3.8 and 3.9) and following TNFα stimulation (Figure 3.5 and 3.6). 
EGFP-p65 and tagRFP-p65 imaging studies performed in this study confirmed 
previous biochemical reports on neuronal insensitivity to TNFα stimulation. To 
exclude the possibility of other NF-κB subunits being involved in TNFα neuronal 
responses, the lentiviral 5κB-Venus reporter was imaged in mixed cultures to 
measure the NF-κB activity (Figure 3.7, Movie 3a). In these studies, 5κB-Venus 
levels only increased in astrocytes (Figure 7 B-E). However, neurons did show a 
strong basal expression of the 5κB-Venus signal, indicating a high basal activity of 
NF-κB in those cells (Figure 3.7D, Movie 3a).  
Again, there are mixed reports on degree of neuronal NF-κB signalling in response 
to stress stimuli in the literature. Recent study by Listwak et al. reported that 
neuronal p65 responses to TNFα are minimal and testing other inputs, including 
LPS, ATP and Glutamate did not show significant evidence of NF-κB activation. 
However, the authors also argued that the NF-κB basal activity is inherently low in 
neurons.  This conclusion is however not consistent with data from this study 
showing high expression from the 5xκB-Venus NF-κB reporter expression in 
isolated primary mouse neurons. This result is in agreement with studies by 
Kaltschmidt et al, which presented evidence of continuous activation of NF-κB in 
neurons, but failed to respond to inflammatory cues (Kaltschmidt et al, 1994). The 
reason for the observed insensitivity of neurons to TNFα stimulation remains 
unclear. TNFR1 is expressed on the surface of neurons, which were previously 
reported to respond to physiological levels of TNFα by enhancing neurite outgrowth 
in a RhoA GTPase dependent manner (Neumann et al, 2002). Therefore, TNFα 
signaling may be activating the TNFR1 signaling cascade, without triggering nuclear 
translocation of p65.  
The neuronal NF-κB (p65) has distinct functions to the astrocyte counterpart in that 
it has been shown to act mainly in synapse maintenance, plasticity and GABAnergic 
signalling (Kaltshmidt et al, 2005). It is possible that the classical cytokine mediated 
transcriptional activation of p65 is not activated in neurons as these cells need to 
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maintain a stable basal activity, in order to fulfil other essential functions, with 
astrocyte and microglial cells being available to mediate and respond to local 
inflammatory signalling in the brain. 
 
NF-κB nuclear oscillations in response to cytokine signalling have been well 
characterised by Ashall et al, in neuroblastoma SK-N-AS cells (Ashall et al, 2002). 
However, this study reports of this phenotype in primary astrocytes observed for the 
first time. Interestingly the amplitude of basal p65 nuclear oscillations varied 
significantly, depending on weather primary astrocytes were grown under the same 
media conditions in the presence or absence of neurons (Figure 3.6F, Movie 2 &1a). 
The cause of this difference has not yet been fully investigated, however the 
amplitude and the frequency of NF-κB oscillations have been associated with the 
feedback mediated by three NF-κB regulatory components including, A20, IΚK, 
IΚBα and IΚBε (Paszek et al, 2010). Therefore, it is reasonable to hypothesise that 
basal neuronal paracrine communication could lead to changes in the astrocytic 
expression levels of those components. 
 
3.4.2. The Autonomous NF-κB Activation 
 
Live cell imaging of EGFP-p65 and tagRFP-p65 in astrocyte enriched and 
neuron/astrocyte mixed cultures provided clear evidence of autonomous p65 
oscillations, which were frequently observed in neighbouring cells (Figure 3.8). 
Furthermore, the observed spontaneous oscillatory shuttling of p65 directly 
correlated with an increase in NF-κB transcriptional activity, as measured by use of 
the 5κB-Venus reporter construct (Figure 3.8C, Movies 4& 5b). The role of neuronal 
glutamate signalling in inducing this phenotype was rejected, since neither inhibition 
of the glutamate receptors (Figure 3.9B) nor lack of L-glutamate induced NF-κB-Luc 
activation (Figure 3.9C). The occurrence of spontaneous nuclear oscillations in pure 
astrocyte cultures (Figure 3.9D & E) also excludes this possibility. It is intriguing 
that sequential oscillatory behaviour was frequently observed in neighbouring cells, 
such that the peak of nuclear p65 in one cell was often reciprocal to transient 
accumulation of p65 in the other (Movie 5a). This suggests that the phenotype may 
be in some way controlled by short-range paracrine communication, however it is 
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worth noting that although, multiple neighbouring cells often exhibit this behaviour, 
single isolated cells can also exhibit the phenotype with no detectable consequences 
within the whole field of imaging (Figure 3.8D, Movie 5).  
Interestingly we also found that the amplitude of the spontaneous p65 nuclear 
oscillations was higher when serum free Neurobasal medium was added to cells just 
before imaging (this media was also used for mixed cell culture), in comparison to 
cells maintained in 5% serum supplemented Neurobasal medium (Figure 3.9D & E, 
Movie 6a & 6b). Serum derived growth factors and signals could mask the effect of 
the signalling molecule involved in this phenomenon. Alternatively, starvation could 
induce stress-associated responses in cells, but in this case the occurrence of 
spontaneous p65 activity would be anticipated to be present more frequently, with 
some cells also undergoing apoptosis. Spontaneous p65 oscillations were previously 
observed in GFP-p65 knock-in fibroblasts, however this phenotype was not linked to 
an increase in κB-driven gene transcription (Zambrano et al, 2014). The authors 
hypothesised that this voluntary nuclear translocation phenotype could act as an NF-
κB “resetting system”, resulting from a decreased in IΚBα gene transcription. Thus 
allowing p65 to shuttle into the nucleus; where it would then reestablish NF-κB gene 
target gene expression, including the synthesis of new regulatory IΚBα and anti-
apoptotic genes. Thus conferring sensitivity to local inflammatory cues within the 
cellular vicinity. In our studies this voluntary or spontaneous behavior was frequently 
observed in neighboring astrocytes, suggesting that there is an inherent mechanism 
of paracrine communication (Figure 3.8). There are several candidates that may 
trigger the observed pattern of voluntary p65 nuclear shuttling, such as TNFα and 
the chemokine SDF-1. SDF-1 secretion is induced by glutamate and its strongly 
chemotactic properties attract leukocytes (Han et al, 2001).  SDF-1 has also been 
shown to activate the TACE enzyme, expressed on cellular membranes, which 
subsequently cleaves the TNFα monomer and releases it into the extracellular space. 
It can act either by autocrine or paracrine fashion and eventually amplify the 
inflammatory signaling (Han et al, 2001). This process was reported to be dependent 
on an increase in intracellular calcium concentration. Therefore, the role of SDF-1 in 
triggering spontaneous p65 nuclear shuttling could be validated by applying calcium 
chelators such as BAPTA and monitoring the effects in live cells. Nevertheless, the 
SDF-1 signaling relies on the release of glutamate and is expected to be enhanced in 
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the presence of neurons.. Taking into account the sequential behavior of these 
nuclear events, and the timing between the p65 nuclear peaks in proximal cells, it is 
quite likely that these events were triggered by paracrine TNFα signaling, which is a 
classical inducer of the p65 oscillatory behavior. Another argument for TNFα-
mediated effects is that nuclear translocation of NF-κB can be elicited with pM 
concentrations of the cytokine (Turner et al, 2010). To validate the role of TNFα in 
the induction of spontaneous p65 activity, this phenotype could be targeted by using 
anti-TNFα antibodies, or by using TNFR1 and TNFR2 specific inhibitors to block 
signaling by released cytokines. Interestingly, cells undergoing senescence display 
high NF-κB chromatin association indicating its possible input in maintaining this 
phenotype. The senescent cells exhibit senescence- associated secretory phenotype 
(SASP), where IL-6 and IL-8 cytokines are used as means of paracrine 
communication between cells. Therefore, another explanation for the autonomous 
NF-κB signalling observed in astrocytes could be associated with paracrine 
senescent signalling (Chien et al, 2011). 
The observation of this phenomenon again highlights the relevance of using single 
live cell imaging, as population level techniques would obscure these spontaneous 
nuclear p65 oscillations.  
 
3.4.3. Low Expression Molecular Tools are Required for Optimal Imaging of 
Physiologically Relevant Nrf2 Dynamic Responses 
 
Convincing detection of Nrf2 by western blots required the testing of several 
commercially available antibodies, eventually the rabbit anti-Nrf2 antibody (H300, 
Santa Cruz) was selected as it detected a clear Nrf2-specific band at a MW of around 
100kDa (Figure 3.10A & B). The Nrf2 protein runs higher than its predicted MW 
(69kDa) and this has also been confirmed by data from other laboratories (Lau et al, 
2013). The ARE-Luc reporter encoding 8xARE repeats, based on the sequence 
contained in the mouse GCLC promoter (Kratschmar et al, 2012), was effectively 
used for measuring Nrf2 activity by dual luciferase assay in response to 
pharmacological inducers (Figure 3.10C). To make the assay more sensitive to 
dynamic changes in the intercellular environment, the luciferase reporter protein has 
been destabilised by addition of a peptide degradation sequence (PEST), thus 
135	  	  
enhancing the sensitivity of this assay to fast changes in intracellular redox 
conditions. 
 
It was essential to analyse the functionality of the fluorescent Nrf2 protein fusion by 
measuring mCherry-Nrf2 mediated ARE-Luc expression (Figure 3.10D). The 
plasmid expression led to significantly higher ARE-Luc levels, however it was not 
sensitive to further induction by CDDO-Me (Figure 3.10D). This may be due to out-
titrating the normal mechanism of Nrf2 negative regulation by Keap1. Live cell 
imaging experiments using mCherry-Nrf2 confirmed that expression of Nrf2 from a 
high activity UBC promoter was not only insensitive to pharmacological Nrf2 
induction by CDDO-Me (Figure 3.11A), but was also frequently associated with 
deleterious structural nuclear defects, leading to an apparent nuclear oscillation 
artefact in mCherry-Nrf2 dynamic behaviour (Figure 3.11B & D). Astrocytes 
transfected with the mCherry-Nrf2 plasmid frequently exhibited modified nuclear 
morphology characterised by formation of nuclear blebs, which were prone to 
repetitive “bursting” events during imaging (Figure 3.11D, Movie 7 & 8). This 
frequently led to changes in the nuclear levels of Nrf2 and most likely other nuclear 
proteins, inducing a false phenotype for nuclear protein dynamics. It is unlikely that 
the expression of mCherry-Nrf2 plasmid was specifically causing this aberrant 
nuclear phenotype, as expression of mCherry-UBE2D2 had a similar effect (Figure 
3.11C).  
 
This nuclear expulsion phenotype has been observed by other labs studying other 
nuclear proteins, such as HIF1α (Violaine See group, University of Liverpool) and 
the nuclear behaviour itself has been associated with a cancer phenotype, or virus 
induced cellular stress (Hatch et al, 2013). However, it is increasingly evident that 
this behaviour is not exclusive to cancer related cells, since is also detected in 
primary cells. The frequent observations of this phenotype by expression of 
fluorescent nuclear protein fusions may be due to the fact that cells with weakened 
nuclear membrane are favoured for transfections, as plasmid expression requires the 
cDNA to enter the nuclear space. Therefore, as astrocyte division rate is quite slow 
the transfection efficiency could be enhanced by the fact that some cells exhibit the 
nuclear expulsion artefact permitting cDNA entry without the need of cell division. 
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The underlying cause of this phenotype has been associated with defective Lamin 
expression, and perhaps the 2D culture mode taken out of tissue context could 
enhance the structural stress on the nuclear envelope (De Vos et al, 2011). Therefore, 
researchers imaging nuclear fluorescent protein fusions should be cautious about this 
phenomenon especially if the analysed cells show clear signs of nuclear blebbing or 
rupture, which is associated with the nuclear expulsion phenotype. This is 
particularly relevant in the Nrf2 field as an oscillatory Nrf2 nuclear behaviour has 
been previously reported in human mammary epithelial cells (HMEC) transiently 
transfected with fluorescent Nrf2 protein. In this study the dynamic changes in 
nuclear Nrf2 levels were proposed to be a key event in the Nrf2 transcriptional cycle 
in response to oxidative stress (Xue et al, 2014).  
 In this study we clearly demonstrate that near-endogenous expression levels of Nrf2 
did not confer any such nuclear artefacts thus enabling Nrf2 imaging of response to 
various pharmacological stimuli in primary cells. The 2kb-Venus-Nrf2 fusion driven 
from its endogenous promoter, responded to induction with SFN and CDDO-Me and 
the occurrence of the spontaneous nuclear envelope breakdown was rarely observed 
(Figure 3.12C-E, Movies 9-11). Also, by limiting the levels of Nrf2 protein 
expression the potential for over-powering or out titrating Keap1 mediated regulation 
is much less likely to occur and hence the Nrf2 fusion protein itself will be more 
appropriately sensitive to Keap1 inhibition. The unequivocal benefit of lentiviral 
transduction is gene delivery to non-dividing cells such as neurons and the 
expression of fluorescently labelled Nrf2 not favoured by the cells exhibiting nuclear 
structure defects. 
In our studies the triterpenoid CDDO-Me (50nM) proved to be a more potent inducer 
of Nrf2 than SFN (2µM), nearly doubling the nuclear accumulation of Nrf2 in 
comparison to SFN (Figure 3.12E), whereas control treatment with DMSO failed to 
induce Nrf2 response (Movie 12). 
 
Finally bringing tools generated for both pathways together, the mixed cultures were 
transduced with both tagRFP-p65 and 2kb-Venus-Nrf2 and treated with 50nM 
CDDO-Me (Figure 3.13). The drug caused a robust activation of 2kb-Venus-Nrf2 in 
both astrocytes and neurons without triggering the nuclear translocation of the 
fluorescent p65. Significantly, as CDDO-Me is a compound that has ben shown to 
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cross-the BBB, it has the potential to prevent neurodegeneration (Neymotin et al, 
2011). The 2kb-Venus-Nrf2 expression was driven from 2kb fragment of the mouse 
Nrf2 gene promoter region, which served as a good indicator of the Nrf2 promoter 
activity. The presence of 2kb-Venus-Nrf2 and its activation in hippocampal neurons 
was promising, however it has been recently reported that the Nrf2 promoter in adult 
neurons is methylated and therefore inactive, so the Nrf2 activity is likely to be kept 
to minimal levels in adult neurons (Bell et al, 2015). In this study, neuronal cultures 
were obtained from embryonic neurons, therefore the difference in Nrf2 promoter 
activity could be due to the developmental stage of the animals used for the isolation 
of primary cells, or methylation may occur in a more upstream promoter sequence, 
which was not included in the 2kb sequence used in this study.  
 
3.4.4. GFAP-LaminB1-Cyan Drives Astrocyte-Specific Nuclear Marker 
Expression 
 
Initial assessment of cell specific responses were performed based on the shape of 
the cells present in the culture, as astrocytes and neurons have quite distinct cell 
morphologies. However, it can be challenging to perform effective large-scale data 
analysis on mixed cell populations, as cultures from hippocampal region of the brain 
can also support growth of occasional oligodendrocytes and meningeal cells. In order 
to ensure the astrocyte-specific p65 dynamic behaviour was being measured, a 
GFAP-LaminB1-Cyan construct was generated (Figure 3.14C & D). The GFAP 
promoter allowed expression to be confined to astrocytes, thereby facilitating 
detection of astrocyte specific nuclear protein changes (Figure 3.14D). This will help 
to automate the analysis in future studies by providing a stable nuclear labelling by 
laminB1, which could be readily detected by a Cell-Tracker and other software. 
Unfortunately, due to time constraints, use of the construct has not been explored 
further in this study. 
 
    The results obtained demonstrate the lentiviral transduction system used for 
expression of near-endogenous proteins is a superior method of gene delivery and 
imaging fluorescent proteins in primary neural cells. Data generated provided novel 
evidence of oscillatory dynamics of p65 in astrocytes and confirm the lack of 
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neuronal activation of p65 by TNFα, in addition, we report the novel phenotype of 
autonomous, astrocytic NF-κB activity. 
 
3.4.5. Characterisation of BACNrf2-Venus 
 
3.4.5.1. The BACNrf2-Venus is an Excellent Imaging Tool for Dissecting Nrf2 
Pathway Regulation 
 
   The primary aims of this PhD project were to investigate the interplay between 
Nrf2 and NF-κB signalling responses and to provide further information into 
conditional mechanisms of transcriptional and post-transcriptional regulation of Nrf2 
responses. The large number of assays required for this purpose made it challenging 
to base all experimental studies on primary cell cultures. Therefore, an alternative 
cell culture model was vital to allow easy cell manipulation and maintenance. Use of 
the neuroblastoma SK-N-AS BACNrf2-Venus cell line allowed many aspects of the 
transcriptional and post-translational regulation of dynamic Nrf2 responses to be 
analysed in live cells. Due to the extremely low basal level of Nrf2-Venus expression 
in these cells (Figure 3.15B & C) it was only possible to detect the Venus 
fluorescence using the state of the art Zeiss 7.80 confocal imaging system. 
The imaging of the BACNrf2-Venus cells required spectral unmixing as described 
previously in transduced Venus-Nrf2 astrocytes (Figure 3.12A & B). The 
background autofluorescence was mostly present in the cytoplasm and could be 
separated from the genuine Venus fluorescence by utilising the lambda scan imaging 
mode (Figure 3.16). The live cell imaging of BACNrf2-Venus cells provided a novel 
spatio-temporal data on Nrf2 dynamics in response to 2 µM SFN, 10 µM MG132 
and 100nM CDDO-Me, showing a distinct pattern of Nrf2 responses to different 
pharmacological stimulus (Figure 3.17A, Movies 13-15). This emphasised the value 
of BACNrf2-Venus cells in obtaining information on the temporal dynamics of Nrf2 
induction and confirmed that the BACNrf2-Venus cells could be used in further study. 
 
3.4.5.2. The mCherry-Keap1 and Nrf2-Venus Form Stable Complexes in 
Live Cells 
 
The Keap1 protein acts as the main regulator of the cellular Nrf2 levels; therefore it 
was crucial to establish if the tag modification of Nrf2 did not interfere with Keap1 
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dependent degradation. This has ben verified by live cell imaging of BACNrf2-Venus 
cells expressing mCherry-Keap1 plasmid. As expected, the transfection of mCherry-
Keap1 (CMV driven) led to decrease of Nrf2-Vensu fluorescence in the transiently 
transfected cells (Figure 3.17B). 
The Fluorescence Cross-Correlation Spectroscopy (FCCS) was performed to assess 
mCherry-keap1 and Nrf2-Venus complex formation in live cells (Figure 3.18). The 
FCCS measures fluorescently labelled protein diffusion through the confocal volume 
and the similarity of the diffusion pattern is assessed by mathematical logarithm, and 
further represented by a cross-correlation curve (Methods 2.13.4). The gradient 
decline of the curve is a measure of complex formation with the measurements taken 
binned every 200ns for 10x10sec and each fluorescence signal is correlated to the 
previous one by mathematical function and this is then plotted as the Gτ against the 
time (Δt) (Bacia et al, 2006).  
The diffusion speed of proteins is slower as a complex therefore by measuring the 
diffusion speeds of proteins through the known confocal volume, it is possible to 
calculate the size and the proportion of free and complexes Nrf2-Venus and 
mCherry-Keap1. The mCherry-Keap1 and Nrf2-Venus form strong complex in live 
cells of KD~300nM (Figure 3.18E) (protein-protein dissociation constant) and a 
significant proportion of Nrf2-Venus being part of a complex with mCherry-Keap1 
(Figure 3.18E and F). Therefore placing the Venus tag at the C-terminus of the Nrf2 
protein was unlikely to alter the Nrf2 protein interaction profile as confirmed by 
stable complex formation with the Keap1 E3 ligase. 
  
3.4.5.3. Nrf2 Protein Levels are Regulated in Cell-Cycle Dependent 
Manner 
 
The acquisition of long time-lapse images of live cells requires a stable experimental 
environment conditions and low sample irradiation, to prevent cellular damage. As 
Nrf2-Venus levels remained stable under unstimulated conditions even after 
prolonged imaging time, we can be confident that imaging conditions did not trigger 
Nrf2 activation (Figure 3.19A). Under these stable optimised imaging conditions we 
were able to identify an interesting novel pattern of Nrf2, which occurs in a cell-
cycle dependent manner immediately after cell division (Figure 3.19B & C, Movie 
16). This transient increase of Nrf2 nuclear levels occurred consistently with every 
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division process in both basal and stimulated conditions. The biological function of 
the transient rise in Nrf2-Venus expression was not defined, however cellular redox 
status is very tightly coupled to cell division and a proportion of cell-cycle regulating 
proteins contain highly reactive cysteine residues that can alter their activity in 
response to the ROS levels (Chiu & Dawes, 2012). It is therefore possible that the 
temporary increase of Nrf2 expression acts to sense and appropriately re-set the 
redox environment within the cell, in order to ensure appropriate progression of the 
subsequent division process. The consequence of Nrf2 activity on the cell cycle has 
been studied in a few laboratories and published reports show a dual effect of Nrf2 
activity on cell-cycle progression. Mouse hepatocytes isolated from regenerating 
liver, expressing a constitutively active Nrf2 mutant displayed a diminished rate of 
growth (Kohler et al, 2014). Therefore, high levels of Nrf2 have been shown to 
decrease the rate of cell division in proliferating cells.  On the other hand, Nrf2 KO 
cells showed a G2/M phase arrest, due to aggravated DNA damage, which did not 
allow continuing the division process (Reddy et al, 2008). Unfortunately, the 
attempts to synchronize the SK-N-AS cells in the Sanderson lab by double thymidine 
block or by the Nocodazole treatment to study this phenotype did not yield positive 
results. The effect of Nrf2 modulation could be further examined by cell-cycle 
analysis of the BACNrf2-Venus by FACS following application of Nrf2 inducers, such as 
SFN, CDDO-Me, or by addition of brusatol. It would be very interesting to 
investigate the effect of interruption of the post-cell division Nrf2 enhancement to 
clarify its functional role. In this context it is important to note that the proliferation 
of BACNrf2-Venus cells is greatly reduced as compared with WT SK-N-AS cells 
(personal observations), therefore expression of extra copies of Nrf2 also seems to be 
associated with a slower rate of cell proliferation. Significantly, this tendency was 
also observed in primary Nrf2-Venus MEF cells, which were isolated in Prof. 
White’s laboratory (University of Manchester, personal communication).  
 
The live cell imaging methodology provided interesting information on temporal 
changes in localisation of Nrf2 and NF-κB proteins. It is anticipated that changes in 
their nuclear localisation will correlate with responses in the target gene expression. 
However it is challenging to directly associate changes in dynamic protein 
localisation with the changes in its post-translational modification status by single 
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cell microscopy. Therefore additional biochemical analysis on Nrf2 activity, target 
DNA binding and post-translational modifications could be performed to 
complement this study. 
To conclude the BACNrf2-Venus is a robust tool for imaging near-physiological levels of 
Nrf2 protein. This live cell imaging approach holds a great potential to deliver high 
resolution of information about real-time protein dynamics and providing new 
insight into regulatory networks that maintain the cellular anti-oxidant potential 
driven by the Nrf2 activity. The summary of the main findings from this chapter is 
presented in diagram in Figure 3.20 below. 
 
Figure 3.20 Summary of key findings from Results Chapter 1. Low 
expression model of p65 achieved through lentiviral transduction allowed for 
real-time imaging of dynamic responses of NF-κB under basal and 
inflammatory conditions. 1) p65 nuclear translocation in response to TNFα is 
observed exclusively in astrocyte cells. The response of p65 to TNFα displays 
altered temporal behaviour in astrocytes grown in the presence of neurons and 
those observed in 2) pure astrocytic cultures. 3) Astrocytes demonstrate 
spontaneous p65 activation, which is likely to be a consequence of paracrine 
communication. 
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RESULTS CHAPTER 2 
 
4. Investigating Dynamic Crosstalk Between Nrf2 and NF-
κB Signalling Responses  
 
4.1. CHAPTER 2 AIMS: 	  
• Investigating the effect of inflammation on antioxidant activityat a 
single-cell level 
• Deciphering molecular interplay between Nrf2 and NF-κB  
• Investigating the Keap1 and GSK-3 mediated regulation of Nrf2 in 
response to inflammation 
 
4.2. Introduction 
 
As demonstrated in Results Chapter 1 the human SK-N-AS BACNrf2-Venus cell line is a 
physiologically relevant system to investigate dynamic conditional Nrf2 responses 
using both conventional biochemical and advanced live single-cell imaging 
techniques. The Nrf2 transcription factor is a master regulator against oxidative and 
chemical stress and a crucial player in resolving the potentially harmful effects of 
chronic inflammation. The cytoprotective effects of Nrf2 activating compounds and 
their potent inhibitory action on NF-κB mediated gene transcription is well 
characterised (Caccamo et al, 2005). Therefore, it is feasible that drugs that confer 
antioxidant protection may also provide opportunities for the treatment of a diverse 
group of human diseases that result from chronic inflammation. However, in 
comparison, the affects of NF-κB pathway activation on antioxidant defence 
mechanisms is much less well understood, despite numerous reports proposing 
points of potential cross-talk or interference between these two pathways. Finally, 
although there is functional evidence for imposed reciprocal effects between these 
pathways, the molecular mechanism of this crosstalk and key points of regulation 
remain unclear and may vary between cell-type or disease state.   
Live cell imaging studies provide single-cell resolution of dynamic physiological 
processes, a major benefit of this approach is that the temporal sequence of transient 
or changing conditional responses can be defined with clarity. Due to the inherent 
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heterogeneity that exists between cells within a population, common response 
mechanisms may be masked simply because they are not temporally synchronised 
throughout the population. For this reason important spatiotemporal details of 
signalling pathways may only be revealed through detailed live single-cell imaging 
studies, as was the case for the discovery of the existence and functional importance 
of NF-κB oscillatory signalling responses (Hoffmann et al, 2002).  
In this study we extended live cell imaging procedures used to define p65/RelA 
dynamic behaviour to assess the dynamic reciprocal consequences of Nrf2 and NF-
κB pathway activation in BACNrf2-Venus cells. To facilitate these studies a p65-
dsRedXP plasmid, or a lentivirally integrated tagRFP-p65 fusion-proteins were used 
to imaged dynamic responses to inflammatory and antioxidant signalling in parallel 
in real-time.  
 
4.3. RESULTS 	  
4.3.1. Effects of TNFα  Stimulation on the Nrf2 Pathway in SK-N-AS 
Neuroblastoma Cells 
 
As expected stimulation of BACNrf2-Venus cells with TNFα (10ng/ml) led to an increase 
in NF-κB transcriptional activity, as measured by the NF-κB-Luc dual Luciferase 
assay (Figure 4.1A) (Methods 2.4.6). In addition, live cell imaging of BACNrf2-Venus 
cells showed that TNFα (10ng/ml) modestly increased nuclear levels of Nrf2-Venus 
(Figure 4.1B and 4.C, Movie 17). This effect was confirmed by western blot 
analysis, showing a maximal peak of nuclear Nrf2 accumulation at ~2hr post-
stimulation (Figure 4.1D, Quantification in Supplementary Figure 8.4). In contrast, 
the initial peak of nuclear p65 accumulation occurred at 30min post-stimulation, 
remaining higher than pre-stimulation levels for 24h (Figure 4.1D, Supplementary 
Figure 8.5). Significantly, no increase in cytoplasmic Nrf2 levels was observed in 
these studies (Figure 4.1E).  
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Figure 4.1. TNFα treatment increases nuclear Nrf2 levels. A) Results from NF-
κB-Luc the NF-κB transcriptional reporter assay performed on lysates from 
BACNrf2-Venus cells, which were incubated with or without 10ng/ml TNFα for 8h 
(n=2, triplicates). The imaging experiments were performed in a humidified 
atmosphere, at 37oC and 5% CO2. To ensure that the imaging process itself did not 
trigger changes in measured proteins, three time-lapse images were taken before 
any drug treatment was applied (equivalent to at least 21min of imaging, for more 
details refer to Methods Section 2.13). B) Averaged results from live-cell imaging 
analysis showing a rise in nuclear Nrf2-Venus levels in response to 10ng/ml TNFα 
in BACNrf2-Venus cells (n=3, c=48) (Movie 17). C) Representative time-lapse images 
of BACNrf2-Venus cells from the experimental data presented in panel B. D) Western 
blot of nuclear (quantified in Supplementary Figure 8.5) and E) cytoplasmic 
BACNrf2-Venus lysates fractions showing changes in Nrf2 and p65 changes in 
response to 10ng/ml TNFα. Blots emphasize the fact that most Nrf2 is restricted to 
the nuclear compartment. Error bars=STDEV(luciferase)/SEM(imaging). Scale 
bar=20µm. 
 
B) A) 
C) 
D) E) 
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4.3.1.1. Measuring Expression of Nrf2 Target Genes 	  	  
Next, it was important to verify if the increase of Nrf2 levels in response to TNFα 
were associated with parallel activation of ARE target genes. Before measuring the 
consequences of inflammatory signalling on Nrf2-mediated gene transcription, the  
relative induction of known Nrf2 response genes was investigated by Q-PCR 
(Methods 2.9) in BACNrf2-Venus cells following application of 2µM SFN for 8h (Figure 
4.2). As expected SFN treatment significantly increased expression of all tested Nrf2 
response genes, with the largest induction being observed with sulfiredoxin 
(SRXN1) (Figure 4.2E) and the smallest increase being NQO1 mRNA (Figure 4.2A). 
This confirmed that these target genes are responsive to Nrf2 activation in BACNrf2-
Venus neuroblastoma cells and can therefore be used as markers of Nrf2 activity in 
further conditional studies. 
 
To investigate if the observed TNFα−mediated rise in Nrf2 protein levels was 
associated with a parallel increase in Nrf2 mRNA and the expression of Nrf2 target 
genes, a Q-PCR analysis was performed to compare relative mRNA expression 
levels, under control or stimulated conditions (Figure 4.3A-F). Exposure to TNFα (10ng/ml)	  for	  8hr led to a significant rise in NRF2 mRNA expression in both 
the primary astrocytes and the BACVenus-Nrf2 cells (Figure 4.3G & H). Interestingly, 
although significant increases in NQO1, GCLC, HO-1 and Bach1 mRNA levels were 
also observed (Figure 4.3A, B, C, F respectively), no detectable changes in TXNRD1 
or SRXN1 expression were detected (Figure 4.3D, E). To test the effect of ectopic 
p65 expression on NRF2 gene transcription, the Nrf2-specific transcriptional reporter 
(kindly provided by Professor David MacEwan, University of Liverpool) was used, 
in which Luciferase expression is under transcriptional control of a 1.2kbp region of 
the NRF2 proximal promoter, to generate the pNRF2-Luc plasmid (Figure 4.3I). This 
enabled to directly quantify the p65-mediated effect on Nrf2 gene expression.   
 
Transfection of BACNrf2-Venus cells with p65-dsRedXP plasmid (Prof. M.White, 
University of Manchester) significantly increased pNRF2-Luc reporter activity in  
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Figure 4.2 Analysis of SFN activation of Nrf2-mediated target gene 
expression in BACNrf2-Venus neuroblastoma cells. A-F) Relative induction of 
Nrf2 target gene expression in response to 8hr incubation with DMSO (Control) 
or 2µM SFN. In each case target mRNA levels were normalised to β-Actin 
mRNA levels (n=3, in triplicates). The p-values were denoted as follows: 0.01-
0.05=*; 0.01-0.001=**, 0.001-0.0001=*** and p value< 0.0001=****. Error 
bars=Min/Max values. 	  
A) B) 
C) D) 
E) F) 
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Figure 4.3 TNFα-mediated NF-κB signalling induces Nrf2 transcription 
leading to enhanced expression of selective Nrf2 response genes in BACNrf2-
Venus cells. A-F) Relative induction of six Nrf2 target genes in response to 8hr 
stimulation with 10ng/ml TNFα (n=3, in triplicates). G) Relative induction of 
Nrf2 mRNA expression in response to 8hr exposure to 10ng/ml recombinant 
human TNFα in BACNrf2-Venus cells or H) stimulation of mouse cortical astrocytes 
with 10ng/ml murine, recombinant TNFα (n=3 in triplicates). I) Diagram 
showing pNRF2-Luc construct. J) Comparison of NRF2 promoter activity 
following co-transfection of BACNrf2-Venus cells with pNRF2-Luc + empty Blue 
script vector (BS) used as a control to define endogenous Nrf2 activity, or 
pNrf2-Luc + p65dsRedXP to assess the effects of enhanced levels of p65 on 
NRF2 transcription. Co-transfection studies using the NRF2 promoter region in 
which the κB2 site has been deleted (ΔκB2) show that its activity almost totally 
abolished. n=3 in triplicates, Error bars=SEM(luciferase)/Min/Max values 
(QPCR). 	  
C) A) B) 
F) D) E) 
G) H) I) 
J) 
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response to TNFα (10ng/ml)	   stimulation (Figure 4.3J). Significantly, deletion of 
the consensus NF-κB binding sequence (κB2) in the Nrf2 promoter region greatly 
reduced both basal and p65 enhanced pNRF2-Luc expression (Figure 4.3J). 
Therefore, some part of the basal Nrf2 expression and the majority of the observed TNFα−  mediated increase in nuclear Nrf2-Venus is mediated by NF-κB-mediated 
Nrf2 gene transcription. 
 
4.3.1.2. Imaging Nuclear Dynamics of p65 and Nrf2 Transcription 
Factors in Live Cells 	  	  
Having established the mild positive effect of TNFα on Nrf2 activity, next we 
proceeded to investigate the correlation spatio-temporal dynamics of both 
transcription factors. For this purpose, it was necessary to select the optimal imaging 
protocol to obtain an optimal specific signal for the near-endogenous levels of Nrf2-
Venus fluorescence, while also allowing parallel imaging of p65-dsRedXP 
dynamics. As described in (Chapter 1, 3.5A) the lambda scan imaging mode 
provided an excellent method for resolving low-level Nrf2-Venus signals from non-
specific autofluorescence.   In theory, this spectral unmixing approach should enable 
p65-dsRedXP to be imaged alongside Venus fluorescence, as the dsRedXP 
excitation spectrum also includes the 514nm wavelength that is usually used for 
illuminating Venus (Figure 4.4A and B). Initial imaging studies showed that the 
Nrf2-Venus could be spectrally unmixed from both autofluorescence and p65-
dsRedXP fluorescence (Figure 4.4B). However, lambda scan imaging relies on 
illumination with a single laser, and collection of the entire fluorescent signal with 
one detector set. Measurements of nuclear protein levels following TNFα in live 
cells using this method showed that high nuclear p65-dsRedXP levels correlated with 
a subsequent decrease of Nrf2-Venus signal (Figure 4.4C). To test whether this was 
an imaging artefact Nrf2-Venus and p65-dsRedXP signals were imaged using a 
stringent two channel imaging mode (Figure 4.4D), where the 514nm laser was used 
to illuminate the Venus signal passed through the narrow band pass filter (521-
539nm) and emission signals were collected using the ChS1 detector. Alternatively, 
p65-dsRedXP was sequentially excited by the 561nm laser and emission signals 
were collected using a separate ChS detector (filter range 600nm-630nm). Using this  
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Figure 4.4 Imaging BACNrf2-Venus transfected with p65-dsRedXP construct in 
response to TNFα . A) Lambda scan was used to simultaneously acquire Venus 
and dsRedXP fluorescent signals. B) Spectrally unmixed images showing 
separate green (Nrf2) and red (p65) channel emission profiles. C) Combined 
analysis of nuclear p65dsRedXP and Nrf2-Venus fluorescence following 
addition of 10ng/ml TNFα (added at 21min) treatment obtained by live cell 
imaging using the lambda scan mode. The Nrf2-Venus signal appeared to be 
quenched by increase in nuclear p65-dsRedXP levels. D) Comparable 
p65dsRedXP and Nrf2-Venus signals obtained under identical conditions using a 
stringent two-channel sequential illumination method with 514nm (for Venus) 
and 561nm (for dsRedXP) lasers and separate detectors to record green or red 
fluorescence signals respectively. Scale bar=20µm. 	  
C) 
A) 
D) 
B) 
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restricted two channel imaging method, no reduction in Nrf2-Venus was observed 
when p65-dsRedXP levels were high (Figure 4.4D). Therefore, in lambda scan 
analysis it appears that disproportionately high levels of dsRedXP artificially 
suppressed the detected Nrf2-Venus signal, although this effect was less significant 
when fluorescence signals were more evenly matched. Therefore, in order to perform 
an accurate quantitative analysis of conditional dynamics for both p65 and Nrf2 the 
two-channel mode of analysis was adopted in all subsequent combined Nrf2/p65 live 
cell imaging studies.  
 
One of the main aims of this study was to monitor dynamic changes in Nrf2 and p65 
distribution and abundance in response to inflammatory and anti-oxidant stimuli. 
Two different cell models were used to investigate these phenotypes. Firstly, 
BACNrf2-Venus cells transiently transfected with the p65-dsRedXP plasmid, or stably 
transduced with tagRFP-p65 lentivirus to generate the tagRFP-p65/BACNrf2-Venus cells, 
(Methods), resulting in the stable integration of the tagRFP-p65 fusion (Figure 4.5A). 
The lysates obtained from the BACNrf2-Venus and tagRFP-p65/BACNrf2-Venus were 
compared by western blot confirming the presence of bands representing both 
endogenous p65 and a higher molecular weight form corresponding to the 
fluorescently tagRFP-p65 fusion (Figure 4.5A). Treatment of the BACNrf2-Venus cells 
with 10ng/ml TNFα triggered classic p65-dsRedXP nuclear oscillations, resulting a 
subsequent increase in nuclear Nrf2-Venus levels (Figure 4.5B-G, Movie 19).  
Comparative Nrf2-Venus responses to stimulation with 10ng/ml TNFα  are shown in 
Figure 4.5C, with the highest induction of nuclear Nrf2 levels being exhibited in 
tagRFP-p65/BACNrf2-Venus cells.  Significantly, both tagRFP-p65 and p65-dsRedXP 
expressing cells demonstrated oscillatory p65 dynamics in response to the TNFα 
treatment (Figure 4.5D & E). Averaged nuclear fluorescence traces of tagRFP-p65 
and p65-dsRedXP are presented in Figure 4.5H. Both model systems show 
comparable temporal dynamics in nuclear p65 levels in response to 10ng/ml TNFα,  
although nuclear levels of p65-dsRedXP were slightly higher than tagRFP-p65, 
possibly due to high plasmid expression as compared to lentiviral method.  
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Figure 4.5 Nuclear translocation of p65 precedes increased levels of 
nuclear Nrf2-Venus. A) Western blot of lysates from BACNrf2-Venus cells and 
lentivirus transduced tagRFP-p65/BACNrf2-Venus cells, stably expressing the 
tagRFP-p65 fusion protein. B) Representative time-lapse images of BACNrf2-
Venus cells expressing the p65-dsRedXP plasmid in response to TNFα 
10ng/ml) stimulation. C) Comparison of averaged (n=3-7, c=13-46) nuclear 
Nrf2-Venus levels in either non-transfected BACNrf2-Venus, BACNrf2-Venus 
transfected with p65-dsRedXP or tagRFP-p65/BACNrf2-Venus cell models in 
response to 10ng/ml TNFα.  D) Representative single-cell traces of BACNrf2-
Venus transiently expressing p65-dsRedXP (Movie 19) or E) tagRFP-
p65/BACNrf2-Venus stably expressing the tagRFP-p65 fusion (Movie 18), each 
following stimulation with 10ng/ml TNFα. F) Average nuclear fluorescence 
levels of BACNrf2-Venus transfected with p65-dsRedXP in response to 10ng/ml 
TNFα (n=7, c=48) or G) tagRFP-p65/BACNrf2-Venus in response to 10ng/ml 
TNFα (n=3, c=13). H) Comparison of dynamic changes in nuclear p65-
dsRedXP and tagRFP-p65 proteins following stimulation with 10ng/ml 
TNFα. Error bars=SEM, Scale bar=20µm. 	  
A) 
C) D) 
B) 
E) 
F) G) H) 
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4.3.2. Measuring the Consequences of Concerted Nrf2 and p65 Activation 
 
To examine the consequences of combined pathway activation, BACNrf2-Venus 
expressing p65-dsRedXP cells were imaged following simultaneous stimulation with 
both 2µM SFN and 10ng/ml TNFα (Figure 4.6).  Quantification of dynamic changes 
in nuclear Nrf2-Venus and p65 levels showed that co-administration of SFN and 
TNFα did not inhibit TNFα induced p65-dsRedXP nuclear accumulation (Figure 
4.6A). However, co-stimulation did impose distinct changes in Nrf2 expression 
patterns. In addition to inducing higher overall levels of nuclear Nrf2-Venus (Figure 
4.6A and B), co-stimulation with TNFα and SFN imposed periodic fluctuations in 
nuclear Nrf2 levels, which were frequently sequential to oscillatory increases in 
nuclear p65. These periodic changes were far less pronounced when cells were 
stimulated with either SFN alone (Figure 4.6B). However, it is significant to note 
that imposed periodic changes in nuclear Nrf2 were observed in both p65-dsRedXP 
transfected (Figure 4.6A, Movie 20) and non-transfected BACNrf2-Venus cells (Figure 
4.6B). Analysis of Nrf2 transcriptional activity using the, ARE-Luc reporter 
confirmed that co-stimulation with TNFα and SFN enhanced Nrf2 transcriptional 
activity in comparison to levels observed when cells were stimulated with either 
TNFα or SFN alone (Figure 4.6D), which was in agreement with imaging data 
showing higher Nrf2 protein levels in SFN+TNFα treated cells as opposed to ones 
treated only with SFN compound (Figure 4.6C). This suggested that under conditions 
in which both pathways are activated, periodic increases in nuclear Nrf2-Venus 
result in increased Nrf2 transcriptional activity as a result of p65 sequential nuclear 
entry events.  
To compare the effects of increasing p65 expression on nuclear Nrf2 induction 
following SFN+TNFα co-stimulation, nuclear levels of Nrf2-Venus were measured 
in three different conditions: (i) BACNrf2-Venus cells with endogenous levels of p65, (ii) 
BACNrf2-Venus cells also stably expressing near endogenous levels of tagRFP-p65, or 
(iii) BACNrf2-Venus cells transiently expressing higher levels of p65-dsRedXP (Figure 
4.6E).  Interestingly, the stable low-level tagRFP-p65 expressing BACNrf2-Venus cell 
line displayed the highest Nrf2 induction in response to SFN+TNFα co-stimulation, 
with non-transfected and p65-dsRedXP transfected BACNrf2-Venus cells exhibiting 
similar lower levels of Nrf2-Venus induction.  
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Figure 4.6 Co-stimulation with TNFα and SFN imposes sequential periodic 
oscillations in nuclear levels of p65-dsRedXP and Nrf2-Venus. A) 
Representative single-cell measurement of p65-dsRedXP and Nrf2-Venus 
nuclear dynamics in response to co-stimulation with TNFα (10ng/ml) and SFN 
(2μM) (Movie 20). B) Representative nuclear fluorescence traces of BACNrf2-Venus 
cells following exposure to SFN or SFN + TNFα. C) Averaged levels of nuclear 
Nrf2-Venus following stimulation with SFP alone or SFN+TNFα (n=4, c=31-
49). D) Comparative ARE-Luc reporter activity in BACNrf2-Venus cells treated for 
8hr with either DMSO, TNFα (10ng/ml), SFN (2μM) or SFN+TNFα (n=3, in 
triplicates). E) Comparison of mean Nrf2-Venus levels following SFN+TNFα 
co-stimulation in BACNrf2-Venus cells transiently expressing p65-dsRedXP or 
BACNrf2-Venus cells with lentivirally-integrated tagRFP-p65.  F) Relative levels of 
nuclear Nrf2-Venus expression in BACNrf2-Venus cells following stimulation with 
2μM SFN in the presence or absence of p65-dsRedXP expression (n=3, c=36-
39). Error bars=SEM(imaging)/STDEV(luciferase). 	  
A) 
E) 
C) D) 
B) 
F) 
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To measure the effect of p65-dsRedXP expression on SFN mediated induction of 
Nrf2-Venus, BACNrf2-Venus cells expressing p65-dsRedXP were treated with 2µM SFN 
(Figure 4.6F). Comparison of transfected and non-transfected cells showed no 
significant difference in Nrf2-Venus induction between these experimental models, 
implying that expression of higher levels of p65 did not simply translate into greater 
levels of Nrf2-Venus expression in response to SFN activation. 
To assess if p65-imposed changes in Nrf2 nuclear dynamics was unique to SFN 
stimulation, an alternative Nrf2 activating compound (CDDO-Me) was used instead 
(Figure 4.7). Co-administration of CDDO-Me+TNFα also evoked a p65-imposed 
increase in nuclear Nrf2-Venus expression (Figure 4.7A).  In addition, application of 
100nM CDDO-Me did not prevent p65-dsRedXP nuclear entry in response to TNFα 
Figure. 4.7 Nuclear translocation of p65 induces subsequent increases in 
nuclear Nrf2 nuclear in response to combined CDDO-Me and TNFα 
stimulation. A) Representative and B) averaged nuclear fluorescence levels 
in BACNrf2-Venus cells expressing p65-dsRedXP following co-stimulation with 
100nM CDDO-Me and 10ng/ml TNFα (n=4, c=49). C) Representative time-
lapse images from the experiment shown in A&B. Error bars=SEM, scale 
bar=20µm. 	  
A) B) 
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activation (Figure 4.7). Therefore, co-stimulation with TNFα and either CDDO-Me 
or SFN led to analogous temporal changes in Nrf2-Venus nuclear fluorescence. 
 
4.3.3. Investigating The Effect of IL-1β  on Nrf2 Signalling 
 
To determine if TNFα induced changes in Nrf2-Venus nuclear dynamics could also 
be initiated by other activators of NF-κB signalling, the effects of IL-1β application 
on BACNrf2-Venus cells was investigated. IL-1β is known to be a potent activator of the 
NF-κB pathway in many cell types (Heyden & Ghosh, 2008). Measurement of NF-
κb-Luc transcriptional reporter activity in BACNrf2-Venus cells showed a significant 
increase in 5xκB driven Luciferase activity following 8hr treatment with 10ng/ml IL-
1β (Figure 4.8Α). 
 
In addition, live cell imaging studies show that 10ng/ml IL-1β triggered tagRFP-p65 
nuclear/cytoplasmic oscillations in tagRFP-p65/BACNrf2-Venus cells, which in turn 
caused a sequential rise in Nrf2-Venus levels shortly after p65 nuclear accumulation 
(Figure 4.8B), leading to an almost two-fold increase in nuclear Nrf2 levels (Figure 
8D, Movie 21).  
Consistent with this observation, IL-1β also enhanced CDDO-Me mediated Nrf2 
induction in BACNrf2-Venus cells (Figure 4.8E). Therefore, stimulation of cells with 
either TNFα or IL-1β trigger similar effects on the Nrf2 responses. 
 
4.3.4. Investigating The Role of Keap1 Regulation of Nuclear Nrf2 Dynamics 
Under Inflammatory Conditions 
 
The application of CDDO-Me and SFN led to transient stabilisation of p65 induced 
Nrf2 nuclear increases (Figure 4.6A & 4.7A) and both compounds act by inhibiting 
Keap1 mediated Nrf2 proteasomal degradation (Hayes & Dinkova-Kostova, 2014). 
Therefore, to investigate the role of Keap1 in controlling cytokine-induced nuclear 
Nrf2-Venus levels, Keap1 expression was knocked down by siRNA in both tagRFP- 
p65/BACNrf2-Venus and BACNrf2-Venus cell models (Figure 4.9). Depletion of Keap1 
caused a substantial rise in levels of both endogenous and Venus labelled Nrf2 
proteins as demonstrated by data from western blot analysis (Figure 4.9A). 
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Figure 4.8 IL-1β  induces the accumulation nuclear Nrf2-Venus and 
enhances CDDO-Me-mediated Nrf2 induction. A) NF-κb-Luc reporter 
activity in response to 8hr 10ng/ml IL-1β treatment in BACNrf2-Venus cells (n=1, 
in triplicates). B) Nuclear fluorescence levels of p65 and Nrf2 in tagRFP-
p65/BACNrf2-Venus cells treated with 10ng/ml IL-1β (n=1, c=7) (Movie 21). C) 
Representative time-lapse images of BACNrf2-Venus cells treated with 10ng/ml IL-
1β. D) Nuclear levels of Nrf2-Venus in response to 10g/ml IL-1β (n=3, c=37). 
E) Nrf2-Venus nuclear levels in response to 100nM CDDO-Me, or combined 
treatment with 100n MCDDO-Me and 10ng/ml IL-1β (n=4, c=48). Error 
bars=SEM, scale bar 20µM. 
 
A) B) 
C) 
D) E) 
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Figure 4.9 Keap1 controls the levels of newly transcribed Nrf2-Venus. A) 
Western blot comparing lysates from mock control, siCTR and siKeap1 
transfected BACNrf2-Venus cells, following 48hr of transfection. Keap1 siRNA 
effectively reduces Keap1 protein levels and led to higher basal levels of Nrf2 
and Nrf2-Venus proteins. B) Keap1 knockdown increased Nrf2-Venus 
expression in BACNrf2-Venus cells (c=40). C) Time-lapse images of tagRFP-
p65/BACNrf2-Venus cells transfected with siCTR (control) (Movie 23) or D) 
siKeap1 (Movie 22), in both cases cells were treated with 10ng/ml TNFα and 
imaged over an 8h period. E) Comparison of Nrf2-Venus levels in siCTR and 
siKeap1 treated cells following stimulation with 10ng/ml TNFα showing higher 
Nrf2-Venus accumulation in cells with reduced Keap1 expression (n=3). F) 
Averaged nuclear tagRFP-p65 and Nrf2-Venus fluorescence in tagRFP-
p65/BACNrf2-Venus cells following stimulation with 10ng/ml TNFα 48hr after 
Keap1 depletion (n=3, c=13-31). Error bars=SEM. Scale bar=20µm. 
 
A) B) 
C) 
D) 
E) F) 
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Imaging of unstimulated BACNrf2-Venus cells displayed a >2fold increase in nuclear 
fluorescence in cells treated with siKeap1 in comparison to control siCTR treated 
cells (Figure 4.9B). Interestingly, real-time imaging of Nrf2-Venus in response to 
TNFα stimulation showed that levels of nuclear Nrf2-Venus were significantly 
higher in Keap1 depleted tagRFP-p65/BACNrf2-Venus cells, in comparison to control 
siRNA transfected cells (Figure 4.9C-F).  Significantly, TNFα induced robust 
nuclear accumulation of tagRFP-p65 in Keap1 depleted cells and this preceded a 
subsequent increase in nuclear Nrf2-Venus levels (Figure 4.9F, Movie 22 & 23). To 
summarise, Keap1 plays a significant role in regulating the inflammatory driven 
increase in Nrf2. 
 
4.3.5. Investigating the GSK-3-mediated Nrf2 Regulation Following Cytokine 
Induced Inflammatory Stress 
 
While Keap1 is believed to be the primary cytoplasmic regulator of Nrf2 expression 
levels, the GSK-3α/β kinase has been identified as a negative regulator of nuclear, 
Nrf2 expression (Chowdhry et al, 2013). To investigate the effect of GSK-3 on Nrf2 
nuclear dynamics live cell imaging was performed on BACNrf2-Venus cells grown in 
media containing 2% or 10% serum, in the presence or absence of the GSK-3 
inhibitor CHIR99021 (Figure 4.10). Cells imaged in low serum conditions showed 
small increase in nuclear Nrf2 levels in response to the GSK-3 inhibition (Figure 
4.10A). Also, co-application of TNFα further enhanced Nrf2-Venus protein 
induction; although these cells exhibited a greater variability in consequent levels of 
Nrf2-Venus protein (Figure 4.10B). Also, stimulation with TNFα further enhanced 
Nrf2-Venus induction; although these cells exhibited a greater variability in levels of 
Nrf2-venus expression (Figure 4.10B). Comparison of the relative levels of 
TNFα mediated Nrf2-Venus induction, in the presence or absence of CHIR99021 
showed a slight enhancement of TNFα mediated Nrf2 induction as a result of GSK-3 
inhibition, and an alteration to Nrf2 nuclear dynamics (Figure 4.10C). Time-lapse 
imaging of TNFα induced tagRFP-p65 protein dynamics showed a greater and more 
rapid initial peak of p65 nuclear accumulation in tagRFP-p65/BACNrf2-Venus cells 
(Figure 4.10D) compared to BACNrf2-Venus cells (Figure 4.10C).  
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Figure 4.10 The effect of GSK-3 inhibition on the Nrf2 nuclear 
accumulation and activity. A) Nuclear Nrf2-Venus fluorescence was 
monitored in BACNrf2-Venus cells treated with 10µM CHIR99021 inhibitor in cell 
media supplemented with low or high serum (n=1, c=12) (inhibitor addition 
indicated by dashed line *). B) The BACNrf2-Venus cells treated with 10µM 
CHR99021 (at time indicated *) did not show significant enhanced nuclear 
stabilisation of Nrf2-Venus as a results of 10ng/ml TNFα stimulation (marked 
as **) in both, low and high serum environments (n=1, c=15). C) The Nrf2-
Venus nuclear levels following GSK-3 inhibition (dashed line *) +/- 10ng/ml 
TNFα (dashed line ∗∗) in BACNrf2-Venus cells grown in 10% FBS containing 
media (n=2, c=20). D) The comparison of tagRFP-p65 nuclear dynamics 
following TNFα stimulation 30min after +/- addition of 10µM CHIR99021 
inhibition, displayed slightly shorter nuclear accumulation event in cells pre-
treated with GSK-3 inhibitor. E) The ARE-Luc expression levels following 6hr 
DMSO, 10µM CHIR99021, 10ng/ml TNFα or joint treatment of TNFα and 
CHIR99021 (n=3, in triplicates). (F-G) Relative mRNA expression of GCLC 
and NQO1 do not show significant changes under basal and TNFα induced 
(8hr) activity as a result of CHIR99021 treatment (added 30min before TNFα) 
(n=1, in triplicates). Error bars=SEM(imaging)/STDEV(luciferase and QPCR). 
 
A) B) 
C) D) 
E) F) G) 
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The effect of GSK-3 inhibition on Nrf2 transcriptional activity was investigated by 
measuring ARE-Luc reporter activity and Q-PCR was performed to quantify levels 
of expression of Nrf2 target genes (Figure 4.10 E-G).  Inhibition of GSK-3 with 
10µM CHIR99021 resulted in a slight increase in ARE-Luc activity, however neither 
single nor combined treatment with TNFα induced any further enhancement of this 
effect (Figure 4.10E). Inhibition of GSK-3 (addition of 10µM CHIR99021 for 8h) 
did not significantly change NQO1 or GCLC mRNA expression levels, even in 
combination with TNFα stimulation (Figure 4.10F & G). Therefore, it would appear 
that GSK-3 kinase has a negligible effect on Nrf2 transcriptional activity and did not 
enhance TNFα mediated gene expression.  
 
4.3.6. Effect of Prolonged TNFα  Stimulation on Nrf2 Dynamics and 
Transcriptional Activity  
 
So far the experimental design focused on investigating acute inflammation by 
TNFα, however we were interested if chronic cytokine signalling is associated with 
dampening of the protective antioxidant responses. To investigate the effect of 
longer-term TNFα activation of NF-κB signalling on Nrf2 responses, BACNrf2-Venus 
cells were continuously exposed to TNFα (10ng/ml) stimulation for 64h, before 
measuring Nrf2 transcriptional activity and conditional changes in Nrf2 dynamics 
(Figure 4.11). 
In contrast to short-term (8h) TNFα stimulation of BACNrf2-Venus cells, prolonged 
exposure to 10ng/ml TNFα significantly reduced basal ARE-Luc activity and 
diminished induction of Nrf2 by 2µM SFN (Figure 11A). However, live cell imaging 
studies showed no significant differences between cells pre-treaded with TNFα for 
64hrs, compared to control (mock-stimulated) cells (Figure 4.11B & C). In each case 
SFN (2µM) induction led to a robust increase in levels of nuclear Nrf2-Venus 
(Figure 4.11B & C). Measurement of changes in gene expression for a selection of 
well-known Nrf2-target genes (NQO1, GCLC and HO-1) following 64hr exposure to 
TNFα again showed pleiotropic effects (Figure 4.11D-F). While NQO1 showed a 
reduced response to the SFN induction following 64h exposure to TNFα (Figure 
4.11F), the levels of GCLC mRNA remained unchanged (Figure 4.11D) and HO-1 
gene expression was amplified (Figure 4.11E). Therefore, from this data the  
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Figure 4.11 Long TNFα exposure does not prevent effective Nrf2 
activation with SFN. A) ARE-Luc expression levels following 64hr 
10ng/ml TNFα treatment, showing impaired induction in response to (8hr) 
2μM SFN (n=2, in triplicates). B) Nrf2-Venus protein levels following the 
2μM SFN treatment are not impaired by 64hr TNFα pre-treatment. C) 
Representative images from the experiment. D-F) Relative mRNA 
expression levels of GCLC, HO-1 and NQO1 following 8hr 2μM SFN 
induction (n=2, in triplicates). Error bars=STDEV(luciferase, QPCR)/SEM 
(imaging). 	  
A) B) 
C) 
D) E) F) 
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net effect of longer-term TNFα stimulation on cellular anti-oxidant responses 
remains unclear. 
 
4.3.7. Impact of Nrf2 Activation on NF-κB Pathway Dynamic Responses 
    
To investigate how activation of the Nrf2 pathway may modulate NF-κB 
transcriptional activity several canonical target genes were measures in response to 
TNFα or joint TNFα+SFN stimulation (Figure 4.12). Levels of IΚBα, IL-6 and 
SOD-2 mRNA were significantly reduced in BACNrf2-Venus cells in response to SFN 
activation (Figure 4.12A-C). Although, IL-8 expression also followed this trend, 
measured differences in mRNA levels were not significant (Figure 4.12D). 
As previously demonstrated (Section 4.3.1.1) transcription of the NRF2 gene can be 
driven by NF-κB (p65). Therefore it is possibly not surprising that TNFα triggered 
expression of Nrf2 was also reduced in response to inhibitory SFN effect (Figure 
4.12E) and the co-stimulation with SFN caused a significant reduction in levels of 
Nrf2 mRNA expression in response to acute inflammation.  
 
Live cell imaging studies show that induction of the Nrf2 pathway by SFN or 
CDDO-Me did not interfere with nuclear translocations of p65 in response to TNFα. 
It was evident that nuclear accumulation of p65 peaked about 30min after TNFα 
addition, and was not affected by the co-treatments with either the SFN or CDDO-
Me drugs.  
In order to investigate how changes in cellular Nrf2 levels influence p65 dynamics 
further, Nrf2 was expressed from a high expression CMV-Venus-Nrf2 plasmid and 
imaged in p65-dsRedXP expressing SK-N-AS cells in response to TNFα (Figure 
4.13). Nuclear fluorescence levels of Venus-Nrf2 and p65-dsRedXP demonstrate that 
high levels of Nrf2 inhibit nuclear accumulation of p65-dsRedXP in response to 
TNFα (Figure 4.13A-C). Comparison of the near-endogenous Nrf2 expression 
system BACNrf2-Venus with plasmid-transfected cells highlighted the fact that p65-
dsRedXP accumulation was significantly inhibited in the high expression model 
system (Figure 4.13C).  What is more, the BAC encoded Nrf2-Venus and plasmid 
expressed Venus-Nrf2 behaved differently in response to TNFα (Figure 13D). 
Specifically, the Venus-Nrf2 plasmid failed to show 
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Figure 4.12 SFN reduces expression of TNFα induced NF-κB target genes. 
A-D) The canonical NF-κB target genes expression profiles, in response to 8hr 
TNFα or co-treatments with 10ng/ml TNFα and 2µM SFN, normalised to β-
actin. E) Administration of SFN with TNFα led to reduction in Nrf2 mRNA 
expression. Error bars=STDEV, (n=3, in triplicates). 	  
A) B) 
C) D) 
E) 
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Figure 4.13 Nrf2 overexpression disrupts the p65-dsRedXP dynamics in 
response to inflammatory stimuli. A) Averaged nuclear fluorescence of 
Venus-Nrf2 (expressed from a plasmid) and p65-dsRedXP in response to 
10ng/ml TNFα in SK-N-AS cells (n=3, c=17). B) Representative single cell 
traces. C) Comparison of p65 responses to 10ng/ml TNFα in BACNrf2-Venus and 
in SK-N-AS cells expressing Venus-Nrf2 plasmid, showing less effective p65 
nuclear accumulation. D) Comparison of Nrf2 responses in BACNrf2-Venus and 
SK-N-AS cells transfected with Venus-Nrf2. E) Representative images from 
the experiment. Scale bar=10µM, Error bars=SEM. Scale bar=20µm. 	  
A) B) 
C) D) 
E) 
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cytokine dependant increases in nuclear levels (Figure 4.13D). Data from these 
experiments highlight the need for strict regulation of Nrf2 activity, as high levels 
can disrupt NF-κB activity in response to inflammation. 
 
4.4. DISCUSSION 
 
Work presented in this chapter describes the combined use of both population-level 
and advanced live cell imaging techniques to investigate the extent and consequence 
of conditional crosstalk between the NF-κB and Nrf2 response pathways.  
 
In chapter evidence was presented to demonstrate the utility of the recently generated 
BACNrf2-Venus stable cell-line as a physiologically relevant model to study dynamic 
conditional Nrf2 responses. In this cell-line the Nrf2-Venus fusion protein is 
expressed from an endogenous genomic context, enabling all of the sequential stages 
of gene expression and protein dynamics to be investigated in real-time. Having 
established that the Nrf2-Venus protein is expressed at near endogenous levels and 
responds as predicted to canonical methods of Nrf2 pathway activation, we were 
interested to use the BACNrf2-Venus stable cell-line as a sensitive model system to 
investigate the relative conditional dominance and reciprocal affects of NF-κB and 
Nrf2 signalling in live cells.   
 
The temporal dynamics of TNFα induced p65 responses have been extensively 
characterised in the SK-N-AS cell line, using both live cell imaging methods and 
NF-κb-Luc transcriptional reporter assays (Ashall et al, 2002; Nelson et al, 2004).  
Initial work in this study, replicated the reported oscillatory dynamics of 
TNFα−induced p65 nuclear/cytoplasmic shuttling (Figure 4.5D, Movie 19), and the 
associated rise in NF-κB transcriptional activity in the BACNrf2-Venus stable cell-line 
(Figure 1A) previously reported by Ashall et al (Ashall et al, 2002). Considering the 
reported anti-inflammatory action of the Nrf2 pathway (Chen et al, 2003), it is 
significant to note that under basal/unstimulated conditions, the extra genomic copies 
of Nrf2-Venus in the BACNrf2-Venus cell-line, did not impart TNFα mediated activation 
of the NF-κB pathway as the cytokine signalling was able to trigger nuclear 
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translocation of endogenous p65 and activate the transcription of target genes (Figure 
4.1A & Figure 4.5). 
 
The TNFα induced Nrf2 was previously observed in monocytes and astrocytes and 
in agreement with those observations it was also detected in the neuroblastoma cell 
model in this study (Figure 4.1B-D) (Rushwoth et al, 2012; Correa et al, 2012). To 
assess whether TNFα stimulation conferred universal, or selective, increases in Nrf2 
target gene expression, the induction of a panel of Nrf2 target genes was investigated 
following addition of 10ng/ml TNFα and compared to effect following well-
characterised Nrf2 inducer SFN. Following stimulation with SFN alone, mRNA 
levels of HO-1, NQO1, GCLC, SFXN1, Bach1 and TRXN1 were all significantly 
increased (Figure 4.2), confirming that these canonical Nrf2 response genes are 
responding to Nrf2 pathway stimulation in BACNrf2-Venus cells. However, when qPCR 
was performed on extracts prepared from cells treated for 8h with TNFα (10 ng/ml), 
only 4/6 tested Nrf2 response genes (GCLC, HO-1, NQO1 and Bach1) showed 
marked increase in transcript abundance (Figure 4.3A-C & F). With SRXN1 and 
TRXN1 consistently showing no significant increase in expression following TNFα 
stimulation (Figure 4.4D & E). Expression of NQO1 is believed to be an excellent 
marker of Nrf2 activity, as so far no other transcription factor binding sites have been 
identified in the promoter region of the NQO1 gene (Habas et al, 2013).  In contrast, 
the promoter sequence of HO-1 is complex and more promiscuous, as it also encodes 
κB elements upstream the start codon. Therefore, HO-1 may be jointly regulated by 
both NF-κB and Nrf2 response pathways (Kim et al, 2013).  
Almost all of the selected Nrf2 regulated genes have prominent functions in 
antioxidant defence, with the exception of Bach1, which is atypical, as it is able to 
inhibit the expression of antioxidant genes.  Like Nrf2, Bach1 recognises the ARE 
consensus sequences however, it lacks the transactivation domain, required to initiate 
transcription, therefore it is though to compete with Nrf2 for access to ARE-elements 
in the promoters of Nrf2 target genes (Jyrkkanen et al, 2011). Thus providing a 
negative regulatory loop, which may act to tune down expression of Bach-1 sensitive 
genes. The reason why the SFXN1 and TRXN1 genes did not respond to TNFα 
treatment is unclear, however it can be speculated that they are more prone to Bach1 
negative feedback, which demonstrated an increase in mRNA levels following TNFα 
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(Figure 4.3F) or they are not favoured for transcription under conditions of 
inflammatory stress.  
 
The promoter of the SFXN1 gene was previously analysed by Harpers et al (Harpers 
et al, 2015) in order to study the effects of inflammation on Nrf2 activity in human 
hepatocytes. In this study no changes in Nrf2 transcriptional activity were observed 
following stimulation with TNFα (20ng/ml) . However, it should be emphasised that 
in the Harpers et al study Nrf2 transcriptional activity was assessed by measuring 
promoter activity of the SFXN1 gene alone. In this context, our results concur with 
their findings, however the broader analysis of potential Nrf2 response genes 
performed in this study shows that although TNFα stimulation of SK-N-AS cells 
increases both nuclear Nrf2, the expression profiles of ARE-containing target genes 
is selective. This may be due to differential epigenetic modification of ARE genes, or 
conditional changes in co-factor availability etc. Significantly, both of these 
scenarios may be cell type specific and in this context it should be noted that SK-N-
AS cells are neuroblastoma derived and may have undergone cancer-induced 
changes in genes expression profiles.  
 
 Combining the results obtained from quantitative single-cell imaging studies and Q-
PCR data we have established that a ~50% increase in nuclear Nrf2 levels (as 
measured by nuclear Nrf2-Venus fluorescence) is sufficient to trigger expression of a 
selective majority of ARE containing Nrf2 response genes.  
 
As the human Nrf2 promoter region contains two NF-κB binding sites (κB1 & κB2 
sites) (Rushworth et al, 2012) we were keen to establish whether TNFα stimulation 
was directly enhancing Nrf2 transcription. For this reason a new reporter of Nrf2 
gene transcription pNRF2-Luc was generated, in which luciferase expression was 
under control of the endogenous 1.2kb proximal Nrf2 transcriptional promoter region 
(Figure 4.3I).  Using this reporter it was possible to show that cells expressing a p65-
dsRedXP plasmid exhibited three times more Nrf2 transcription compared to cells 
transfected with a Blue Script control plasmid (Figure 4.4J). Significantly, deletion 
of the κB2 sites in the NRF2 promoter sequence reduced both basal and p65-
dsRedXP driven Nrf2-promoter activity. 
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Therefore, our data is consistent with previous reports showing that Nrf2 activity in 
acute myeloid leukaemia (AML) is driven by NF-κB activity (Rushwort et al, 2012). 
Significantly, our data primary mouse astrocytes (Figure 4.3H) shows that TNFα 
mediated activation of NRF2 transcription is not restricted to cancer derived cells.   
 
The fundamental aim of this study was to perform live cell imaging experiments on 
Nrf2 and p65 transcription factors to investigate the extent of molecular crosstalk 
between these processes. Therefore, it was essential to define the best imaging 
method to simultaneously monitor the localisation and relative abundance of  
fluorescently labelled proteins under investigation. The lambda scan approach was 
validated as a effective method for imaging low levels of Nrf2-Venus expression, 
leading to the enhancement of the Venus signal and reduction of the background 
autofluorescence (Fig 4.2. Chapter1). Therefore, this imaging mode was also initially 
used to monitor the combined spatio-temporal dynamics of Nrf2-Venus and p65-
dsRedXP proteins in response to TNFα stimulation (Figure 4.4A).  This was possible 
as the dsRedXP excitation spectrum includes the 514nm wavelength, which is also 
usually used to excite the Venus tag; therefore both fluorescent proteins could be 
excited by the same 514nm laser. However, after extensive profiling we became 
concerned that in the context of co-expression studies this approach may impose 
errors in Venus fluorescence values, especially when levels of the p65-dsRedXP 
fusion protein were relatively high. (Figure 4.4C).  We believe the cause of this 
problem was that the acquisition of images using the lambda-scan mode relies on 
signal detection with a single set of detectors. These can become temporarily 
saturated by a very bright fluorescent signal (e.g. p65-dsRedXP nuclear 
accumulation), as a result they are unable to detect subtle difference in Venus and 
p65-dsRedXP emission spectra. This problem highlights the importance of selecting 
appropriate imaging parameters, especially when the protein under study needs to be 
expressed at very low levels. Having identified this problem, it was possible to 
design an alternative two-channel imaging strategy to solve this technical challenge. 
In this approach separate lasers and detector sets were used to sequentially illuminate 
and collect Venus and dsRedXP fluorescence signals (Figure 4.4D). One drawback 
of this approach was an inevitable loss of sensitivity in detecting the Nrf2-Venus 
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signal, however as it was clearly a more stringent method for the combined imaging 
of the two transcription factors, without the risk of introducing technical artefacts, 
this approach was adopted in all subsequent combined imaging studies.  
 
The first combined imaging study focused on the simultaneous measurement of p65 
and Nrf2 dynamic responses to TNFα stimulation in BACNrf2-Venus cells following 
transient transfection with the p65-dsRedXP plasmid, or lentiviral transduction with 
a tagRFP-p65 fusion protein (Figure 4.5).  Despite varying levels of p65 expression 
(plasmid >> lentivirus > endogenous), both systems displayed comparable TNFα-
imposed activation and oscillatory p65 nuclear dynamics, followed by a subsequent 
increase in Nrf2-Venus fluorescence (Figure 4.5A, B, F and G). Surprisingly, 
quantitative comparison of TNFα induced nuclear Nrf2-Venus levels showed that 
the highest level of Nrf2 induction was achieved in lenti-transduced tagRFP-
p65/BACNrf2-Venus cells (Figure 4.5C). It is as yet unclear why a model system in 
which p65 is expressed at near-physiological levels imposes a more potent effect on 
Nrf2 induction then one in which p65 is expressed at higher, and possibly saturating 
levels.  One possible explanation is that high expression levels of p65 could trigger 
formation of high proportion of p65-p65 homodimers, which are not as 
transcriptionally effective as the p65-p50 heterodimers (Chen et al, 1998). Therefore, 
even though more p65-dsRedXP protein is available than in tagRFP-p65 transduced 
cells, not all of it could be incorporated into transcriptionally superior NF-κB 
complex with p50. 
 
Significantly, data from live cell imaging studies revealed a novel dynamic 
consequence of simultaneous pathway activation.  In contrast to the single broad 
peak of Nrf2 induction, which was observed when BACNrf2-Venus were stimulated with 
SFN (Figure 4.6B); co-stimulation of p65-dsRedXP expressing BACNrf2-Venus cells 
induced an extended pattern of periodic changes in Nrf2 nuclear expression. 
Interestingly, it was possible to establish that these repetitive short-lived increases in 
nuclear Nrf2 levels were preceded by p65 nuclear shuttling events (Figure 4.6A & 
4.7A). Given that nuclear p65 increases the levels of nuclear Nrf2 in BACNrf2-Venus 
cells, we proposed a model in which the observed periodic changes in nuclear Nrf2 
levels result from enforced changes in the dynamic balance between Nrf2 production 
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and degradation. In this model, periodic increases in nuclear Nrf2 are driven by 
periodic TNFα−mediated increases in nuclear p65, which then drive Nrf2 
transcription, thus increasing the nuclear pool of Nrf2-Venus. The magnitude of this 
effect is amplified by the presence of SFN, which would reduce the negative effects 
of Keap1 mediated Nrf2 degradation. In combination these two effects cause the 
observed sharp increases in nuclear Nrf2 levels that follow bursts of p65 nuclear 
translocation (Figure 4.6A and 4.7A). Conversely, as p65 enters the cytoplasmic 
phase of its oscillatory cycle, transcription of Nrf2 decreases and degradation 
becomes the dominant phenotype, thus leading to a decrease in nuclear Nrf2 levels, 
until the next cycle of p65 nuclear translocation. 
Although this model explains the basic principles that we believe operate in the 
BACNrf2-Venus cells, several key issues remain unclear. In particular, it was not clear if 
imposed sequential variations in nuclear Nrf2 levels occur in response to alternate 
stimulation of both pathway and if they can be observed in other cell types. 
 
To address the same issue, with respect to differential activation of NF-κB 
signalling, IL-1β was used as an alternate method of stimulating NF-κB signalling in 
BACNrf2-Venus cells.  IL-1β activates NF-κB signalling via the ILR cell-surface 
receptor, which is distinct to that activated by TNFα (Hayden & Ghosh, 2008). 
(Figure 4.8 B-D). Significantly, application of IL-1β triggered	 an increase of ≈50% 
in nuclear Nrf2-venus levels, which was equivalent to the response achieved by 
TNFα induction (Figure 4.8D vs. 4.1B). As with TNFα stimulation, IL-
1β also enhanced the effects of CDDO-Me induced Nrf2-Venus nuclear 
accumulation (Fig 4.8E). Therefore, both IL-1β and TNFα cytokines drive enhanced 
sequential increases in nuclear Nrf2-Venus levels and both activators of NF-κB 
signalling increased antioxidant responses when added in combination with Keap1 
inhibiting compounds (SFN or CDDO-Me) (Figure 4.6C & 4.8E). 
 
Both CDDO-Me and SFN exert their effects by inhibiting Keap1 mediated 
degradation of Nrf2. Therefore, depletion of Keap1 was expected to enhance levels 
of nuclear Nrf2 in response to TNFα stimulation. Our data shows that siRNA 
knockdown of Keap1 increases basal Nrf2-Venus nuclear fluorescence (Figure 4.9A, 
B, C). Interestingly, reduction of Keap1 cellular levels dramatically augmented 
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TNFα induced Nrf2 nuclear accumulation (Figure 4.9E, Movie) 22 & 23. This data 
is consistent with the idea that newly translated Nrf2 is under robust Keap1 mediated 
regulation in the neuroblastoma derived BACNrf2-Venus cells. However, it remains 
unclear whether newly translated Nrf2 is subjected to Keap1 assisted degradation in 
the cytoplasm directly after translation; or if nascent Nrf2 proteins are allowed to 
freely enter the nucleus and are then degraded, either within the nucleus, or 
following subsequent export into the cytoplasm. As such, further analysis of the 
mechanism underlying this phenotype is required, in order to facilitate the 
development of rational strategies to therapeutically manipulate these processes, 
under different conditions or disease states. These issues are addressed further in 
Results Chapter 3. 
 
In the proposed model for sequential p65-driven changes in nuclear Nrf2 levels, we 
propose the periodic increases in nuclear Nrf2 levels are driven by p65, enhanced 
levels of Nrf2 transcription. However, the down phase of each period is less easily 
explained. The sequential periodic pattern of nuclear Nrf2 expression is most clearly 
seen when cells are stimulated with activators of NF-κB signalling in the presence of 
SFN or CDDO-Me. The transcriptional increase of Nrf2 combined with Keap-1 
mediated degradation was expected to lead to a stable increase of Nrf2 levels over 
time. However, from our data it would appear that this trend does not operate under 
conditions of co-stimulation, suggesting that the primary mechanism of Nrf2 
degradation occurring during the ‘down-phase’ of p65 driven Nrf2 nuclear 
fluctuations, is likely to be Keap1 independent.   
 
An alternative mechanism of Nrf2 degradation has been reported which involves the 
GSK-3/β-TrCP axis, which primarily acts in the nucleus.  In this case, GSK-
3α/β targets Nrf2 for phosphorylation, which then acts as a signal for β-TrCP-
mediated ubiquitination and target degradation (Cuadrado, 2015). 
To explore the role of GSK-3-mediated Nrf2 regulation in BACVenus-Nrf2 cells, the 
effect of the GSK-3 inhibitor CHIR99021 (which effects both α and β isoforms of 
GSK-3) was investigated, in both low and high serum conditions (Figure 4.10A). As 
high-serum concentrations favour activation of PI3K, which is a potent GSK-3 
inhibitor, GSK-3 activity has been shown to be higher in low-serum media (Lee & 
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Kim, 2007). In this study, reduction of FBS to 2% modestly enhanced the Nrf2-
Venus accumulation in response to 10µM CHIR99021. However, the difference 
between 2% and 10% serum containing media was very small. Additionally, 
sequential treatment of BACNrf2-Venus cells with CHIR99021 for 30min, followed by 
10ng/ml TNFα did not significantly increased TNFα imposed Nrf2-Venus nuclear 
accumulation (Figure 10B & C). Therefore, under these conditions it did not appear 
that GSK-3 was playing a significant role in regulating Nrf2 levels following 
TNFα stimulation.  
There is also evidence in the literature that GSK-3 regulates the NF-κB pathway, 
although the net outcome of GSK-3 activity on inflammation is difficult to predict, as 
it is dependant on multiple combinatorial factors. In our studies, inhibition of GSK-
3α/β before TNFα stimulation, led to a slight reduction in the timing of the initial 
peak of p65-dsRedXP/tagRFP-p65 nuclear accumulation, and a small increase in 
ARE-Luc reporter activity (Figure 4.10). In combination with TNFα, CHIR99021 
did not led to significant changes in Nrf2 activity (Figure 4.10E). Equally, 
CHIR99021 did not increase basal or TNFα-induced expression of the Nrf2 target 
genes GCLC and NQO1 (Figure 10 F & G). Therefore, in the context of our model 
BACNrf2-Venus cells, GSK-3 appears to play a negligible role in controlling Nrf2 
activity under basal or inflammatory conditions. 
Prolonged acute inflammation has been associated with inhibition of the antioxidant 
pathway (Correa et al, 2012). Previous research on primary astrocytes has shown that 
24hr treatment with TNFα increased Nrf2 mRNA levels and the expression of 
antioxidant Nrf2 target genes (Correa et al, 2012). In contrast, Nrf2 activity was 
significantly reduced following 48hr exposure to TNFα. Interestingly, this effect was 
then reversed by inhibition of either the p38 MAPK or GSK-3α/β kinases. Therefore 
the chronic inflammation underlying many diseases could potentially interfere with 
effective physiological and pharmacological Nrf2 activation. 
 
To test whether long exposure to inflammatory cytokines reduced the potency of 
antioxidant activation, ARE-Luc expression was measured in BACNrf2-Venus 
neuroblastoma cells that had been pre-incubated for 64h with 10ng/ml TNFα with 
2µM SFN being added for the final 8h of the experiment (Figure 4.11A). 
Interestingly, we found that ARE-Luc expression was reduced following prolonged 
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cytokine exposure, also addition of 2µM SFN did not significantly increase Nrf2 
transcriptional activity (Figure 4.11A).  However, further investigation by live cell 
imaging of BACNrf2-Venus showed that Nrf2 protein levels were induced equally well in 
response to SFN either with or without 64hrs exposure to TNFα (Figure 4.11B & C). 
Measurements of Nrf2 target gene expression, following prolonged inflammatory 
stimulation displayed pleiotropic effects (Figure 4.11 D-F). However this approach 
was sub-optimal as the half-life of TNFα in media is limited and there is an 
increased possibility of non-NF-κB mediated effects following prolonged cytokine 
application (Paszek et al, 2010). Therefore, it would be more appropriate to study a 
relevant disease model where pathogenesis is correlated with chronic inflammation. 
The cellular changes that occur during chronic inflammation are complex and still 
not well defined. Also, they may differ in the magnitude and signaling pathways 
involved between tissue specific microenvironments.  
To summarise this data, there is conflicting evidence that long TNFα exposure has 
an inhibitory effect on Nrf2 transcriptional activity in the BACNrf2-Venus neuroblastoma 
cell line and requires more investigation.   
 
Numerous studies have shown that Nrf2 activating compounds, such as curcumin, 
SFN and tBHQ inhibit NF-κB-mediated expression of inflammatory genes (Hayes & 
Dinkova-Kostova, 2014). This outcome is believed to be mediated by HO-1 
expression, and an enhanced cellular redox status, which effectively inhibits NF-κB 
nuclear translocation (Lu et al, 2012). Evidence from this study suggests, that TNFα 
mediated induction of NF-κB response genes was significantly reduced when SFN 
was applied in parallel (Figure 4.12). This indicates that activation of both pathways 
at the same time may favour Nrf2 mediated responses, as joint TNFα and SFN 
application enhances both Nrf2 transcriptional activity and levels of Nrf2 expression 
(Figure 4.6). Interestingly, robust Nrf2 activation could also inhibit its own cytokine-
mediated transcription (Figure 4.12E) as combined SFN/TNFα treatment reduced 
Nrf2 mRNA levels, in comparison to TNFα stimulation alone.  
 
Therefore as Nrf2 activating compounds such as SFN are though to act 
predominantly on Keap1, it could function as an important regulator of balance 
between the conditional dominance of NF-κB or Nrf2 responses, as it limits the level 
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of Nrf2 protein available thereby ensuring levels do not reach levels at which NF-κB 
are inhibited, thus allowing an effective on-going response to inflammatory stress. 
This hypothesis was confirmed by study of the effect of high expression model of 
Nrf2 protein by the (CMV driven) Venus-Nrf2 construct in SK-N-AS cells (Figure 
4.13). The cells expressing the Venus-Nrf2 plasmid displayed reduction of p65-
dsRedXP nuclear accumulation in response to TNFα stimulation combined with the 
significant inhibition of the oscillatory shuttling behaviour (Figure 13A, B & E). 
This experiment demonstrated that high antioxidant activity acts to limit the NF-κB 
inflammatory responses by modulating its spatio-temporal behaviour.  
The data presented above highlights the importance of stringent Nrf2 regulation, 
since shifting the cellular redox balance may prevent effective inflammatory stimuli. 
NF-κB activity plays a vital role in anti-apoptotic signalling. It has been reported that 
high Nrf2 activity can trigger cell death however this phenomenon has not been 
studied in this investigation. Moreover, the CMV-Venus-Nrf2 plasmid does not 
contain an endogenous Nrf2 promoter sequence, or any other endogenous NRF2 
derived gene regulatory elements.  Therefore, the fact that TNFα did not increase 
nuclear levels of plasmid expressed Nrf2-Venus further supports the proposed 
transcriptional role of NF-κB in regulating the antioxidant master regulator by 
driving increased transcriptional activity (Figure 4.13D).  
 
To conclude, data presented in this chapter describe a novel pattern of sequential 
crosstalk between the Nrf2 and NF-κB pathways, in which inflammatory stress leads 
to a short sequential p65 mediated increase of Nrf2 transcription, leading to higher 
levels of Nrf2 protein, which is continually cleared away in the cytoplasm by Keap1-
dependent degradation. This stringent regulation ensures limited Nrf2 activation, 
allowing the NF-κB activity to continue, while providing enough antioxidant input to 
dampen the effect of inflammation. 
The results from this study provide new insight into the understanding of how 
inflammation modulates the antioxidant pathway activity and it is anticipated that it 
will contribute to design improved pharmacological interventions. The functional 
model summarising the data obtained in this chapter is presented in Figure 4.14 
below. 
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Having established to physiological relevance and utility of these protein expression 
systems it was possible to initiate a detailed series of experiments to investigate the 
changes in Nrf2 nuclear levels in response to inflammatory signalling, which are 
presented in the following chapters. 
Figure 4.14 Nrf2 regulation during acute inflammatory stress. Diagram 
summarising the experimental findings from Results Chapter 2. 1. Acute 
inflammatory signal such as TNFα triggers cascade of events, which lead to 2. 
nuclear accumulation of p65. 3. p65 binds to the κB consensus sequence 
within NRF2 promoter and initiates transcription. 4. Newly synthesises Nrf2 is 
subjected to Keap1-mediated degradation or nuclear accumulation 5., which 
leads to expression of Nrf2 target genes 6. such as HO-1. 7. High Nrf2 activity 
inhibits NF-κB function dampens inflammatory target gene expression. 8. 
TNFα leads to potentiated accumulation of Nrf2 protein levels stabilised by 
application of CDDO-Me or SFN compounds. 
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RESULTS CHAPTER 3 
 
5. Single-Cell Analysis of Nrf2 Dynamic Regulation in a 
Neuroblastoma Cell Model 
 
5.1. CHAPTER 3 AIMS 
 
• Detailed characterisation of Nrf2 regulation at a single-cell level 
• Assessment of the contribution of Keap1 and GSK-3 regulation in basal 
and induced antioxidant gene expression 
• Direct measurements of nuclear import and export rates of Nrf2 to 
determine Nrf2 life-cycle 
• Assessment of alternative Nrf2 post-translational regulation by 
acetylation 
 
5.2. Introduction 
 
In order to respond effectively to changes in local environmental conditions, 
individual cells must maintain non-cytotoxic basal levels of Nrf2 activity. Interplay 
of cellular signalling cascades and redox status ensures basal regulation of 
antioxidant activity while allowing for rapid activation in the event of stress. 
Several proteins have been identified as critical players in regulating Nrf2 protein 
stability, with Keap1 and GSK-3 being the most studied examples, however the 
conditional nature or redundancy of these two regulatory processes remains unclear. 
To design more effective therapeutic strategies for modulating antioxidant signalling 
and drug resistance, it is essential to understand the intricate dynamic control of Nrf2 
in living cells. As analysis of dynamic changes in single cells can reveal insights into 
the molecular mechanisms that are masked by intracellular heterogeneity, when 
dynamic signalling responses are studied using population level techniques.      
 
Work presented in this Chapter represents an extensive examination of conditional 
Nrf2 signalling responses, using both single-cell and population level techniques. 
Firstly, the extent of negative regulation of antioxidant responses by the cooperative 
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action of both Keap1 and GSK-3 is examined. Also, we present novel data relating to 
Nrf2 nuclear import/export dynamics obtained by using the photo-switchable 
pDendra2-Nrf2 fluorescent fusion. Lastly this investigation touches on the effect of 
Nrf2 accumulation in PML-NB nuclear structures, and the role of acetylation in 
modulating the antioxidant responses. 
 
The data presented below provides new evidence of dynamic Nrf2 regulation by 
multiple signalling cascades at single cell resolution, which act in concert to ensure 
stringent control the cellular antioxidant activity. 
 
5.3. RESULTS 
 
5.3.1. Analysis of Single-Cell Keap1 Dependent Nrf2 Regulation 
 
The FCCS measurements of mCherry-Keap1 and Nrf2-Venus protein diffusion in 
BACNrf2-Venus neuroblastoma cells provided strong evidence that the Nrf2-Venus and 
mCherry-Keap1 fluorescent fusions form stable complexes in the cytoplasm 
(Chapter 1, Figure 3.18).  
ARE-Luc dual luciferase assays were performed to investigate how modulation of 
Keap1 expression levels impacts on Nrf2 transcriptional activity (Figure 5.1A) 
(Methods 2.4.6). The transient expression of the mCherry-Keap1 plasmid in BACNrf2-
Venus cells reduced the basal ARE-luc activity by over 75%. Therefore, increased 
Keap1 protein levels were sufficient to inhibit basal Nrf2 transcriptional activity. 
Furthermore, live cell imaging experiments using BACNrf2-Venus cells, demonstrated 
that transient transfection with the mCherry-Keap1 construct led to the depletion of 
Nrf2-Venus fluorescence in Keap1 expressing cells (Figure 5.1B). However, the 
efficiency of Keap1-mediated Nrf2 clearance decreased when SK-N-AS cells were 
co-transfected with plasmid encoded Venus-Nrf2 (Figure 5.1C), as Venus-Nrf2 was 
retained in the cytoplasm. Therefore, although enhanced levels of plasmid encoded 
Keap1 were able to prevent nuclear entry of Venus-Nrf2, this interaction did not 
result in effective Nrf2 degradation (Figure 5.1C). Next, the effect of siRNA 
mediated Keap1 depletion on Nrf2 protein levels and localisation was measured in 
BACNrf2-Venus cells (Figure 5.1D). Reduction of Keap1  
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Figure 5.1 Keap1 regulates Nrf2 protein levels and activity. A) ARE-Luc 
reporter activity is reduced in cells transiently transfected with the mCherry-
Keap1 plasmid (n=1, in triplicates). B) Representative confocal images of 
BACNrf2-Venus cells expressing mCherry-Keap1, showing lower Nrf2-Venus 
plasmid levels in transfected cells. C) Cells transiently expressing Venus-Nrf2 
and mCherry-Keap1 plasmids exhibit co-localisation in SK-N-AS cells. D) 
Relative levels of Keap1 mRNA following 48hr knockdown with Keap1-
siRNA or a control siRNA (siCTR) (n=1, in triplicates). E) BAC Nrf2-Venus cells 
show enhanced levels of nuclear Nrf2-Venus following treatment with Keap1-
siRNA. Error bars=STDEV, scale bar=20µm.	  	  
A) B) 
C) 
D) E) 
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mRNA by approximately 75% led to high levels of nuclear Nrf2-Venus (Figure 
5.1E).  
Therefore, fine-tuning of Keap1 levels ensure robust control of Nrf2 under basal 
cellular conditions in the SK-N-AS neuroblastoma cell model. 
 
5.3.2. The Effect of Keap1 Overexpression on Nrf2 Localisation in Response to 
CDDO-Me 
 
To understand the impact of high cellular levels of Keap1 on Nrf2-Venus dynamic 
responses to CDDO-Me, single-cell analysis was performed using live-cell imaging 
of BACNrf2-Venus following addition of 100nM CDDO-Me (Figure 5.2). The 
representative time-lapse images from this experiment show that Nrf2-Venus 
cytoplasmic accumulation is confined to cells expressing the mCherry-Keap1 
plasmid (Figure 5.2A, Movie 24). In contrast, non-transfected cells, nuclear 
accumulation of Nrf2 was more pronounced in non-transfected cells (Figure 5.2A). 
Comparison of cytoplasmic and nuclear levels of Nrf2-Venus in mCherry-Keap1 
transfected cells show that CDDO-Me induced accumulation of Nrf2 was more 
pronounced in the cytoplasmic fraction (Figure 5.2B). Measurements of relative 
nuclear:cytoplasmic Nrf2-Venus fluorescence provided clear evidence that 
cytoplasmic Nrf2 levels were far higher in cells expressing high levels of Keap1, as a 
result of the CDDO-Me treatment (Figure 5.2C). Therefore the mCherry-Keap1 
expression greatly impeded nuclear shuttling of Nrf2-Venus in response to the 
CDDO-Me. 
 
To investigate the stability of nuclear Nrf2-Venus, the nuclear export inhibitor 
Leptomycin B (LMB) was added in combination with the CDDO-Me. 
Real-time imaging of the BACNrf2Venus cells expressing the mCherry-Keap1 show that 
inhibition of nuclear export with 10ng/ml LMB led to a more equal accumulation of 
Nrf2-Venus in the cytoplasm and nucleus in response to 100nM CDDO-Me (Figure 
5.3A, Movie 25). This was trend was confirmed by quantitative analysis of nuclear 
and cytoplasmic levels of Nrf2-Venus (Figure 5.3B). Comparison of the 
nuclear:cytoplasmic ratio of Nrf2-Venus between CDDO-Me alone, or joint CDDO-
Me and LMB treatments, clearly show that Nrf2-Venus nuclear accumulation was 
enhanced as a result of inhibiting nuclear export (Figure 5.3C).  Moreover, LMB  
180	  	  
 
A) 
Figure 5.2 Keap1 controls cytoplasmic Nrf2-Venus levels. A) 
Representative time-lapse images of BACNrf2-Venus cells expressing mCherry-
Keap1 in response to 100nM CDDO-Me (Movie 24). B) Nrf2-Venus 
accumulates more rapidly in the cytoplasm than the nucleus of mCherry-
Keap1 expressing cells in response to 100nM CDDO-Me (n=5, c=19). C) 
Temporal profile of nuclear to cytoplasmic ratios of Nrf2-Venus in mCherry-
Keap1 transfected cells following addition of 100nM CDDO-Me. Error 
bars=SEM. Scale bar=20µm. 	  
B) C) 
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Figure 5.3 Inhibition of nuclear export enhances Nrf2-Venus accumulation 
in mCherry-Keap1 expressing cells following addition of CDDO-Me. A) 
Representative confocal images of BACNrf2-Venus neuroblastoma cells transfected 
with mCherry-Keap1 plasmid treated with 100nM CDDO-Me and 10ng/ml 
LMB (Movie 25). B) Measurements of Nrf2-Venus fluorescence in the 
cytoplasm and nucleus of BACNrf2-Venus cells expressing mCherry-Keap1 (n=4, 
c=12). C) Nuclear to cytoplasmic ratio of Nrf2-Venus fluorescence over time in 
cells transfected with mCherry-Keap1 following addition of 100nM CDDO-Me 
and 10ng/ml LMB. D) mCherry-Keap1 shows nuclear accumulation following 
combined treatment with 100nM CDDO-Me and 10ng/ml LMB. Error 
bars=SEM. Scale bar=20µm.	  
A) 
B) D) 
C) 
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application also led to a significant accumulation of mCherry-Keap1 in the nuclear 
compartment in BACNrf2-Venus cells, following 5hr treatment with 100nM CDDO-Me 
and 10nM LMB as shown in Figure 5.3D. Therefore, LMB had an effect on the 
subcellular distribution of both proteins, suggesting that both Nrf2 and Keap1 
undergo dynamic shuttling in and out of the nucleus. 
 
5.3.3. Quantitative Live Cell Analysis of Nrf2 Nuclear Import and Export 
Dynamics 
 
Currently, there is limited information about the dynamics of basal or induced Nrf2 
nuclear import. The temporal stability of Nrf2 once it enters the nuclear space is also 
unclear. To address these points, and to clarify the role of Keap1 as a dynamic 
regulator of nuclear import we have utilised a sophisticated fluorescence live cell 
imaging approach, to measure Nrf2 nuclear import and export dynamics using the 
photoswitchable pDendra2 flourophore. A pDendra2-Nrf2 fusion protein was created 
using Gateway cloning approach (Methods 2.13.2) and the plasmid was transiently 
expressed in SK-N-AS neuroblastoma cells. The great benefit of using pDendra2 is 
that it enables quantitative real-time tracking of two distinct Nrf2 protein 
subpopulations. The pDendra2-Nrf2 protein is expressed as a green fluorescent 
fusion, however the pDendra2 fluorophore can be irreversibly photoshifted to emit 
light at a red fluorescence wavelength, as a result of brief irradiation with blue laser 
light, such as the 405nm laser or UV diode lamp (Chudakov et al, 2007).  Therefore, 
following the UV-induced change in colour the decay in red fluorescence (old 
protein) can be imaged in real time alongside the synthesis of new green protein.  
 
To investigate the dynamics of Nrf2 nuclear entry the pDendra2-Nrf2 was locally 
irradiated in the cytoplasm (ROI1) and the resulting changes in red pDendra2-Nrf2 
fluorescence were measured in the nucleus (ROI2), Figure 5.4A depicts the 
experimental procedure employed. The representative cell shown in Figure 4B 
(Movie 26) demonstrates the effect of cytoplasmic UV irradiation in SK-N-AS 
neuroblastoma cells expressing the pDendra2-Nrf2 fusion. The green fluorescence is 
rapidly switched to red fluorescence following local irradiation with UV 405nm laser 
for 20 iterations (Methods 2.13.2). As a result, it is possible to observe the rate of red 
pDendra2-Nrf2 accumulation in the nucleus over time (>6min). The measurements 
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Figure 5.4 Measuring Nrf2 nuclear import dynamics in SK-N-AS cells 
using a photoswitchable pDendra2-Nrf2 fusion protein. A) Schematic 
representation of local pDendra2-Nrf2 photoconversion using the 405nm UV 
laser. The initial green fluorescence of pDendra2-Nrf2 was shifted to red 
emission by local irradiation with the 405nm laser. B) Representative time-
lapse pictures, before and after UV irradiation in the cytoplasm (ROI1), 
showing a subsequent gradual accumulation of photoswitched red pDendra2-
Nrf2 in the nucleus (ROI2) (Movie 26). C) Temporal changes in cytoplasmic 
photoconverted pDendra2-Nrf2. D) Corresponding rate of red nuclear 
pDendra2-Nrf2 accumulation (n=3, c=14). E) Treatment of cells with 10µM 
MG132 causes a slight increase in the rate of red pDendra2-Nrf2 cytoplasmic 
decay, which correlates with a higher rate of increase in nuclear accumulation 
of photoconverted red Dendra2-Nrf2 (n=3, c=11) (F). G) Parameters used to 
calculate nuclear dynamics, which were calculated by plotting changes in 
nuclear import and fitting the data to a non-linear regression, one phase 
association equation, where t1/2 is the time required to reach half of the 
maximum measured fluorescence and τ represents the time constant [s]. Error 
bars=SEM, scale bar=10µm.	  
E) 
A) B) 
C) D) 
F) 
G) 
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of ROI1 (cytoplasm) red fluorescence levels, exhibited a steady decay (Figure 5.4C), 
as the red florescence of the photoconverted pDendra2-Nrf2 accumulated in the 
nucleus (ROI2) (Figure 5.4D).  
To measure the relative effect of proteasome mediated degradation on both 
populations of pDendra2-Nrf2, an equivalent experiment was performed in cells 
imaged in the presence of 10µM MG132. Inhibition of proteasome activity did not 
enhance cytoplasmic levels of photo-switched (red) pDendra2-Nrf2 (Figure 5.4E) in 
comparison to control (mock treated) cells. However, MG132 treatment prompted a 
slight increase of red pDendra2-Nrf2 in the nucleus (ROI2), in comparison to control 
cells (Figure 5.4F). 
Quantitative data from pDendra2 imaging experiments was obtained by measuring 
the increase in nuclear red signal and fitting the data by non-linear regression 
analysis with a one-phase association equation using GraphPad Prizm (Methods 
2.13.3). Measurements of red pDendra2-Nrf2 accumulation in the nucleus are plotted 
in Figure 5.4G. In this analysis, the half-time of nuclear fluorescence increase 
describes the relative dynamics of protein accumulation. The comparison between 
control and MG132 treated cell populations show that control cells exhibited a faster 
rate of Nrf2 nuclear import as evident from the nuclear accumulation rates τ (control 
τ=115.5s vs MG132 τ=176.2s) (Figure 5.4G). 
    
To investigate the impact of Keap1 overexpression on the rate of Nrf2 nuclear 
import, pDendra2-Nrf2 was co-transfected with a plasmid encoding a tagBFP-Keap1 
fluorescent fusion protein (Figure 5.5). The selection of a blue fluorescent label for 
Keap1 allowed simultaneous imaging of green and red pDendra2-Nrf2 fluorescence, 
while also being able to select cells expressing high levels of Keap1.  The expression 
of tagBFP-Keap1 led to a rapid degradation of pDendra2-Nrf2, prior to 
photoshifting, therefore, to image the Nrf2 fusion it was necessary to perform the 
following experiment in the presence of 10µM MG132. Expression of tagBFP-
Keap1 in combination with proteasomal inhibition led to enhanced cytoplasmic 
localisation of pDendra2-Nrf2 fusion (Figure 5.5A). As in previous experiments, 
cytoplasmic pDedra2-Nrf2 was subjected to brief, local-irradiation with the 405nm 
laser and dynamic changes in red fluorescent signal were measured in both the 
cytoplasm (ROI1) and nucleus (ROI2) (Figure 5.5, Movie 27). It was evident that 
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C) D) 
A) 
Figure 5.5 Keap1 blocks Nrf2 nuclear import even following inhibition of 
proteasomal degradation. A) Representative image of a cotransfected cell 
showing strong colocalisation of tagBFP-Keap1 and pDendra2-Nrf2 following 
addition of 10µM MG132 (Movie 27). B) Representative time-lapse images 
from the same experiment showing unchanged nuclear levels of 
photoconverted Nrf2. C) Measurement of the redistribution of red Dendra2-
Nrf signal in the photoactivated region (ROI1) over time (n=2, c=14). D) 
Nuclear accumulation (ROI2) of photoactivated red Dendra2-Nrf2 originated 
from the cytoplasm in tagBFP-Keap1 expressing cells. Error bars=SEM, scale 
bar=10µM 	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Figure 5.6 Use of Dendra2-Nrf2 to define the nuclear exported rate of 
Nrf2. A) Schematic representation of local nuclear pDendra2-Nrf2 
photoconversion. Green pDendra2-Nrf2 is shifted to red fluorescence by brief 
irradiation with 405nm laser in the nucleus in (ROI1), and its accumulation in 
the cytoplasm is measured in the cytoplasmic in (ROI2). B) Representative 
time-lapse images from before and after local UV irradiation in the nucleus 
(ROI1) (Movie 28). C) Stable decline of photoconverted red pDendra2-Nrf2 in 
nuclear ROI1 of control cells. D) Measurements of cytoplasmic red Dendra2-
Nrf2 show half maximal fluorescence increase at around 41s in the 
cytoplasmic space (n=2, c=11). Error bars=SEM, scale bar=10µm. 	  
A) 
B) 
C) D) 
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expression of tagBFP-Keap1 effectively prevented nuclear translocation of the 
photo-converted pDendra2-Nrf2 as displayed by the measurements of nuclear red 
Nrf2 fluorescence (Figure 5.5C), as shown in the representative images of cell from 
the experiment (Figure 5.5B). Therefore, in this study, high levels of Keap1 
effectively prevented Nrf2 nuclear accumulation even in the presence of proteasome 
inhibitors. 
 
Next, the rate of nuclear export of pDendra2-Nrf2 was investigated using a slightly 
modified experimental approach. To measure the accumulation of pDendra2-Nrf2 in 
the cytoplasmic space, SK-N-AS cells transfected with the pDendra2-Nrf2 construct 
were targeted by local UV irradiation in the nucleus (Figure 5.6A). This allowed the 
cytoplasmic influx of photoconverted pDendra2-Nrf2 from the nucleus to be 
measured (Figure 5.6B, Movie 28). The red fluorescent signal was quickly depleting 
in the nucleus (ROI1) (Figure 5.6C) and consequently the levels of photoconverted 
Nrf2 gradually increased in the cytoplasm, with a fluorescence half-time of ~40s 
(Figure 5.6D). 
  
To measure the relative contribution of proteasomal activity and nuclear export on 
Nrf2 nuclear stability, SK-N-AS cells expressing the pDendra2-Nrf2 fusion were 
pre-treated with either DMSO, 10µM MG132 or 10ng/ml LMB for 1hr, prior to 
photoswitching and image acquisition (Figure 5.7, Movie 29). Representative image 
from this experiment (Figure 5.7A), together with measurements of cytoplasmic red 
fluorescence (Figure 5.7D), both strengthen the evidence that Nrf2 are exported from 
the nucleus when proteasome activity is inhibited. Also, blocking nuclear export with 
10ng/ml LMB prevented the cytoplasmic increase of red pDendra2-Nrf2 (Figure 
5.7B & D), and slightly decreased the rate of nuclear decay in comparison to MG132 
treated cells (Figure 5.7C).  
 
A summary of nuclear import measurements is presented in Figure 5.8. Comparison 
of nuclear import of the cytoplasmically photoconverted red pDendra2-Nrf2 was 
most increased in cells through stabilisation of Nrf2 protein through treatment with 
proteasome inhibitors, and no nuclear accumulation was observed in cells expressing 
the tagBFP-Keap1 (Figure 5.8B). 
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Figure 5.7 Leptomycin B blocks nuclear export of pDendra2-Nrf2. A) 
Representative images of 10µM MG132 treated SK-N-AS expressing 
pDendra-Nrf2 targeted by nuclear 405nm UV laser irradiation. Red 
fluorescence spreads gradually to the cellular space over time. B) 10ng/ml 
LMB treatment stops cytoplasmic accumulation of the red nuclear 
fluorescence of the photoconverted pDendra2-Nrf2 (Movie 29). C) 
Comparison of Nuclear and D) Cytoplasmic red fluorescent signal changes 
following DMSO (C=13), LMB (c=16) and MG132 treatment (c=19). LMB 
prevents cytoplasmic entry of the photoconverted pDendra2-Nrf2. E) 
Quantitative data obtained from cytoplasmic import of dynamics of pDendra2-
Nrf2, fitted using non-linear regression, one-phase association function. The 
half-time of cytoplasmic red fluorescence increase in 10µM MG132 treated 
cells is equal to 72.61s. Error bars=SEM, scale bar=10µm.	  
A) 
B) 
C) D) E) 
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Figure 5.8 Live cell quantification of Nrf2 nuclear import and export 
dynamics. A) Comparison of Nrf2 cytoplasmic decay rates following local 
cytoplasmic photoconversion of Dendra2-Nrf2 in either control cells, cells 
treated with the proteasomal inhibitor MG132, or cells co-transfected with a 
plasmid expressing high levels of tagBFP-Keap1. B) Comparison of nuclear 
accumulation of photoconverted red pDendra2-Nrf2 in either control cells, cells 
treated with the proteosomal inhibitor MG132, or cells co-transfected with a 
plasmid expressing high levels of tagBFP-Keap1. C) Comparison of import and 
export dynamics in control cells or D) cells treated with 10µM MG132 are 
shown in (C&D) respectively. E) Relative balance between nuclear import and 
export of Dendra-Nrf2 in control or MG132 treated cells. F) Comparison of the 
relative levels of nuclear import and export in control cells or cells treated with 
10µM MG132. Error bars=SEM. 	  
A) B) 
C) D) 
E) E) 
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Data presented in Figure 5.8C, E and D show a comparison of nuclear import and 
export dynamics in control and MG132 treated cells respectively. The calculated 
half-time values for increases in fluorescence were faster during nuclear export in 
both cases (NUC-CYT), even though the nuclear accumulation reached higher 
increase over time (Figure 5.8C & D). This suggests that the net ratio of protein 
entering the nucleus was higher overall than that which was being exported out or 
degraded (Figure 5.8E & F). 
 
To investigate the impact of nuclear degradation of Nrf2 the pDendra2-Nrf2 
construct was employed to measure the rate of decay of Nrf2 in the nuclear 
compartment, allowing defining the kinetics of the nuclear degradation in both 
control and LMB treated cells (Figure 5.9). For this purpose instead of locally 
photoconverting the green pDendra2-Nrf2 fluorescence using a 405nm laser, the UV 
lamp was used to irradiate the whole field of view turning all the cells in the imaging 
area into the photoshifted red version of pDendra2-Nrf2 (Methods 2.13.2). A 
schematic of this approach is shown in Figure 5.9A. Briefly, the selected cells of 
interest were imaged every 3min for ~3.5h. After establishing levels of baseline 
fluorescence, control or LMB (10ng/ml) treatment was performed and cells were 
then UV irradiated. Cells were effectively photoconverted from green to red 
fluorescence by irradiation for 1min with UV light (75% power). Representative 
images from the control experiment are presented in Figure 5.9B, showing effective 
photoconversion of the pDendra2-Nrf2 from green to red (Movie 30). Normalised 
measurements of nuclear red and green fluorescence are shown in Figure 9C 
(control) and Figure 5.9D (+10ng/ml LMB). Comparison of the level of green 
fluorescence detected in both experiments (Figure 5.9E) show a steady recovery over 
time, returning to basal levels approximately 1hr after UV irradiation. The observed 
decay in red signal, which could result from either degradation or photobleaching of 
the photoconverted pDendra2-Nrf2, followed the same dynamics in control and 
LMB treated cells (Figure 5.9F & G). The half-life of the pDendra2-Nrf2 can be 
calculated from the red fluorescence signal decay curve (Methods 2.13.2). The 
stability of pDendra2-Nrf2 was estimated to be around 38min in LMB treated cells 
and around 43min in the control cells (Figure 5.9G). Unexpectedly, inhibition of 
nuclear export did not significantly decrease the degradation rate of nuclear Nrf2 
protein, suggesting Nrf2 degradation does not reply on nuclear export.  
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Figure 5.9. Inhibition of nuclear export does not stabilise pDendra-Nrf2 
protein levels. A) Diagram depicting the experimental procedure used to 
perform pDendra2-Nrf2 imaging in whole cells. The UV halogen lamp was used 
for 45sec to photoconvert all cells in the selected imaging location. B) 
Representative images of control cells showing red fluorescence decay and 
stable accumulation of newly formed green pDendra2-Nrf2. C) Measurements of 
nuclear pDendra2-Nrf2 fluorescence in control cells (n=3, c=14). Red signal 
representing photoconverted pre-formed Nrf2 while the green signal represents 
newly made protein. D) Nuclear levels of red and green pDendra-Nrf2 treated 
with 10ng/ml LMB (n=3, c=27) (Movie 30). Comparison of green and red 
nuclear pDendra2-Nrf2 fluorescence in control and 10ng/ml LMB treated cells 
are shown respectively in (E&F). G) Reduction in photoconverted red pDendra-
Nrf2 half-life in response to inhibition of nuclear export by LMB. H) LMB 
treatment significantly reduced ARE-Luc activity in BACNrf2-Venus cells (n=2, in 
triplicates). Error bars =SEM (imaging), =STDEV (dual luciferase). Scale 
bar=20µm. 	  
B) A) 
C) D) 
F) E) 
H) G) 
192	  	  
Next, the ARE-Luc dual luciferase reporter was used as a surrogate to quantify the 
impact of nuclear export inhibition on Nrf2 transcriptional activity (Figure 5.9H). 
Basal Nrf2 driven ARE related transcriptional activity was significantly diminished 
following 8h incubation with 10ng/ml LMB. Therefore, it is important to note that 
even though the stability of the Nrf2 protein remained unmodified, Nrf2 
transcriptional activity was greatly inhibited.  
 
5.3.4. Comparing the Relative Effects of the Keap1 and GSK-3 on the 
Regulation of Nrf2 in Live SK-N-AS Neuroblastoma Cells 
 
Previous data from this study indicate that Keap1 plays a more pronounced role than 
GSK-3 in the regulation of Nrf2 and Nrf2-mediated responses in BACNrf2-Venus 
neuroblastoma cells (Chapter 2, Figure 4.9 and 4.10). To measure the extent of the 
regulatory overlap between Keap1 and GSK-3 mediated regulation of Nrf2 
expression and activity, the effect of 10µM CHIR99021 inhibition was measured 
under conditions of Keap1 deactivation by either siRNA or addition of SFN (Figure 
5.10). Measurement of the ARE-Luc activity in BACNrf2-Venus cells highlighted that 
inhibition of the GSK-3 kinase had the most significant effect when combined with 
SFP treatment (Figure 5.10A). To confirm this result, Keap1 was depleted by siRNA 
knockdown (Figure 5.10B). Inhibition of GSK-3α/β by 10µM CHIR99021 (8hr) in 
siCTR treated cells did not lead to significant changes in ARE-Luc luciferase activity 
in contrast to cells transfected with Keap1 siRNA, which displayed significantly 
higher levels of ARE-Luc activity (Figure 5.10B). Interestingly, the highest ARE-
Luc levels were detected when siKeap1 was used in combination with CHIR99021.  
This result was further reinforced by live cell imaging of BACNrf2-Venus cells with 
either Keap1 or CTR siRNA (Figure 5.10C, Movie 31a & 31b). Application of 
10µM CHIR99021 significantly increased levels of nuclear Nrf2-Venus in cells with 
depleted Keap1.  The above data suggests that the inhibition of Keap1 leads to a shift 
in the mechanism of Nrf2 regulation towards a GSK-3 dependent regulation. 
 
5.3.5. The PML-Dependent Nuclear Nrf2 Regulation 
 
Previous results from this study (Chapter 2, Figure 4.10) show that the reduction of 
Keap1 protein expression leads to increased accumulation of Nrf2-Venus in response  
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Figure 5.10 Keap1 inhibition enhances cells to negative regulation by 
GSK-3. A) Relative ARE-Luc activity in BACNrf2-Venus cells following 8h 
incubation with either 2µM SFP or 10µM CHIR99021, or both in 
combination (8hrs) (n=3, in triplicates). B) Relative ARE-Luc activity in 
BACNrf2-Venus cells transfected with Keap1 siRNA (siKeap1) (Movie 31b), or 
control siRNA (siCTR) (Movie 31a) following 8h incubation with DMSO or 
10µM CHIR99021 (n=3, in triplicates). C) Temporal changes in Nrf2-Venus 
expression in BACNrf2-Venus cells transfected with siCTR or siKeap1 
following addition of 10µM CHIR99021 (n=4, c=50). D) Representative 
images from the experiment shown in (C). Scale bar=, Error bars=SEM 
(imaging), STDEV (luciferase). Scale bar=20µm. 	  
A) B) 
C) D) 
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to acute inflammatory signalling. To measure the effect of downregulation of both 
Keap-1 and GSK-3 pathways on cytokine activated Nrf2 synthesis, BACNrf2-Venus 
cells were treated with 10µM CHIR99021 and siKeap1 before addition of 10ng/ml 
TNFα (Figure 5.11A). The extent of Nrf2-Venus induction was significantly 
amplified in cells treated with both siKeap1 and CHIR99021, as compared to cells 
treated with control siRNA and CHIR99021. However, the difference in relative 
nuclear Nrf2-Venus levels in cells where Keap1 and GSK-3 were both 
downregulated was only significantly different in a narrow temporal window 
approximately 3h after stimulation with TNFα (Fig. 11Α).  Significantly, inhibition 
of both of the two main Nrf2 regulators did not lead to a stable pool of Nrf2-Venus 
increase, even in the presence of the TNFα signalling, suggesting the possibility that 
an alternative degradation mechanism may also be involved in regulating cellular 
Nrf2 responses the antioxidant responses. 
Live cell imaging of Nrf2-Venus in BACNrf2-Venus neuroblastoma cells, revealed an 
interesting pattern of Nrf2 accumulation, which was maximally observed following 
inhibition of nuclear export with Leptomycin B (LMB).  However, under these 
conditions, only a very small increase in nuclear Nrf2-Venus was observed, 
suggesting a tight balance is maintained between Nrf2 nuclear import and 
degradation (Figure 5.11B, Movie 32). Combined addition of LMB and 10ng/ml 
TNFα led to only a minimal rise in nuclear Nrf2-Venus levels but this treatment was 
accompanied by the appearance of Nrf2-Venus positive promyelocytic leukaemia 
nuclear bodies (PML-NB) like structures in the nucleus (Figure 5.11B, Movie 33). 
Therefore, it appears that Nrf2-Venus is targeted to PML-NB-like structures under 
specific cellular conditions.  
To measure of the effect of TNFα stimulation on the quantity of PML nuclear 
structures, BACNrf2-Venus cells were co-immunostained for both p65 and PML proteins 
after addition of 10ng/ml TNFα for 2h. This treatment increased the abundance and 
the mean size of nuclear PML structures suggesting a positive effect of TNFα on 
PML body formation (Figure 5.11C & E). 
 
To investigate if high levels of p65 expression had a similar effect as elevated Nrf2 
expression on PML body formation, theBACNrf2-Venus cells were transfected with either 
WT p65-dsRedXP or a transcriptionally impaired phosphorylation mutant  
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Figure 5.11 Leptomycin B augments the accumulation of Nrf2 in punctate 
nuclear structures. A) Relative nuclear fluorescence of Nrf2-Venus in siCTR 
and siKeap1 transfected cells following addition of 10µM CHIR99021 +/-  for 
30min before 10ng/ml TNFα (n=3). B) Dynamic changes in nuclear Nrf2-
Venus levels in response to addition of 10ng/ml LMB treatment +/- TNFα 
(n=2, c=17-19) (Movie 32 & 33). C) Representative time lapse images of 
Nrf2-Venus taken 7h after addition of 10ng/ml LMB alone or 10ng/ml TNFα 
+ 10ng/ml LMB in combination. D) Quantitative analysis of Nrf2 positive 
PML-like structures obtained using ImageJ of immunofluorescent images from 
E). E) Immunofluorescent staining of BACNrf2-Venus cells, showing PML-Cy3 
and p65-488 conjugates in control or in cells treated with TNFα for 2h. Error 
bars=SEM. Scale bar=20µm. 	  
A) B) 
C) 
D) 
E) 
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Figure 5.12 Effect of NF-κB on PML regulation. A) Immunofluorescence 
images of BACNrf2-Venus cells stained with PML-488 conjugates showing no 
change in the abundance of PML structures in cells expressing either WT p65-
dsRedXP or a transcriptionally inactive mutant ΔS276A p65-dsRedXP protein. 
B) Western blot of BACNrf2-Venus nuclear extracts stained for the PML protein. 
TNFα	   stimulation did not cause significant changes in any of the detected 
bands. C) The relative level of PML mRNA increases slightly in response to 
8hr stimulation with 10ng/ml TNFα. D) Addition of 2µM SFN (8hr) does not 
induce significant changes in PML mRNA expression (n=3, in triplicates). 
Error bars=STDEV. Scale bar=20µm. 	  
A) 
B) C) 
D) 
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ΔS276A-p65-dsRedXP (plasmid kindly gifted by Mike White’s group in 
Manchester) (Figure 5.12A). However, the pattern of PML expression appeared very 
similar between mutant and WT p65-dsRedXP expressing cells, therefore we can 
conclude that overexpression of p65 does not have an equivalent effect as Nrf2 on 
PML expression or PML nuclear bodies formation. 
To validate these results the BACNrf2-Venus lysates were collected at intervals during a 
24h period of TNF-α stimulation. Nuclear fractions were then analysed by western 
blot (Figure 5.12B). Unfortunately, the PML antibody used in this study showed a lot 
of unspecific staining and even though PML has several isoforms between 78-
97kDa, none of the bands displayed changes as a result of cytokine application 
(Figure 5.12B). 
To test the possibility that PML expression may be regulated by either Nrf2 or NF-
κB driven transcription BACNrf2-Venus cells were treated for 8hrs with either 2µM SFP 
or 10ng/ml TNFα and lysates were processed for Q-PCR analysis. Using primers 
designed to detect all 5 isoforms of PML, a significant increase in PML mRNA 
expression was only detected in samples treated with TNFα (Figure 5.12C and D). 
Therefore, evidence from this study suggests that TNFα enhances PML expression 
in the neuroblastoma cell model, possibly by a transcriptional mechanism.  
 
5.3.6. The Role of Acetylation in Modulating Nrf2 Activity 
 
Nrf2 is known to be a target for p300/CBP-mediated acetylation in the nucleus. In 
addition, this post-translational modification of Nrf2 is though to be essential for its 
transcriptional activity (Sun & Zhang, 2009). To investigate the role of acetylation in 
modulating Nrf2 activity, live cell imaging and ARE-Luc transcriptional reporter 
assays were performed to monitor the effects of inhibiting p300/CBP catalytic 
activity, following addition of 10µM C646 (viability assay in Supplementary 8.2C). 
Unexpectedly, inhibition of acetylation by C646 caused a dramatic increase in 
nuclear Nrf2 levels in both BACNrf2-Venus cells and primary cortical astrocytes, which 
stably express the 2kb-Venus-Nrf2 fusion protein (Figure 5.13A and B) (Viability 
assay on C646 in Figure 8.3C).  
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Figure 5.13 Inhibition of acetylation strongly enhances Nrf2 nuclear 
accumulation and transcriptional activity. A) Dynamic changes in Nrf2-
Venus levels in the nuclei of BACNrf2-Venus (n=2, c=15) (Movie 34), or B) 
primary hippocampal astrocytes transduced with the 2kb-Venus-Nrf2 
construct (n=1, c=3), following addition of 10µM C646. C) Representative 
images of BACNrf2-Venus cells treated with 10µM C646, showing accumulation 
of Nrf2-Venus in PML-NB like nuclear structures. D) ARE-Luc activity 
increases in response to application of 10µM C646 for 6h (n=2, in 
triplicates). E) BACNrf2-Venus cells transfected with mCherry-Keap1 show a 
significant accumulation of nuclear Nrf2-Venus (n=3, c=13). F) 
Representative time-lapse images of cells from experiment (Movie 35). Error 
bars=SEM(imaging)/STDEV(luciferase). Scale bar=20µm. 	  
A) B) 
C) 
D) E) 
F) 
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Significantly, the C646 induced accumulation of Nrf2-Venus containing PML-NB-
like structures (Figure 5.13C), was accompanied by a corresponding increase in Nrf2 
transcriptional activity, as demonstrated by a significant rise in ARE-Luc activity in  
BACVenus-Nrf2 cells (Figure 5.13D).  To test whether the inhibition of acetylation 
affected Keap1-mediated Nrf2 degradation, BACNrf2-Venus cells transiently transfected 
with the mCherry-Keap1 plasmid were imaged following incubation with 10µM 
C646 (Figure 5.13E and F). Interestingly, the inhibition of p300/CBP acetyl 
transferase activity led to a substantial accumulation of nuclear Nrf2-Venus even in 
mCherry-Keap1 expressing cells (Figure 5.13F, Movie 35).  
To veryfy if the increase in protein acetylation by repressing  histone deacetylatase  
(HDACs) activity had an opposite effect on Nrf2 transcriptional function, ARE-Luc 
signal was measured following application of pharmacological HDACs inhibiting 
compounds (Figure 5.14). Inhibition of both classes of HDACs by 3.3µM TSA 
caused a significant decrease in ARE-Luc activity, while selective inhibition of Class 
II HDACs with 2µM MC1568 led to a two-fold increase in ARE-Luc activity (8h 
treatments). Selective inhibition of Class I HDACs with 1µM Mocetinostat (Class I) 
had no effect of Nrf2 driven ARE-Luc activity (Figure 5.14). Therefore, different 
classes of HDAC enzymes may have differential effects on the regulation of 
antioxidant responses, however the nature of this regulation is largely unexplored 
and requires a more thorough study. 
 
5.4. DISCUSSION 
 
Keap1/Cullin3/Rbx1 mediated ubiquitination of Nrf2 is central to the regulation of 
cellular antioxidant responses. Compounds that modulate this process have been at 
the centre of drug design against cancer, neurodegenerative diseases, inflammatory 
disorders and many more (Vargas & Johnson, 2009). The first live cell imaging 
studies of the Keap1 and Nrf2 complex using FLIM led to the proposal of a 
conformational cycling model of regulation, where Nrf2 forms a closed complex 
with Keap1 under basal conditions (Baird et al, 2014). Inducers of Nrf2 activity 
induce a conformational change in the Keap1 protein, which shifts the Keap1:Nrf2 
complex into an open state, in which bound Nrf2 cannot be degraded. In this model it 
is proposed that newly synthesized Nrf2 is able to translocate to the nucleus, where it 
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drives transcription of ARE response genes (Baird et al, 2013). Data presented in this 
study supports the conformational cycling model of the Keap1:Nrf2 complex, but 
also provides novel insight into alternative modes of Nrf2 regulation in the nucleus.  
  
Transient plasmid mediated-Keap1 expression was used as a mechanism to assess 
the effect of high Keap1 levels on basal and activated Nrf2 protein levels and 
transcriptional activity (Figure 4.1). Overexpression of mCherry-Keap1 expression in 
BACNrf2-Venus cells was sufficient to significantly diminish Nrf2-Venus fluorescence 
and reduce ARE dependent transcriptional activity under basal conditions (Figure 
5.1A & B). However, simultaneous overexpression of both Venus-Nrf2 and 
mCherry-Keap1 led to the accumulation of Venus-Nrf2 in the cytoplasm. This effect 
may indicate that Nrf2 out-titrated Keap1 mediated degradation, even under basal 
conditions (Figure 5.1C). The third phenotype was observed in cells expressing high 
levels of mCherry-Keap1 in cells treated with CDDO-Me. In this case, induction led 
to a gradual accumulation of Nrf2 in the cytoplasm (Figure 5.2A). This effect may be 
due to the effective capture of Nrf2 in the cytoplasm by Keap1, even though 
subsequent degradation is blocked. Therefore, even though under these conditions, 
nuclear Nrf2 levels steadily increased, the cytoplasmic accumulation was dominant 
(Figure 5.2B & C, Movie 24). This phenotype can be explained by a model in which 
Keap1 can bind and sequester Nrf2 in the cytoplasm, but not as part of an active 
degradation complex, possibly because high levels of Keap1 out-titrate available 
Cullin3/Rbx1 proteins. Addition of Nrf2 activating compounds such as CDDO-Me 
would further enhance this effect, by inhibiting degradation of the pool of Nrf2 that 
is bound to Keap1 within the Cullin3/Rbx1 complexes.  
 
In live cell imaging studies where cells were treated with a combination of both 
CDDO-Me and LMB, a proportion of Nrf2-Venus was seen to accumulate in the 
nucleus (Figure 5.3A&B). Inhibition of nuclear export led to the accumulation of 
Nrf2-Venus in the nucleus, showing that Nrf2 cycles through the nucleus, even when 
Keap1 is overexpressed. However, Nrf2 nuclear accumulation without LMB is not 
pronounced in CDDO-Me only treated cells (Figure 5.2) suggesting this phenotype is 
likely to be transient.  
As depletion of Keap1 by siRNA, enhanced nuclear accumulation of Nrf2-Venus, it 
would appear that Keap1 protein acts like a molecular net, which not only mediates 
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the degradation process, but also efficiently retains Nrf2 within the cytoplasm 
(Figure 5.1C, 2A, Movie 25). The substantial cytoplasmic accumulation supports the 
evidence that the inducers do not stop Keap1:Nrf2 protein interaction, otherwise 
Nrf2 would accumulate in the nucleus shortly after synthesis, despite high 
cytoplasmic Keap1 levels. Data from this study supports the hypothesis that levels of 
Nrf2 must exceed levels of Keap1, in order to enter the nucleus. This requirement 
provides a more stringed control of Nrf2 and restricts activation of the antioxidant 
pathway to situations where synthesis of the new Nrf2 protein is possible.  
 
Inhibition of nuclear export also resulted in increased mCherry-Keap1 levels in the 
nucleus. This highly reproducible phenotype (Figure 5.3D) is consistent with 
previous reports that nuclear entry of Keap1 may be essential for the removal of Nrf2 
from ARE containing promoter sequences and may also assist with its nuclear export 
(Sun et al, 2011).   
Levels of Nrf2 protein are very effectively regulated within the cytoplasm, which 
makes the measurements of dynamic changes in cytoplasmic Nrf2 levels challenging 
to monitor, as the rapid clearance obscures discrete fluctuations resulting from the 
changing balance between Nrf2 synthesis and nuclear export. The photoswitchable 
pDendra2-Nrf2 fusion protein provides a valuable imaging tool, which allows 
dynamic changes in Nrf2 protein sub-populations to be monitored in real time. The 
pDendra2 fluorescent protein is especially helpful in studying short-lived proteins 
and as Nrf2 has a very short half-life of approximately 30 minutes it was an excellent 
candidate for pDendra2 tagging (Belleza et al, 2010).  
 
The local pDendra2-Nrf2 photoswitching experiments provided novel insight into 
the conditional dynamics of Nrf2 nuclear import and export, parameters that would 
be extremely difficult, or impossible to measure by traditional biochemical methods. 
Data from these studies show that the rate of Nrf2 nuclear accumulation was fastest 
in untreated cells (Figure 5.8B), although, the ratio of nuclear accumulation of Nrf2 
was predictably highest in the presence of MG132 (Figure 5.8B). The reason for the 
decreased rate of nuclear import when proteasomal degradation is inhibited is 
unclear. Interestingly, the nuclear decay of the photoswitched red pDendra-2-Nrf2 
protein was actually enhanced in cells treated with MG132, indicating that more 
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protein could be relocating to the nucleus as a result of proteasome inhibition, but 
simply being imported at a lower speed (Figure 5.8A). 
Overexpression of the tagBFP-Keap1 protein neatly demonstrated the role of Keap1 
as an effective cytoplasmic Nrf2 retention barrier, as the rate of Nrf2 nuclear import 
was dramatically decreased in the presence of high levels of Keap1 (Figure 5.5, 
Movie 27). Whereas, the process of Nrf2 activation has been studied in great depth 
the fate of Nrf2 protein once it enters the nucleus has not been clarified. The GSK-3 
kinase is though to mediate both the nuclear export and/or degradation of Nrf2, with 
the latter being currently favoured (Cuadrado et al, 2015). As noted before the 
difficulty in analysing the role of GSK-3 in Nrf2 protein depletion is the difference in 
nuclear degradation and export phenotype for Nrf2, as no changes of cytoplasmic 
levels are detected due to robust Keap1-mediated degradation once it enters the 
cytoplasm.  However, Dendra2-Nrf2 single-cell imaging enabled the nuclear levels 
of the photoswitched protein to be measured, thus providing definitive evidence for 
Nrf2 nuclear export (Figure 5.6). The nuclear levels of photoactivated (red) 
pDendra2-Nrf2 were very rapidly depleted from the nuclear space and this is likely 
to occur due to photobleaching, export and degradation. It was possible to distinguish 
between the export and the degradation processes, as the LMB treatment slowed 
down the decay of red nuclear fluorescent signal, even more than in MG132 treated 
cells (Figure 7C). Interestingly, this suggests that the rate of export is slightly faster 
than the rate of degradation, however the overall effect will again depend on the 
proportion of protein being exported vs. degraded. Furthermore, the red nuclear 
pDendra2-Nrf2 protein was stably accumulating in the cytoplasm in both control 
(CTR) and MG132 treated cells (Figure 5.7D), but not when nuclear export was 
blocked. The rate of increase of cytoplasmic Nrf2 fluorescence was higher in CTR 
cells with a t½ of approximately 41s, in comparison to MG132 treated cells, which 
show a t1/2=72sec (Figure 5.7E). This could result from higher levels of protein 
leaving the nucleus as their transport is limited by the constant rate of export.  
Comparison of the t1/2 of fluorescence recovery indicates that levels of nuclear 
fluorescence increased faster in the cytoplasm compared to the nucleus, in both 
control and MG132 treated cells (Figure 5.8 C and D). This result was 
counterintuitive since previous results from this study (Results Ch1, 3.4.5) show that 
the basal Nrf2 levels were found to be constantly higher in the nucleus than in the 
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cytoplasm. However, comparing the relative nuclear Nrf2 movement (import vs. 
export), the proportion of protein entering the nucleus is higher than the proteins 
leaving it, therefore the net result is a higher net rate or import (Figure 5.8 E & F).  
    
Measurement of nuclear pDendra2-Nrf2 stability exposed a surprising result (Figure 
5.9); as the photoshifted (red) nuclear fluorescence decay of Nrf2 very closely 
followed the dynamics and half-life measurements in DMSO and LMB treated SK-
N-AS (Figure 5.9). This data shows that Nrf2 nuclear export is not necessary for 
degradation to occur and importantly, LMB did not prevent the synthesis of new 
Nrf2 protein (Movie 30. Therefore the nuclear dynamics of newly made or ‘old’ 
pDendra2-Nrf2 follow similar dynamics in both control and LMB-treated cells 
(Figure 5.9E & G). The lack of change of Nrf2 protein stability suggests that nuclear 
degradation of Nrf2 is a very efficient process, but may not be mediated by Keap1, 
as current knowledge would not support its function in nuclear degradation.  
However, even though the stability of Nrf2 remain unaltered as a consequence of 
LMB application, analysis of Nrf2 transcriptional activity displayed a significant 
reduction of ARE-Luc transcriptional activity, indicating that inhibition of nuclear 
export could potentially lead to changes in Nrf2 DNA-binding (Figure 5.9H).  
 
Keap1 mediated regulation of Nrf2 stability is known to be sensitive to changes in 
intracellular redox status, whereas GSK-3α/β regulation has been proposed to 
differentially modulate Nrf2 responses, depending on the combinatorial activation 
status of different cell signalling pathways.  Using the pDendra2-Nrf2 construct it 
was possible to investigate the regulatory potential of GSK-3 in SK-N-AS 
neuroblastoma cells. Previous experiments (Figure 4.10) demonstrated that GSK-3 
inhibition, either alone or in combination with TNFα stimulation, did not lead to a 
significant increase in Nrf2-Venus levels, or transcriptional activity. However, it 
became clear that the inactivation of GSK-3 by 10µM CHIR99021, in combination 
with Keap1 inhibitor or depletion of Keap1 by siRNA knockdown, greatly enhanced 
the effect of GSK-3 inactivation on the Nrf2 pathway (Figure 5.10). Measurement of 
ARE-Luc activity confirmed that reduced Keap1-mediated Nrf2 regulation caused a 
significant increase in ARE-Luc activity in response to CHIR99021 application 
(Figure 5.10 & B). Enhanced Nrf2 transcriptional activity was also observed as a 
204	  	  
result of Nrf2 nuclear accumulation following GSK-3 downregulation, in cells with 
reduced levels of Keap1 (Figure 5.10 C & D).  Previously, the lack of Nrf2 responses 
as a result of GSK-3 inactivation in SK-N-AS cells was attributed to high levels of 
PI3K activity; such as when cells were maintained in serum rich growth medium 
(Figure 4.10). However, previous studies suggest that a strict cytoplasmic regulation 
of Nrf2 may limit the amount of protein that is subjected to GSK-3-mediated nuclear 
regulation. This would be especially relevant if, as demonstrated before, the 
residency of nuclear Nrf2 is only temporary, due to effective nuclear export. 
Therefore, depletion of Keap1 may lead to a switching of Nrf2 regulation, to a GSK-
3 dependent mode. In a physiological context, Keap1 down-regulation could be 
associated with increased oxidative stress, or functional mutations potentiating the 
GSK-3/β-TrCP regulatory role. This could be particularly relevant in aging, which is 
associated with higher GSK-3 activity and an increasingly oxidative redox 
environment (Cuadrado et al, 2009). The GSK-3/β-TrCP axis activity is dependent 
on the cells metabolic status. Under normal conditions this process is inhibited by 
PI3K activity. Therefore, it is reasonable to presume that the negative effect of GSK-
3 on the antioxidant pathway will be also be dependent on nutrient availability 
(Chowdhry et al, 2013).  
 
The GSK-3/β-TrCP/Cullin1 and Keap1/Rbx/Cullin3 mechanisms of Nrf2 
degradation may both play central, yet distinct roles in down regulation of Nrf2 
signalling responses (Suzuki & Yamamoto, 2015). As such, it may be anticipated 
that the combined inhibition of GSK-3 and Keap1 would lead to the stable 
accumulation of basal Nrf2-Venus, especially in cells expressing higher levels of 
Nrf2 as a result of TNFα application (Figure 5.11A). However, single cell imaging 
experiments performed in this study, show that induction of Nrf2 is relatively short-
lived (Figure 5.11A). Although it is possible that the pharmacological activity of 
CHIR99021 inhibitor and siRNA mediated inhibition of Keap1/GSK-3 are both 
transient effects, it is also possible that there are other conditional mechanisms of 
Nrf2 protein degradation or inhibition of Nrf2 transcriptional activity. The RNF4 E3-
ubiquitin-protein ligase was previously identified as an alternative regulator of 
nuclear Nrf2 stability, by initiating the sequential sumoylation and ubiquitination of 
Nrf2, prior to degradation in PML-NBs (Malloy et al, 2013). It is possible, that 
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involvement of PML NBs in the clearance of Nrf2 could be extremely robust and 
completely independent of Keap1 and GSK-3 activity. In order to observe rapid 
Nrf2-Venus turnover within the PML-NBs it may be necessary to use more 
sophisticated atomic force microscopy methods, or spinning disc microscopy in 
future studies.  The PML-NBs are very dynamic structures located predominantly in 
the nuclear space and can act to modulate both transcriptional activity and protein 
stability. The PML protein is fundamental in orchestrating the assembly of protein 
complexes to form the PML NBs structures, however the mechanism that leads to 
their formation is not simply dependent on PML protein availability, but additionally 
requires extensive post-translational modifications of PML, and other involved 
proteins (Lallemand-Breitenbach & de The, 2010).  
 
Inhibition of nuclear export did not have a significant effect on Nrf2 nuclear 
accumulation, or depletion, leading to a steady state of Nrf2-Venus nuclear 
expression (Figure 5.11B, Movie 32). However, combined treatment with TNFα and 
LMB led to the formation of Nrf2-Venus containing punctate structures, which were 
present exclusively in the nuclear compartment (Figure 5.11D, Movie 33). As this 
phenotype was more evident following TNFα treatment, it was possible that NF-κB 
in some way controlled the expression of the PML protein, which plays a key role in 
the formation of the PML-NBs structures (Gao et al, 2008). Incubation of BACNrf2-
Venus cells with 10ng/ml TNFα for 2h, increased the average number of PML punctate 
structures per/nucleus, as well as slightly increasing their size (Figure 5.11C & E). 
However, these changes cannot be considered to be statistically significant, as only 
two experimental replicates have so far been performed.  
To investigate the possible role of p65 in the increase of PML protein, BACNrf2-Venus 
cells were transfected with either wild type p65-dsRedXP or a transcriptionally 
impaired mutant, containing a substitution of the regulatory phospho-Serine 276 
residue (Figure 5.12A). However, expression of both constructs failed to changes 
PML nuclear staining in comparison to the non-transfected cells (Figure 5.12A). 
Unfortunately, analysis of nuclear PML levels by western blot was not successful, 
due to the low specificity of the anti-PML antibody, also none of the detected bands 
displayed TNFα dependant changes in expression (Figure 5.12B). TNFα stimulation 
augmented the expression of PML mRNA. Therefore, the increase of PML observed 
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by immunofluorescence could be due to the enhanced PML gene expression (Figure 
5.12C). TNFα is known to enhance expression of PML mRNA levels, possibly by 
augmenting STAT1 transcription factor activity (Gao et al, 2008), consequently, 
increasing the quantity of nuclear speckles, which was also observed in our study 
(Figure 5.11).  
 
Nevertheless, the accumulation of Nrf2 in the punctate structures may have not 
occurred as a result of increased net PML expression but as a result of increased 
Nrf2-Venus synthesis, triggered by TNFα stimulation and combined with nuclear 
retention, as a result of LMB treatment. Suppression, of proteasomal activity also led 
to the accumulation of Nrf2-Venus in discrete nuclear speckles therefore, higher 
levels of Nrf2 protein could lead to considerable accumulation in PML-NBs, which 
are otherwise too small to be observed, or are rapidly removed before accumulating 
into larger structures.  	  	  To	   reinforce	   the	   observation	   that	  Nrf2-­‐Venus	   is	   targeted	   to	   PML-­‐NB	  punctate	  and	  not	  similar	  structures;	  therefore	  the	  conditional	  co-­‐localisation	  of	  Nrf2	  and	  PML	  proteins	  should	  be	  investigated	  in	  more	  detail.	  	  
 
PML NBs formation requires extensive post-translational modifications including 
sumoylation. This modification is only possible on proteins containing specialised 
SIM domains that form a hydrophobic pocket allowing non-covalent attachment of 
the sumo tag (Nisole et al, 2013). Acetylation of Lys487 at the center of the SIM 
domain within the PML protein prevents Lys490 SUMO1 conjugation due to a 
change in the net charge within the SIM pocket, consequently preventing the 
assembly of the PML NBs. Therefore, the activity of p300 was reported to inhibit the 
PML NB formation by inhibition of SUMO attachment on the PML proteins (Nisole 
et al, 2013). However, the effect of Nrf2 acetylation on its degradation in the PML 
NBs has not been previously investigated. The application of C646 was expected to 
decrease ARE-Luc signaling, as p300 activity is necessary for Nrf2 transcriptional 
activity. In contrast, inhibition of p300/CBP by C646 in BACNrf2-Venus led to amplified 
relative ARE-Luc luminescence levels (Figure 5.13, Chapter 3). Furthermore, 
addition of C646 to both BACNrf2-Venus and primary cortical mouse astrocytes induced 
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a transient nuclear accumulation of Nrf2 (Figure 5.13 A & B, Movie 34). Thus 
suggesting that the inhibition of p300/CBP mediated acetylation may act as a potent 
inducer of Nrf2 responses. To test whether this effect arose as a consequence of 
changes in Keap1-dependent Nrf2 control, mCherry-Keap1 was over-expressed in 
BACNrf2-Venus cells and temporal changes in Nrf2 dynamics were measured following 
addition of 10µM C646 (Figure 5.13 E & F, Movie 35). In contrast to the addition of 
CDDO-Me, inhibition of acetylation did not promote Nrf2 accumulation in the 
cytoplasm, but instead led to a more substantial increase in nuclear Nrf2 (Figure 
5.13F).  Therefore the induced pattern of Nrf2 accumulation was more similar to that 
achieved with the combined application of CDDO-Me and LMB (Figure 3A). In 
addition, prolonged C646 treatment led to the accumulation of Nrf2-Venus into 
PML-NB-like structures, which was also a hallmark associated with the blocking of 
nuclear export by LMB (Figure 5.11D). Hypothetically, inhibition of acetylation 
could result in either inhibition of Keap1:Nrf2 interaction, reduced export, or 
suppression of PML mediated degradation. The increase of cytoplasmic Nrf2 levels 
in cells expressing mCherry-Keap1 following C646 application, suggest that a 
significant proportion of Nrf2 is still able to be retained in the cytoplasm by Keap1-
mediated mechanism, therefore the inhibition of Keap1 binding is an unlikely 
explanation (Figure 5.13, Chapter 3). There are several possibilities of how C646 
application could promote an increase in nuclear Nrf2 levels, the most likely being 
the inhibition of Keap1 binding, as the protein accumulates rapidly in the nucleus 
without a substantial rise in cytoplasmic levels.  	  
 
The inhibition of acetylation was expected to have a positive effect on Nrf2 since the 
HAT inhibition was stimulatory on ARE gene expression (Figure 5.13).  
In order to measure the effect of hyper-acetylation on Nrf2 expression or function, 
the removal of acetyl groups was blocked by addition of three drugs, which target 
different classes of HDAC proteins (Figure 5.14). Application of HDAC inhibiting 
compounds induced variable effects on ARE-Luc transcriptional activity, with TSA 
being inhibitory, while the MC1568 inhibitor augmented antioxidant gene 
transcription (Figure 5.14). The pleiotropic effects of HDAC inhibition on 
antioxidant responses has been reported in several previous studies (Chen at el, 
2014; Kawai et al, 2011; Mercado et al, 2011). It is possible that Nrf2 activity could 
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be modulated by acetylation at a transcriptional level, as the canonical role of HDAC 
proteins is to facilitate chromatin condensation, which prevents access of the 
transcriptional apparatus to the DNA template. It should be noted that that we have 
not examined the net effect of C646 on the Nrf2 acetylation status and surprisingly 
no reports so far described the effect of p300/CBP inhibition on the activity of the 
antioxidant pathway, therefore this effect remains to be investigated in more detail. 
It is evident that acetylation and de-acetylation may regulate both Nrf2 protein levels 
and activity. Nevertheless, pharmacological inhibition of acetylation, or de-
acetylation, is a multifaceted event and hence is expected to be associated with 
multiple off-target effects. As such, it is not yet possible to predict what the role of 
acetylation may be in conditionally regulating antioxidant pathway activity, due to 
the complex nature of the process and time constraints of this project, however, this 
issue remains an interesting avenue for future exploration.  
To summarise, in order to fully appreciate the potential effects of inflammatory 
signalling on the Nrf2 pathway, it is necessary to have a good understanding of the 
molecular processes that regulate basal and induced Nrf2 responses. The results of 
this study reinforced the proposed conformational cycling model of Keap1-Nrf2 
complex formation, and provide new quantitative insight into the Nrf2 protein life 
cycle, in a live single-cell context (Baird et al, 2013). The employment of 
sophisticated low-level Nrf2 expression and imaging techniques and photoswitchable 
protein tagging has provided the first quantitative insight into the conditional 
dynamics of Nrf2 nuclear import and export parameters. Including the conditional 
sequestration of Nrf2 into discrete PML-NB like structures. This data is now being 
incorporated into a pertinent based mathematical model of the antioxidant pathway 
responses in health and disease. The functional model summarising the data obtained 
in this chapter is presented in Figure 5.15.  
The utilisation of photoswitchable Nrf2 protein fusion provided a new insight into 
monitoring discrete Nrf2 protein populations. This powerful imaging tool has been 
further used in investigating the mechanism of action of brusatol, the results of this 
study are presented in the next, final chapter. 
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Figure 5.15 Nrf2 regulation through Keap1, GSK-3 and PML axis of 
degradation. 1. Keap1 mediates ubiquitination and degradation of Nrf2 within 
the cytoplasmic space. 2. A small proportion of Nrf2 escapes Keap1-mediated 
regulation and translocates to the nucleus. 3. In the nuclear space CBP 
facilitates Nrf2 association with the ARE sequences. 4. Nrf2 can be observed 
in the PML-NBs where it is likely to be turnovered. 5. GSK-3 phosphorylates 
Nrf2 and allows 6. β-TrCP association and degradation of Nrf2. 7. A 
proportion of Nrf2 can be exported from the nuclear space into the cytoplasm. 
8. Keap1 can enter the nuclear space and it is possible that it can serve as 
nuclear export facilitator for Nrf2. 9. CDDO-Me and SFN prevent Keap1-
mediated degradation, but do not dissociate Nrf2-Keap1 complex. 10. Nrf2 
out-titrates Keap1 dimers and enters the nuclear space.  
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RESULTS CHAPTER 4 
 
6. Investigating the Mechanism of Action of Brusatol 
 
6.1. CHAPTER 4 AIMS: 	  
• Live cell imaging of BACNrf2-Venus neuroblastoma in response to 
brusatol application 
• Investigating the effect of brusatol on the NF-κB pathway 
• Investigating the effect of brusatol on Nrf2 stability using 
fluorescent photoswitchable pDendra2-Nrf2 protein fusion 
• Determining the mechanism of action of brusatol and its off-
target effects 
 
6.2. Introduction 
 
Expression of the Nrf2 transcription factor tightly controlled, normally being 
maintained at very low levels in normal tissues (Suzuki et al, 2013). However, high 
levels of expression have been observed in several types of cancer, such as 
pancreatic, thyroid, liver cancer and several others (http://www.proteinatlas.org) and 
what is more, Nrf2 has been previously identified as an important proliferative factor 
in neuroblastoma cells (de Miranda et al, 2015). This phenotype is a major obstacle 
to the effective treatment of these cancers as the resulting increase in expression of 
Nrf2 target genes contributes to resistance to both chemo- and radiotherapy. 
Recently, brusatol, a natural compound from the Brucea javanica plant was 
identified as a potent inhibitor of the antioxidant pathway and has been shown to 
sensitise cancer cells and tumours to chemotherapy, however consensus has not yet 
been reached on how brusatol leads to Nrf2 downregulation (Ren et al, 2011; 
Olayanju et al, 2015). 
 
The following chapter describes a series of experiments that were designed to define 
the mechanism by which brusatol triggers Nrf2 protein depletion, using a 
combination of advanced live-cell imaging methods, alongside functional and 
quantitative studies in SK-N-AS neuroblastoma cells.  
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6.3. RESULTS 
 
6.3.1. Brusatol Depletes Nrf2 Protein Levels and Transcriptional Activity in 
BACNrf2-Venus SK-N-AS Neuroblastoma cells 
 
The ability of brusatol to deplete Nrf2 protein expression has been demonstrated in 
several cell types (Ren et al, 2011; Olayanju et al, 2015). Initial results in this study 
confirmed that brusatol effectively depleted Nrf2 levels in BACNrf2-Venus cells. As 
expected, brusatol induced depletion of Nrf2 was accompanied by a concomitant in 
ARE-Luc transcriptional reporter activity, which was detectable over a broad a range 
of brusatol concentrations from 1nM-300nM (Figure 6.1A) (viability assay in 
Supplementary Figure 8.2A). The 100nM concentration was selected for use in 
further studies, due to its potent reduction of the Nrf2 transcriptional activity and low 
toxicity, as demonstrated by the maintenance of cell viability, even after 24hrs of 
treatment (Figure 6.1B). Time course analysis of BACNrf2-Venus cells treated with 
100nM brusatol revealed that Nrf2 transcriptional activity was greatly reduced, even 
after 2hr of drug application and appeared most potent following 8hr of treatment 
(Figure 6.1D). To verify the effect of brusatol on endogenous Nrf2 and Nrf2-Venus 
proteins, BACNrf2-Venus cells were treated with 100nM brusatol for 2h, 4h or 6h and 
lysates were processed for western blotting (Figure 6.1C). Both endogenous Nrf2 
and Nrf2-Venus proteins showed an equivalent rapid depletion in response to the 
addition of brusatol, therefore modification of Nrf2 by fusion with the Venus fusion 
protein did not appear to significantly affect the rate of brusatol mediated 
degradation. Live cell imaging studies were then performed on BACNrf2-Venus cells to 
obtain more accurate information about Nrf2-Venus depletion kinetics (Figure 6.1E). 
Addition of 100nM brusatol reduced Nrf2-Venus nuclear fluorescence levels within 
30min, with subsequent recovery occurring at around 8hr from the time of brusatol 
addition (Figure 6.1E, Movie 36).  
 
6.3.2. Brusatol Triggers p65 Nuclear Translocation 
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Figure 6.1 Brusatol mediated depletion of Nrf2 protein expression and 
inhibition of ARE-Luc transcriptional reporter activity. A) Relative effects of 
1nM-300nM brusatol on ARE-Luc activity in BACNrf2-Venus neuroblastoma cells 
(6h treatment) (n=1, in triplicates). B) ATP-based cell viability analysis of of 
BACNrf2-Venus cells, following 24h treatment with DMSO, 100nM brusatol, or 0.1% 
Triton-X. Data shows minimal cytotoxicity of 100nM brusatol (n=2, in triplicates). 
C) Western blot of BACNrf2-Venus cell extracts showing comparable rates of 
depletion of endogenous Nrf2 and Nrf2-Venus proteins, following addition of 
100nM brusatol at indicated time points. D) Changes in ARE-Luc activity 
following addition of 100nM brusatol in BACNrf2-Venus cells over-time (n=1, in 
triplicates). D) Representative time course images of BACNrf2-Venus cells following 
addition of 100nM brusatol (Movie 36). Error bars=SDEV, scale bar=20µm 	  
A) B) 
C) 
D) 
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Data presented in previous chapters established that the NF-кB and the Nrf2 
pathways are closely linked. Therefore to determine if the effects of brusatol on Nrf2 
also modulate NF-кB activity, p65 dynamics were imaged in parallel with Nrf2-
Venus in tagRFP-p65/BACNrf2-Venus cells (Figure 6.2), and in BACNrf2-Venus cells  
transiently transfected with the p65-dsRedXP construct (Figure 6.2A-D). 
Interestingly, 100nM brusatol triggered different nuclear responses of Nrf2-Venus 
and p65 in both model systems (Figure 6.2A & B).  Although Nrf2-Venus depletion 
followed the same kinetics in both systems, however the recovery phase was 
enhanced in cells stably expressing tagRFP-p65 (Figure 6.2C). Also, comparison of 
p65 responses observed with integrated tagRFP-p65, as opposed to plasmid encoded 
p65-dsRedXP, exposed differences in p65 responses to 100nM brusatol. In 
particular, p65-dsRedXP showed enhanced nuclear accumulation following addition 
of brusatol (Figure 6.2D). This trend was also validated by western blot analysis of 
nuclear lysates extracted from the BACNrf2-Venus neuroblastoma cells treated with 
100nM brusatol (Figure 6.2E). 
 
In order to measure the functional responses of Nrf2 and NF-κB to addition of 
100nM brusatol in BACNrf2-Venus cells the relative expression profiles of canonical 
gene targets of both transcription factors were investigated by Q-PCR (Figure 6.3). 
The effect of brusatol-induced Nrf2 depletion was assessed by measuring relative 
changes in mRNA levels of four classical Nrf2 gene targets GCLC, NQO1, TRXN1, 
and Bach 1 (Figure 6.3A-D). Significantly, 8hr exposure to 100nM brusatol did not 
reduce mRNA levels of all canonical Nrf2 target genes. Surprisingly, we observed an 
increase in levels of GCLC (Figure 6.3B) and Bach1 mRNA (Figure 6.3D). In 
contrast, TRXN1 mRNA did show a decrease in response to brusatol (Figure 6.3C), 
whereas NQO1 did not exhibit any change in expression between control or brusatol 
treated cells (Figure 6.3A). Interestingly, 8hr exposure to 100nM brusatol was 
sufficient to evoke a potent increase in all measured NF-κB target genes including 
IL-6, SOD-2 and IΚBα (Figure 6.3E-G), and significantly, also in the Nrf2 
expression (Figure 6.3I). To further validate this result, quantification of NF-κb-Luc 
luciferase activity was performed following addition of 100nM brusatol for 6hrs in 
BACNrf2-Venus cells (Figure 6.3H). In contrast to the results obtained by Q-PCR, the  
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Figure 6.2 Brusatol causes changes in p65 nuclear levels. A) Imaging nuclear 
fluorescence levels of Nrf2-Venus and p65 in tagRFP-p65/BACNrf2-Venus (n=2, 
c=13) and B) BACNrf2-Venus expressing p65-dsRedXP in response to 100nM 
brusatol (n=1, c=8). C) Comparison of the effect of 100nM brusatol on the 
nuclear Nrf2-Venus depletion and recovery in BACNrf2-Venus transiently 
expressing p65-dsRedXP and stably transduced with tagRFP-p65. D) 
Comparison of the p65-dsRedXP and tagRFP-p65 nuclear dynamics in response 
to 100nM brusatol. E) Western Blot on nuclear BACNrf2-Venus fractions following 
100nM brusatol time course showing increased nuclear translocation of p65 
protein. F) Quantification of relative nuclear p65 protein changes from Western 
blot analysis, using ImageJ. Error bars=SEM. 	  
A) B) 
C) D) 
E) F) 
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Figure 6.3 Effects of 100nM brusatol on Nrf2 and NF-κB transcriptional 
activity.  Relative mRNA levels of A) NQO1, B) GCLC, C) TRXN1 and D) 
Bach1 following addition of 100nM brusatol for 8h. E-G) Relative 
expression of the NF-κB target genes was significantly increased by 8hr 
incubation with 100nM brusatol. H) NF-κB transcriptional activity was 
assessed by measuring the relative levels of NF-κb-Luc luminescence 
following 6h incubation with 100nM brusatol. I) Relative expression levels 
of Nrf2 mRNA following 8h incubation with 100nM brusatol. Error 
bars=STDEV, n=1, in triplicates. 	  
A) B) C) D) 
E) F) G) 
H) I) 
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5xκB driven luciferase reporter did not show any changes in activity as a result of 
brusatol application (Figure 6.3H). 
 
6.3.3. Brusatol Does Not Inhibit NRF2 Gene Expression 
 
To investigate the possibility of inhibiting Nrf2 transcription, an analysis of the 
regulation of NRF2 promoter activity was performed using the pNRF2-Luc 
transcriptional reporter construct. Results from this analysis show that transcriptional 
activity driven by the Nrf2 promoter sequence was significantly reduced following 
addition of brusatol (Figure 6.4A).  To further validate this result, lentiviral 
transduction of SK-N-AS cells was performed with a Venus tagged mouse Nrf2 
protein sequence driven by either a UBC or the mouse NRF2 gene proximal (2kb) 
promoters region (Maps in Supplementary 8.3). Changes in Venus-Nrf2 nuclear 
fluorescence driven by either UBC or 2kb sequence are shown in Figure 6.4B, which 
demonstrated that brusatol induces a decline in Nrf2 fluorescence regardless of the 
promoter sequences used to drive the Venus-Nrf2 expression (Figure 6.4B & Figure 
6.4C). Therefore from this data we can conclude that brusatol does not act by 
inhibiting Nrf2 transcription. 
 
6.3.4. Use of a Photoswitchable pDendra2-Nrf2 Fusion Protein to Investigate 
the Mechanism of Action of Brusatol on Nrf2.   
 
To study the effect of brusatol on Nrf2 protein stability and synthesis the pDendra2-
Nrf2 was used for live cell imaging experiments (Figure 6.5). In these studies, 
pDendra2-Nrf2 was transiently expressed in SK-N-AS cells and the imaging 
procedure was performed as previously described (Methods Section 2.13.2). Initially, 
a whole field UV illumination method was used to photoconvert the green pDendra2-
Nrf2 into a red photoshifted form of pDendra2-Nrf2 in all cells 
within the field of view (Figure 6.5). The nuclear levels of pDendra2-Nrf2 were 
investigated following UV photoconversion and treatment with DMSO (Figure 
6.5A), protein translation inhibitor CHX 10µg/ml (Figure 6.5B) or 100nM brusatol 
(Figure 6.5C). Changes in green and red fluorescence of Dendra2-Nrf2 enabled a 
distinction to be made between brusatol effecting either the stability or synthesis of 
Nrf2. Data presented in Figure 6.5A & D shows that DMSO treatment led to a stable 
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Figure 6.4 Brusatol does not regulate Nrf2 transcription. A) pNRF2-luc 
transcriptional reporter activity in BACNrf2-Venus cells treated with either DMSO or 
100nM brusatol for 6h (n=3). B) Normalised nuclear fluorescence levels of Venus-
Nrf2 measured during live-cell imaging of  SK-N-AS cells transduced with 
lentivirus encoding either UBC-driven (UBC-Venus-msNrf2) or proximal 
promoter-driven (2kb-Venus-msNrf2) Venus-msNrf2, following addition of 
100nM brusatol (c=11-14). C) Representative images from UBC-Venus-msNrf2 or 
2kb-Venus-msNrf2 experiments shown in C). Error bars= 
SEM(imaging)/STDEV(luciferase). Scale bar =20µm. 	  	  
A) B) 
C) 
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Figure 6.5 Brusatol inhibits Nrf2 protein synthesis. A) Relative nuclear 
fluorescence of red and green pDendra2-Nrf2 expressed in SK-N-AS cells, 
following addition of DMSO (n=4, c=14) (Movie 37a), B) 10µg/ml CHX 
(n=4, c=16) (Movie 37c) or C) 100nM brusatol (n=4, c=17) (Movie 37b). D) 
Representative time-lapse images from live cell imaging experiments 
showing green and red populations of pDendra2-Nrf2 before and after 
photoconversion. Drugs were applied immediately before UV light treatment 
(indicated by purple, dashed line). Error bars=SEM. Scale bar=20µm. 	  
A) B) C) 
D) 
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decline in photoconverted red pDendra2-Nrf2 and a parallel recovery of green 
pDendra2-Nrf2 signal, which eventually exceeded the initial nuclear fluorescence 
levels. The increase in green pDendra2-Nrf2 observed following brusatol addition, 
was transient and decreased rapidly after 1hr exposure to the drug. (Figure 6.5C & 
D). Therefore, this data shows that brusatol interferes with the production of new 
pDendra2-Nrf2 protein. Significantly, application of cycloheximide resulted in a 
very similar trend in green Dendra2-Nrf2 nuclear fluorescence, as that observed in 
response to brusatol (Figure 6.5B & D).  
The relative nuclear fluorescence of green and red pDendra2-Nrf2 is compared in 
Figure 6.6. It was evident that brusatol and CHX both impair the synthesis of newly 
formed green pDendra2-Nrf2, which exhibited a distinct recovery pattern to that 
observed in DMSO treated control SK-N-AS neuroblastoma (Figure 6.6A).  Half-life 
measurements of the red pDendra2-Nrf2 were slightly different between 
experimental conditions, with the most stable Nrf2 protein  (t1/2=48min) measured in 
control cells, while the least stable (t1/2=29min) was observed in CHX treated cells 
(Figure 6.6B), however the relative nuclear fluorescence decay of the photoconverted 
Nrf2 protein was very similar between DMSO, brusatol and CHX samples (Figure 
6.6B). 
 
The comparable inhibition of Nrf2 protein synthesis promoted by brusatol and CHX 
drugs was further confirmed by measuring pDendra2-Nrf2 fluorescence following 
inhibition of proteasomal degradation with 10µM MG132 (Figure 6.7). MG132 
treatment resulted in a gradual accumulation of newly made green pDendra2-Nrf2 
over time together with an increased stability of photoconverted red pDendra2-Nrf2 
(Figure 6.7A, Movie 38a). Combined application of MG132 with either 10µg/ml 
CHX (Figure 6.7B, Movie 38b) or 100nM brusatol (Figure 6.7C, Movie 38c) led to 
the stabilisation, rather than an increase in green pDendra2-Nrf2 nuclear 
fluorescence (Figure 6.7D). What is more, the stability of nuclear photoconverted 
(red) Dendra2-Nrf2 was comparable between cells treated with MG132 alone or in 
combination with either brusatol or CHX (Figure 5.7E). 
 
Therefore both CHX and brusatol impaired the accumulation of newly made 
Dendra2-Nrf2 without affecting the stability of pre-formed Nrf2 protein.  
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Figure 6.6 Brusatol acts by inhibiting Nrf2 translation. A) Comparison of the 
relative, nuclear photoconverted red pDendra2-Nrf2 or newly made green 
pDendra2-Nrf2 levels, in cells treated with DMSO, 10µg/ml CHX or 100nM 
brusatol. Comparable dynamic trends of newly made Nrf2 fluorescence (green) are 
observed in CHX and brusatol treated cells. Control cells maintain steady levels of 
new Nrf2 (green) synthesis. B) The half-life of pDendra2-Nrf2 proteins was 
calculated from the decay rate of red fluorescence, and did not display 
considerable variation between the samples. Half-life calculations were performed 
by fitting data to exponential non-linear regression function using a one-phase 
decay equation (Methods 2.13.2). Error bars=SEM. 	  
A) 
B) 
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Figure 6.7 Brusatol and CHX block the gradual accumulation of Nrf2 
protein following inhibition of proteasomal activity. A) Comparison of 
dynamic changes in green and red forms of pDendra2-Nrf2 in response to 10µM 
MG132 (n=6, c=21) (Movie 38a) or B) co-administration of 10µM MG132 + 
10µg/ml CHX (n=4, c=14) (Movie 38b) or C) 10µM MG132 + 100nM brusatol 
(n=4, c=20) (Movie 38c). D) Co-administration of CHX or brusatol with MG132 
stabilised pDendra2-Nrf2 fluorescence. The green fluorescence of pDendra2-
Nrf2 logarithmically increased following addition of 10µM MG132 to SK-N-AS 
cells. E) Comparison of the photoconverted (old) pDendra2-Nrf2 protein did not 
show considerable differences in Nrf2 protein stability between the treatments. 
F) Representative images from live-cell imaging experiments. Error bars=SEM, 
scale bar=20µm.	  	  
A) B) C) 
D) E) 
F) 
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Figure 6.8 The inhibition of Nrf2 protein synthesis by brusatol is more 
transient than the action of CHX. A) Relative levels of nuclear Nrf2-Venus in 
BACNrf2-Venus cells treated with 100nM brusatol or 10µg/ml CHX measured in 
live cells (n=3, c=23-34). B) Representative images taken from the BACNrf2-Venus 
cells treated with 10µg/ml CHX (Movie 39). Scale bar=20µm. 	  
A) 
B) 
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Furthermore, live cell imaging was performed on BACNrf2-Venus neuroblastoma to 
compare the effect of CHX and brusatol on the kinetics of Nrf2 protein depletion  
(Figure 6.8, Movie 39). Measurement of the rate of depletion of nuclear Nrf2-Venus 
demonstrated that the speed of depletion of Nrf2 was similar between both 
treatments, however the recovery of Nrf2 was faster following brusatol application 
(Figure 6.8A).  
 
6.3.5. Determination of brusatol target specificity 
 
In order to verify if brusatol acts specifically on Nrf2 protein synthesis, or generally 
inhibits global translation, a functionally unrelated cytoplasmic protein Dendra2-
MARCH5 was transiently expressed and imaged in SK-N-AS cells treated with 
DMSO (Figure 6.9A, Movie 40a), 10µg/ml CHX (Figure 6.9B, Movie 40c) or 
100nM brusatol (Figure 6.9C, Movie 40b). The kinetics of photoconverted 
pDendra2-MARCH5 in control cells followed slow decay concomitantly with 
accumulation of the new (green) pDendra2-MARCH5 expression (Figure 5.9A). 
Dynamic changes in green and red Dendra2-MARCH5 following CHX and brusatol 
treatments are presented in Figures 6.9D & E. Comparison of the cytoplasmic 
fluorescence levels of pDendra2-MARCH5 between the experimental conditions 
exposed differences in the synthesis levels of pDendra2-MARCH5, which appeared 
to be reduced in both CHX and brusatol treated cells (Figure 6.9E). However, the 
dynamics of red pDendra2-MARCH5 fluorescence decay were closely matched in all 
experiments (Figure 6.9F), indicating that brusatol, may have a nonspecific effect on 
the synthesis of a wider array of proteins, without compromising their stability.  
To further reinforce this hypothesis the SV40-Renilla (Promega) was transiently 
expressed in BACNrf2-Venus cells and the luminescence output was compared between 
100nM brusatol treated cells treated for different time-points (Figure 6.10A). The 
Renilla luminescent signal was significantly reduced in brusatol treated cells with 
time, with the most pronounced reduction in Renilla luminescence following 24h 
treatment (Figure 6.10B) suggesting the drug can alter the translation of the Renilla 
protein itself, indicating its non-specific mode of action. 
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Figure 6.9 Investigating the specificity of brusatol-mediated inhibition of 
protein synthesis. A) pDendra2-MARCH5 was transiently expressed in SK-N-
AS cells and green and red fluorescence levels were analyzed following 
photoconversion and treatment with either DMSO (n=2, c=21) (Movie 40a), B) 
10µg/ml CHX (n=3, c=12) (Movie 40c) or C) 100nM brusatol (n=4, c=19) 
(Movie 40b). D) Representative images of green fluorescence taken from live 
cell imaging experiments shown in panels A-C (Movies 40a-c (See 
supplementary list)). E) Comparison of dynamic changes in newly-made green 
pDendra2-MARCH5 or F) photoconverted red pDendra2-MARCH5 protein 
dynamics. The green fluorescence levels of pDendra-MARCH5 displayed 
differences in the dynamic recovery profiles between control (DMSO) and 
10µg/ml CHX or 100nM brusatol treated cells. Error bars=SEM. 	  
A) B) 
D) 
C) 
E) F) 
225	  	  
 
 
 
6.4. Discussion 
 
The Nrf2 signalling pathway acts as the double edge sword in disease, providing 
protection against oxidative stress, but also promoting tumourgenesis by rendering 
the cancer cells resistant to radio- and chemotherapy. Therefore, it is anticipated that 
pharmacological targeting of the Nrf2 pathway can lead to sensitisation of cancer 
cells to chemotherapy (Ren et al, 2011).  Although previous studies identified 
brusatol as a potent inhibitor of Nrf2 antioxidant signalling however; there have been 
conflicting reports as to how this negative regulation is achieved (Olayanju et al, 
2015). 
Data presented in this chapter provide novel evidence into the mechanism, by which 
brusatol mediates the downregulation of Nrf2 protein expression, using sophisticated 
live-cell imaging approach combined with complementary population-level 
functional studies. 
 
The BACNrf2-Venus neuroblastoma cell line provides an excellent experimental model 
for imaging the dynamic changes imposed by exposure to brusatol, as endogenous 
Nrf2 and the Venus labelled Nrf2 were shown to exhibit very similar responses to 
Figure 6.10 Brusatol reduces expression of Renilla luminescent signal. 
A) 100nM brusatol was applied for indicated time-points in BACNrf2-Venus 
cells transfected with SV40-Renilla. The Renilla luminescence decreases 
sharply with prolonged brusatol treatment, n=3 in triplicates. B) Comparison 
of control and Brusatol treated SV40-Renilla signal in BACNrf2-Venus cells 
following 24h treatment (n=3, in triplicates). Error bars=STDEV 	  
A) B) 
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100nM brusatol (Figure 6.1C). The inhibitory effect of brusatol on antioxidant gene 
expression has not been previously investigated in neuroblastoma cell lines, however 
we have demonstrated that even extremely low concentrations of brusatol (1nM) 
were sufficient to inhibit the 5xARE expression in SK-N-AS cells (Figure 6.1A). 
Data presented in Result Chapters 2 and 3 demonstrate the close link between 
antioxidant and inflammatory pathways in neuroblastoma cells. In addition, studies 
by Cuendet et al show evidence that brusatol induced differentiation of HL-60 cells 
by activating NF-κB nuclear translocation and DNA binding (Cuendet et al, 2004). 
Therefore, in this context, it was important to verify if brusatol could modulate NF-
кB pathway activity. Interestingly, the behaviour of p65 in response to brusatol 
varied between the plasmid-encoded p65-dsRedXP protein and stably expressed 
fluorescent tagRFP-p65 fusions (Figure 6.2A, B & D), the latter showing clear 
evidence of nuclear translocation. Significantly, nuclear entry of p65 was also 
correlated with a subsequent depletion of nuclear Nrf2-Venus, thus reinforcing 
evidence for the functional reciprocity between antioxidant and inflammatory 
signalling (Figure 6.2B). The reason for p65 activation remains unclear, however it 
was additionally correlated with increased transcription of a selection of canonical 
NF-кB target genes (Figure 6.2E). At this stage it cannot be concluded that brusatol 
leads to a general increase in NF-κB transcriptional activity (Figure 6.3B), as 5xκB 
driven luciferase expression remained unchanged (Figure 6.3C). However, in the 
context of our data there may be a logical explanation for these apparently 
dichotomous results. If, as our data suggests, brusatol acts by inhibiting protein 
translation but not transcription it is reasonable that mRNA levels may increase 
without a correlated increase in luciferase reporter expression, as this system is 
dependant on both transcription and translation of the luciferase reporter. 
  
Equally, inhibition of Nrf2 by brusatol has previously been associated with a 
decrease in expression of Nrf2 target genes (Ren et al, 2011; Olayanju et al, 2015), 
however, this was not observed in SK-N-AS cells by Q-PCR (Figure 6.3A.) in 
contrast to results obtained with ARE-Luc transcriptional reporter assays, which was 
very sensitive to brusatol induced changes in Nrf2 inhibition (Figure 6.1A and D). 
As the reduction in Nrf2 target gene expression in A549 and Hepa-1c1c7 cells was 
detected after a more prolonged exposure to brusatol (12-16h), it would be 
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interesting to see if extending the time of brusatol application would have a more 
pronounced effect on antioxidant gene transcription in SK-N-AS cells (Ren et al, 
2011; Olayanju et al, 2015). 
 
Interestingly, our data shows that brusatol actually promotes the accumulation of 
Nrf2 mRNA (Figure 6.3D), even though the NRF2 promoter activity was sharply 
reduced (Figure 6.4A), suggesting that the increase of mRNA levels was not simply 
associated with an increased rate of Nrf2 gene expression, as a result of increased 
conditional NF-κB driven transcriptional activity.  Furthermore, live-cell imaging 
experiments using UBC and 2kb driven Venus-Nrf2 fusions demonstrate that the 
promoter sequence did not have an effect on the sensitivity of Nrf2 expression to 
brusatol (Figure 6.4B and C), therefore the possibility of transcriptional inhibition of 
Nrf2 by brusatol was rejected.  
 
The results from our studies confirm that brusatol induces depletion of Nrf2 protein 
levels, while mRNA levels remained high. This phenotype was previously described 
by Olanyu et al, who also demonstrated that the depletion of Nrf2 protein was 
independent of the proteasome activity (Olayanju et al, 2015). However, an earlier 
report on the mechanism of brusatol-mediated Nrf2 inhibition presented evidence 
that brusatol does not affect Nrf2 mRNA levels, but did enhance ubiquitin-mediated 
degradation (Ren et al, 2011).  
 
Live-cell imaging of pDendra2-Nrf2 dynamics has provided new and definitive 
evidence as to the molecular mechanism of brusatol inhibition, in terms of the 
existing debate between the regulation of Nrf2 synthesis or degradation (Figure 6.5-
6.9). The stability of pDendra2-Nrf2 was not affected in DMSO (Figure 6.5A), 
10µg/ml CHX (Figure 6.5B), or 100nM brusatol (Figure 6.5C) treated samples, 
indicating that in neuroblastoma cells, brusatol does not compromise Nrf2 protein 
stability as suggested previously (Ren et al, 2011). The key to understanding the 
pharmacological effect of brusatol was the ability to measure dynamic changes in the 
production of new Nrf2 protein in single cells, using the pDendra2-Nrf2 construct. 
The relative nuclear fluorescence of newly formed green pDendra2-Nrf2 displayed a 
parabolic shape in cells treated with 100nM brusatol and 10µg/ml CHX, in contrast 
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to control cells, which exhibited a gradual increase (Figure 6.6A) in Nrf2 abundance. 
The comparison of CHX and brusatol treated SK-N-AS cells expressing pDendra2-
Nrf2 demonstrated that both drugs exhibit comparable dynamic profiles of green 
Dendra2-Nrf2 depletion, reinforcing the hypothesis that brusatol acts to impede Nrf2 
protein translation (Figure 6.6A). 
  
The speed by which brusatol leads to a reduction in protein synthesis was previously 
estimated to occur following a lag of 2-4min at 30oC in rabbit reticulocytes, however 
the concentration of drug used was 1000x higher then that applied here (Willingham 
et al, 1984). Therefore, due to the fast pharmacokinetics of brusatol the observed 
initial increase of green Dendra2-Nrf2 following addition of 10µg/ml CHX and 
100nM brusatol treated samples was not anticipated (Figure 6.6A). However, we 
hypothesise that this transient increase in pDendra2-Nrf2 synthesis (following UV 
treatment) is caused by the post-translational folding time of the pDendra2 
fluorescent tag (Chudakov et al, 2007). Therefore, as brusatol and CHX are expected 
to act at the stage of translation they will inevitably be a pool of already translated 
pDendra2-Nrf2, which acquires fluorescent properties after inhibition of protein 
synthesis (Figure 6.6A).  
 
Stabilisation of pDendra2-Nrf2 by proteasome inhibition the direct comparison of 
dynamic changes in levels of newly synthesised pDendra2-Nrf2 in cells treated with 
MG132 alone, or in combination with brusatol or CHX (Figure 6.7). In both cases, 
inclusion of CHX or brusatol prevented the accumulation of newly formed protein, 
which was reflected by a steady decrease in nuclear green pDendra2-Nrf2. In 
contrast, to cells treated with MG132 alone, where protein translation was unaffected 
(Figure 6.7D).  
Additional similarities between brusatol and CHX effects were demonstrated by live-
cell imaging of BACNrf2-Venus cells, showing very similar Nrf2-Venus protein depletion 
dynamics (Figure 6.8B). However, the reduction of Nrf2-Venus fluorescence was 
more transient in brusatol treated cells compared to CHX mediated depletion. This 
difference may highlight key differences between the relative kinetics of drug 
stability or action. This observation may also reflect a more selective mode of action 
of brusatol compared to CHX.  In this scenario a short window of inhibition, will 
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have a greater effect on reducing the levels of short-lived proteins, compared to those 
with longer half-lives. 
 
Lastly, in order to investigate the potential specificity of brusatol action, it was 
important to compare the effects of brusatol on another relatively unstable with and 
functionally unrelated protein pDendra2-MARCH5 with half-life of around 1h, 
which is usually localised to the cytoplasm and mitochondria (Figure 6.9) 
(Nagashima et al, 2014). Live-cell imaging experiments show that brusatol did not 
exclusively affect Nrf2 or components of the antioxidant response pathway, but also 
had an effect on the levels of green cytoplasmic pDendra2-MARCH5 levels, which 
showed impaired recovery following the photoconversion process (Figure 6.9A-D). 
The changes in green fluorescence signal followed similar dynamics following 
addition of CHX or brusatol, both of which were distinct to the pattern observed in 
control cells (Figure 6.9E). This effect was likely to result from the fact that brusatol 
and CHX both act by inhibiting translation of pDendra2-MARCH5, without 
affecting the stability of the photoconverted red pDendra2-MARCH5 (Figure 6.9E & 
F). This data suggests that brusatol is likely to have a global effect on protein 
synthesis, which could also explain the observed non-specific action of brusatol on 
the NF-κB pathway. The half-life of free IΚBα is reported to be <10min (Berggvist 
et al, 2009), therefore a transient enforced decrease in IΚBα expression could result 
in a burst of p65 nuclear translocation and the subsequent activation of NF-κB target 
gene transcription.  
 
What is more, the discrepancies observed between the mRNA measurements used to 
assess the transcriptional activity of Nrf2 and NF-κB in response to brusatol were not 
in agreement with results obtained by luciferase reporter assays (Figure 6.1A & 3C). 
However, it should be noted that as brusatol appears to have a general effect on 
protein translation, it would also diminish the luminescence signal of the SV40-
Renilla luminescence, which was used as a transfection control (Figure 6.10). This 
can result in misleading measurements of transcription factor activity assays based 
on dual luminescence of luciferase and Renilla proteins and interpretation of results 
obtained with this assay should be treated with caution. This will be especially 
relevant in the application ARE-Luc reporter, which contains a destabilising PEST 
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sequence that enhances luciferase degradation process and leads to shortening the 
half-life of luciferase from 3h to 15min (Promega). Therefore, the dramatic 
inhibition of the ARE-Luc expression following very low (1nM) brusatol 
concentration could be caused by inhibition of both the luciferase and Renilla 
synthesis, rather than a decrease in transcriptional activity (Figure 6.1A). This 
highlights the importance of selecting appropriate methods for investigating brusatol 
and other compounds that may inhibit translation, as assays relying of short-lived 
protein tags (e.g. luciferase) are expected to generate different results to those 
obtained by measuring more stable proteins such as EGFP (half-life around 24h) or 
those based on the measurement of mRNA expression.  
 
To summarise, this chapter provides essential evidence on the mechanism of action 
of brusatol on the Nrf2 pathway. Rather than compromising the Nrf2 protein stability 
as shown before by Ren et al (2011) brusatol actually leads to rapid depletion of 
Nrf2 by inhibition of protein translation, by an as yet unknown mechanism. This 
study emphasises the benefits of using photoswitchable fluorescent protein fusions 
and live cells imaging techniques to investigate the molecular mechanisms of poorly 
understood drug action. Nrf2 may well be particularly vulnerable to the action of 
brusatol due to its very short half-life, however the specificity of brusatol action 
remains to be defined, in order to evaluate potential off-target effects that may hinder 
its application in future clinical applications. 
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CONCLUDING DISCUSSION 
 
The Nrf2 and NF-κB pathways are responsible for sustaining optimal cellular 
function, consequently deregulation of their activity precipitates the progression of a 
wide array of diseases. Both pathways are under intense research because of their 
involvement in a range of neurodegenerative disorders, such as amyotrophic lateral 
sclerosis, multiple sclerosis, Alzheimer’s and Parkinson’s diseases. To tackle these 
conditions it is imperative that we develop new therapeutic strategies to ameliorate 
the harmful consequences of chronic inflammation.  With an increasing average age 
of the population, it is now even more important to understand how manipulation of 
anti-inflammatory and antioxidant pathways could contribute to the healthy aging 
process and ensure appropriate preventative measures. 
  
To understand the interplay between these pathways, we performed a detailed 
analysis of Nrf2 and NF-кB temporal dynamics at single-cell resolution, in both 
murine neural cells and human SK-N-AS neuroblastoma cancer. The most 
significant outcomes of this study are discussed in the following paragraphs together 
with suggestions of future research directions. The thesis concludes with an 
assessment of the potential impact or utility of data generated in this study.  
 
The function of the NF-κB pathway in the brain is not well defined, as there are 
conflicting reports on the stimuli that trigger cell-specific NF-κB signalling in 
neurons, astrocytes and microglia. It has became evident that glia play a prominent 
role in driving inflammatory responses in the nervous system. These cells have been 
shown to display a protective role, but can also drive chronic inflammation, leading 
to the development of neurological disorders (Vargas & Johnson, 2009). This study 
was initiated by investigating the NF-κB dynamics in primary cells isolated from the 
murine hippocampi. 
 
The oscillatory pattern of the p65 nuclear shuttling was more prominent and 
prolonged in astrocytes grown in single cultures (Figure 3.6) as compared to the 
dampened oscillatory behavior observed in glia that were co-cultured with neurons. 
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It has been shown that the amplitude and frequency of NF-κB signaling defines the 
profile of expressed NF-κB response genes. This process is regulated by three 
components: IΚKα, IΚBα/ε and A20 (Paszek et al, 2010). It is possible that the 
observed difference in nuclear oscillatory patterns in astrocytes may occur as a result 
of a change in the expression of one or all of these components, which could result 
from neuronal paracrine signaling. This compelling result emphasizes the importance 
of investigating dynamic changes in simple, single culture environments, as well as 
in more complex experimental setups, which incorporates signaling output from 
different cell types. Interestingly, we also observed spontaneous p65 nuclear 
translocations in resting astrocytes, which were also associated with the subsequent 
increase of inflammatory transcription (Figure 3.8). 
 
Surprisingly, there is a significant lack of literature addressing single cell Nrf2 
responses to inducers using plasmid expression. The latest report by Xue et al 
presented evidence that addition of SFN did not cause Nrf2 nuclear accumulation, 
but prompted an increase in the frequency of nuclear shuttling events (Xue et al, 
2014). However, the Nrf2 phenotype described in this study most likely results from 
stress related nuclear blebbing, leading to periodic nuclear rupture events, which we 
also observed in primary astrocytes expressing plasmid encoded mCherry-Nrf2 
fusion and which have been previously well documented in the literature (De Vos et 
al, 2011; Hatch et al, 2013). 
 
The tools generated for imaging the activity of the Nrf2 and NF-κB in neurons and 
astrocytes provided interesting and exciting insights into both pathways during basal 
and induced conditions (Results Chapter 1). The use of primary cells for 
investigating the molecular basis of cross-talk between the anti-oxidant and 
inflammatory pathways was very challenging and needed to be supported by an 
alternative cell culture model, which was more readily available for additional 
functional study. The human SK-N-AS BACNrf2-Venus neuroblastoma cells, which 
stably express Nrf2-Venus provided a perfect model for live-cell imaging of Nrf2 
and p65 proteins, additionally providing information on a cancer (neuroblastoma) 
specific phenotype. The Venus tag had been chosen for imaging Nrf2 because of its 
bright fluorescence and very fast folding-time (~ 15min), which allows imaging of 
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newly synthesized Nrf2 without considerable delay caused by the maturation of the 
fluorescent protein tag. The BAC integrated Nrf2-Venus protein enables 
physiologically relevant changes in protein expression to be correlated with changes 
in native transcriptional and translational control mechanisms (Spiller et al, 2010). 
This meant that the Nrf2 dynamic behavior in response to inducers and during basal 
activity could be effectively correlated with dynamic changes in Nrf2-Venus nuclear 
fluorescence in living cells in real time. 
 
The impact of acute and chronic inflammation on cellular antioxidant protection 
capacity has not been studied in detail. The first study, by Rushoworth et al showed 
that TNFα promoted the induction of Nrf2 protein levels and activity in AML cells, 
where the resulting high levels of Nrf2 expression confer resistant to treatment with 
the proteasomal inhibitor Bortezomib (Rushworth et al, 2011). The observed 
increase in Nrf2 levels in the SK-N-AS neuroblastoma cells in response to TNFα and 
induction was modest, but sufficient to switch on the genetic antioxidant protection 
program (Figure 4.3). The TNFα mediated Nrf2-Venus increase has been associated 
with a rise in NRF2 gene transcription following p65-dsRedXP nuclear entry, which 
indicates that Nrf2 may be an early p65 gene target of p65 in neuroblastoma cells 
(Figure 4.5). Furthermore, Nrf2 promoter activity and Nrf2 mRNA levels both 
increased in response to p65 overexpression and TNFα respectively (Figure 4.3). It 
is possible that the speed of Nrf2 transcription could be important in determining the 
timing of the inflammatory signaling resolution, with being an early gene having a 
more immediate, negative feedback potentially leading to faster dampening of 
inflammation. Live-cell imaging experiments performed in this study revealed a 
novel trend in Nrf2 dynamics, involving a sequential accumulations of nuclear Nrf2 
in response to a prior peak of p65 nuclear translocation (Figure 4.6). This is a unique 
example of how the temporal dynamics of one transcription factor (p65) modulates 
the dynamic expression of a second transcription factor (Nrf2) leading to changes in 
its activity. Significantly, the Venus-Nrf2 plasmid, which is driven by the 
constitutive CMV promoter did not show the TNFα mediated increase in relative 
Nrf2-nuclear fluorescence, indicating that this phenotype is dependent on the 
expression of Nrf2 being driven by its proximal promoter sequence (Figure 4.13). 
TNFα stimulation is associated with increased intracellular ROS levels and so it was 
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possible that Nrf2 may become activated as a result of TNFα-induced GSH depletion 
(Correa at el, 2012). However, this effect requires post-translational modifications of 
Keap1 and should also cause an increase in plasmid encoded Venus-Nrf2 levels, 
which has not observed in our studies (Figure 4.13).  
 
The function of cytokine mediated Nrf2 expression is expected to be especially 
relevant in the context of immune cell physiology, where NF-κB mediated 
antioxidant signaling could facilitate the resolution of inflammatory responses and 
counteract the generation of ROS, which may result from increased NADPH activity 
during phagocytosis (Bedard & Krause, 2007). It would be interesting to measure the 
effect of concomitant activation of Nrf2 to validate its role in the protection of 
immune cells against their own weapons by dampening of the inflammatory 
signaling.  
Both Nrf2 and NF-κB pathways are thought to have redundant roles in expression of 
the anti-inflammatory genes (Kohler et al, 2015; Buelna-Chontal & Zazueta, 2013). 
This has been demonstrated using knockdowns of Nrf2 and p65 in mouse liver by 
Kohler et al. The authors demonstrated that the single knockdown of either of the 
transcription factors did not result in dramatic changes of liver oxidative 
homeostasis, however double knockdown of both led to chronic inflammation and 
liver fibrosis, which eventually led to tumor development in female mice (Kohler et 
al, 2015). Therefore, NF-κB driven antioxidant protection could have profound 
effects on various aspects of health and may have a significant role in disease 
prevention. 
 
Importantly, we show for the first time that the inflammatory signalling can 
modulate the nuclear dynamics of Nrf2 by amplifying its transcriptional activity 
(Figure 4.6C & D, and 4.8E).  This mechanism forms an elegant functional cycle, 
which is initiated by an acute inflammatory response, followed by transient 
sequential activation of Nrf2 and a consequent dampening of the ROS signalling 
coupled with a concomitant decrease in NF-κB gene transcription. This in-turn leads 
to a reduction in Nrf2 transcription, thus eventually leading to reestablishment of 
resting cellular state levels of Nrf2, without inducing an apoptotic phenotype (Figure 
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4.6A & 4.7A, Chapter 2), which would result from unquenched elevation of cellular 
Nrf2 levels. 
The transcribed Nrf2 protein is synthesized in the cytoplasm, where it normally 
rapidly interacts with Keap1. It was therefore anticipated that Keap1 would serve as 
the prime regulator of newly made Nrf2 protein levels. Indeed, knockdown of Keap1 
expression by siRNA demonstrated an enhanced nuclear accumulation of Nrf2 in 
response to TNFα (Figure 4.9, Chapter 2). Therefore, the levels of Keap1 will 
determine the net increase in Nrf2 levels that result from inflammatory signaling. 
However, the magnitude of this response would be expected to vary between cell 
types. We have demonstrated that acute inflammatory signaling can be an effective 
inducer of Nrf2 protein expression, however this increase was short lived. The role 
of Keap1 in clearing away the newly made Nrf2 as a result of inflammation is 
expected to be especially relevant in cancers such as some lung cancers, which are 
associated with Keap1 mutations, or its suppressed expression as a result of promoter 
methylation. In these cases the resulting reduction of Keap1 levels could further 
amplify Nrf2 activity driven by the inflammatory status within the cancer tissue 
microenvironment, thus leading to an upregulation of antioxidant gene transcription, 
which in turn would selectively protect the tumor against therapeutic drug treatment.  
In theory, if inflammation led to inhibition of Keap1 mediated regulation in parallel 
with an increase in Nrf2 synthesis, the potentiated increase of Nrf2 activity could 
confer anti-aging and anti-oxidant protection. However this does not occur during 
chronic inflammation for the following reason. Induction of Nrf2 leads to the 
inhibition of NF-κB transcription as shown in this study, and by other previous 
reports (Figure 4.12, Chapter 2) (Kim et al, 2013; Buelna-Chontal & Zazueta, 2013). 
High antioxidant activity has been shown to impede anti-apoptotic signaling 
following application of compounds that trigger DILI and induce Nrf2, leading to 
inhibition of NF-κB signaling (Harpers et al, 2015). Therefore, tight regulation of 
Nrf2 ensures that in the event of inflammation the cell is able define the balance that 
allows appropriate, but time limited, activation of the appropriate signaling program. 
It can act to withstand the insult by activating the NF-κB responses and switching on 
the anti-apoptotic signaling, or alternatively to protect itself from the generated ROS 
that leads to DNA damage. Although, the latter scenario is associated with a 
compromise in the anti-apoptotic signaling, and could lead to cell death. Currently, it 
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is unclear as to what extent the two mechanisms are mutually exclusive, but this may 
well depend on the relative levels of both proteins and the robustness of the 
regulatory networks. 
 
The current model of Nrf2 regulation is explained by the conformational cycling 
model (Intro Chapter Section 1.1.2), but this does not take into account the fate of the 
Nrf2 protein once it enters the nucleus and accomplishes its role as a transcription 
factor (Baird et al, 2013).  Keap1 has been previously demonstrated to shuttle in and 
out of the nucleus, however this observation remains controversial, nevertheless the 
nuclear accumulation of Keap1 was also observed in this study, and this was found 
to be highly reproducible phenotype (Figure 5.3, Chapter 3) (Sun et al, 2011). LMB 
treatment combined with CDDO-Me triggered the nuclear localisation of the 
mCherry-Keap1 suggesting that it can shuttle between the cytoplasm and the 
nucleus. The role of this phenotype has not been confirmed by our results, however 
Zhang et al speculated that nuclear shuttling of Keap1 is necessary for effective Nrf2 
export from the nucleus and cessation of ARE-Luc transcription. Considering the 
evidence for mCherry-Keap1 nuclear shuttling it would be intriguing to validate the 
role of acetylation in Nrf2 nuclear export.  This could be achieved by monitoring 
pDendra2-Nrf2 protein nuclear export in the absence of Keap1 protein, following 
addition of C646. It would also explain the effect of LMB inhibition on the ARE-Luc 
transcription, as perhaps Keap1-bound nuclear Nrf2 is not able to bind to DNA, due 
to the proximity of Neh1 and Neh2 domains, which are involved in DNA binding 
and Keap1 interaction respectively (Suzuki & Yamamoto, 2015; Smirnova et al, 
2011). The acetyl group attachment on Nrf2 could act as a marker of completed 
transcriptional function, thus labeling it for more efficient nuclear clearance, in order 
to prevent over activation of antioxidant signaling. This possibility could also explain 
the increased levels of nuclear Nrf2-Venus observed following pharmacological 
inhibition of p300/CBP, which may block its nuclear exit. The affinity of nuclear 
Nrf2 for the nuclear Keap1 protein could also be investigated further by FCCS 
studies. 
 
The pattern of Nrf2-Venus nuclear fluorescence following addition of LMB 
demonstrates that there is a homeostasis between the synthesis and nuclear 
degradation of Nrf2.  This data presents the first example of a condition where Nrf2 
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protein levels are uncoupled from measured transcriptional activity (Figure 5.9, 
Chapter 3). Understanding the consequences of Nrf2 nuclear import will be an 
essential part of deciphering the complex regulation of antioxidant protection. There 
are limited mechanistic studies on what may happen to Nrf2 proteins after driving 
antioxidant gene transcription. Currently, the most extensive study of the mechanism 
regulating nuclear Nrf2 activity describes the GSK-3 mediated degradation of Nrf2, 
as well as activation of Nrf2 nuclear export by Fyn kinase, which is also linked to 
GSK-3 activity (Niture et al, 2011). However, both reports failed to provide 
conclusive evidence to differentiate between GSK-3 mediated Nrf2 degradation or 
export. By using photoswitchable Nrf2 proteins we have demonstrated that Nrf2 can 
be effectively transported into the cytoplasmic space under basal conditions 
providing the first, direct evidence of Nrf2 export (Figure 5.6, Chapter 3). There are 
several lines of research that could be addressed with pDendra2-Nrf2 imaging, 
focusing on the role of GSK-3 to discern between export and degradation. What is 
more, the redundancy of GSK-3 and Keap1 negative regulation could be investigated 
more thoroughly using pharmacological inhibitors and imaging of the pDendra-Nrf2 
half-life and cytoplasmic accumulation.  This will be particularly relevant in studying 
the nuclear degradation mechanism of Nrf2 using when Keap1 expression is depleted 
by siRNA knockdown, in order to validate its role in nuclear Nrf2 regulation, as 
results obtained in this study indicated that nuclear export is not required for efficient 
Nrf2 clearance (Figure 5.9, Chapter 3).  This demonstrates the robustness of the 
regulatory loops ensuring appropriate timing/limitation of antioxidant signaling 
responses, to prevent deleterious interference with other pathways, especially with 
NF-κB responses.  The relative participation of the RNF4, Keap1 and GSK-3 in Nrf2 
control still remains to be addressed to verify the degree of redundancy or 
combinatorial action between the different mechanisms of negative regulations of 
cellular antioxidant responses. 
Lastly, data presented in Chapter 4 provides the first definitive evidence of the 
mechanism of Nrf2 inhibition by anti-cancer drug, brusatol. Brusatol is a quasinoid 
compound isolated from the Chinese medicinal plant Brucea javanica, which is 
known for its anti-cancer properties. Pioneering studies in 1983 revealed similarities 
between the bruceantin compound (from Brucea antidysenterica) and brusatol, 
demonstrating that both drugs reversibly target global protein translation process in 
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rabbit reticulocytes, although the 100µM concentration of drugs applied in this study 
was extremely high (Willingham et al, 1981; Willingham et al, 1984). Donna 
Zhang’s group were the first to describe the inhibitory effects of Brusatol on the Nrf2 
pathway. However, in that study, inhibition was attributed to decreased Nrf2 
stability, due to enhanced ubiquitination (Ren et al, 2011). This conclusion diverted 
attention from the potential low dose effect of the drug on protein translation. As a 
result, further studies have focused on investigating the mechanism of brusatol 
evoked Nrf2 degradation. However, so far researchers have failed to identify a 
brusatol-induced mechanism of proteosomal degradation (Olayanju et al, 2015). 
Classical protein turnover studies have relayed on pulse chase metabolic labelling 
and quantification of immunoprecipitated proteins. This approach is time consuming 
and does not allow protein stability changes to be measured real time in live cells 
(Khmelinskii et al, 2012). 
With the help of photoswitchable pDendra2 tagging of Nrf2 we were able to 
discriminate between the Nrf2 protein degradation and the effect of brusatol on the 
newly made protein synthesis (Figure 6.5, Chapter 4). This approach led to the 
identification of substantial similarities between the comparative effects of brusatol 
and cycloheximide (CHX), as both compounds led to the inhibition of Nrf2 protein 
synthesis, rather than any increase in the degradation of preformed Nrf2 protein. Our 
data also strongly suggests that even in low therapeutic dose ranges brusatol is likely 
to inhibit the global translation of proteins, in contrast to reports published by Ren et 
al and Olayanju et al (Figure 6.9 and 6.10, Chapter 4). This hypothesis is supported 
by the fact that brusatol application increased NF-κB target gene transcription 
(possibly by decreasing IKBα levels), as well as led to reduction in Renilla 
luminescence and MARCH5 protein synthesis (Figure 6.10, Chapter 4). Interestingly 
brusatol has been previously observed to deplete c-Myc protein levels in leukemic 
cells, which suggest this compound is likely to have many off-target effects by 
inhibiting global translation process (Mata-Greenwood et al, 2002). Consequently, 
the shorter the protein half-life, the more likely it is to be affected by the transient 
generic inhibition of translation. It is feasible that brusatol may target a more 
selective portfolio of proteins than CHX, simply due to the transient nature of its 
action, therefore reducing cytotoxicity (Figure 6.8, Chapter 4). 
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At present, we can only speculate that brusatol acts by inhibiting the 80S ribosomal 
function, since this is the exclusive target of the 16 remaining translation protein 
inhibitors screened previously by Garreau de Loubresse et al. Compounds such as 
CHX, lactimidomycin, lycorine and others, were co-crystallised with the yeast 80S 
ribosome and the authors demonstrated that the inhibitors were primarily bound to 
the domain responsible for mRNA or tRNA binding on the ribosome subunits 
(Garreau de Loubresse et al, 2014). Proteomic studies to assess the specificity of 
action of this compound are planned for the near future in order to explore the 
potential therapeutic benefits of other transient inhibitors of protein synthesis.  
 
CONCLUSIONS 
 
 
Generation of sophisticated, low-level expression systems enabled physiologically 
relevant imaging of fluorescently labelled Nrf2 and p65 proteins.  Providing real-
time quantitative insight into the temporal dynamics of conditional responses in 
single live-cells. This approach has provided novel insights into cell specific 
responses to stress stimuli in mixed primary hippocampal cultures and the molecular 
mechanisms of crosstalk between antioxidant and inflammatory pathways in SK-N-
AS BACNrf2-Venus neuroblastoma cells. The results from this study suggest that NF-κB 
modulates dynamic nuclear localisation of Nrf2 by driving the transcriptional 
regulation of the κB2 site located within the NRF2 gene promoter. Thus resulting in 
a transient increase in Nrf2 expression in response to cytokines.  This effect was 
amplified by knockdown, or inhibition, of the Keap1-mediated Nrf2 degradation 
axis. Implying that Keap1 fine-tunes the balance between the antioxidant Nrf2 
responses and p65 mediated inflammatory signalling, by titrating cellular levels of 
Nrf2 and allowing effective NF-κB signalling. It acts by the retention and 
degradation of Nrf2 within the cytoplasm on a basal level and changes in Keap1 
activity, or in the rate of Nrf2 synthesis will enable nuclear accumulation of Nrf2 to 
adjust the intracellular redox environment. Once Nrf2 completes its transcriptional 
task it can be efficiently regulated by nuclear degradation, or export to the 
cytoplasmic space.  Live cell imaging approaches presented in this thesis facilitated 
investigation of Nrf2 regulation at multiple levels, including cell cycle dependant 
temporal changes, transcription, translation, regulation of protein stability by Keap1 
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and GSK-3, nuclear v/s cytoplasmic rates of degradation and nuclear import/export 
dynamics. We now aim to integrate the quantitative data generated in this study into 
a mathematical model, which will permit the in silico prediction of conditional Nrf2 
and p65 responses to inflammatory, antioxidant and potential therapeutic compounds 
in order to design a more informed therapeutic approach aiming to combat diseases 
associated with inflammatory damage.  
 
The summary model of Nrf2 regulation during acute inflammation is presented in 
Figure 7.1.  
Figure 7.1 Model of Nrf2 regulation. 1. TNFα signalling triggers NF-кB 
signalling cascade activating IKBα phosphorylation and degradation. 2. 
Translocation of p50/p65 heterodimer into the nucleus. 3. Transcription of 
NRF2 gene. 4. Translation of Nrf2 mRNA. 5. Nrf2 nuclear import. 6. Nrf2 
binding to Keap1. 7. Nrf2 degradation by the 26S proteasome. 8. Nrf2 target 
gene expression. 9. Nrf2 nuclear export. 10. Nrf2 phosphorylation by GSK-3 
and subsequent nuclear degradation by SCF-β-TrCP proteolysis. 11. Nrf2 
accumulation into PML NBs. 12. HO-1 inhibition of the NF-кB pathway 
activity. 13. Keap1-mediated Nrf2 nuclear export. 14. Induction of Nrf2 levels 
by CDDO-Me, SFN and ROS by preventing Nrf2 degradation. 	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Supplementary Information 
 
8. Supplementary Movies (attached) 
 
8.1. List of Movies (avi. format) 	  
(Open in QuickTime Player 7 or other compatible software) 
 
Movie 
 
 
Title 
 
Movie 1a 
Movie 1b 
Movie 2 
Movie 3a 
 
Movie 4 
 
 
 
Movie 5a 
 
Movie 5b 
 
 
Movie 6a 
 
 
Movie 6b 
 
Movie 7 
 
Movie 8 
 
 
Mixed Culture Astrocytes TNFα (EGFP-p65/GREEN) 
Mixed Culture Neurons TNFα (EGFP-p65/GREEN) 
Pure Astrocytes TNFα (EGFP-p65/GREEN) 
5xκB-Venus in Neurons +TNFα (Mixed culture transduced 
eith tagRFP-P65/RED and 5xκB-Venus/GREEN) 
Spontaneous p65 Oscillations in Mixed Culture (tagRFP-
p65/RED and 5xκB-Venus/GREEN) 
 
 
Spontaneous Oscillations Mixed Culture (tagRFP-p65/RED 
and 5xκB-Venus/GREEN) 
Spontaneous Oscillations Mixed Culture 2 (tagRFP-
p65/RED and 5xκB-Venus/GREEN) 
 
Spontaneous Oscillations Pure Astrocytes 5% Horse Serum 
(EGFP-p65/GREEN)  
 
Spontaneous Oscillations Pure Astrocytes Serum Free 
(EGFP-p65/GREEN)  
Nuclear Envelope Breakdown, Nrf2 plasmid (mCherry-
Nrf2/RED) 
Nuclear Envelope Breakdown, Nrf2 plasmid (mCherry-
Nrf2/RED) 
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Movie 9 
Movie 10 
Movie 11 
 
Movie 12 
 
Movie 13 
Movie 14 
Movie 15 
Movie 16 
Movie 17 
Movie 18 
Movie 19 
Movie 20 
 
Movie 21 
Movie 22 
Movie 23 
Movie 24 
Movie 25 
 
Movie 26 
Movie 27 
Movie 28 
Movie 29 
Movie 30 
 
Movie 31a 
Movie 31b 
Movie 32 
Pure Astrocytes DMSO (2kb-Venus-Nrf2/GREEN) 
Pure Astrocytes SFN Treatment (2kb-Venus-Nrf2/GREEN) 
Pure Astrocytes CDDO-Me Treatment (2kb-Venus-
Nrf2/GREEN) 
Mixed Culture CDDO-Me (tagRFP-p65/RED and 2kb-
Venus-Nrf2 
BACNrf2-Venus MG132 
BACNrf2-Venus SFN 
BACNrf2-Venus CDDO-Me 
BACNrf2-Venus Dividing Cells (Untreated) 
BACNrf2-Venus TNFα 
tagRFP-p65/BACNrf2-Venus with TNFα 
BACNrf2-Venus p65dsRedXP with TNFα 
BACNrf2-Venus p65dsRedXP TNFα and SFN 
 
BACNrf2-Venus with IL-1β 
tagRFP/BACNrf2-Venus siKeap1 with TNFα 
tagRFP/BACNrf2-Venus siCTR with TNFα 
 
BACNrf2-Venus and mCherry-Keap1(RED) with CDDO-Me 
BACNrf2-Venus and mCherry-Keap1(RED) with CDDO-Me and 
LMB 
 
pDendra2-Nrf2 Nuclear Import Control 
pDendra2-Nrf2 expressing tagBFP-Keap1 
pDendra-Nrf2 Nuclear Export CTR 
pDendra-Nrf2 Nuclear Export after LMB 
pDendra-Nrf2 with LMB 
 
BACNrf2-Venus siCTR with CHIR99021 
BACNrf2-Venus siKeap1 with CHIR99021 
BACNrf2-Venus with LMB 
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Movie 33 
Movie 34 
Movie 35 
Movie 36 
 
Movie 37a 
Movie 37b 
Movie 37c 
Movie 38a 
Movie 38b 
Movie 38c 
 
Movie 39 
Movie 40a 
Movie 40b 
Movie 40c 
 
BACNrf2-Venus with LMB and TNFα 
BACNrf2-Venus with C646 
BACNrf2-Venus C646 expressing mCherry-Keap1 (RED) 
BACNrf2-Venus with Brusatol 
 
pDendra2-Nrf2 with DMSO 
pDendra2-Nrf2 with Brusatol 
pDendra2-Nrf2 with CHX 
pDendra2-Nrf2 with MG132 
pDendra2-Nrf2 with MG132 and CHX 
pDendra2-Nrf2 with MG132 and Brusatol 
 
BACNrf2-Venus with CHX 
pDendra2-MARCH5 with DMSO 
pDendra2-MARCH5 with Brusatol 
pDendra2-MARCH5 with CHX 
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8.2. Viability Assays on BACNrf2-Venus    
 
 
 
 
 
 
 
 
Figure 8.2 ATP-based viability assays on BACNrf2-Venus cells (Methods 
Section) in response to 8hr treatments of various compounds used 
throughout the project. A) Viability assay of various brusatol 
concentrations. B) Viability assay on drugs commonly used throughout 
the project. C) Viability assay following 24h treatment with various 
concentrations of C646. Error bars=STDEV 
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8.3. Vector Maps of Generated Constructs (Figure 8.3 and 8.4) 
 
1. 2kb-Venus-(ms)Nrf2  
2. UBC-Venus-(ms)Nrf2 
3. UBC-tagRFP-(hm)p65 
4. UBC-tagRFP-(ms)p65 
5. GFAP-Cyan 
6. GFAP-LaminB1-Cyan 
7. 5xkB-Venus 
8. pDendra2-(hm)Nrf2 
 
 
Figure 8.3 Vector maps of the lentiviral expression constructs. 
1) 2kb-Venus-(ms)Nrf2, 2) UBC-Venus-(ms)Nrf2, 3) UBC-
tagRFP-(hm)p65, 4) UBC-tagRFP-(ms)p65. 	  
1) 2) 
3) 4) 
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Figure 8.4 Vector maps of the lentiviral expression constructs. 
5) GFAP-Cyan, 6) GFAP-LaminB1-Cyan, 7) 5xκB-Venus, 8) 
pDendra2-(hm)Nrf2. 
8) 7) 
6) 5) 
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8.4. Quantification of Protein Levels from Western Blot Analysis 
 
 
 
 
 
 
 
 
Figure 8.5 Quantification of Western Blot Figure 1 from Results 
Chapter 2 	  
